


Scientific report

2018

contents

01 // DIRECTOR'S FOREWORD	pg. 4
02 // GOVERNANCE AND STRUCTURE	pg. 8
03 // STAFF	pg. 18
04 // GOALS ACHIEVED IN 2018	pg. 22
05 // PLATFORMS AND NETWORKS	pg. 26
06 // FUNDING	pg. 32
07 // INSTITUTIONAL PROJECTS	pg. 36
08 // RECURRENT TRAINING	pg. 42
09 // BIOMEDICAL RESEARCH	pg. 60
10 // SCIENTIFIC PRODUCTION	pg. 80
11 // INNOVATION AND TRANSFER	pg. 174
12 // FACTS & FIGURES	pg. 180
13 // COMMUNICATIONS	pg. 196
14 // GOALS FOR 2019	pg. 200
// ANNEXED	pg. 202



DIRECTOR'S
FOREWORD

Director's FOREWORD for 2018 Scientific Report

The present report provides a detailed summary of the activity of the Maimonides Biomedical Research Institute of Córdoba, IMIBIC, during 2018, a very special year for all of us, for it marked the first decade of life of the institute. The celebration of our 10th anniversary through different activities in 2018 was an opportunity to reflect on the accomplishments accreted over this period, on how they have provided the fertile grounds for the current and future growth of our research community, as well as on the challenges and difficulties that we can expect ahead.

The progressive development of the research activity at IMIBIC has enabled the recruitment of novel, competitive and young groups, which in 2018 accounted for a total of 27 Consolidated Groups, 5 Emerging Groups, and 12 Associated Groups. This structure ensures a solid basis for our activity, while promoting generational renewal and collaboration and cross-fostering among disciplines, which is the root for the development of productive research programs, oriented towards solving health problems of the society through translational research. The total number of persons associated to this growing research activity surmounted this year 800, an impressive figure for a decade of life. The basic index of the research production of this community, the number and quality of scientific publications, has continued their steady growth, with a total of 459 articles published in 2018, 53% of them in the first quartile of their area, reflecting the efforts of the researchers to reach higher quality objectives each year. Of note, through our International Area, we attained a long-pursued goal, the funding of the IMIBIC Fellowship Programme for Personalised and Precision Medicine (IMIBIC-P²Med) (H2020 MSCA-Cofund FP 2018), a Research Training Programme that will bolster our capacity to advance in the fields of bioinformatics and precision medicine by incorporating young and competitive junior postdoctoral researchers. Along these lines, it should be recognized and praised that the results of all areas of activity of the institute, from Innovation and Transfer of Technology to Core Support Services, from Research Training to Communication and Science Dissemination, have also continued their progress and consolidation. Advances in registered patents and innovation grants, incorporation of new equipment and methodologies, organization of Seminars, the 10th Young Investigators Meeting, the 8th Maimonides Lecture, and our active participation in a number of events aimed at science communication illustrate the plethora of areas currently covered by the IMIBIC community. Meanwhile, our budget raised to reach 9.8 M€, confirming the economical robustness of the institute amidst the uncertain situation of research funding in our environment. Maintaining a balanced budget over time is only possible through an active and joint work to obtain research


funding from public and private institutions, by promoting high quality Clinical Research and by linking the institute closely to its society milieu, this latter having been a very active area in 2018. Indeed, to cite just an example, a well-established association with social prestige in Córdoba, recognized the work of the institute at their 30th Anniversary, a gratefully appreciated testimony of the determined implication of IMIBIC with the citizens and institutions of this city and the province of Córdoba.

Nevertheless, the fertile grounds ensuring the future of IMIBIC are not just economic or based solely on scientific production or social recognition, but largely rely on a pivotal change in the way biomedical research is nowadays conceptually and practically appreciated by our young and senior researchers alike. These 10 years have provided a novel view, a new perspective over the future of the biomedical research based in a profound self-confidence in the capacity of our research community to attain more difficult and superior goals. Not only the number and quality of publications but also the projects obtained by our researchers have continued growing in an environment of scarce research funding and decreasing resources, within a highly competitive and demanding environment. Most importantly, the research community encompassing scientist of clinical, translational and basic background, nurses, managers, technicians, support personnel, and, remarkably, volunteering personnel, patients and their families, have together achieved to build an overarching research environment capable to reach for goals that were unattainable an even unthinkable just a few years ago. The feeling of sincere gratitude and recognition for all those persons and institutions that made this advancement possible is as immense as their generosity.

There are many steps and goals yet to be fulfilled, there are many challenges and difficulties to be overcome, but the spirit of the IMIBIC has humbly shown the path to blend basic and clinical research, to combine competitiveness with cooperation, to support profound changes while maintaining coherent and solid project goals, to attain excellence and quality in research while ensuring a steady growth through efficient economic management, to maintain its obliged functional autonomy while nurturing loyal institutional integration, and, most importantly, this spirit has helped us to identify worthwhile goals to pursue, those targets where it is necessary to spend our efforts. Over the next pages, you will have the opportunity to realize the results of this continued growth and the consolidation of our efforts to progress in the field of biomedical research, but most of all, you will witness the robust willingness to continue rising altogether in this common and enduring pathway.

Justo P. Castaño
Scientific Director






02

GOVERNANCE
AND STRUCTURE

1. Organization Chart

IMIBIC's governing and representative bodies are detailed below:



2. Governance and structure

A. Collegiate Bodies

The collegiate bodies composing IMIBIC are the Governing Council, the Executive Committee, the Scientific Council and the External Scientific Board. Each body has its competencies and is composed of several specialists.

- **Governing Council**

The Governing Council is the uppermost governing body of IMIBIC. The Governing Council is composed of the following members:

- » Two representatives from the Regional Ministry of Health of the Andalusian Regional Government
Teresa Molina López. General Director of Research and Knowledge Management of the Ministry of Health.
Valle García Sánchez. Managing Director of the Reina Sofia University Hospital and President of FIBICO
- » Two representatives from the Regional Ministry of Economy, Innovation, Science and Business
Manuel García León. General Director of Research and Knowledge transfer
Manuel Carmona Jiménez. Territorial Delegate of Economy, Innovation, Science and Employment of Córdoba
- » Two representatives from the University of Córdoba
Antonio J. Cubero Atienza. Vice rector of Institutional Coordination and Infrastructures
Luisa M. Rancaño Martín. Managing Director.
- » IMIBIC's Scientific Director
Justo P. Castaño Fuentes

- » One representative from the Progress and Health Foundation (FPS)

Ana Madera Molano. Managing Director.

- » IMIBIC's General Manager

José Miguel Guzmán de Damas (til Jun 2018) / **Álvaro Granados del Río** (from Jul 2018).

- **Executive Committee**

In order to facilitate agile decision making, the Governing Council adopted, on July 27 2015, an agreement to create an Executive Committee. The Executive Committee is composed of one member from each of the institutions that constitute the Governing Board, as set forth in the collaboration agreement between the Regional Ministry of Health, the Ministry of Economy, Innovation, Science and Business and the University of Córdoba. The Scientific Direction, General Manager and the Governing Council will participate with voice but without vote.

- **Scientific Council**

The Scientific Council is an advisory body to the Scientific Director. It is composed of the Scientific Director, the Deputy Scientific Director of IMIBIC, the Principal Investigators (PI), the Emerging Researchers (ER), the Associated Researchers (AR), a representative of the Reina Sofia University Hospital Board of Directors (RSUH), the IMIBIC's General Manager and representatives of the technical and management staff. It was established on July 9, 2009.

- **External Scientific Advisory Board**

The External Scientific Advisory Board is a body appointed by the Governing Council, whose mission is to assist the

Scientific Director in the performance of his duties. It is an advisory body to the Scientific Direction but its decisions are not legally binding. It was established on July 9, 2009 under the name of External Advisory Board, and it was ratified by the Governing Council on December 21, 2009

The composition of the External Scientific Advisory Board was modified in 2014. The members of the board are:

Dr. Lina Badimon Maestro. Director of the Cardiovascular Research Centre (CSIC-ICCC) (Barcelona)

Dr. Carlos Diéguez González. Director of the Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS) (Santiago de Compostela)

Dr. José María Ordovás. Senior Scientist and Director for the Nutrition and Genomics Laboratory and Chair of the Functional Genomics Core of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USA). Scientific Director of IMDEA Food (Madrid)

Dr. Francisco Sánchez Madrid. Professor of Immunology at the Universidad Autónoma de Madrid and Scientific Director of La Princesa Research Institute (Madrid)

Dr. Carlos López-Otín. Professor of Biochemistry and Molecular Biology at the University of Oviedo (Oviedo)

The annual ordinary meeting took place on June in 2018. The members expressed their opinions on matters such as the management of the Institute, incorporation of new research groups, the implementation of strategic initiatives, the scientific structure, and budget for 2018.

B. Individual Bodies

The Management Team is responsible for ensuring the correct performance, in order to increase the quality and impact of IMIBIC's research activity.

• Scientific Director

Justo P. Castaño Fuentes. Full Professor of Cell Biology of University of Cordoba. He was appointed scientific director of IMIBIC by the Governing Council at a meeting held on April 08, 2015.

• Deputy Scientific Director of Basic Research

Manuel Tena Sempere. Full Professor of Physiology at the Faculty of Medicine of the University of Córdoba. He was re-appointed deputy scientific director of Basic Research of IMIBIC by the Governing Council at a meeting held on April 08, 2015.

• Deputy Scientific Director of Clinical Research

José López Miranda. Full professor of the University of Cordoba and Head of the Internal Medicine Unit at Reina Sofia University Hospital. He was appointed deputy scientific director of clinical research of IMIBIC by the Governing Council at a meeting held on April 08, 2015.

• General Manager

José Miguel Guzmán de Damas. BSc in Pharmacy, BSc in Business Administration, MSc in Health Economics and Health Care Management, MBA. He was appointed General Manager of IMIBIC by the Governing Council at a meeting held on December 21, 2010 til on June 19, 2018.

Álvaro Granados Del Río. BSc in Business Administration and Management. Senior Management Program of Health Institutions. He was appointed General Manager of IMIBIC by the Governing Council at a meeting held on July 25, 2018.

3. Scientific Structure

The research activities of IMIBIC are organized into five scientific programs, which integrate various different research groups. The scientific programs target prevalent and highly relevant health problems, identifying areas in which the researchers of the institute can join their efforts by transversal collaborative projects and are inspired and aim to give response to the main health challenges faced by the European society today, in line with the priorities set by the European Union's Horizon 2020 program. The structure defines a framework that guides researchers towards the improvement of health of patients and the community through excellent translational and clinical research and innovation. It encourages interaction and cooperation among the different groups, as well as aims for attraction of talent and continuous improvement of career development opportunities of young researchers. Our Scientific Programs are a reflection of the strength of our research teams and show the unique specialization of IMIBIC. The programs are as follows:

1. Active ageing and Frailty

This program is oriented towards understanding the molecular pathogenic basis of the aging process, its relation to quality of life and the search for new strategies for patient care assistance. It includes the following lines of research:

- » Immunology and senescence
- » Attention and care of the chronically ill
- » Frailty and quality of life in the elderly

2. Nutrition and endocrine and metabolic diseases

This program is oriented towards studying diseases of the metabolism and the endocrine system, with particular interest in the role of nutrition in the prevention and management of

these processes at different stages of life. It also focuses on the study of reproductive health and neuroendocrine tumors. It includes the following lines of research:

- » Metabolic syndrome
- » Reproductive Health
- » Pediatric and perinatal diseases
- » Neuroendocrine Tumors

3. Infectious and immunological diseases and organ transplants

This program focuses on the study of diseases by different infectious agents, with a special emphasis on the infections in immunocompromised patients. It includes the following lines of research:

- » HIV + Hepatitis C Virus
- » Transplants
- » Multi-drug resistance

4. Cancer (Oncology and Oncohematology)

This program focuses on the study of neoplastic diseases, including both solid tumors and hematologic neoplasms. It includes the following lines of research:

- » Lung Cancer
- » Breast Cancer
- » Hepatocellular carcinoma
- » Leukemia and Lymphomas
- » Digestive Tumors
- » Other tumors

5. Chronic and Inflammatory Diseases

This program focuses on the study of a number of chronic diseases of modern society, with special emphasis on those of an inflammatory nature. This program includes both basic research and clinical studies, with the ultimate



aim of promoting a better understanding of the basis of chronic/inflammatory diseases and the improvement of their therapies. It includes the following lines of research:

- » Cardiovascular diseases
- » Diseases of the locomotor system and connective tissue
- » Neurological diseases
- » Mental health
- » Kidney and urologic diseases

- » Liver and digestive diseases
- » Chronic inflammation and signaling

Research Groups

GC / Consolidated Group

GE / Emerging Groups

GA / Associated Group

CODE	GROUP and PROGRAMS	PRINCIPAL INVESTIGATOR(s)
GC01	Immunology and Allergy PROGRAMS 1, 3, 4, 5	Dr. Rafael Solana Lara (PI)
GC02	Oxidative and nitrosative stress in acute and chronic liver disease PROGRAMS 3, 4, 5	Dr. Manuel De La Mata García (PI) Dr. José Antonio Bárcena Ruiz (CO-PI)
GC03	Infectious diseases PROGRAM 3	Dr. Julián De La Torre Cisneros (PI)
GC04	Inflammation and cancer PROGRAMS 2, 4, 5	Dr. Eduardo Muñoz Blanco (PI) Dr. Marco A. Calzado (ER)
GC05	Systemic and chronic inflammatory autoimmune diseases of the locomotor system and connective tissue. PROGRAM 5	Dr. Rosario López Pedrera (PI) Dr. Eduardo Collantes Estévez (CO-PI) Dr. Nuria Barbarroja Puerto (ER)
GC06	New therapies in cancer PROGRAM 4	Dr. Enrique Aranda Aguilar (PI) Dr. Antonio Rodríguez Ariza (CO-PI) Dr. Juan de la Haba Rodríguez (ER)
GC07	Nephrology. Cell damage in chronic inflammation PROGRAMS 1, 3, 5	Dr. Alejandro Martín Malo (PI) Dr. Pedro Aljama García (CO-PI)
GC08	Hormones and cancer PROGRAMS 2, 4, 5	Dr. Justo P. Castaño Fuentes (PI)
GC09	Nutrigenomics. Metabolic syndrome PROGRAMS 1, 2, 5	Dr. José López Miranda (PI) Dr. Francisco Pérez Jiménez (CO-PI) Dr. Yolanda Almadén Peña (CO-PI) Dr. Javier Delgado Lista (CO-PI) Dr. Pablo Pérez Martínez (CO-PI) Dr. Antonio Camargo García (ER) Dr. Antonio García Ríos (ER)
GC10	Hormonal regulation of energy balance, puberty and reproduction PROGRAM 2	Dr. Manuel Tena Sempere (PI)
GC11	Metabolism and adipocyte differentiation. Metabolic syndrome PROGRAM 2	Dr. María del Mar Malagón Poyato (PI)
GC12	Epidemiological research in primary care PROGRAMS 1, 3, 4, 5	Dr. Luis Ángel Pérula de Torres (PI)
GC13	Calcium metabolism. Vascular calcification PROGRAMS 2, 5	Dr. Mariano Rodríguez Portillo (PI) Dr. Juan Rafael Muñoz Castañeda (ER)

CODE	GROUP and PROGRAMS	PRINCIPAL INVESTIGATOR(s)
GC14	Cell therapy PROGRAM 5	Dr. I. Concepción Herrera Arroyo (PI)
GC15	Invasive cardiology and cell therapy PROGRAM 5	Dr. Manuel Pan Álvarez-Ossorio (PI)
GC16	Cell biology in hematology. Hypercoagulability PROGRAMS 3, 4	Dr. Joaquín Sánchez García (PI) Dr. Francisco Velasco Gimena (CO-PI)
GC17	Pathophysiology of the endocrine system of vitamin D. Biotechnology and aging PROGRAMS 1	Dr. José Manuel Quesada Gómez (PI)
GC18	Translational research in surgery of solid organ transplants PROGRAMS 3, 4	Dr. Javier Briceño Delgado (PI)
GC19	Artificial Vision Applications (A.V.A.) PROGRAMS 1, 4, 5	Dr. Rafael Medina Carnicer (PI)
GC20	Genetics and behavioural diseases PROGRAM 5	Dr. Manuel Ruiz Rubio (PI) Dr. Juan A. Moriana (CO-PI)
GC21	Metabolomics. Identification of bioactive components PROGRAMS 2, 4, 5	Dr. Feliciano Priego Capote (PI) Dra. M ^a Dolores Luque de Castro (CO-PI)
GC22	Epigenetics PROGRAM 4	Dr. Teresa Roldán Arjona (PI)
GC23	Metabolism in childhood PROGRAMS 2, 5	Dr. Mercedes Gil Campos (PI)
GC24	Clinical and molecular microbiology PROGRAM 3	Dr. Luis Martínez Martínez (PI)
GC25	Knowledge discovery and intelligent systems PROGRAMS 2, 3, 4	Dr. Sebastián Ventura Soto (PI)
GC26	Clinical virology and zoonosis PROGRAM 3	Dr. Antonio Rivero Román (PI) Dr. Antonio Rivero Juárez (ER)
GC27	OncObesity and Metabolism PROGRAMS 2, 4, 5	Dr. Raúl M. Luque Huertas (PI) Dr. Manuel David Gahete Ortiz (ER)
GE01	Oxidative stress and nutrition PROGRAMS 1, 2, 5	Dr. Isaac Túnez Fiñana (PI)
GE02	Preventive Medicine and Public Health PROGRAM 1	Dr. Bernardo R Guzmán Herrador (PI)
GE03	Skin immune mediated inflammatory diseases (SIMID) PROGRAMS 4, 5	Dr. Juan A. Ruano Ruiz (PI)
GE04	Applied psychology PROGRAMS 1, 2	Dr. Bárbara Luque Salas (PI)
GE05	Diseases of the genitourinary system PROGRAMS 2, 4	Dr. María José Requena Tapia (PI)
GA01	Lung transplantation. Thoracic malignancies PROGRAMS 3, 4	Dr. Ángel Salvatierra Velázquez (PI) Dr. Paula Moreno Casado (ER)
GA02	Comprehensive care nurses - a multidisciplinary perspective PROGRAMS 1, 2, 5	Dr. M ^a Aurora Rodríguez Borrego (PI)
GA03	Pneumology PROGRAMS 2, 4, 5	Dr. Bernabé Jurado Gámez (PI)
GA04	Endocrinology and nutrition. Insulin resistance, diabetes and metabolism PROGRAMS 1, 2	Dr. M ^a Ángeles Gálvez Moreno (PI)




CODE	GROUP and PROGRAMS	PRINCIPAL INVESTIGATOR(s)
GA05	Study of growth. Endocrinology and child nutrition PROGRAM 2	Dr. Ramón Cañete Estrada (PI)
GA06	Clinical analysis PROGRAMS 1, 2	Dr. Fernando Rodríguez Cantalejo (PI)
GA07	Visual Quality PROGRAM 3	Dr. José M ^a Gallardo Galera (PI)
GA08	Radiology PROGRAMS 4, 5	Dr. Daniel López Ruiz (PI)
GA09	Cardiovascular Pathology PROGRAMS 3, 5	Dr. Ignacio Muñoz Carvajal (PI)
GA10	Nuclear Medicine PROGRAMS 2, 4	Dr. Juan A. Vallejo Casas (PI)
GA11	Learning and Artificial Neural Networks-AYRNA PROGRAM 3	Dr. César Hervás Martínez (PI)
GA12	Severe Mental Illness-Health alerts PROGRAM 5	Dr. Fernando Sarramea Crespo (PI)

New entries in 2018 and begin in 2019:

CODE	GROUP and PROGRAMS	PRINCIPAL INVESTIGATOR(s)
GE06	Pathophysiology of renal and vascular damage PROGRAMS 1, 3, 5	Dr. Juan Antonio Moreno Gutiérrez (PI)







STAFF

Staff

TOTAL* 807

*This data includes everything the staff enrolled in IMIBIC groups as well as the staff that integrates the IMIBIC Structure



1. PREDOCTORAL RESEARCHERS (R1)
2. POSTDOCTORAL RESEARCHERS (R2)
 - 2.1 POSTDOCTORALS I (< 3 YEARS) (R2A)
 - 2.2 POSTDOCTORALS II (> 3 YEARS) (R2B)
3. RESEARCHERS (R3)
 - 3.1 RESEARCHERS (R3A)
 - 3.2 ASSOCIATED GROUPS LEADERS (R3B)
 - 3.3 EMERGING RESEARCH (R3C)
 - 3.4. EMERGING GROUP LEADERS (R3D)
4. CONSOLIDATED GROUPS LEADERS (R4)
5. TECHNICAL SUPPORT (T)
6. CORE FACILITIES (UCAIB)
7. MANAGEMENT STAFF (MS)






GOALS
ACHIEVED
IN 2018

End of 2018		
<p>1. To promote and consolidate human resource integration in the institution (See Plan 1. To promote and consolidate human resource integration in the institution (See Integration Plan _ OE.1 actions 10,11 and 13)</p>	<p>Goal to be achieved</p> <p>-Action 10. To create Corporate Social Responsibility (CSR) project synergies between IMIBIC institutions, in particular, to develop and implement a Transparency and Equality Plan</p> <p>- Action 11. To offer IMIBIC professionals social benefits based on pre-existing agreements between the member institutions and other businesses (e.g. special arrangements with financial institutions, travel agencies, hotels, etc.)</p> <p>- Action 13. To foster strategic partnerships promoted by the institution for the development of collaborative ventures and activities with businesses (e.g. the Roche Grant "Stop the Brain Drain")</p>	<p>-Action 10. To create Corporate Social Responsibility (CSR) project synergies between IMIBIC institutions, in particular, to develop and implement a Transparency and Equality Plan.</p> <p>The Equality Plan was presented to the FIBICO-IMIBIC Quality Committee and is expected to be implemented by the end of the year.</p> <p>A series of meetings has been held with the Environmental Management Unit of the HURS (Hospital Universitario Reina Sofía) to deal with energy efficiency issues in the organization and to coordinate waste collection from the IMIBIC animal facility.</p> <p>- Action 11. To offer IMIBIC professionals social benefits based on pre-existing agreements between the member institutions and other businesses (e.g. special arrangements with financial institutions, travel agencies, hotels, etc.)</p> <p>Training courses have been organized with suppliers of both institutions. Likewise, at FIBICO, we called for tenders for the supply of gases and the contract was awarded to the same supplier of medical gases that supplies the HURS. Since they maintain infrastructures in the hospital, we have been able to take advantage of more economical prices. We are also waiting for tenders for the Natural Gas contract, with competitive prices deriving from the contract that the same company has with the UCO. Furthermore, we and the HURS jointly negotiated a contract to supply diagnostic kits for the early detection of breast cancer and this will be analyzed jointly by the HURS and the IMIBIC. This would represent a significant saving for the HURS and provides an opportunity to develop this technique in the Institute.</p> <p>- Action 13. To foster strategic partnerships promoted by the institution for the development of collaborative ventures and activities with businesses (e.g. the Roche Grant "Stop the Brain Drain")</p>
<p>2. To develop strategies to increase the quality and number of scientific publications and the leadership of IMIBIC researchers in this area</p>	<p>50 articles in the top decile</p>	<p>92 articles in the top decile as of December (18% in the top decile)</p>
<p>3. To promote and improve clinical research at the IMIBIC by increasing the development, quality and efficiency of independent clinical research projects</p>	<p>≥ 11 trials as trial promoter.</p>	<p>≥ 11 trials as trial promoter.</p>
<p>4. To promote and improve the self-sustainability of the IMIBIC via optimization of internal resource management, attraction of more European and competitive public funding and by fostering partnerships with the business world</p>	<p>Core funding ≥ 2.1 million euros Revenue from private/public activity ≥ 44%</p>	<p>Core funding ≥ 2.1 million euros (2018) Revenue from private/public activity ≥ 62% (2018)</p>



End of 2018		
<p>5. Development of a strategy for the incorporation of new university and clinical groups, and to promote those that already exist</p>	<p>2 new research groups (at least one emerging group)</p>	<p>-One new emerging research group GE06 Pathophysiology of renal vascular disorders * One new Associated Group from the University Hospital Reina Sofía: GA12 Mental Health Alert</p>
<p></p>	<p>1 promoted group</p>	<p>* Two promoted groups: GC26 led by Dr. Antonio Rivero, and GC27 led by Dr. Raúl M. Luque</p>
<p>6. To increase recruitment of talented researchers and promote their professional development</p>	<p>Human resources funded through competitive calls > 66</p>	<p>Human resources funded through competitive calls > 69</p>
<p>7. To foster, define and consolidate international research alliances and partnerships</p>	<p>Apply for 38 projects</p>	<p>Applied for 35 projects in international calls</p>
<p>8. To promote and increase the protection of intellectual property generated and the transfer of technology to the business community</p>	<p>>20% of patents exploited</p>	<p>22% of patents exploited</p>
<p>9. To guarantee the quality of service provided by the central biomedical research support unit (UCAIB) and management units of the Institute and to stimulate innovation through transversal collaboration</p>	<p>User satisfaction ≥ 85%</p>	<p>User satisfaction ≥77%</p>
<p>11. To develop and implement an action plan to promote research in primary care and nursing</p>	<p>Active projects > 7</p>	<p>Active projects > 9 (Including those that are FIBICO Primary Care)</p>






05

PLATFORMS
AND NETWORKS

IMIBIC researchers are involved in a wide range of strategic initiatives coordinated by the National Institute of Health Carlos III (ISCIII) and they participate in its National Research Networks program, through the Networks for Cooperative Research in Health (RETICs in Spanish) and the Biomedical Research Networking Centers (CIBERs in Spanish). In addition, IMIBIC is member of the new platforms that support research in health sciences and technologies.

Among the 44 (27GC, 5GE, 12GA) groups integrated in the IMIBIC, 23 participate in partnership programs related to different ISCIII strategic initiatives. 12 groups are involved in 8 different RETICs. Additionally, 11 groups are involved in 5 CIBERs and there are 35 groups involved in the Andalusian Plan for Research, Development & Innovation (PAIDI Program).



CIBER Program

Our researchers lead the following CIBER nodes:

Principal Investigator (PI) / Collaborators

CIBER on Obesity and Nutrition (CIBERobn)

- José López Miranda (PI)
- Manuel Tena-Sempere (PI)
- Mercedes Gil Campos (PI)
- M^a Mar Malagón Poyato
- Justo P. Castaño Fuentes

CIBER on Liver and Digestive Diseases (CIBERehd)

- Manuel de la Mata García (PI)

CIBER on Rare Diseases (CIBERER)

- Eduardo López Laso
- Rafael Camino León

CIBER on Fragility and Healthy Aging (CIBERFES)

- José Manuel Quesada Gómez (PI)
- Feliciano Priego Capote

CIBER on Cancer (CIBERONC)

- Enrique Aranda Aguilar (PI)

CIBER on Mental Health CIBERSAM

- Fernando Sarramena Crespo

RETICS Program

List of ISCIII thematic network centers that IMIBIC is involved in:

Principal Investigator (PI)/ Collaborators

AIDS Research Network (RIS)

- Antonio Rivero Román (PI)

The Spanish Renal Research Network (REDinREN)

- Pedro Aljama García (PI)
- Mariano Rodríguez Portillo

Spanish Network for Research in Infectious Diseases (REIPI)

- Julián de la Torre Cisneros (PI)
- Rafael Solana Lara
- Luis Martínez Martínez

The Spanish National Biobank Network

- Manuel Medina Pérez

Primary Care Prevention and Health Promotion Network (RedIAPP)

- Luis A. Pérula de Torres

Spanish Network for asthma, adverse and allergic reactions (ARADYAL)

- Carmen Moreno Aguilar (PI)

The Research Network for Inflammation and Rheumatic Diseases (RIER)

- Eduardo Collantes Estévez (PI)

The Spanish Network of Multiple Sclerosis (REEM)

- Eduardo Agüera Morales (PI)
- Túnez Fiñana

Healthcare Research Unit (Investén-ISCIII)

- Manuel Rich Ruiz

Eye Diseases: Prevention, early detection and treatment of prevalent, degenerative and chronic ocular pathology
OFTARED ISCIII

- José María Gallardo Galera (PI)

PLATFORMS

IMIBIC has become member of the following new platforms that support research in health sciences and technologies of the National Institute of Health Carlos III:

- » Medical Technology Innovation Platform (ITEMAS)
- » Clinical Research and Clinical Trials Units Platform —SCReN

The Andalusian Plan for Research, Development and Innovation (PAIDI)

Many IMIBIC researchers belong to or lead groups formed under the Andalusian Plan for Research, Development and Innovation (PAIDI, in Spanish).

» **BIO-139. Principal investigator.**

Justo P. Castaño Fuentes

» **BIO-139. Collaborator.**

María Del Mar Malagón Poyato

» **BIO-216. Principal investigator.**

José Antonio Bárcena Ruiz

» **BIO-272. Principal investigator.**

Manuel Ruiz Rubio

» **BIO-301. Principal investigator.**

Rafael Rodríguez Ariza

» **BIO-310. Principal investigator.**

Manuel Tena Sempere

» **BIO-304. Collaborator.**

Ángel Salvatierra Velázquez

» **CTS-208. Collaborator.**

Rafael Solana Lara

» **CTS-179. Principal investigator.**

Escolástico Aguilera Tejero

» **CTS-212. Principal investigator.**

Pablo Pérez Martínez

» **CTS-273. Principal investigator.**

Manuel de la Mata García

» **CTS-234. Principal investigator.**

Enrique Aranda Aguilar

» **CTS-260. Principal investigator.**

Pedro Aljama García

» **CTS-273. Collaborator.**

Francisco Javier Briceño Delgado

» **CTS-329. Principal investigator.**

Ramón Cañete

» **CTS-413. Principal investigator.**

José Manuel Quesada Gómez

» **CTS-452. Principal investigator.**

Luis A. Pérula de Torres

» **CTS-525. Principal investigator.**

José López Miranda

» **CTS 550. Principal investigator.**

Fernando Sarramea

» **CTS-639. Principal investigator.**

María Mercedes Gil Campos

» **CTS-620. Principal investigator.**

Francisco Velasco Gimena

» **CTS-624. Principal investigator.**

Isaac Túnez Fiñana

» **CTS-647. Principal investigator.**

Julián Carlos de la Torre Cisneros

» **CTS-651. Principal investigator.**

Juan Antonio Paniagua González

» **CTS-666. Principal investigator.**

Aurora Rodríguez Borrego

» **CTS-985. Principal investigator.**

José Peña Amaro

» **CTS-992. Principal investigator.**

Bernabé Jurado Gámez

» **CTS-1004. Principal investigator.**

Eduardo Collantes Estevez

» **CTS-1041. Principal investigator.**

Juan Alberto Ruano Ruiz

» **FQM-227. Principal investigator.**

María Dolores Luque de Castro

» **HUM-414. Principal investigator.**

Carmen Taberero Urbieto

» **HUM-924. Principal investigator.**

Juan Antonio Moriana

» **TIC-122. Principal investigator.**

Sebastián Ventura Soto


» **TIC-148. Principal investigator.**

César Hervás Martínez

» **TIC-161. Principal investigator.**

Rafael Medina Carnicer






106

FUNDING

The year 2018 has been a year of consolidation for the economic structure of IMIBIC. After the period between 2013 and 2015 in which the budget of the Institute was strongly marked by obtaining extraordinary funding for the development of 3 Pre-commercial Public Procurement projects, for a total of 9 million euros, the funding raised for the 2018 has managed to reach similar levels. It is also noteworthy to mention that the funding from private sources has increased.

The evolution of the funding raised since 2012:


	2012	2013	2014	2015	2016	2017	2018
TOTAL FUNDS RAISED	11.277.608,23	18.499.562,55	12.424.933,05	11.325.478,50	10.351.059,17	9.628.230,27	9.873.721,68



Considering that the above mentioned figures include also the funding raised for the acquisition of infrastructures (i.e. scientific equipment), we consider presenting the same figures without the budget item for infrastructures. This

allows to evaluate the growth and capacity to attract specific financing for the development of R & D projects. The total funds raised, excluding the funds for infrastructures, has been as follows:


	2012	2013	2014	2015	2016	2017	2018
TOTAL FUNDS RAISED WITHOUT INFRASTRUCTURE	4.231.754,11	9.535.436,81	8.915.342,79	11.175.450,2	9.616.514,4	9.628.230,27	9.873.721,68



The division of the funds is as follows:

PUBLIC	5.330.188,56
Regional	1.353.135,00
National	3.927.053,56
International	50.000,00
PRIVATE	4.543.533,12
Investigación Clínica	2.471.922,79
Contratos con Empresas y Donaciones	2.071.610,33


Similar to previous years, the balance between private and public funding shows that public funding remains higher than private funding. However, an increase in obtaining private funding in the last year can be observed:



	2012	2013	2014	2015	2016	2017	2018
PUBLIC	65%	77%	70%	76%	70%	65%	54%
PRIVATE	35%	23%	30%	24%	30%	35%	46%

Regarding private funding from industry for the development of clinical studies, it is evident from the figures presented in the following table and the results reflecting the development of the institution's Plan for Clinical Research, that there has been growth in the amount of raised funds over the last years. This fact is due to IMIBIC is taking appropriate measures to reactivate the attraction of funding from industry:

PRIVATE FUNDS	2012	2013	2014	2015	2016	2017	2018
Clinical Research	975.149,79	1.132.818,84	1.772.682,05	1.786.513,67	1.689.229,30	1.789.050,00	2.471.922,79
Contracts with companies and donations	491.816,75	1.014.231,85	882.070,62	870.238,09	985.203,45	1.607.453,56	2.071.610,33



○ Clinical Research ● Contracts & Donations



077

INSTITUTIONAL
PROJECTS



HR EXCELLENCE IN RESEARCH

HRS4R Human Resources Strategy for Researchers


WEB

<https://www.imibic.org/ofertasempleo/index>

IMIBIC is awarded with the logo “**HR Excellence in research**” since 2017.

All activities was included in the 2016-2020 Strategy Plan IMIBIC.





RECURRENT TRAINING

contents

- 1. Introduction
- 2. Training Programmes
- 3. Training Activities
 - 3.a. Courses and Workshop
 - 3.b. Events and conferences
 - 3.c. Other activities
 - 3.d. IMBIC Research Seminars
- 4. Institutional Events
- 5. Results of the Training Activities
 - 5.a. Doctoral Theses
 - 5.b. Research Stays

1. Introduction

The Institute conceives training as a fundamental institutional tool to fulfil and improve its scientific goals. Thus, a multifaceted program is designed on an annual basis to foster and provide high-quality scientific training to our researchers, which is adapted to the different stages of their scientific career. It includes the organization of an annual program of seminars by known national and international leaders in trending scientific topics, and courses that cover concepts related to our current lines of research as well as practical applications on the latest technologies. Along with these activities, the Institute maintains two key training activities: the annual Young Investigators Meeting, aimed at fostering the interaction and exchange of knowledge among our youngest researchers, and the “Maimonides Commemorative Lecture” which includes lectures by leading experts in Biomedicine, and is intended to recognize and award our top scientists. Finally, the IMIBIC is responsible of a PhD Program in Biomedicine and also participates in two additional PhD programs of the University of Cordoba, that, in all, are aimed to train highly qualified researchers, promote teaching and favour professional qualification in the field of biomedical sciences.

The Training Program Director: **Prof. Raúl M. Luque Huertas, PhD.**

2. Training Programmes

2.a. PhD in Biomedicine

IMIBIC leads a unique PhD Program in Biomedicine. This program, coordinated by Prof. Dr. Pablo Pérez Martínez, aims to train qualified professionals and to promote the development of professional skills in the field of biomedical sciences.

Website: <https://www.uco.es/estudios/idep/doctorado-programas-biomedicina>

2.b. Master's Degrees

The Master's Degree Program associated to the IMIBIC encompasses three degrees, one of them led by a member of the IMIBIC, as follows

- Translational Biomedical Research

Academic Director: **Prof. Raúl M Luque Huertas, PhD. (IMIBIC)**

Website: <https://www.uco.es/estudios/idep/investigacion-biomedica-traslacional>

3. Training Activities

3.a. Courses and Workshops

Specific courses, seminars and other training activities in different research areas were held during 2018 at the IMIBIC.

TITLE	DURATION	ORGANIZER
Evaluación neuropsicológica tractográfica: Metodología y Aplicaciones	4 h	IMIBIC-UCO
Actualización en VIH y VHC para Especialistas en Drogas y Adicciones	3,5 h	IMIBIC
Prevención de Riesgos Laborales para personal de trabajo de oficina	1 h	IMIBIC-QuirónPrevención
Prevención de Riesgos Laborales para personal de trabajo de laboratorio	3 h	IMIBIC-QuirónPrevención
Sesión informativa sobre la Nueva Ley de Contratos del Sector Público	1 h	IMIBIC
Sistematic reviews and meta-analyses course	7,9 créditos	IMIBIC
Interpretación de datos ómicos en medicina de sistemas: modelos de pathways	5 h	IMIBIC
Talleres de formación en gestión clínica en los servicios de urgencias de atención primaria y hospitales	12 días	IMIBIC-HURS
CVN para convocatorias nacionales: Como cumplimentarlo correctamente	2 h	IMIBIC
Control de calidad con los centros de ensayos clínicos	1 h	IMIBIC
De Maimónides a Einstein, las mismas preguntas	1 h	IMIBIC
Elaboración de protocolos en ensayos clínicos	1 h	IMIBIC
Pilotaje de la app mlistable en CMA cataratas		IMIBIC
Scientific communication: Getting started Writing & Speaking	16 h	IMIBIC - Fundación Dr. Antoni Esteve
Medicina Personalizada de Precisión: Claves para la Traslación de la Investigación Biomédica a la Aplicación Clínica en el Paciente	5 h	IMIBIC
Riesgos y medidas preventivas frente al Acoso Laboral (enquadramiento, procedimiento de actuación y prevención)	5 h	IMIBIC
Presentación convocatoria de ayuda de Innovación de la Consejería de Salud	2 h	IMIBIC
III Curso teórico-práctico del tratamiento del queratocono	2 h	IMIBIC-HURS
Curso de Bioestadística Básica en Investigación Biosanitaria	7 días	IMIBIC
Evaluación biomecánica de la movilidad espinal.	5 h	IMIBIC



TITLE	DURATION	ORGANIZER
Bench to bedside: Experiencias de innovación aplicada Ponente: David Cotán - CSO in Pronacera Therapeutics S.L. & CSO in SINAEL SL	1 h	IMIBIC
Curso de PRL específico de riesgos biológicos	1 h	IMIBIC
Evaluación biomecánica de la movilidad espinal.	5 h	IMIBIC
El reto de la innovación en salud Ponente: Annarita Gabriele - Directora médica de Roche	1 h	IMIBIC
Bench to bedside: Experiencias de innovación aplicada Ponente: David Cotán - CSO in Pronacera Therapeutics S.L. & CSO in SINAEL SL	1 h	IMIBIC
Riesgos y Medidas Preventivas en el puesto de trabajo de oficina	1 h	IMIBIC
Simposio "La medicina y la investigación biomédica del futuro"	6 h	IMIBIC-COLEGIO DE MÉDICOS
III Curso Iberoamericano. Knee & Hip Concepts	10 h	IMIBIC
Taller sobre investigación clínica: cómo poner en marcha un estudio clínico	1 h	IMIBIC
"Cómo y dónde publicar literatura científica. Analizando la producción Científica del SSPA"	4 h	IMIBIC-BVSSPA
Publicación de resultados de citometría de flujo ¿qué debemos considerar?	3 h	IMIBIC
El papel de la Bioestadística en la Investigación Biomédica	1 h	IMIBIC
El Proceso de transferencia de resultados de investigación en biomedicina	1 h	IMIBIC
Funcionamiento, reglamento y composición del Comité para la Integridad de la Investigación	1 h	IMIBIC – Comité para la integridad de la Investigación
Análisis de datos procedentes de estudios observacionales	10 h	IMIBIC
Análisis de viabilidad de proyectos biotecnológicos	4,5 h	IMIBIC
Nuevos abordajes de la fatiga en la Esclerosis Múltiple	8 h	IMIBIC
Manejo de Insectos Himenópteros en Alergia (MIHA)	4 h	IMIBIC-HURS
III Curso Iberoamericano de cadera y rodilla	2 días	IMIBIC-HURS-EXACTECH
Curso sobre Oftalmología. Allergan	4 h	IMIBIC-ALLERGAN
Jornada de Investigación Traslacional Enfermedades Raras	10, 5 h	IMIBIC-CIBERER
Escenarios Clínicos De La Práctica Diaria En Diabetes Tipo 2	4,5 h	IMIBIC-HURS
Manejo del Riesgo Cardiovascular	4 días	IMIBIC-Ferrer

3.b. Events and conferences

TITLE	DURATION	ORGANIZER
Actualización en VIH y VHC para Especialistas en Drogas y Adicciones	4,5	IMIBIC
Controversias en cáncer colorrectal	7 h	IMIBIC- Universidad Francisco de Vitoria
Abordaje Multidisciplinar de las Enfermedades Dislipémicas Raras	5,5 h	IMIBIC-HURS
II Ciclo de Conferencias Tribuna Joven sobre Seguridad Alimentaria y Salud	5 días	IMIBIC- Real Academia de Ciencias, Bellas Letras y Nobles Artes de Córdoba
Abordaje Multidisciplinar de las Enfermedades Dislipémicas Raras	6,5	IMIBIC-HURS
Interpretación de datos ómicos en medicina de sistemas: modelos de pathways	4 h	IMIBIC
XVIII Jornadas de Medicina Familiar y Comunitaria de Córdoba	16,5 h	IMIBIC
Décimo aniversario IMIBIC	1 h	IMIBIC
Formación Educadores para el Tratamiento Grupal de la Obesidad Infantil	20 h	IMIBIC-HURS
Acto de despedida de los residentes	1,5 h	IMIBIC-HURS
Medicina Personalizada de Precisión: Claves para la Traslación de la Investigación Biomédica a la Aplicación Clínica en el Paciente	5 h	IMIBIC-ROCHE
IX Jornadas de Jóvenes Investigadores	17 h	IMIBIC
Reunión Regional sobre Enfermedad de Fabry	5 h	IMIBIC-HURS
Seminario PROMEGA: ANALISIS CELULAR	3,5 h	IMIBIC
IV Premio de Innovación Biomédica IMIBIC-ROCHE	4 h	IMIBIC-ROCHE
Jornada Medicina del Futuro (Trashumanismo)	11,5 h	IMIBIC
Jornada de Diabetes	5 h	IMIBIC - HURS, DS Córdoba-Guadalquivir - AGS Norte Córdoba y AGS Sur de Córdoba
Reunión sobre Asistencia Ventricular e Insuficiencia Cardíaca severa	5 h	IMIBIC- Medtronic, Salvador Mercé - Novartis y Servier
Lección Conmemorativa Maimónnides	2,5 h	IMIBIC
Nuevos abordajes de la fatiga en la Esclerosis Múltiple	8 h	IMIBIC-HURS
Proyecto Europeo FAME	10 h	IMIBIC-HURS
PLR Gestión del Estrés	4 h	IMIBIC-QuirónPpublicar revención



3.c. Other activities

TYPE OF ACTIVITY	TITLE	DURATION	ORGANIZER
INFO SESSION	Presentación de la Acción Estratégica en Salud	-	Instituto de Salud Carlos III
CLINICAL SESSION	Reunión con Silvia Rubio NOVARTIS “CLINICAL QUESTION”	5 h	IMIBIC-Novartis
INFO SESSION	II Jornada de puertas abiertas para futuros residentes	3,5 h	IMIBIC-HURS
INFO SESSION	Sesión informativa sobre la Nueva Ley de Contratos del Sector Público	1 h	IMIBIC
-	Paseo por la Ciencia	8 h	Ayuntamiento de Córdoba y la Asociación del Profesorado de Córdoba por la Cultura Científica
TYPE OF ACTIVITY	TITLE	DURATION	ORGANIZER
CLINICAL SESSION	Control de calidad con los centros de ensayos clínicos	1 h	IMIBIC
INFO SESSION	Presentación de la convocatoria de financiación de proyectos de investigación	1 h	IMIBIC
INFO SESSION	Renovación Tecnológica en Oncología Radioterápica	2 h	IMIBIC-HURS
INFO SESSION	Bienvenida de residentes	1 h	IMIBIC
INFO SESSION	Entrega premio FPS/Roche en IMIBIC	6 h	IMIBIC-Roche

3.d. IMIBIC Research Seminars

Regular seminars and research events offer the opportunity to meet recognized national and international speakers covering a diverse range of topics in biomedicine. IMIBIC research seminars promote networking and contribute to strengthen the knowledge of the research community of the Institute. The Institute launches a yearly cycle of seminars aimed at promoting interactions, sharing ideas, and strengthening the bonds among IMIBIC scientists and recognised scientist from other research institutions. In 2018, a total of 20 external seminars were presented.

In addition, young researchers (preferentially post-doctoral researcher) of our Institute have the opportunity to present their ongoing studies in a fortnight-scheduled cycle of intramural seminars, which was launched for the first time in 2015. In 2018, a total of 8 intramural seminars were held.

JANUARY	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
Date: 09 de enero de 2018 - 13:00h Speaker: Dra. Laura López Sánchez Group: GC06 Title: “Nitric oxide and tumor stem cells in breast cancer: Therapeutic implications”.	Date: 11 de Enero de 2018 Speaker: Alexander Leemans Organisation: Instituto de Ciencias de la Imagen (PROVIDI) Title: Key concepts and practical considerations of data processing and analysis of diffusion MRI data
Date: 16 de enero de 2018 – 13:00h Speaker: Dra. Raquel Requejo Aguilar Group: GC02 Title: “mTOR activation as trigger of neurodegenerative processes associated to Parkinson’s disease”.	Date: 19 de Enero de 2018 Speaker: Miguel López Organisation: Universidad de Santiago de Compostela/ CIMUS Title: Es AMPK hipotalámica una diana para tratar la obesidad?
	Date: 25 de Enero de 2018 Speaker: Joaquin Dopazo Organisation: Fundación Progreso y Salud Title: Precision medicine, systems medicine and genomic big data
Date: 30 de enero de 2018 – 13:00h Speaker: Dr. Juan Roa Rivas Group: GC10 Title: “Metabolic Regulation of Puberty via Hypothalamic AMPK-Kisspeptin Signaling”.	

FEBRUARY	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Date: Jueves, 1 de Febrero de 2018 - 13:00h. Speaker: Lluis Montoliu Organisation: CBN, Madrid. Title: Preclinical models for the study of rare diseases
	Date: Jueves, 15 de Febrero de 2018 Speaker: María Blasco Organisation: Directora del CNIO Title: Telomeres as therapeutic targets in cancer and aging
Date: 20 de febrero de 2018 – 13:00h Speaker: Dra. Valeria Barresi Group: Universidad de Messina Title: “Molecular Markers and Targets in Gliomas”	Date: Jueves, 22 de Febrero de 2018 Speaker: Paolo Giaconini Organisation: INSERM, Lille (Francia). Title: Pathophysiology of the polycystic ovary syndrome: Lessons from preclinical models



MARCH	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	<p>Date: Jueves, 1 de Marzo de 2018 Speaker: Francisco Real y Nuria Malats Organisation: CNIO Title: Understanding human pancreatic ductal adenocarcinoma (PDAC) through the study of genetic mouse models” y “Understanding human PDAC aetiology through the study of human models</p>
	<p>Date: Martes, 6 de Marzo de 2018 Speaker: Rubén Nogueiras Organisation: Universidad Santiago de Compostela Title: Role of p53 in Energy Balance</p>
	<p>Date: Jueves, 15 de Marzo de 2018 Speaker: Beatriz Martín Antonio Organisation: Hospital Clinic de Barcelona Title: Immune cell-tumor cell communication. Implications for immunotherapy and tumor cell survival mechanisms</p>
	<p>Date: Jueves, 22 de Marzo de 2018 – 13:00h. Speaker: Guillermo López Lluch Organisation: Universidad Pablo de Olavide Title: Mitochondrial pathology due to deficiency in coenzyme Q10</p>

APRIL	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	<p>Date: Miércoles, 4 de Abril de 2018 – 13:00h. Speaker: Mayte Suárez-Fariñas Organisation: Icahn Institute for Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai. New York, USA Title: “Of machine learning and epitopes: developing precision medicine algorithms to food allergy”</p>
	<p>Date: Jueves, 5 de Abril de 2018 – 15:30h. Speaker: Sonia Forcales Organisation: Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain Title: Chromatin regulators as biomarkers and combinatorial drug targets in colorectal cancer therapy</p>
	<p>Date: Jueves, 12 de Abril de 2018 – 13:00h. Speaker: Bruno Sainz Anding Organisation: Instituto de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM, Madrid, España Title: “The ever changing landscape of pancreatic cancer stem cells”</p>
<p>Date: 17 de abril de 2018 – 13:00h Speaker: Dr. Manuel Rodríguez-Perálvarez Group: GC02. Title: “Transplant, immunosuppression and cancer.”</p>	
	<p>Date: Jueves, 26 de Abril de 2018 - 13:00h. Speaker: Andrés Hidalgo Alonso Organisation: CNIC, Madrid Title: “Rhythms in immunity”</p>

MAY	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	<p>Date: Jueves, 3 de Mayo de 2018- 13:00h Speaker: Belén Gutiérrez Gutiérrez Organisation: UGC Enfermedades Infecciosas Hospital Universitario Virgen Macarena de Sevilla. Title: INCREMENT international project: Clinical management and treatment of bacteraemias caused by multiresistant enterobacteria</p>
<p>Date: 8 de mayo de 2018 – 13:00h Speaker: Dra. Mª Ángeles Riscalde Group: GC03 Title: “Study of new methods of diagnosis and control of zoonosis of medical and sanita importance”.</p>	

JUNE	
INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	<p>Date: Jueves, 7 de Junio de 2018 – 13.00h Speaker: Jesús S. Aguilar Ruiz Organisation: Universidad Pablo de Olavide, Sevilla Title: Data analytics: technological present and evolution in biomedicine</p>
	<p>Date: Jueves, 22 de Junio de 2018 – 13.00 Speaker: José Córdoba Chacón Organisation: Universidad Illinois chicago Title: Role of hepatic PPARGgamma in non-alcoholic steatohepatitis</p>
	<p>Date: Jueves, 28 de Junio de 2018 – 13.00h Speaker: Rafael Sánchez Sánchez Organisation: Biobanco del Hospital Universitario Reina Sofía. Title: Biobank: basic tool for research</p>

OCTOBER		
WEEK	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
22		<p>Date: Jueves, 7 de Junio de 2018 – 13.00h Speaker: Jesús S. Aguilar Ruiz Organisation: Universidad Pablo de Olavide, Sevilla Title: Data analytics: technological present and evolution in biomedicine</p>



4.b. Maimonides Commemorative Lecture and IMIBIC awards 2018

The aim of this initiative is to recognize the biomedical research carried out by IMIBIC staff and to emphasize the importance of the results obtained at the Institute. In 2018 the “Enrique Aguilar Benítez de Lugo” Prize was awarded to the most relevant scientific publication in collaboration with international groups, together with an Award for the best master’s degree thesis, and two Awards for the most relevant translational research results. A special price was also awarded to the most valuable news that had been published in press regarding IMIBIC activities.

In each edition, an outstanding biomedical scientist is invited to give the “Maimónides Lecture”, a conference focusing on the latest knowledge on basic, applied, and/or translational biomedical science of excellence. In 2018, the guest was Dr. Mariano Barbacid. Dr. Mariano Barbacid got his Ph.D. in Madrid’s Universidad Complutense (1974) and trained as a postdoctoral fellow at the US National Cancer Institute (1974-78). In 1978, he started his own research group to study the molecular events responsible for the development of human tumours. His work led in 1982, to the isolation of the first human oncogene and the identification of the first mutation associated with the development of human cancer. These findings, also made independently by two other groups, have been seminal to establish the molecular bases of human cancer.

He is also credited with the isolation of the TRK oncogene from a colon carcinoma. This work led 30 years later to a new paradigm of tumorigenic therapies thanks to the development of selective inhibitors by Loxo and Ignyte, two biotech companies. The discovery of the TRK oncogene also led to the identification of the TRK family of tyrosine protein kinase receptors as the functional receptors for the NGF family of neurotrophins.

In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In this position, he pioneered the development of what we know now as targeted therapies. In 1998, he returned to Madrid

VIII LECCIÓN CONMEMORATIVA MAIMÓNIDES Y PREMIOS IMIBIC 2018

17 de diciembre. Salón de Actos IMIBIC

PROGRAMA

10:30h Acto de apertura

10:45h Presentación y entrega de premios anuales

- **Premio al mejor Trabajo de Máster defendido en 2016/2017**
Antonio Carlos Fuentes Fayos
“Desregulación de la maquinaria de splicing en astrocitomas: Efecto modulador de las biguanidas”
- **Premio a la traslacionalidad de los resultados de investigación**
Rafael Medina Carnicer. GC19
“Surgical robotic system and method for handling a surgical robotic system”
- **Premio al trabajo periodístico de mayor valor para el IMIBIC**
Francisco José Durán López
Entrevista a Luis Martínez. “Encontrados nuevos mecanismos de defensa frente bacterias resistentes a antibióticos”
- **Premio a la publicación científica más relevante en colaboración con grupos internacionales**
Raúl M. Luque Huertas. GC27
“The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness”
- **Premio a “Enrique Aguilar Benítez de Lugo” a la publicación más relevante**
Juan Miguel Díaz Tocados. GC13
“Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats”

12:00h Lección Conmemorativa Maimónides
Dr. Mariano Barbacid (CNIO)

13:00h Acto de Clausura



to create and direct the Spanish National Cancer Research Center (CNIO) which in less than 10 years became one of the top cancer research centres in the World.

In 2011, Barbacid stepped down as CNIO Director to return to his early research interests aimed at identifying novel therapeutic strategies against K-RAS mutant tumors. To this end, the Barbacid group has embarked in a long term project to validate the therapeutic potential of each member of the MAPK and PI3K pathways using genetically engineered mouse models of lung and pancreatic cancer that faithfully reproduce the natural history of the corresponding human tumors.

Barbacid was inducted to the US National Academy of Sciences as a foreign member in 2012 and in 2014, elected Fellow of the Academy of the American Association for Cancer Research. He holds Honorary Degrees from the Universidad Internacional Menéndez y Pelayo (1995), University of Cantabria (2011) and University of Barcelona (2014).

His work has been recognized by several domestic and international awards including the Steiner Prize (Bern, 1988), Ipsen Prize (Paris, 1994), Brupbacher Cancer Research Prize (Zurich, 2005), the Medal of Honor of the International Agency for Cancer Research (Lyon, 2007) and the Burkitt Medal (Dublin, 2017). In 2011, he received an Endowed Chair from the AXA Research Fund (Paris)



5. Results Of The Training Activities

5.a. Doctoral Theses

The Institute holds the PhD Program on Biomedicine, which helps prepare young scientists in biomedical and clinical research. Experienced mentors in the IMIBIC supervise the research training in health and health-related areas of a considerable number of pre-doctoral students. A list is provided below of the 26 Doctoral Theses supervised by researchers from the Institute that were presented in the course 2017/2018.

DOCTORANDO/A	TÍTULO TESIS	DIRECTORES		
Eloisa Clementina López Medina	Evaluación de Comorbilidades en la espondiloartritis *	Eduardo Collantes Estevez		
Sonia García Carpintero Fernández Pacheco	IDENTIFICACION DEL PATRON DE MICROBIOTA INTESTINAL PARA LA PREDICION DEL DESARROLLO DE SINDROME METABÓLICO Y SU MODULACION POR LA DIETA *	Francisco Pérez Jiménez	Antonio Camargo García	
Fakhri Hassouneh	Senescence of cytotoxic lymphocytes changes and role of CMV *	Rafael Solana Lara		
Eleonor Helena Rivin del Campo	Control de Calidad de la Radioterapia de Cáncer de Cervix – Radiotherapy Quality Control in Cervical Cancer *	María Martínez-Paredes	Amalia Palacios Eito	Eric Deutsch
Andrés Carmona Muñoz	Implicación de las microvesículas endoteliales en el desarrollo de daño vascular	Pedro Aljama García	Julia Carracedo Añón	
Maria Dolores Carmona Luque	Estudio comparativo de los efectos de la Inyección Intramiocárdica de Células Mononucleadas derivadas de Médula Ósea, Células Mesenquimales derivadas de Médula Ósea y Células Mesenquimales derivadas de Tejido Adiposo sobre la Recuperación Funcional y Morfoestructural del Tejido Cardíaco en un Modelo Murino de Miocardiopatía Dilatada.	Inmaculada Concepción Herrera Arroyo	Sonia Noguerras Martín	
M ^a Raquel Arias Vega	¿Cuál es la prevalencia y factores asociados a la litiasis renal en la población española de 40 a 65 años?. Un estudio realizado mediante encuesta telefónica personal. Estudio PreLiRenE	Luis Angel Pérula de Torres		
Francisco Carrasco Ávalos	La endocarditis infecciosa del siglo XXI: una entidad distinta a la clásica?	Manuel Anguita Sánchez	Manuel Pan Alvarez-Ossorio	



DOCTORANDO/A	TÍTULO TESIS	DIRECTORES		
Diana Moreno Muñoz	Análisis de la relación entre el sistema renina-angiotensina y la respuesta al tratamiento con antiangiogénicos en pacientes con cáncer colorrectal y cáncer de mama avanzado.	Enrique Aranda Aguilar	Juan Rafael De la Haba Rodríguez	
Jesús Serrano Merino	Calidad de vida en mayores de 65 años enfermos de SAHS en tratamiento con CPAP	Luís Ángel Pérula de Torres	Bernabé Jurado Gámez	
Francisco José Gómez García	Evaluación de la magnitud y la calidad de la evidencia de los estudios secundarios relacionados con la psoriasis: utilidad de las revisiones sistemáticas, los meta-análisis en red y los estudios meta-epidemiológicos	Antonio Vélez García-Nieto	Juan Ruano Ruiz	
Juan Eduardo Molina Alcaide	Impacto de la capacidad de fijación de C1q de los anticuerpos preformados específicos de don ante sobre la evolución del aloinjerto renal.	Rafael Solana Lara	Corona Alonso Díaz	
Jon Peñarando Sáez	ROLE OF NITRIC OXIDE IN THE BIOLOGY OF INTESTINAL CANCER STEM CELLS: NEW OPTIONS IN THE TREATMENT OF COLORECTAL CANCER *	Antonio Rodríguez Ariza	Enrique Aranda Aguilar	
Carmen Martínez Losada	Estudio molecular de leucemias agudas mieloblasticas de bajo riesgo *	Joaquín Sánchez García	Josefina Serrano López	Francesco Lo Coco
Jorge Duro Gómez	EFFECTIVIDAD Y SEGURIDAD DEL DOBLE BALÓN INTRACERVICAL, DE LA DINOPROSTONA 10MG Y DEL MISOPROSTOL 25MCG COMO MÉTODOS DE INDUCCIÓN DEL PARTO EN FETOS CIR A TÉRMINO (PESO FETAL ESTIMADO EN PERCENTIL <3 Y ESTUDIO DOPPLER NORMAL)	JOSÉ EDUARDO ARJONA BERRAL	CAMIL CASTELO BRANCO FLORES	
Francisco Javier González Gasca	La producción de interferón gamma por los linfocitos T CD8+ CMV - específicos confiere protección frente a la reactivación de citomegalovirus en el paciente crítico	Juan José Castón Osorio	Sara Cantisán Bohórquez	Julián de la Torre Cisneros
Diego Rodríguez Cano	BIOLOGÍA MOLECULAR DEL VIRUS DE LA HEPATITIS C EN LA TOMA DE DECISIONES CLÍNICAS	Antonio Rivero Román	Antonio Rivero Juárez	
Francisco de Borja Quero Espinosa	Valor diagnóstico del lenguaje de las manos en la evaluación inicial del dolor torácico de origen isquémico	José López Miranda	Francisco Javier Montero Pérez	
Francisco José Hidalgo Lesmes	Efecto del tratamiento precoz con bloqueadores beta más ivabradina frente a solo bloqueadores beta en pacientes hospitalizados con insuficiencia cardíaca y fracción de eyección deprimida	Manuel P. Anguita Sánchez	Manuel Pan Álvarez-Ossorio	
Carla Jiménez Jiménez	Identificación de marcadores predictivos en cáncer y enfermedad metabólica relacionados con la ruta de respuesta a hipoxia	Marco Antonio Calzado Canale	Eduardo Muñoz Blanco	



DOCTORANDO/A	TÍTULO TESIS	DIRECTORES		
Elena Gutiérrez Casado	Regulación fisiológica mitocondrial y de señalización autofágica a través de intervenciones nutricionales con diferentes fuentes lipídicas y antioxidantes *	José M. Villalba Montoro	Jose Antonio González Reyes	
Francisco José Castillo Bernal	“Endocarditis infecciosa en ausencia de lesión Cardíaca predisponente conocida: patogenia, Epidemiología y características clínicas. Conducta de los profesionales sanitarios ante las recomendaciones de profilaxis de endocarditis infecciosa en nuestro medio”	Manuel Pan Álvarez Ossorio	Manuel Anguita Sánchez	
Beatriz Gómez Marín	Influencia de un patrón de dieta saludable en la respuesta lipémica postprandial en pacientes con enfermedad cardiovascular establecida	Pablo Pérez Martínez	José López Miranda	
Javier López Moreno	Efecto de la grasa de la dieta sobre la endotoxemia y los niveles de los productos finales de glicación avanzada en pacientes con síndrome metabólico y en personas de edad avanzada	Pablo Pérez Martínez	Elena M. Yubero Serrano	Antonio Camargo García
Isabel Ruiz Sánchez	Variaciones en la expresión proteica de niños pre-puberales con déficit de GH y tras tratamiento con hormona de crecimiento	Ignacio Ortea García	Mercedes Gil Campos	Ramón Cañete Estrada
Diana Marisol Valencia Núñez	Inflamación y daño endotelial en Cirugía coronaria *	Julia Carracedo Añón	Pedro Aljama García	

* *Theses with International Mention*

5.b. Research Stays

IMIBIC is committed to foster training of our PhD students in national and international centers of reference in biomedical research in order to allow the opportunity to experience research in a foreign environment, facilitate the integration of graduates into the scientific community and create networks.

Twenty seven researchers from the IMIBIC completed a research stay in a national or international center in 2018.

3 of them were financed by public competitive grants, 2 by private competitive grants, 10 stays of doctoral students to obtain the international mention and 9 by the institutions own research visit grants.

Likewise, external visitors are invited to carry out their research in our Institute. Altogether 19 visiting scientists stayed at IMIBIC during 2018.





09

BIOMEDICAL
RESEARCH
SUPPORT UNITS

STAFF

Eduardo Muñoz Blanco, Phd
Supervisor

Antonia Sánchez Arroyo (til Nov 2018)
Operator

BRIEF DESCRIPTION

The unit has two laboratories dedicated to working with radioactive isotopes both μ and β . One is located on the -2 floor and the other on the third floor.

The unit has been authorized by the Nuclear Safety Council since December of 2014 to work with the following isotopes:

ISOTOPES	MAXIMUM ACTIVITY (Mbq)
Carbon (C-14)	370
Tritium (H-3)	370
Phosphorous (P-32)	370
Phosphorous (P-33)	370
Sulfur (S-35)	370
Chrome (Cr-51)	370
Iodine (I-125)	370

The Radiological Protection Service of the University of Córdoba is responsible for the supervision of this Unit and its operative procedures. The Service is also responsible for checking that the laboratories are free from contamination and is in charge of waste management and removal.

EQUIPMENT AND FACILITIES

» **Gamma Counters. 3 units:**
Brand: Wizard
Model: 2470-0100 Beta counter

» **UN Beta Counter.1 unit:**
Brand: Tricard
Model: 2810 TR

» **Microbeta Counter.1 unit:**
Brand: Microbeta2
Model: 2450-0020

» **Harvester Cell**

» **A sample preparer**
Brand: Janus

» **Two refrigerated ultracentrifuges with capacity for 200 samples.**

» **Three exclusive gas cabinets for working with radioactive isotopes, two of which are used with a lead guillotine and one with a methacrylate guillotine.**

» **Two radiation detectors:**
Brand: Lamse
Model: RM 10013-RDM

SERVICES

- » Training in the handling of μ and β counters.
- » Labeling of proteins with I-125.
- » Identification of protein levels in serum, plasma and other biofluidos using the RIA technique.
- » In situ hybridization (ISH) with P-33 labelled probes.
- » Radioactive techniques for analysis of cell death and proliferation.
- » Consultation regarding the different isotopic techniques that are employed in the laboratory.
- » Optimization of protocols.

The necessary infrastructure to house within the Animal Experimentation Unit a PET-RM and MicroTAC Preclinical Imaging Systems has been designed in collaboration with the Radiological Protection Service of the University of Córdoba and the Radio diagnostic and Nuclear Medicine Unit of the hospital. This work has been carried out in order to define the optimal equipment and workflows prior to the bidding process of said equipment.

STAFF

The Animal Experimentation Unit is composed of:

Director of SAEX
Ana M^a Molina López

Anabel Pozo Salas
sae@imibic.org

Estefanía Escudero Jabonero
sae@imibic.org

BRIEF DESCRIPTION

The animal experimentation unit is associated to the Animal Experimentation Service (SAEX) of the University of Córdoba.

The unit provides integral support to its users, at consultation and experimental levels, with the objective of carrying out research for the Institute and other associated organizations through the use of animal subjects, mainly rodents (mice and rats) and pigs.

EQUIPMENT AND FACILITIES

The unit comprises:

- » **7 rooms for housing rodents.**
- » **1 healing / metabolism room:** This room has a respirometry system, two racks for metabolic cages, optogenetics and quantitative analysis equipment as well as a bodily composition MRI.
- » **4 multi-purpose rooms:** These rooms have 2 rodent anesthesia system with 4 seats, 2 ductless fume hoods and 2 laminar flow cabinets among other equipment.
- » **1 micro-CT/PET/RMN**
- » **Operating Room:** Suitable for surgery in both rodents and larger animals, consisting of: 3 3D laparoscopy towers, 7 TV video monitors, 3 anesthesia machines for large animals, 6 surgery tables, 6 gas towers, 1 surgical microscope for large animals, 1 high-end ultrasound, 3 magnifiers, 1 microscope and 1 C-arm.
- » **Quarantine Zone:** 5 ventilated racks for rats / mice, 1 replacement cabinet and 1 triple gate SAS.
- » **In 2017**, coordinated by the Animal Experimentation Service of the University of Córdoba, the animal experimentation unit of IMIBIC obtained the favourable resolution to open its facilities.

HIGHLIGHTS

NUMBER OF
IMIBIC USERS **5**

STAFF

Esther Peralbo Santaella, PhD
Senior technician

Gema García Jurado, PhD
Microscopy technician

BRIEF DESCRIPTION

The Unit comprises two technological areas which are of great importance in the field of biomedical research, because they are a powerful tool for studies at cellular and tissue level.

- » Flow cytometry, including cell sorting.
- » Confocal/fluorescence microscopy.

The Unit offers access to specialized equipment in flow cytometry, cell sorting and confocal microscopy to IMIBIC researchers and external users, providing technical expertise and training. The Unit also provides scientific-methodological advice and support on experimental design, sample preparation, cytometry data analysis and image processing and analysis to develop efficient and reliable assays and to obtain high-quality results.

EQUIPMENT AND FACILITIES

» Flow Cytometry and Sorting Laboratory

Equipped with:

- BD LSR Fortessa SORP analyzer: 4 lasers and 20 detectors (18 fluorescence parameters + FSC/SSC).
- BD FACSCalibur analyzer: 1 laser and 5 detectors (3 fluorescence parameters + FSC/SSC).
- BC Cytomics FC500 MCL analyzer: 2 lasers and 7 detectors (5 fluorescence parameters + FSC/SSC).
- BD FACSAria III Cell Sorter: 3 lasers and 13 detectors (11 fluorescence parameters + FSC/SSC).

» Advanced Optical Microscopy Laboratory

Equipped with:

- Zeiss LSM 710 spectral confocal laser scanning microscope, with inverted motorized stand. 7 laser lines: 405, 458, 488, 514, 543, 594 and 633 nm. Scanning module with 3 spectral R/FL detection channels (PMTs) and 1 transmitted-light channel (PMT). Integrated large incubation chamber.
- Zeiss LSM 5 Exciter confocal laser scanning microscope, with inverted motorized stand. 6 laser lines: 405, 458, 488, 514, 543 and 633 nm. Scanning module with 2 R/FL detection channels (PMTs). Stage top incubator.
- Zeiss Axio Vert.A1 inverted fluorescence microscope.

MAIN SERVICES

- » Self-use (Operator-unassisted) of flow cytometry analyzers and microscopy equipment (only for internal users properly trained in using the equipment).
- » Operator-assisted use of the instruments.
- » Technical support for instrument setup and troubleshooting.
- » Cell sorting: only provided as a staff-assisted service.
- » Advice on experimental design, sample preparation methods, analysis and interpretation of flow cytometry data and microscopy image processing/analysis.

HIGHLIGHTS

In 2018, the Microscopy and Cytometry Unit provided scientific and methodological services and support to 13 consolidated groups and 1 emerging group of the IMIBIC. It also provided services to other external users: 2 research groups belonging to the University of Cordoba, and the biotechnology company Canvax Biotech S.L.

The Unit also continued its training and communication activity among researchers in connection with the technological areas of flow cytometry and microscopy. In 2018, as part of these activities, it organised a seminar on the proper use of controls and good practices for the publication of flow cytometry data.

In the course of year, the University increased the number of its services, developing a total of 527 services.

NUMBER OF
IMIBIC USERS **12**

NUMBER OF
EXTERNAL USERS **2**

STAFF

Ignacio Ortea, PhD
Core Facility Coordinator

Eduardo Chicano, PhD
Specialized Technician

Rocío Pérez
Assistant Technician

BRIEF DESCRIPTION

The Proteomics Unit provides researchers with state-of-the-art technologies in the field. Currently, the Proteomics Unit is a specialized platform in LC-MS quantitative proteomics and MALDI Imaging. The skilled staff provides individualized, fit-for-purpose support including project planning, sample preparation, mass spectrometry analysis and data analysis.

EQUIPMENT

- » **Q-TOF mass spectrometer, Triple TOF 5600+ (Sciex)**
- » **Triple quadrupole mass spectrometer, Xevo TQS (Waters)**
- » **MALDI-TOF/TOF mass spectrometer, 5800 (Sciex)**
- » **nano-HPLC, Eksigent LC415 (Sciex)**
- » **nano-UPLC, nanoAcquity M-Class (Waters)**
- » **Sprayer, Sunchrom Suncollect (Sunchrom)**

MAIN SERVICES

- » Identification and characterization of proteins by MALDI-TOF/TOF
- » Identification and characterization of proteins by LC-MS/MS
- » Quantitative Proteomics:
 - SWATH
 - SRM (Selected Reaction Monitoring)
 - pseudoSRM (Parallel Reaction Monitoring, PRM)
- » MALDI Imaging mass spectrometry
- » Project supervision and collaboration
- » Training in software used for data analysis

HIGHLIGHTS

**NUMBER OF
IMIBIC USERS 14**

**NUMBER OF
EXTERNAL USERS 7**

**PRIZES OR
GRANTED RECEIVED 2**

**SCI ARTICLES
PUBLISHED 3**

**PATENTS
REGISTEREDS 1**

**PARTICIPATION IN INTERLABORATORY
COMPARISON STUDIES 1**

**GRANTED
PROJECTS 1**

FEATURED ARTICLES

Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection.

Ortea I, Ruiz-Sánchez I, Cañete R, Caballero-Villarraso J, Cañete MD. *J Proteomics* 2018, 175:105-113.
Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma.
Fernández A, et al. *Hum Mol Genet.* 2018, 27:3046-3059.

Proteomics Study Reveals That Docosahexaenoic and Arachidonic Acids Exert Different in Vitro Anticancer Activities in Colorectal Cancer Cells.

Ortea I, González-Fernández MJ, Ramos-Bueno RP, Guil-Guerrero JL. *J Agric Food Chem.* 2018, 66:6003-6012.

INSTITUTIONAL PROJECT

Project: Configuration of a High-Throughput Next-Generation Quantitative Proteomics Platform for Precision Medicine.

Equipment: Hybrid mass spectrometer with a new-generation high-field Orbitrap or high-resolution TOF mass analyzer, coupled to a UHPLC nano-liquid chromatography system.

STAFF

Sebastián Ventura Soto, PhD
Head of Unit

Jesús Fernández Chaichio
Technicians

José Luis Fernández Rueda (till May 2018)
Technicians

BRIEF DESCRIPTION

The mission of the Bioinformatics and technological innovation Unit is to provide engineering and computing resources to satisfy both the bioinformatics analysis requirements and the different technological needs that result from research and clinical practice, with an emphasis on the promotion and implementation of state-of-the-art technologies.

In the field of bioinformatics, the main objective is to develop and design and execute pipelines for the analysis of genomic and proteomic data. A top priority is the implementation of reporting guidelines pertinent to each particular case (MIAME, MIAPE, etc.) and the use of standardized formats (MAGE-ML, MAGE-TAB, mzML, mzIdentM, etc.) is a top priority whose aim is to burnish robust reporting and facilitate the publication of findings.

EQUIPMENT AND FACILITIES

» **Computing resources:** BullX R428-E3 node. 4x Intel Xeon E5-4610v2 8c, 32 cores. 256 GB RAM

» **3D Printer:** BCN3D+ Fused Deposition Material Printer.

» **Development resources:** Apple Mac Mini for iOS app development.

MAIN SERVICES

The unit's services can be divided in two main categories:

» Bioinformatic services

- Biocomputing tools to support groups conducting relevant research projects
- Direct analysis of relevant research projects and technical data needed for support
- Bioinformatics covers varying fields and diverse applications such as:
 - Analysis of nucleic acids (DNA / RNA)
 - Analysis of peptide sequences, structures, functions, metabolic pathways and interactions with genes
 - Generation of knowledge relative to the study of new drugs
- Engineering services
- Software development
- Design and implementation of algorithms
- Construction of databases and Electronic Data Capture instruments
- 3D modeling and printing
- Engineering & consulting

HIGHLIGHTS

The Bioinformatics and Technological Innovation Units has continued its activity of promoting the use of computer technologies among the different research groups. As part of these activities, the Unit has started a cycle of seminars, which began with one centered on the use of Electronic Data Capture instruments and databases in clinical research. This cycle will be continued on the following years with more advanced topics. As a result, the Unit has increased its activity and the number of both collaborations and funded projects in which it participates.

NUMBER OF IMIBIC USERS **21**

NUMBER OF EXTERNAL USERS **58**

NUMBER OF MEETINGS WITH IMIBIC GROUPS **25**

NUMBER OF MEETINGS WITH EXTERNAL GROUPS **10**

NUMBER OF NEW ACTIVE PROJECTS **5**

STAFF

Álvaro Jiménez Arranz
Senior specialized technician

Pilar Rubín González de Canales
Laboratory technician

BRIEF DESCRIPTION

The mission of the IMIBIC Genomics Unit is to make very high level equipment available and provide scientific and technical advice for the development of various analytical techniques to researchers both at the institute and at other public and private institutions. Said equipment and technical knowledge is dedicated to the comprehensive study of DNA and RNA (genotyping / expression / regulation), which in turn will produce high-quality results for the development of excellent biomedical research. To this end, the unit has cutting-edge, high throughput performance platforms in the field of genomics. It is also important to note the high level of interaction with the other UCAIBs, which are located in the same building, such as Bioinformatics, Proteomics and Cytometry.

EQUIPMENT AND FACILITIES

Currently, the resources that the Genomics Unit has at its disposal are:

» **Illumina MiSeq**

MiSeq is an Illumina platform sequencing technology based on SBS (sequencing by synthesis), which is currently the most widely adopted NGS (next-generation sequencing) technology in the world on account of its speed, accuracy and quality. This sequencer can generate up to 15 Gb/run and can perform 2x300bp paired-end reads, leading to greater accuracy, especially in problem areas such as with homopolymers. The MiSeq system allows for DNA-Seq, RNA-Seq, Methyl-Seq and ChIP-Seq, with a wide range of applications.

» **nCounter DX / NanoString technology**

The NanoString nCounter system uses a novel technique of molecular barcodes linked to specific probes that can detect and count hundreds of targets in a single reaction without amplification, thus letting users study a large number of

mRNAs, miRNAs and DNAs simultaneously with sensitivity and “gold standard” reproducibility. Its applications include gene expression analysis, gene fusion, copy-number variation (CNV) and simultaneous analysis of mRNAs and RNA regulators such as miRNAs and lncRNAs.

The nCounter DX is CE and IVD certified for conducting analyses that ensure care quality and, along with these applications, make the nCounter a tool with high potential for clinical use. Currently there is a CE-marked test for in vitro diagnostics (CE-IVD) on the market, which was approved by the FDA for breast cancer (Prosigna-PAM50), based on the molecular analysis of the gene expression of 50 genes. This lets it classify the tumor into one of four intrinsic subtypes, related to disease prognosis and choice of treatment. In addition, the launch of another validated kit for in-vitro diagnostics (CE-IVD / FDA) is currently underway, based on 20 differential gene expression patterns, aimed at determining DLBCL subtypes (diffuse large B-cell lymphoma), and related disease treatment.

» **Digital PCR (dPCR): QX200 Droplet Digital PCR System**

The digital PCR offers a more precise and sensitive alternative to conventional qPCR for absolute quantification and detection of rare alleles without need of standards or endogenous controls due to droplet partitioning.

» **Quantitative PCR (qPCR):**

The unit currently has 3 platforms aimed at genotyping PCR and gene expression studies:

- Light Cycler 480 (96-well platform)
- Light Cycler 96 (96-well platform)
- 7900 HT Fast (384-well platform)

With regard to IMIBIC research staff, the unit offers the possibility of using the qPCR platforms under a “self-service” scheme (without technical operator).

» **Others:**

The unit has additional appliances designed for quantification, quality analysis and determining the size of nucleic acid fragments:

- Nanodrop ND1000 (Spectrophotometer)
- DeNovix DS-11 (Spectrophotometer)
- Quantus (Fluorometer)
- 2200 TapeStation (Microelectrophoresis)

Additionally, IMIBIC has a computation cluster (bulk computing node R418-E3), for mandatory use in next-generation sequencing (NGS) protocols.

MAIN SERVICES

- » Technical support and scientific and methodological advice on the choice and optimization of genomic techniques
- » Design support for NGS or NCounter targeted panels
- » Technical and scientific support in the use of qPCR platforms and probe design
- » Nucleic acid quality controls (spectrophotometry, fluorometry and microelectrophoresis)
- » Analysis of targeted gene expression panels (up to 800 genes) using NCounter System
- » PAM50-signature Analysis (Prosigna™) for breast cancer prognosis
- » Screening of up to 800 miRNA in tissue, peripheral blood cells and serum/plasma by NanoString Technologies (NCounter System)
- » Gene expression and genotyping studies using real-time PCR
- » Absolute quantification by Droplet Digital PCR System (viral load analysis...)
- » Liquid biopsy: Rare mutation detection in cfDNA by ddPCR
- » NGS library preparation
- » Characterization of microbiome by sequencing of 16S rRNA gene using NGS
- » Sequencing NGS (next generation sequencing) by Illumina Miseq
- » Training and support in the use of data analysis software related to the unit’s technology
- » Project supervision and partnerships

HIGHLIGHTS

In 2018, the Genomics Unit has continued with the progressive increase in the number of projects and users since its inception in 2015, analyzing more than 2000 samples from research and clinical diagnosis this last year. The previously implemented protocols and services have been improved following the GLP principles (good laboratory practices) to guarantee the quality, reproducibility and reliability of the results, and new services such as the characterization of microbiomes by NGS have been initiated. The integration of the Genomics Unit into a multidisciplinary team with the Reina Sofia University Hospital to implement protocols for genetic/genomic diagnosis, for instance the PAM50-signature (Prosigna™) for breast cancer prognosis, has been established. In addition, the Unit has participated as a testing lab within the Translational Research Program of Nanostring to test the Lymphoma Subtyping Test (LST) for the determination of cell-of-origin subtypes of diffuse large B-cell lymphoma and has also been integrated into the Pharmagenetics Work Group of SCReN - The Spanish Clinical Research Network of the National Institute of Health Carlos III – inside the Cordoba group.

NUMBER OF
IMIBIC USERS **20**

NUMBER OF
EXTERNAL USERS **4**

STAFF

Jose López Miranda, PhD
Head of Unit

María Esther Pacheco Rodríguez, PhD
Clinical Pharmacologist

Antonio Miguel Luque Pineda
Project Managers/CRA's

Juan Manuel Escandell Morales
till Dec 2018

Inés Carmen Rodríguez García
Nurse Coordinator

Manuel Rejano Castañeda
Nurses

Pilar Mesa Blanco
Nurses

Araceli Chicano Gálvez
Nurses

Rubén Sánchez Nieves
Nursing Assistants

BRIEF DESCRIPTION

The IMIBIC Clinical Research Unit promotes clinical research at IMIBIC and at the Reina Sofia University Hospital and also aims to establish collaborations with other research centers. Currently, IMIBIC is part of the Spanish Clinical Research Network (SCReN). The Unit focuses on the development of clinical trials including design, feasibility, regulatory affairs, launch, management, monitoring, pharmacovigilance, data management, statistics and delivery of clinical assistance. All operations are GCP compliant. The IMIBIC Clinical Research Unit consists of two facilities: the Provincial Hospital Clinical Research Unit and the General Hospital Clinical Research Unit. Both are adapted to perform clinical trials of phases I-IV in patients.

EQUIPMENT AND FACILITIES

- » **10 doctor's consultation rooms and a storehouse**
- » **2 hospital wards each containing:** crash trolley with semi-automatic defibrillator and emergency medication, intravenous fluids, an insulin pump, heating trolleys, oxygen outlets in all positions and audiovisual system
- » **14 armchairs and rooms with 3 single beds, all with ongoing monitoring**
- » **Pediatric area**
- » **12-lead ECGs**
- » **Measuring boards and scales**
- » **Blood pressure meter in each office**
- » **Customized Bathrooms**
- » **Individual lockers for patients**
- » **2 Living rooms for patients**
- » **2 Waiting rooms for patients and family**
- » **1 multi-purpose room**
- » **2 Laboratories for sample processing and centrifuges**
- » **Freezers (-80°C and -20°C)**
- » **2 storehouse for materials**
- » **High Definition Ultrasound Scanner**
- » **2 Study coordinators' offices**
- » **2 CRAs' offices**
- » **2 Archives**

MAIN SERVICES

- » Methodological support
- » Launch and Regulatory affairs
- » Study development
- » Monitoring
- » Pharmacovigilance
- » Delivery of clinical assistance

HIGHLIGHTS

During 2018, the Unit provided assistance and support in the start-up, coordination, data management or monitoring of 25 independent clinical research projects in the following Units, among others: Cardiology, Hematology, Internal Medicine, Pediatrics, General Surgery, Nephrology, Rheumatology, and Infectious Diseases. Concerning research activity, 634 patients were treated at the facilities of the Clinical Research Unit. 145 clinical research projects have been carried out. The main areas that have developed their activity in the unit are Oncology, Internal Medicine, Nephrology, Infectious Diseases, Dermatology, Urology, Rheumatology, Cardiology, Pediatrics, Psychiatry, Endocrinology, Ophthalmology, Digestive System, Allergy and Immunology.

As a member of the Spanish Clinical Research Network (SCReN), the Unit has coordinated as sponsor 2 multicenter clinical trials and has actively participated in 8 other clinical trials interacting with different groups within Spain. The Unit also collaborates with several working groups within the network.

To promote clinical research, the Unit has organized working meetings with health professionals in different areas: Urology, Pediatrics, Immunology, General Surgery, Palliative Care, Cardiac Surgery, Diagnostic Radiology, etc. The research lines of the main pharmaceutical companies and the capacity of participation of these units have been evaluated. Meetings have been organized with the medical departments of the pharmaceutical companies.

NUMBER OF IMIBIC USERS 29

NUMBER OF EXTERNAL USERS 2

STAFF

Manuel Medina Pérez, PhD
Scientific Manager

Javier Herruzo
Technician

BRIEF DESCRIPTION

The Biobank Unit is one of the research support platforms whose mission is to act as a liaison between doctors, researchers and patients who donate biological samples for the purpose of biomedical research to uphold the current legal constraints and appropriate ethical safeguards.

The IMIBIC Biobank is part of the Biobanks of the Andalusian Public Health System (SSPA), an initiative of the Department of Equality, Health and Social Policy of the Regional Government. It is part of the Thematic Network of Hospital Biobanks pertaining to the National Institute of Health Carlos III (ISCIII), and the subprogram of the Thematic Networks of Cooperative Research in Health (RETICS)

EQUIPMENT AND FACILITIES

The Unit has its own laboratory resources for sample transformations (Safety booths, PCR Booths, Microtomes, Chryostate, Flotation Bath, Centrifuge, Histobath, Automatized Processor for Paraffin Inclusion, Paraffin Dispenser, etc.) as well as other machinery such as:

- » **Tissue Safe:** fully automated preparation of tissue samples in a vacuum.
- » **Tissue Arrayer:** assembles different tissue samples in a single multiple matrix for subsequent histological analysis.
- » **Quiacube:** Automatic, compact system for analysis of DNA, RNA, plasmids and proteins from varying samples.

For sample storage, there are currently two freezers: one for temperatures of -20 degrees Celsius, seven for -80 degrees Celsius, as well as paraffin storage rooms for room temperature.

MAIN SERVICES

The service portfolio is divided into four main areas:

1. Custody for storing samples at different temperatures.
2. Processes for transforming multiple types of biological samples in accordance with the procedures and technical criteria commonly used by researchers in their projects.
3. Provision of human samples and data on human health and disease research, selected according to clinical and diagnostic criteria specified by researchers.
4. Technical, scientific and ethical consulting regarding the collection, storage, and management of human samples in biomedical research.



STAFF

Ipek Guler Caamano Fajardo
Specialized biostatistician

BRIEF DESCRIPTION

The Unit offers methodological consulting and statistical support for IMIBIC's researchers and for the healthcare professionals belonging to the Andalusian Public Health System in the Province of Córdoba ensuring high quality responds to the researcher's needs and offering robust statistical results on research projects.

The Unit's main objectives are:

- » Provide methodological support to researchers including assistance writing in grant applications, designing studies, data management and data analysis.
- » Provide support for researchers in descriptive and advanced statistical analysis.
- » Provide support during the development and revision of scientific articles as one of the co-authors of the scientific publication.
- » Organize training, seminars and specialized courses on statistical methodologies and statistical software for researchers.

EQUIPMENT AND FACILITIES

The main statistical programs used for data analysis are:

- » **IBM SPSS 24 (Copyright 2010 by SPSS Inc.)**
- » **R (versión 3.5.0)**
- » **GranMo versión 7.12 (abril 2012)**

MAIN SERVICES

The services offered by the Unit of Methodology and Biostatistics by personalized consultations (face to face, telematic or virtual meetings) include:

- » Revision of the research methodology and protocols: presentation of hypotheses, formulation of objectives, selection of epidemiological design, definition of variables, selection of statistical analysis etc.
- » Guidance for literature search concerning statistical techniques and methodologies
- » Sample size calculation.
- » Validation of questionnaires and other measuring instruments.
- » Exploratory and descriptive analysis of data.
- » Inferential analysis (univariate and multivariate).
- » Evaluation of diagnostic tests: sensitivity, specificity, predictive values, ROC curves, decision curves, optimal cut-point analysis.
- » Survival analysis
- » Longitudinal data analysis
- » Joint modeling of longitudinal and survival data in observational studies.
- » Functional data analysis.
- » Basic statistical analysis for omics data (gene expressions, enrichment analysis).
- » Other statistical techniques (Bayesian analysis, meta-analysis, etc.).
- » Interpretation of results
- » Guidance in presenting and disseminating research results
- » Revision of scientific publications in terms of quality criteria set by the journal and depending on the type of study.

HIGHLIGHTS

NUMBER OF
IMIBIC USERS **25**



SCIENTIFIC
PRODUCTION



GC01: T and NK cell Immunosenescence Antiviral Immune Response

<https://www.imibic.org/grupo/26>


ACTIVITY

- N° ONGOING PROJECTS: 4 (public) , 3 (private)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 3
- N° THESIS: 2

TEAM

Solana	Lara	Rafael	R4
Alonso	Díaz	Corona	R3
Barasona	Villarejo	Mª Jose	R3
González	Fernández	Rafael	R3
Jurado	Roger	Aurora	R3
Moreno	Aguilar	Carmen	R3
Saiz	Sánchez	Vanessa	R3
Serrano	Delgado	María Del Pilar	R3
Campos	Fernandez	Carmen	R2
Castro	Orgaz	Laura	R2
Hassouneh		Fakhri	R2
Manzanares	Martin	Bárbara	R2
Pera	Rojas	Alejandra	R2
Ruiz	León	Berta	R2
Espinazo	Romeu	Mª Luisa	R2
Cañones	Barceló	Estrella	R1
García	Gallego	Azahara	R1
López	Sejas	Nelson	R1
Molina	Alcaide	Juan Eduardo	R1
Navas	Romo	Ana Maria	R1
Yarce	Bustamante	Oscar Alberio	R1
Formentini		Martina	R1
Guerra	González	Mercedes	T
Velarde	Martínez	Mª Luisa	ADM

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION:

- » **Networks:**
 - REIPI - Spanish Network for Research in Infectious Diseases (Collaborator)
 - ARADyAL - Spanish Network for asthma, adverse and allergic reactions (Asma, Reacciones ADversas y ALérgicas) (PI: Carmen Moreno Aguilar)
 - PAIDI CTS-208 Molecular immunology
- » **Competitive funding obtained for contracts:**
 - 1 Strengthening of research activity Programme (SAS)
- » **5 Agreements with companies**

KEYWORDS

- Immunosenescence
- aging
- melanoma
- NK cells
- NKT cells
- NK receptors
- CMV
- cytotoxic T lymphocytes (CTL)
- Allergy
- Anaphylaxis
- Pollen
- Hymmenoptera
- Food
- Mite
- drugs

HIGHLIGHTED PUBLICATIONS

1. Burgos AMC, Torres-Borrego J, Teran ABM, Corzo JL, Garcia BE, Pacheco RR, Aguilar CM, Davila I. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. PEDIATRIC ALLERGY AND IMMUNOLOGY. 2018; 29(4):369-374.
IF: 4,137 Q1 D1
2. Rodrigues-Santos P, Lopez-Sejas N, Almeida JS, Ruzickova L, Couceiro P, Alves V, Campos C, Alonso C, Tarazona R, Freitas-Tavares P, Solana R, Santos-Rosa M. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. FRONTIERS IN IMMUNOLOGY. 2018; 9:Núm artículo 2587
IF: 5,511 Q1

3. Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. ANTIVIRAL RESEARCH. 2018; 155:97-105.
IF: 4,307 Q1
4. Frias M, Rivero-Juarez A, Rodriguez-Cano D, Camacho A, Lopez-Lopez P, Risalde MA, Manzanares-Martin B, Brieua T, Machuca I, Rivero A. HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. SCIENTIFIC REPORTS. 2018; 8:Núm artículo 659
IF: 4,122 Q1
5. Schiener M, Hilger C, Eberlein B, Pascal M, Kuehn A, Revets D, Planchon S, Pietsch G, Serrano P, Moreno-Aguilar C, de la Roca F, Biedermann T, Darsow U, Schmidt-Weber CB, Ollert M, Blank S. The high molecular weight dipeptidyl peptidase IV Pol d 3 is a major allergen of Polistes dominula venom. SCIENTIFIC REPORTS. 2018; 8:Núm artículo 1318
IF: 4,122 Q1



GC02: Oxidative and Nitrosative stress in acute and chronic liver disease

<https://www.imibic.org/grupo/47>


ACTIVITY:

- N° ONGOING PROJECTS: 6 (public), 1 (private)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 38
- N° THESIS: 2

TEAM

De La Mata	Garcia	Manuel	R4
Bárcena	Ruiz	Jose Antonio	R4
Aguilar	Melero	Patricia	R3
Ferrín	Sánchez	Gustavo	R3
Garcia	Sánchez	Mª Valle	R3
Martínez	Galisteo	Emilia	R3
Montero	Álvarez	Jose Luis	R3
Padilla	Peña	Alicia	R3
Peinado	Peinado	Jose	R3
Poyato	Gonzalez	Antonio	R3
Rodríguez	Perálvarez	Manuel Luis	R3
González	Rubio	Sandra	R2
Linares	Luna	Clara Isabel	R2
Requejo	Aguilar	Raquel	R2
Vida	Perez	Luis	R2
Fernández	González	Rocío	R1
Guerrero	Misas	Marta	R1
Medina	Medina	Rosario	R1
Barrera	Baena	Pilar	CR
Benítez	Cantero	José Manuel	CR
Costán	Rodero	Guadalupe	CR
Iglesias	Flores	Eva	CR
Serrano		Francisco José	CR
Díaz	Sillero	Encarna	T
Gómez	Núñez	Mª Isabel	T
Salgueiro	Rodríguez	Mª Isabel	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - CIBER on Liver and Digestive Diseases (CIBERehd)
 - Spanish workgroup of Crohn's Disease and Ulcerative Colitis (GETECCU)
 - The research team is part of the scientific groups CTS-273 in Study of acute affections of the digestive system, and BIO-216 on Molecular mechanisms of antioxidant and proteomic defense, both pertaining to the Andalusian Plan for Research, Development and Innovation (PAIDI)
 - Andalusian Network for Clinical Research in Infectious Diseases (ANCRAID). RIC-0537-2018
- » **Competitive funding obtained for contracts:**
 - 1 POST-MIR RESEARCHER: STOP FUGA DE CEREBROS ROCHE
 - 1 Strengthening of research activity Programme (SAS)
- » **9 agreements with companies**
- » **Agreement with Janssen CCB.0196.01**

KEYWORDS

- Liver transplant
- hepatocellular carcinoma
- Crohn's disease
- ulcerative colitis
- cholestasis
- liquid biopsy
- proteomic
- anti-TNF

HIGHLIGHTED PUBLICATIONS

- Rodriguez-Peralvarez M, Guerrero M, Barrera L, Ferrin G, Alamo JM, Ayllon MD, Artacho GS, Montero JL, Briceno J, Bernal C, Padillo J, Marin-Gomez LM, Pascasio JM, Poyato A, Gomez-Bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. *TRANSPLANTATION*. 2018; 102(12):2056-2064. **IF: 3,96 Q1 D1**
- Gonzalez R, Molina-Ruiz FJ, Barcena JA, Padilla CA, Muntane J. Regulation of Cell Survival, Apoptosis, and Epithelial-to-Mesenchymal Transition by Nitric Oxide-Dependent Post-Translational Modifications. *ANTIOXIDANTS & REDOX SIGNALING*. 2018; 29(13):1312-1332. **IF: 6,53 Q D1**
- Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. *CLINICAL MICROBIOLOGY AND INFECTION*. 2018; 24(11):1218-1219. **IF: 5,394 Q1 D1**
- Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. *LIVER TRANSPLANTATION*. 2018; 24(2):192-203. **IF: 3,752 Q1**

5. Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. *JOURNAL OF HEPATOLOGY*. 2018; 68(5):940-948. doi: 10.1016/j.jhep.2017.12.019. **IF: 15,040 Q1 D1**

6. Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoz C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. *ALIMENT PHARMACOL THER*. 2018 Oct;48(8):839-851. doi: 10.1111/apt.14930. **IF: 7,357 Q1 D1**

MAIN RESULTS

- » **CLINICAL GUIDES:**
 - García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. H. Virgen del Rocío, H. Universitario Reina Sofía.



GC03: Infectious Diseases

<https://www.imibic.org/grupo/40>

ACTIVITY

- N° ONGOING PROJECTS: 7 (public), 2 (private)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS: 14
- N° THESIS: 1

Transplant Recipients and Donors. TRANSPLANTATION. 2018; 102(2):S8-S15.

IF: 3,96 Q1 D1

MAIN RESULTS

» CLINICAL GUIDES:

• Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24:S10-S20.

IF: 5,394 Q1 D1

• Aguado JM, Silva JT, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C, Martinez-Martinez L, Vidal E, Almenar L, Almirante B, Canton R, Carratala J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernandez J, Farinas MC, Gavalda J, Goyanes MJ, Gutierrez-Gutierrez B, Hernandez D, Len O, Lopez-Andujar R, Lopez-Medrano F, Martin-Davila P, Montejo M, Moreno A, Oliver A, Pascual A, Perez-Nadales E, Roman-Broto A, San-Juan R, Seron D, Sole-Jover A, Valerio M, Munoz P, Torre-Cisneros J. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. TRANSPLANTATION REVIEWS. 2018; 32(1):36-57.

IF: 2,364 Q3

• Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourão PHO, Kotton CN, Aguado JM; working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. TRANSPLANTATION. 2018 Feb; 102(2):193-208.

doi: 10.1097/TP.0000000000002027. PMID: 29381647

IF: 3,960 Q1 D1

• Clemente WT, Mourão PHO, Lopez-Medrano F, Schwartz BS, García-Donoso C, Torre-Cisneros J. Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors. TRANSPLANTATION. 2018 Feb; 102(2S Suppl 2):S8-S15. doi: 10.1097/TP.0000000000002018. No abstract available. PMID: 29381573

IF: 3,960 Q1 D1

TEAM

De La Torre	Cisneros	Julian Carlos	R4
Cantisán	Bohórquez	Sara	R3A
Castón	Osorio	Juan José	R3A
Gallo	Marín	Marina	R2B
Natera	Kindelan	Clara	R2B
Perez	Nadales	Elena	R2B
Vidal	Verdu	Elisa	R2B
Recio	Rufián	Manuel	R1
Cano	Yuste	Angela	R1
Páez	Vega	Aurora	R1
Valle	Arroyo	Jorge	R1
Méndez	Natera	Alejandra	R1
De la Torre	Giménez	Julian	T
Frutos	Adame	Azahara	T
Kindelán	Segador	Lara	T
Salinas	Gavilán	Ana	T
Añon	Gámez	Mª Teresa	ADM
Cantueso	Méndez	Inmaculada	ADM

ADDITIONAL INFORMATION

» Networks:

- Spanish Network for Research on Infectious Diseases (REIPI, <http://reipi.org>).
- INCREMENT-SOT, an international consortium for the clinical study of blood stream infections caused by multi-drug resistant Enterobacteriales in solid organ transplantation (SOT). We promote and coordinate this international network, which includes 40 centers specialized in SOT from 16 countries worldwide.
- PROACTIVE group: Optimization in the use of antibiotics and treatment of complex bacterial infections caused by resistant strains, Ministry of Health, Junta de Andalucía. File: AC-0044-2013. Principal Investigator: Jesús Rodríguez Baño (Hospital Virgen Macarena). PI at Reina Sofía University Hospital: Julián de la Torre Cisneros.
- PAIDI CTS-647 Scientific Group. Coordinator of the Group "Translational Research in Infectious Diseases" that belongs to the Andalusian Research Plan (PAI CTS647), since July 2009.

» 3 International Projects:

- COMBACTE-NET
- COMBACTE-CARE
- INSPIRE-2018-02)

» Competitive funding obtained for contracts:

- 1 Miguel Servet Contract (ISCIII)

» 5 agreements with companies

KEYWORDS

- cytomegalovirus
- multidrug-resistant microorganisms
- immunopathology
- transplantation
- specific immune response

HIGHLIGHTED PUBLICATIONS

1. Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J. Risks of Infection and Mortality Among Patients Colonized With *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae*: Validation of Scores and Proposal for Management. CLINICAL INFECTIOUS DISEASES. 2018; 66(8):1204-1210.

IF: 9,117 Q1 D1

2. Amat T, Gutierrez-Pizarra A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant *Acinetobacter baumannii*. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(6):630-634.

IF: 5,394 Q1 D1

3. Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24:S10-S20.

IF: 5,394 Q1 D1

4. Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. ANTIVIRAL RESEARCH. 2018; 155:97-105.


IF: 4,307 Q1

5. Clemente WT, Mourao PHO, Lopez-Medrano F, Schwartz BS, Garcia-Donoso C, Torre-Cisneros J. Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
DECILE



PUBLICATIONS
IN FIRST
QUARTIL





GC04: Inflammation and Cancer

<https://www.imibic.org/grupo/27>

ACTIVITY:

- N° ONGOING PROJECTS: 2 (public), 2 (public-private)
- N° THESIS: 1

TEAM

Muñoz	Blanco	Eduardo	R4
Calzado	Canale	Marco Antonio	R3C
Navarrete	Rueda	Carmen	R2
Correa	Sáez	Alejandro	R1
Garrido	Rodríguez-Córdoba	Martín	R1
Millán	Ortega	Estrella	R1
Morrugares	Carmona	Rosario	R1
Palomares	Cañero	Belén	R1
Prados	González	María Eugenia	R1
Collado	Rojas	Juan Antonio	T
Mellado	Fuentes	Ana María	T

ADDITIONAL INFORMATION

- » **Networks:**
 - AIDS Research Network (RIS)
 - PAIDI BIO-304 scientific group
- » **Competitive funding obtained for contracts:**
 - 1 Human Research Contrat: 1 i-PFIS Contract (ISCIII)
- » **3 agreements with companies**

KEYWORDS

- Inflammation
- cancer
- tissue regeneration
- HIV-1 latency
- Pharmacology and Nutraceuticals

HIGHLIGHTED PUBLICATIONS

1. Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cancer. *J Exp Med*. 2019 Feb 4;216(2):450-465.

IF: 10.892 Q1 D1

2. Minassi A, Rogati F, Cruz C, Prados ME, Galera N, Jinénez C, Appendino G, Bellido ML, Calzado MA, Caprioglio D, Muñoz E. Triterpenoid Hydroxamates as HIF Prolyl Hydrolase Inhibitors. *J Nat Prod*. 2018 Oct 26;81(10):2235-2243.

IF: 4.257 Q1 D1

3. Moreno P, Jiménez-Jiménez C, Garrido-Rodríguez M, Calderón-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra Á, Muñoz E, Calzado MA. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. *Mol Oncol*. 2018 Oct;12(10):1778-1796.

IF: 5.962 Q1


4. Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C, López-Pedraza C, Appendino G, Calzado MA, Muñoz E. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR - and CB(2) receptor-dependent pathways. *Br J Pharmacol*. 2018 Oct;175(19):3813-3831.


IF: 6.583 Q1

5. Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. *J Neuroinflammation*. 2018 Mar 1;15(1):64.

IF: 5.7 Q1

SCIENTIFIC PRODUCTION





GC05: Systemic and chronic inflammatory autoimmune diseases of the locomotor system and connective tissue

<https://www.imibic.org/grupo/28>


ACTIVITY

- N° ONGOING PROJECTS: 9 (public), 1 (private)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 44
- N° THESIS: 1 • N° PATENTS: 1

TEAM

López	Pedraza	Rosario	R4
Collantes	Estevez	Eduardo	R4
Aguirre	Zamorano	Mª Angeles	R3
Barbarroja	Puerto	Nuria	R3C
Caracuel	Ruiz	Miguel Angel	R3
Escudero	Contreras	Alejandro	R3
Font	Ugalde	Pilar	R3
Gomez	Gracia	Inmaculada	R3
López	Montilla	Mª Dolores	R3
Perez	Guijo	Veronica	R3
Calvo	Gutierrez	Jerusalem	R2
Castro	Villegas	Mª Carmen	R2
Ibáñez	Costa	Alejandro	R2
Jiménez	Gómez	Yolanda	R2
López	Medina	Clementina	R2
Ortega	Castro	Rafaela	R2
Perez	Sanchez	Carlos	R2
Patiño	Trives	Alejandra Mª	R1
Segura	Ruiz	Rocío	R1
Arias	De La Rosa	Ivan	R1
Jurado	Ruiz	Luis	R1
Abalos	Aguilera	Mª Carmen	T
Romero	Gutiérrez	Mª Dolores	T
Ruiz	Vilchez	Desiree	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - Research network in inflammation and rheumatic diseases (RIER) – The Spanish National Institute of Health Carlos III (Instituto de Salud Carlos III)
 - Chronic inflammatory diseases of musculoskeletal system and connective tissue CTS1004, Andalusian Plan for Research, Development and Innovation (PAIDI).
- » **2 International Projects:**
 - Collantes Estevez, E. Title: Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases Mechanisms for the Improvement of Drug Development and Therapy. PRECISESADS (<http://www.precisesads.eu/>). General coordinator: Marta Alarcón-Riquelme, FPS. Financial entity: Innovative Medicine Initiaves (IMI) – EU + EFPIA. Reference: 115565-3. Lenght: 01/02/2014-31/01/2019.

- Collantes Estevez, E. Can Inertial Movement Sensors (IMUs) provide a valid and reliable way of measuring Spinal Mobility in Axial Spondyloarthritis (axSpa): a Clinimetric Evaluation. Funding Agency: Foundation for Research in Rheumatology. Reference: FOREUM-2015-001

» **Competitive funding obtained for contracts:**

- 1 Training Research contract (CS)
- 1 Río Hortega (ISCIII)
- 1 Miguel Servet (ISCIII)
- 1 Juan de la Cierva (MINECO)
- 1 Strengthening of research activity Programme (SAS)

» **5 agreements with companies**

KEYWORDS

- Autoimmune diseases
- spondilarthropathies
- inflammation
- atherothrombosis
- metabolic syndrome
- organ damage
- biomarkers
- new therapies

HIGHLIGHTED PUBLICATIONS

1. Cecchi I, Arias de la Rosa I, Menegatti E, et al. Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. *Autoimmun Rev.* 2018 Nov;17(11):1138-1149. doi: 10.1016/j.autrev.2018.06.006. 2018 Sep 11. Review.
IF: 8,745 Q1 D1
2. Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, et al. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. *Haematologica.* 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15.
IF: 9,09 Q1 D1
3. Arias de la Rosa I, Escudero-Contreras A, Rodríguez-Cuenca S, et al. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. *J Intern Med.* 2018 Jul;284(1):61-77. doi: 10.1111/joim.12743. Epub 2018 Mar 12.
IF: 6,754 Q1 D1
4. Perez-Sanchez C, Font-Ugalde P, Ruiz-Limon P, et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. *Hum Mol Genet.* 2018 Mar 1;27(5):875-890. doi: 10.1093/hmg/ddy008.
IF: 4,902 Q1
5. López-Medina C, Dougados M, Collantes-Estévez E, Moltó A. Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. *Rheumatology (Oxford).* 2018 May 1;57(5):880-890. doi: 10.1093/rheumatology/kex514.
IF: 5,245 Q1 D1





GC06: New Therapies in Cancer

<https://www.imibic.org/grupo/25>

ACTIVITY


- N° ONGOING PROJECTS: 8 (public)
- N° PROJECTS STARTING IN 2019: 1 (public), 1 (private)
- N° CLINICAL TRIALS : 124
- N° THESIS: 2

TEAM

Aranda	Aguilar	Enrique	R4
Rodriguez	Ariza	Antonio	R4
De La Haba	Rodriguez	Juan Rafael	R3C
Barneto	Aranda	Isidoro C.	R3
Gomez	España	Maria Auxiliadora	R3
Martínez	Peinado	Antonio	R3
Villar	Pastor	Carlos	R3
Guil	Luna	Silvia	R2
López	Sánchez	Laura María	R2
Morales	Estévez	Cristina	R2
Valladares	Ayerbes	Manuel Jesús	R2
Mena	Osuna	Rafael	R1
Ortíz	Morales	María Jose	R1
Peñarando	Sáez	Jon	R1
Toledano	Fonseca	Marta del Pilar	R1
Jiménez	Izquierdo	Rafael Manuel	S
Cano	Osuna	María Teresa	CR
Fuentes	Vaamonde	Elena	CR
Méndez	Vidal	María Jose	CR
Moreno	Vega	Alberto Luis	CR
Porras	Quintela	Ignacio	CR
Rodríguez	Alonso	Beatriz	CR
Rodríguez	Alonso	Rosa M ^a	CR
Sánchez	Mauriño	Pedro	CR
Serrano	Blanch	Raquel	CR
Aranda	Aguilar	Asunción	T
Campón	Montilla	Daniel José	T
Díaz	Díaz	M ^a Ángeles	T
Elías	López	Cristina	T
Jaraba	Mezquida	Isabel	T
Leña	Barranco	Amalia	T
López	García	María	T
Marin	Serrano	Jacinta	T
Marin	Serrano	Maria Jose	T

Mesa	Blanco	M ^a Pilar	T
Miranda	Garcia	Rosario	T
Molina	Alcaide	Juan Eduardo	T
Pavón	Gómez	Rebeca	T
Rodriguez	De Julian	Sonia	ADM

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - CIBER on cancer (CIBERONC)
 - PAIDI CTS-234
- » **Competitive funding obtained for contracts:**
 - 1 Juan de la Cierva (MINECO)
 - 1 Nicolás Monardes (SAS)
 - 1 Strengthening of research activity Programme (SAS)
- » **13 agreements with companies.**

KEYWORDS

- Colorectal cancer
- breast cancer
- nitric oxide
- proteomics
- biomarkers
- prognosis
- prediction of response
- liquid biopsy
- targeted therapy
- precision oncology

HIGHLIGHTED PUBLICATIONS

1. Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018; 29(2):439-444.
IF: 13,926 Q1 D1
2. Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018; 16:Núm artículo 3
IF: 5,77 Q1 D1
3. Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Tejjido PG, Viudez A,

Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018; 101:263-272.

IF: 7,191 Q1

4. Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018; 23(11):1271-e128.

IF: 5,306 Q1

5. Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Taberner J, Giralt J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2018; 13(1):69-78.

IF: 3,877 Q2



GC07: Nephrology. Cell Damage In Chronic Inflammation

<https://www.imibic.org/grupo/18>


ACTIVITY

- N° ONGOING PROJECTS: 5 (public)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 11
- N° THESIS: 2

TEAM

Martin	Malo	Alejandro	R4
Aljama	Garcia	Pedro	R4
Espinosa	Hernandez	Mario	R3B
Rodriguez	Benot	Alberto	R3B
Soriano	Cabrera	Sagrario	R3B
Agüera	Morales	Maria Luisa	R3A
Navarro	Cabello	Maria Dolores	R3A
Santamaria	Olmo	Rafael	R3A
Buendía	Bello	Paula	R2B
Ariza	Fuentes	Francisco Javier	R2A
Carmona	Muñoz	Andrés	R2A
Guerrero	Pavon	Fatima	R2A
Crespo	Montero	Rodolfo	R1
Esquivias de	Motta	Elvira	R1
García	Montemayor	Victoria Eugenia	R1
Rabasco	Ruiz	Cristina	R1
Sánchez-Agosta	Martínez	Marina	R1
Amaral	Neiva	Francisco	CR
Ansio	Vázquez	Inmaculada	CR
Calle	Mafía	Oscar	CR
López	López	Isabel	CR
López	Andreu	Maria	CR
Moyano	Pelegrin	Cayetana	CR
Ojeda	López	Raquel	CR
Rosa	Guerrero	Pedro	CR
Torres	De Rueda	José Álvaro	CR
Espejo	Cruz	Mª Lola	T
Jimenez	Moral	Maria Jose	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - Spanish Renal Research Network (REDinREN)
 - Optimazing Dialysis Results ORD group
- » **Competitive funding obtained for contracts:**
 - 1 Researcher Training (CEICE)
 - 1 Rio Hortega expected to start in 2019 (ISCIII)
- » **4 agreements with companies.**


KEYWORDS

- Cell activation
- chronic renal failure
- microinflammation
- cell therapy
- hemodialysis
- renal transplantation
- inflammation
- cellular stress
- genomic damage
- endothelium

HIGHLIGHTED PUBLICATIONS

1. Pérez-García R, Varas J, Cives A, Martín-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. *Nephrol Dial Transplant.* 2018 Jan 1;33(1):187
IF: 4,470 Q1 D1
2. Varas J, Ramos R, Aljama P, Pérez-García R, Moreso F, Pinedo M, Ignacio Merello J, Stuard S, Canaud B, Martín-Malo A. Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. *Nephrol Dial Transplant.* 2018 Jan 1;33(1):160-170
IF: 4,470 Q1 D1
3. Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. *Kidney Int.* 2018 Feb;93(2):450-459
IF: 8,395 Q1 D1
4. Ayasreh N, Bullich G, Miquel R, Furlano M, Ruiz P, Lorente L, Valero O, García-González MA, Arhda N, Garin I, Martínez V, Pérez-Gómez V, Fulladosa X, Arroyo D, Martínez-Vea A, Espinosa M, Ballarín J, Ars E, Torra R. Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKDUMOD and ADTKD-MUC1. *Am J Kidney Dis.* 2018 May 18. pii: S0272-6386(18)30606-1
IF: 7,129 Q1 D1
5. Santamaría R, Díaz-Tocados JM, Pendón-Ruiz de Mier MV, Robles A, Salmerón-Rodríguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Muñoz-Castañeda JR, Martín-Malo A, Aljama P, Rodríguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. *Sci Rep.* 2018 Sep 12;8(1):13701
IF: 4,122 Q1 D2





GC08: Hormones and Cancer

<https://www.imibic.org/grupo/30>


ACTIVITY

- N° ONGOING PROJECTS: 3 (public), 4 (private)
- N° PROJECTS STARTING IN 2019: 1 (public)
- N° PATENTS: 2

TEAM

Castaño	Fuentes	Justo Pastor	R4
Blanco	Acevedo	Cristóbal José	R2
Pedraza	Arévalo	Sergio	R1
Fuentes	Fayos	Antonio Carlos	R1
Caro	Cuenca	M ^a Teresa	R1
Sánchez	Frías	Marina	R1
Blázquez	Encinas-Rey	Ricardo	S
Rivero	Cortes	Esther	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - CIBER Physiopathology of Obesity and Nutrition – CIBERObn
 - Spanish Group on Endocrine and Neuroendocrine Tumors (GETNE)
 - TransBioNet – Spanish Bioinformatics Network for Clinical Research
 - Area of Knowledge of Neuroendocrinology - Spanish Society of Endocrinology and Nutrition
 - Neuroendocrinology Working Group - Andalusian Society of Endocrinology, Diabetes and Nutrition
 - Molecular Registry of Pituitary Adenomas (REMAH): (REMAH)
 - BIO-139 “Cellular and Molecular Endocrinology” Research Group of the Andalusian Plan for Research, Development and Innovation (PAIDI)
 - Agrifood Campus of International Excellence (ceiA3)
- » **International projects:**
 - IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño.
- » **Competitive funding obtained for contracts:**
 - 1 FPU Contract
- » **2 agreements with companies**

KEYWORDS

- Cellular and molecular endocrine oncology
- pancreatic cancer
- neuroendocrine tumors
- pituitary tumors
- alternative splicing
- splice-variants
- spliceosome
- somatostatin
- somatostatin-receptors
- cortistatin
- ghrelin
- signaling

HIGHLIGHTED PUBLICATIONS

1. Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. *Pharmacological Rev* 2018, 70(4):763-835.
IF: 18,886 Q1 D1
2. Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Pérez E, Pedraza-Arévalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) enzyme as a novel potential biomarker in gastroenteropancreatic neuroendocrine tumors. *Clin Transl Gastroenterol* 2018, 9(10):196.
FI: 4,803 Q1
3. Pedraza-Arévalo S, Gahete MD, Alors-Perez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. *Rev Endocr Metab Disord* 2018, 19(2)179-192.
IF: 5,516 Q1
4. Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. *Sci Rep* 2018, 8(1):6173.
IF: 4,011 Q1
5. Gahete MD, Del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. *EBioMedicine* 2018, 3964(18)30479-1.
IF: 6,680 Q1 D1



GC09: Nutrigenomics Metabolic Syndrome

<https://www.imibic.org/grupo/31>

ACTIVITY


- N° ONGOING PROJECTS: 16 (public) , 1 (private)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 23
- N° THESIS: 5
- N° PATENTS: 2

TEAM

López	Miranda	José	R4
Pérez	Jiménez	Francisco	R4
Pérez	Martínez	Pablo	R4
Delgado	Lista	Javier	R4
Almadén	Peña	Yolanda	R4
Camargo	García	Antonio	R3C
García	Ríos	Antonio	R3C
Blanco	Molina	Mª Ángeles	R3A
Fernández	De La Puebla	Rafael Ángel	R3A
Fuentes	Jiménez	Francisco	R3A
López	Jiménez	Luciano	R3A
Montero	Pérez-Barquero	Manuel	R3A
Pérez	Caballero	Anabel	R3A
Rangel	Zuñiga	Oriol	R3A
Yubero	Serrano	Elena M	R3A
Alcalá	Díaz	Juan Francisco	R2
Criado	García	Juan	R2
de la Cruz	Ares	Silvia	R2
Gómez	Luna	Purificación	R2
Gómez	Delgado	Francisco	R2
Gutiérrez	Mariscal	Francisco Manuel	R2
Jimenez	Morales	Anabel	R2
León	Acuña	Ana	R2
Roncero	Ramos	Irene	R2
Arenas	de Larriva	Antonio Pablo	R1
Corina	Baba	Andreea	R1
Fernández	Gándara	Carolina	R1
López	Moreno	Javier	R1
Pérez	Cardelo	Mª Magdalena	R1
Torres	Peña	José David	R1
Vals	Delgado	Cristina	R1
Vega	Rojas	Ana María	R1

Villasanta	González	Alejandro	R1
Carreras	Calero	Rosario	T
Díaz	Marín	Begoña	T
Morales	Martínez	José Andrés	T
Peña	Orihuela	Patricia Judith	T
Pérez	Corral	Isabel	T
Quintana	Navarro	Gracia	T
Redondo	Garrido	Ana	T

SCIENTIFIC PRODUCTION



KEYWORDS

- Atherosclerosis
- endothelium
- metabolic syndrome
- type 2 diabetes mellitus
- Mediterranean diet
- olive oil
- polyphenols
- antioxidants
- inflammation
- oxidative stress
- cholesterol
- polyphenols
- gene expression
- proteomics
- nutrigenetics
- nutrigenomics

ADDITIONAL INFORMATION

» Networks:

- CIBER Physiopathology of Obesity and Nutrition (CIBERObn)
- PAIDI CTS-525: interaction genes and environment
- PAIDI CTS-212: nutrition and disease

» International Projects.

- POWER2DM - Predictive model-based decision support for diabetes patient empowerment. Funding Agency: European Commission H2020
- FAME - Fatty Acid Metabolism - Interlinking Diet with Cardiometabolic Health. Funding agency: JPI HDHL: BIOMARKERS FOR NUTRITION AND HEALTH – MINECO

» Competitive funding obtained for contracts:

- 1 Miguel Servet Contract (ISCIII)
- 1 Sara Borrel Contract (ISCIII)
- 1 PFIS Contract (ISCIII),
- 1 Nicolás Monardes Contract (SAS)
- 1 Juan de la Cierva Contract (MINECO)
- 2 Predoctoral Contract (MINECO)
- 1 Strengthening of research activity Programme (ISCIII)

» 4 agreements with companies

HIGHLIGHTED PUBLICATIONS

1. Gomez-Marin B, Gomez-Delgado F, Lopez-Moreno J, Alcalá-Díaz JF, Jimenez-Lucena R, Torres-Pena JD, Garcia-Rios A, Ortiz-Morales AM, Yubero-Serrano EM, Malagon MD, Lai CQ, Delgado-Lista J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial. *AMERICAN JOURNAL OF CLINICAL NUTRITION*. 2018; 108(5):963-970. **IF: 6,549 Q1 D1**

2. Garcia-Rios A, Alcalá-Díaz JF, Gomez-Delgado F, Delgado-Lista J, Marin C, Leon-Acuna A, Camargo A, Rodriguez-Cantalejo F, Blanco-Rojo R, Quintana-Navarro G, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J, Perez-Martinez P. Beneficial effect of CETP gene polymorphism in combination with a Mediterranean diet influencing

lipid metabolism in metabolic syndrome patients: CORDIOPREV study. *CLINICAL NUTRITION*. 2018; 37(1):229-234.

IF: 5,496 Q1 D1

3. Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, Alcalá-Díaz JF, Perez-Martinez P, Jimenez-Lucena R, Castano JP, Roche HM, Delgado-Lista J, Ordovas JM, Camargo A, Lopez-Miranda J. Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study. *MOLECULAR NUTRITION & FOOD RESEARCH*. 2018; 62(9):Núm artículo 1700960

IF: 5,151 Q1 D1

4. Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcalá-Díaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castano J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES*. 2018; 73(3):327-332.

IF: 4,902 D1

5. Lopez-Moreno J, Quintana-Navarro GM, Delgado-Lista J, Garcia-Rios A, Alcalá-Díaz JF, Gomez-Delgado F, Camargo A, Perez-Martinez P, Tinahones FJ, Striker GE, Perez-Jimenez F, Villalba JM, Lopez-Miranda J, Yubero-Serrano EM. Mediterranean Diet Supplemented With Coenzyme Q(10) Modulates the Postprandial Metabolism of Advanced Glycation End Products in Elderly Men and Women. *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES*. 2018; 73(3):340-346.

IF: 4,902 D1

MAIN RESULTS

» CLINICAL GUIDES:

- Pedro-Botet J, Ascaso JF, Barrios V, De la Sierra A, Escalada J, Millán J, Mostaza JM, Pérez-Martínez P, Pintó X, Salas-Salvadó J, Valdivielso P. COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. *Diabetes Metab Syndr Obes*. 2018 Oct 31;11:683-697. doi: 10.2147/DMSO.S165740. eCollection 2018. PMID: 30464566;
- Pérez-Jiménez F, Pascual V, Meco JF, Pérez Martínez P, Delgado Lista J, Domenech M, Estruch R, León-Acuña A, López-Miranda J, Sánchez-Ramos A, Soler I Ferrer C, Soler-Rivas C, Solá Alberich RM, Valdivielso P, Ros E. Document of recommendations of the SEA 2018. Lifestyle in cardiovascular prevention. *Clin Investig Arterioscler*. 2018 Nov - Dec; 30(6):280-310. doi: 10.1016/j.arteri.2018.06.005. Epub 2018 Sep 17. PMID: 30236615.





GC10: Hormonal Regulation of Energy Balance, Puberty and Reproduction

<https://www.imibic.org/grupo/22>


ACTIVITY

- N° ONGOING PROJECTS: 6 (public), 3 (private)
- N° PROJECTS STARTING IN 2019: 2
- N° THESIS: 1
- N° PATENTS: 1

TEAM

Tena	Sempere	Manuel	R4
Gaytan	Luna	Francisco	R3
Pinilla	Jurado	Leonor	R3
Vázquez	Villar	María Jesús	R3
Castellano	Rodríguez	Juan Manuel	R2B
Roa	Rivas	Juan	R2B
Romero	Ruiz	Antonio	R2B
Avendaño	Herrador	María Soledad	R2A
Herrera	Martínez	Aura Dulcinea	R2A
Franssen		Delphine	R2A
Pineda	Reyes	Rafael	R2A
Ruohonen		Suvi	R2A
Sánchez-Garrido	Nogueras	Miguel	R2A
Barroso	Romero	Alexia	R1
Fernandois	Vicencio	Daniela	R1
Gizem	Erkan	Leman	R1
Heras	Domínguez	Violeta	R1
Perdices	López	Cecilia María	R1
Ruiz	Cruz	Miguel	R1
Ruiz	Pino	Francisco	R1
Torres	Jiménez	Encarnación	R1
Velasco	Aguayo	Inmaculada	R1
Onieva	Jiménez	Rocío	T
Rodríguez	Sánchez	Ana Belén	T
Sánchez	Tapia	Mª Jesús	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - CIBERobn Physiopathology of Obesity and Nutrition.
 - Theme Area: Reproductive Endocrinology (Basic Lead; European Society of Endocrinology)
 - FiDiPro Program – Finnish Academy
- » **Competitive funding obtained for contracts:**
 - 1 Marie Curie Contract (ReproObesity)
 - 1 Miguel Servet Contract
 - 1 Sara Borrell Contract
 - 1 Rio Hortega Contract
- » **International Projects:**
 - FiDiPro Program
 - GAP-2014-655232
 - ESE-2018-01
 - SfE-ECG-2017-001
- » **5 agreements with companies**
- » **1 YOUNG Investigator AWARDS 2018 by European Society Of Endocrinology**

KEYWORDS


- Puberty
- fertility
- obesity
- metabolism
- energy sensors
- kisspeptins
- neuropeptides
- gonadotropins
- gonads
- polycystic ovary syndrome
- endometriosis
- hypogonadism
- microRNAs
- epigenetics

HIGHLIGHTED PUBLICATIONS

1. Vazquez MJ, Toro CA, Castellano JM, Ruiz-Pino F, Roa J, Beiroa D, Heras V, Velasco I, Dieguez C, Pinilla L, Gaytan F, Nogueiras R, Bosch MA, Ronnekleiv OK, Lomniczi A, Ojeda SR, Tena-Sempere M. SIRT1 mediates obesity- and nutrient-dependent perturbation of pubertal timing by epigenetically controlling Kiss1 expression. NATURE COMMUNICATIONS. 2018; 9: 4194
IF: 12,353 Q1 D1
2. Roa J, Barroso A, Ruiz-Pino F, Vazquez MJ, Seoane-Collazo P, Martinez-Sanchez N, Garcia-Galiano D, Ilhan T, Pineda R, Leon S, Manfredi-Lozano M, Heras V, Poutaneng M, Castellano JM, Gaytan F, Dieguez C, Pinilla L, Lopez M, Tena-Sempere M. Metabolic regulation of female puberty via hypothalamic AMPK-kisspeptin signaling. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018; 115(45):E10758-E10767.
IF: 9,504 Q1 D1

3. Manfredi-Lozano M, Roa J, Tena-Sempere M. Connecting metabolism and gonadal function: Novel central neuropeptide pathways involved in the metabolic control of puberty and fertility. FRONTIERS IN NEUROENDOCRINOLOGY. 2018; 48:37-49.
IF: 6,875 Q1 D1
4. Gaytan F, Morales C, Roa J, Tena-Sempere M. Changes in keratin 8/18 expression in human granulosa cell lineage are associated to cell death/survival events: potential implications for the maintenance of the ovarian reserve. HUMAN REPRODUCTION. 2018; 33(4):680-689.
IF: 4,99 Q1 D1
5. Leon S, Velasco I, Vazquez MJ, Barroso A, Beiroa D, Heras V, Ruiz-Pino F, Manfredi-Lozano M, Romero-Ruiz A, Sanchez-Garrido MA, Dieguez C, Pinilla L, Roa J, Nogueiras R, Tena-Sempere M. Sex-Biased Physiological Roles of NPF1R, the Canonical Receptor of RFRP-3, in Food Intake and Metabolic Homeostasis Revealed by its Congenital Ablation in mice. METABOLISM-CLINICAL AND EXPERIMENTAL. 2018; 87:87-97.
IF: 5,963 Q1





GC11: Metabolism and Adipocyte Differentiation-Metabolic Syndrome

<https://www.imibic.org/grupo/49>


ACTIVITY

- Nº ONGOING PROJECTS: 3 (public), 1 (public-private)

TEAM

Malagón	Poyato	Maria Del Mar	R4
Guzman	Ruiz	Rocío	R3
Fernandez	Vega	Alejandro	R1
López	Alcalá	Jaime	R1
Ruiz	Navarro	Maria Del Carmen	R1
Sánchez	Ceinos	Julia	R1
Tercero	Alcázar	Carmen	R1
Molero	Murillo	Laura	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

» Networks:

- CIBER Physiopathology of Obesity and Nutrition (CIBERObn)
- Research Network on Adipose Plasticity and Related Pathologies. Adipoplast. Ministry of Economy and Competitiveness, Spain.
- ADIPOSEQ. CIBERObn, Instituto de Salud Carlos III.

KEYWORDS

- Adipose tissue
- adipocytes
- adipogenesis
- bariatric surgery
- cellular stress
- extracellular matrix
- fibrosis
- cell imaging
- insulin signaling
- insulin resistance
- intracellular traffic
- lipid droplets
- lipids
- microscopy
- obesity
- proteomics
- protein networks

HIGHLIGHTED PUBLICATIONS

1. Quinones M, Al-Massadi O, Folgueira C, Bremser S, Gallego R, Torres-Leal L, Haddad-Tovoli R, Garcia-Caceres C, Hernandez-Bautista R, Lam BYH, Beiroa D, Sanchez-Reboredo E, Senra A, Malagon JA, Valerio P, Fondevila MF, Ferno J, Malagon MM, Contreras R, Pfluger P, Bruning JC, Yeo G, Tschop M, Dieguez C, Lopez M, Claret M, Kloppenburg P, Sabio G, Nogueiras R. p53 in AgRP neurons is required for protection against diet-induced obesity via JNK1. NATURE COMMUNICATIONS. 2018; 9:Núm artículo 3432

IF: 12,353 Q1 D1

2. de la Rosa IA, Escudero-Contreras A, Rodriguez-Cuenca S, Ruiz-Ponce M, Jimenez-Gomez Y, Ruiz-Limon P, Perez-Sanchez C, Abalos-Aguilera MC, Cecchi I, Ortega R, Calvo J, Guzman-Ruiz R, Malagon MM, Collantes-Estevez E, Vidal-Puig A, Lopez-Pedraza C, Barbarroja N. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. JOURNAL OF INTERNAL MEDICINE. 2018; 284(1):61-77.

IF: 6,754 Q1 D1

3. Gomez-Marin B, Gomez-Delgado F, Lopez-Moreno J, Alcalá-Díaz JF, Jimenez-Lucena R, Torres-Pena JD, Garcia-Rios A, Ortiz-Morales AM, Yubero-Serrano EM, Malagon MD, Lai CQ, Delgado-Lista J, Ordoñas JM, Lopez-Miranda J, Perez-Martinez P. Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial. AMERICAN JOURNAL OF CLINICAL NUTRITION. 2018; 108(5):963-970.

IF: 6,549 Q1 D1

4. Roncero-Ramos I, Jimenez-Lucena R, Alcalá-Díaz JF, Vals-Delgado C, Arenas-Larriva AP, Rangel-Zuniga OA, Leon-Acuna A, Malagon MM, Delgado-Lista J, Perez-Martinez P, Ordoñas JM, Camargo A, Lopez-Miranda J. Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes. JOURNAL OF NUTRITIONAL BIOCHEMISTRY. 2018; 62:47-256.

IF: 4,414 Q1

5. Travez A, Rabanal-Ruiz Y, Lopez-Alcala J, Molero-Murillo L, Diaz-Ruiz A, Guzman-Ruiz R, Catalan V, Rodriguez A, Fruhbeck G, Tinahones FJ, Gasman S, Vitale N, Jimenez-Gomez Y, Malagon MM. The caveolae-associated coiled-coil protein, NECC2, regulates insulin signalling in Adipocytes. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2018; 22(11):5648-5661.

IF: 4,302 Q1





GC12: Clinical and Epidemiological Research in Primary Care (GICEAP)

<https://www.imibic.org/grupo/51>


ACTIVITY

- N° ONGOING PROJECTS: 7 (public)
- N° CLINICAL TRIALS: 10
- N° THESIS: 2

TEAM

Pérula	De Torres	Luis Ángel	R4
Varas	Fabra	Francisco José	R3
Aguado	Taberne	Cristina	R3
Arias	Blanco	María Del Carmen	R3
Arias	Vega	Mª Raquel	R3
Blanco	Hungría	Antonio	R3
Carrera	González	María Del Pilar	R3
Fernández	García	Jose Ángel	R3
Fonseca	Del Pozo	Francisco Javier	R3
González	Lama	Jesús	R3
González	Carretero	Juan Ignacio	R3
Hidalgo	Requena	Antonio	R3
Jiménez	García	Celia	R3
Martin	Rioboo	Enrique	R3
Montero	Monterroso	José Luis	R3
Montero	Monterroso	Jose Luis	R3
Muñoz	Del Castillo	Francisco	R3
Olaya	Caro	Inmaculada	R3
Parras	Rejano	Juan Manuel	R3
Pérula	De Torres	Carlos	R3
Ranchal	Sánchez	Antonio	R3
Redondo	Sánchez	Juana	R3
Rich	Ruiz	Manuel	R3
Roldán	Villalobos	Ana	R3
Ruiz	Moral	Roger	R3
Ruiz	Moruno	Fco. Javier	R3
Serrano	Merino	Jesús	R3
Silva	Aycaguer	Luis Carlos	R3
Valero	Martin	Antonio José	R3
Vaquero	Abellán	Manuel	R3
Villegas	Becerril	Enrique	R3
Leiva	Cepas	Fernando	R1
Marín	González	Beatriz	R1
Muñoz	Alcaraz	María Nieves	R1
Muñoz	Gómez	Rafaela	R1
Romero	Rodríguez	Esperanza María	R1
Criado	Larumbe	Margarita	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - redIAPP - Primary Care Prevention and Health Promotion Network (ISCIII)
 - PAIDI CTS-452 Family and Community Medicine
- » **3 agreements with companies.**

KEYWORDS

- Primary Care
- epidemiology
- preventive medicine
- applied pesearch
- family and community edicine
- communication and health
- community health
- public health
- environment

HIGHLIGHTED PUBLICATIONS

1. Martin-Rioboo E, Pérula de Torres LA, Banegas JR, Lobos-Bejarano JM, Cuixart CB, Criado EIG, Martin-Carrillo P, Muro MMR, Cabello MIE, Galan AM. Knowledge, availability, and use of ambulatory and home blood pressure monitoring in primary care in Spain: the MAMPA study. JOURNAL OF HYPERTENSION. 2018; 36(5):1051-1058.
IF: 4,092 Q1
2. Albornos-Muñoz L, Moreno-Casbas MT, Sanchez-Pablo C, Bays-Moneo A, Fernandez-Dominguez JC, Rich-Ruiz M, Gea-Sanchez M. Efficacy of the Otago Exercise Programme to reduce falls in community-dwelling adults aged 65-80 years old when delivered as group or individual training. JOURNAL OF ADVANCED NURSING. 2018; 74(7):1700-1711.
IF: 2,267 Q1 D1
3. Ranchal Sánchez A, Pérula de Torres LA, Santos Luna F, Ruiz-Moral R. Prevalence of tobacco consumption among young physicians at a regional university hospital in southern Spain: a cross-sectional study. BMJ OPEN. 2018; 8(2): Núm artículo e018728
IF: 2,413 Q2

4. Romero-Saldaña M, Tauler P, Vaquero-Abellán M, López-González AA, Fuentes-Jiménez FJ, Aguiló A, Álvarez-Fernández C, Molina-Recio G, Bennasar-Veny M. Validation of a non-invasive method for the early detection of metabolic syndrome: a diagnostic accuracy test in a working population. BMJ Open. 2018 Oct 21;8(10):e020476. doi: 10.1136/bmjopen-2017-020476.
IF: 2,413 Q2
5. Serrano Merino JS, Pérula de Torres LAP, Bardwell WA, Muñoz Gomez R, Roldán Villalobos A, Feu Collado N, Ruiz-Moral R, Jurado-Gamez B. Impact of Positive Pressure Treatment of the Airway on Health-Related Quality of Life in Elderly Patients With Obstructive Sleep Apnea. BIOLOGICAL RESEARCH FOR NURSING. 2018; 20(4):452-461.
IF: 1,579 Q2





GC13: Calcium metabolism. Vascular calcification

<https://www.imibic.org/grupo/42>

ACTIVITY

- N° ONGOING PROJECTS: 4 (public) , 1 (private)
- N° PROJECTS STARTING IN 2019: 1 (public)
- N° CLINICAL TRIALS : 4

TEAM

Rodríguez	Portillo	Mariano	R4
Muñoz	Castañeda	Juan Rafael	R3C
Aguilera	Tejero	Escolástico	R3
Canalejo	Raya	Antonio L.	R3
López	Villalba	Ignacio	R3
Pineda	Martos	Carmen María	R2
Raya	Bermúdez	Ana Isabel	R2
Rodríguez	Ortiz	Mª Encarnación	R2
Díaz	Tocados	Juan Miguel	R1
López	Baltanás	Rodrigo	R1
Pendón	Ruiz De Mier	Mª Victoria	R1
Ríos	Varo	Rafael	R1
Vergara	Segura	Noemí	R1
Rodelo	Haad	Cristian	CR
Andújar	Gil	Alicia	T
Membrives	González	Cristina	T
Ruiz	Mora	Erena	T
García	Valdivia	Sandra	ADM

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - Spanish Renal Research Network (REDinREN)
 - PAIDI CTS-179 Scientific group
 - European Uremic Toxic (EUTOX)
 - CKD-MBD GROUP (ERA-EDTA)
- » **Competitive funding obtained for contracts:**
 - 1 Nicolás Monarde Contract (SAS)
- » **6 agreements with companies**

KEYWORDS

- calcium
- phosphorus
- mineral metabolism
- parathyroid glands
- PTH
- calcification
- uremia
- HPTH2°
- vascular calcification
- renal failure
- bone mineral disease
- VDR
- CaSR
- mesenchymal stem cells
- Wnt / beta-catenin

HIGHLIGHTED PUBLICATIONS

1. Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. Sci Rep. 2018 Oct 29;8(1):15940. Erratum in: Sci Rep. 2018 Dec 10;8(1):17822. **IF: 4,122 Q1**
2. Pineda C, Rios R, Raya AI, Rodríguez M, Aguilera-Tejero E, Lopez I. Hypocaloric Diet Prevents the Decrease in FGF21 Elicited by High Phosphorus Intake. Nutrients. 2018 Oct 13;10(10). **IF:4,196 Q1**

3. Santamaría R, Díaz-Tocados JM, Pendón-Ruiz de Mier MV, Robles A, Salmerón-Rodríguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Muñoz-Castañeda JR, Martín-Malo A, Aljama P, Rodríguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. Sci Rep. 2018 Sep 12;8(1):13701.

IF: 4,122 Q1

4. Rodelo-Haad C, Rodríguez-Ortiz ME, Martín-Malo A, Pendón-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodríguez M. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS One. 2018 Aug 7;13(8):e0201537.

IF:2,766 Q1

5. Rios R, Pineda C, Lopez I, Muñoz-Castañeda J, Rodríguez M, Aguilera-Tejero E, Raya AI. Phosphorus restriction does not prevent the increase in fibroblast growth factor 23 elicited by high fat diet. PLoS One. 2018 Jun 1;13(6):e0198481.

IF : 2,766 Q1





GC14: Cellular Therapy

<https://www.imibic.org/grupo/12>

ACTIVITY

- N° ONGOING PROJECTS: 3 (public)
- N° PROJECTS STARTING IN 2019: 1(public)
- N° CLINICAL TRIALS: 3
- N° THESIS: 1

TEAM

Herrera	Arroyo	Inmaculada Concepción	R4
Centeno	Haro	Macarena	R3
Martin	Palanco	Vanesa	R3
Nogueras	Martin	Sonia	R3
Ortega	Salas	Rosa	R3
Carmona	Luque	María Dolores	R2
Jimenez	Moreno	Rosario	R2
Paco	Meza	Luis Miguel	R1
Pavlovic	Pavlovic	Kristina	R1
Ortiz	Espejo	Lourdes	T
Gutiérrez	Fernández	Rosario	T

ADDITIONAL INFORMATION

- » **Networks:**
 - IATA (Andalusian Initiative for Advances Therapies) [<https://www.juntadeandalucia.es/terapiasavanzadas/index.php/en/>]
 - EATRIS ATMP platform (European Infrastructure for Translational Medicine) [<https://eatris.eu/>]
- » **11 agreements with companies.**
- » **Competitive funding obtained for contracts:**
 - 1 Thecnical Staff -IATA (SAS)
 - 1 Predoctoral Researcher Contract (FPS-ONCOHEMATOLOGÍA)

KEYWORDS


- Stem cells
- cell therapy
- regenerative medicine
- myocardial regeneration
- therapeutic angiogenesis
- cell-gene therapy
- CAR-T cells


HIGHLIGHTED PUBLICATIONS

1. Martin SR, Povedano JLR, Garcia MC, Romero ALS, Garriguet MP, Benito MA. Prospective study aiming to compare 2D mammography and tomosynthesis plus synthesized mammography in terms of cancer detection and recall. From double reading of 2D mammography to single reading of tomosynthesis. EUROPEAN RADIOLOGY. 2018; 28(6):2484-2491.
IF: 4,027 Q1
2. Rubio-Navarro A, Sanchez-Nino MD, Guerrero-Hue M, Garcia-Caballero C, Gutierrez E, Yuste C, Sevillano A, Praga M, Egea J, Roman E, Cannata P, Ortega R, Cortegano I, de Andres B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. JOURNAL OF PATHOLOGY. 2018; 244(3):296-310.
IF: 6,253 Q1
3. Garzon FB, Alvarez-Ossorio MP, Moreno MAR, Palanco VM, Arroyo CH, Conde JSDC. Coronary Flow Reserve and Ventricular Function Following Regenerative Treatment in Patients With Revascularized Acute Anterior Myocardial Infarction. REVISTA ESPANOLA DE CARDIOLOGIA. 2018; 71(5):344-350.
IF: 5,166 Q1

4. Santamaria R, Diaz-Tocados JM, de Mier MVPR, Robles A, Salmeron-Rodriguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Munoz-Castaneda JR, Martin-Malo A, Aljama P, Rodriguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. SCIENTIFIC REPORTS. 2018; 8: Núm artículo 13701
IF: 4,122 Q1
5. Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. ENDOCRINE. 2018; 59(2):426-437.
IF: 3,179 Q2

SCIENTIFIC PRODUCTION





GC15: Invasive cardiology and cell therapy

<https://www.imibic.org/grupo/13>

ACTIVITY

- Nº PROJECTS STARTING IN 2019: 1 (public)
- Nº CLINICAL TRIALS: 18
- Nº THESIS: 3

TEAM

Pan	Álvarez-Ossorio	Manuel	R4
Anguita	Sánchez	Manuel P.	R3
Arizón	Arizón Del Prado	José M ^a	R3
Castillo	Domínguez	Juan Carlos	R3
Delgado	Ortega	Mónica Maria	R3
López	Granados	Amador	R3
Mazuelos	Bellido	Francisco	R3
Mesa	Rubio	Maria Dolores	R3
Ojeda	Pineda	Soledad	R3
Pavlovic	Djurovic	Djordje	R3
Romero	Moreno	Miguel Ángel	R3
Ruiz	Ortiz	Martín	R3
Segura	Saint-Gerons	Jose M ^a	R3
Suárez de Lezo	Herreros de Tejada	Javier	R3
López	Aguilera	José	R2
Hidalgo	Lesmes	Francisco José	R1
Luque	Moreno	Aurora	CR
Cebrián	Salgado	Eva	ADM

ADDITIONAL INFORMATION

» Networks:

- Dr Manuel Pan Álvarez-Ossorio is member of the work group European Bifurcation Club and leader of the organization of many of the meetings and courses organized by the group on an international level.
- One of our researchers, Dr Miguel A Romero Moreno is member of the Working Group on Grown Up Congenital Heart Disease European Society of Cardiology and Dr. Anguita the president of the Spanish Society of Cardiology (Sociedad Española de Cardiología).
- Dr Anguita and Dr Pan are both active members of the group that develops the guidelines for clinical practice of the Spanish Society of Cardiology (Sociedad Española de Cardiología).

» Competitive funding obtained for contracts:

- 1 Research Programme SEC

» 4 agreements with companies

KEYWORDS

- Cardiac interventions
- cellular therapy
- stents
- percutaneous aortic valves
- closing birth defects

HIGHLIGHTED PUBLICATIONS

1. Ramiro-Ortega E, Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Alhambra-Exposito R, Sanchez MA. Nutritional intervention in acute heart failure patients with undernutrition and normalbuminemia: A subgroup analysis of PICNIC study. CLINICAL NUTRITION. 2018; 37(5);1762-1764.

IF: 5,496 Q1 D1

2. Ortiz MR, Muniz J, Miguez PR, Roldan I, Marin F, Esteve-Pastor MA, Cequier A, Martinez-Selles M, Bertomeu V, Anguita M. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry. EUROPACE. 2018; 20(10):1577-1583.

IF: 5,231 Q1

3. Pan M, Ojeda S, Jimenez-Quevedo P, Serrador A, Azzalini L, de Prado AP. Selection of the Best of 2017 on Percutaneous Treatment of Chronic Occlusions. REVISTA ESPANOLA DE CARDIOLOGIA. 2018; 71(3):221-223.

IF: 5,166 Q1


4. Ojeda S, Azzalini L, Chavarria J, Serra A, Hidalgo F, Benincasa S, Gheorghe LL, Diletti R, Romero M, Bellini B, Gutierrez A, de Lezo JS, Mazuelos F, Segura J, Carlino M, Colombo A, Pan M. One Versus 2-stent Strategy for the Treatment of Bifurcation Lesions in the Context of a Coronary Chronic Total Occlusion. A Multicenter Registry. REVISTA ESPANOLA DE CARDIOLOGIA. 2018; 71(6):432-439.

IF: 5,166 Q1

5. Garzon FB, Alvarez-Ossorio MP, Moreno MAR, Palanco VM, Arroyo CH, Conde JSDC. Coronary Flow Reserve and Ventricular Function Following Regenerative Treatment in Patients With Revascularized Acute Anterior Myocardial Infarction. REVISTA ESPANOLA DE CARDIOLOGIA. 2018; 71(5):344-350.

IF: 5,166 Q1

SCIENTIFIC PRODUCTION





GC16: Cellular biology in Hematology. Hypercoagulability

<https://www.imibic.org/grupo/11>

ACTIVITY

- N° ONGOING PROJECTS: 1 (public), 3 (private)
- N° CLINICAL TRIALS : 34
- N° THESIS: 1

TEAM

Sánchez	García	Joaquín	R4
Velasco	Gimena	Francisco	R4
Arqueros	Martínez	Víctor	R3
Martin	Calvo	Carmen	R3
Martínez	Losada	M ^a del Carmen	R3
Molina	Hurtado	Jose Ramón	R3
Rojas	Contreras	Rafael	R3
Serrano	Lopez	Josefina	R3
Serrano	Lopez	Juana	R2
Álvarez	Rivas	Miguel A.	CR
Casaño	Sánchez	Javier	CR
Fernández	de la Mata	Margarita	CR
García	Torres	Estefanía	CR
Rodríguez	Villa	Antonia	CR
Tabares	Carrasco	Salvador	CR
Dorado	Pardo	Javier	T

ADDITIONAL INFORMATION

- » **Networks:**
 - PETHEMA (Acute leukemia Lymphoma allogenic stem cell transplantation hypercoagulability) [<http://www.fundacionpethema.es/>]
 - GESMD - Spanish Group of Myelodysplastic Syndromes [<https://www.gesmd.es/>]
 - European Society for Blood and Marrow Transplantation – EBMT [<http://www.ebmt.org/>]
 - Observational Immune Tolerance Induction research programme - lbsITI [<http://www.obsiti.com/at-a-glance>]
- » **Competitive funding obtained for contracts:**
 - 1 Research Programme FEHH
- » **8 agreements with companies**

KEYWORDS

- Acute leukemia
- lymphoma
- allogenic stem cell transplantation
- hypercoagulability

HIGHLIGHTED PUBLICATIONS

1. Martínez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, García-Ortiz MV, Morales-Ruiz T, Jerez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibanez M, Sempere A, Sanz MA, Lo-Coco F, Sanchez-García J. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. HAEMATOLOGICA. 2018; 103(9):E400-E403.
IF: 9,09 Q1 D1
2. Sanchez-García J, Falantes J, Perez AM, Hernandez-Mohedo F, Hermosin L, Torres-Sabariago A, Bailen A, Hernandez-Sanchez JM, Rodriguez MS, Casano FJ, Calderon C, Labrador M, Vahi M, Serrano J, Lumbreras E, Hernandez-Rivas JM. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. LEUKEMIA & LYMPHOMA. 2018; 59(5):1095-1104.
IF: 2,644 Q2
3. Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, Luque-Tevar M, Ruiz-Limon P, Barbarroja N, Jimenez-Gomez Y, Abalos-Aguilera MC, Collantes-Estevez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martinez C, Gonzalez-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, Lopez-Pedraza C. Circulating microRNAs as

biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. HAEMATOLOGICA. 2018; 103(5):908-918.

IF: 9,09 Q1 D1


4. de la Fuente FDA, Duran MS, Alvarez MA, Sanroman IL, Dios AM, Tamayo RR, Garcia R, Gonzalez MS, Prieto E, Barez A, Escalante F, Tejedor A, Ballesteros M, Cabanas V, Capote FJ, Couto C, Garzon S, Gonzalez-Pardo M, Manteca MVM. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. SEMINARS IN HEMATOLOGY. 2018; 55(4):189-196.

IF: 3,926 Q2

5. Serrano-Lopez J, Nattamai K, Pease NA, Shephard MS, Wellendorf AM, Sertorio M, Smith EA, Geiger H, Wells SI, Cancelas JA, Privette Vinnedge LM. 2.-Loss of DEK induces radioresistance of murine restricted hematopoietic progenitors. EXPERIMENTAL HEMATOLOGY 2018 Mar;59:40-50

IF: 2.436 Q2

SCIENTIFIC PRODUCTION





GC17: Physiopathology of Endocrine Vitamin D System Biotechnology and Aging

<https://www.imibic.org/grupo/32>


ACTIVITY

- N° ONGOING PROJECTS: 3 (public), 1 (private)
- N° PROJECTS STARTING IN 2019: 1 (public)
- N° CLINICAL TRIALS : 2

TEAM

Quesada	Gómez	José Manuel	R4
Cuenca	Acevedo	Rafael	R3
Romero	Sánchez	Mª Concepción	R3
Serrano	Alfárez	Ignacio	R3
Casado	Díaz	Antonio	R3
Rodríguez	Ramos	Ángel	R1
Torrecillas	Baena	Bárbara	S

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - Thematic Network of Research Partnerships on Aging-Frailty (RETICEF).
 - PAIDI CTS-413 scientific group
- » **1 Strengthening of research activity Programme (SAS)**
- » **1 agreement with companies**

KEYWORDS

- Osteoporosis
- vitamin D
- carotenoids
- fatty acids
- human mesenchymal stem cells (MSCh) of adult adipocytes
- osteoblasts
- polyphenols
- gene expression
- proteomics
- nutrigenetics
- nutrigenomics
- endothelial progenitor cells
- exosomes
- aging
- regenerative medicine

HIGHLIGHTED PUBLICATIONS

1. Quesada-Gomez JM, Santiago-Mora R, Duran-Prado M, Dorado G, Pereira-Caro G, Moreno-Rojas JM, Casado-Diaz A. β -Cryptoxanthin Inhibits Angiogenesis in Human Umbilical Vein Endothelial Cells Through Retinoic Acid Receptor. MOLECULAR NUTRITION & FOOD RESEARCH. 2018; 62(2): Núm artículo 1700489
IF: 5,151 Q1 D1
2. Quesada-Gomez JM, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation? OSTEOPOROSIS INTERNATIONAL. 2018; 29(8):1697-1711.
IF: 3,856 Q2
3. Navarro-Valverde C, Caballero-Villarraso J, Mata-Granados JM, Casado-Diaz A, Sosa-Henriquez M, Malouf-Sierra J, Nogues-Solan X, Rodriguez-Manas L, Cortes-Gil X, Delgadillo-Duarte J, Quesada-Gomez JM. High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women. CALCIFIED TISSUE INTERNATIONAL. 2018; 102(6):651-656.
IF: 3,293 Q2

4. Roca-Ayats N, Ng PY, Garcia-Giralt N, Falco-Mascaro M, Cozar M, Abril JF, Gomez JMQ, Prieto-Alhambra D, Nogues X, Dunford JE, Russell RG, Baron R, Grinberg D, Balcells S, Diez-Perez A. Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types. JOURNAL OF BONE AND MINERAL RESEARCH. 2018; 33(12):2091-2098.
IF: 6,314 Q1 D1
5. Nogues X, Nolla JM, Casado E, Jodar E, Munoz-Torres M, Quesada-Gomez JM, Canals L, Balcells M, Lizan L. Spanish consensus on treat to target for osteoporosis. OSTEOPOROSIS INTERNATIONAL. 2018; 29(2):489-499.
IF: 3,856 Q2



GC18: Translational Research in Surgery of Solid Organ Transplantation

<https://www.imibic.org/grupo/33>

ACTIVITY

- N° ONGOING PROJECTS: 4 (public), 1 (private)
- N° PROJECTS START IN 2019: 1 (public)
- N° CLINICAL TRIALS : 1

TEAM

Briceño	Delgado	Francisco Javier	R4
Ciria	Bru	Rubén	R3
Jiménez	Gómez	Jesús	R3
Leva	Vallejo	Manuel	R3
López	Cillero	Pedro	R3
Medina	Fernández	Francisco Javier	R3
Muñoz	Casares	Francisco Cristóbal	R3
Padial	Aguado	Ana Cristina	R3
Pozo	Laderas	Juan Carlos	R3
Regueiro	Lopez	Juan Carlos	R3
Robles	Ariza	Juan Carlos	R3
Rufian	Peña	Sebastián	R3
Ruiz	Rabelo	Juan	R3
Arjona	Sánchez	Álvaro	R2
Pintor	Tortolero	Jose	R2
Pleguezuelo	Navarro	Maria	R2
Gómez	Luque	Irene	R1
Navarro	Rodríguez	Elena	R1

ADDITIONAL INFORMATION

- » **PAIDI CTS-273. Study of acute infections of the digestive system.**
- » **International Projects:**
 - Euromp - European Network on Pseudomyxoma Peritonei. (COST)
- » **Competitive funding obtained for contracts:**
 - 1 Research Programme AEC
- » **2 agreements with companies**

KEYWORDS

- Liver transplant
- pancreas transplant
- kidney transplant
- lung transplant
- heart transplant
- living donor transplantation
- pediatric transplantation
- split transplantation
- expanded criteria donors


HIGHLIGHTED PUBLICATIONS

1. Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(11):1218-1219.
IF: 5,394 Q1 D1
2. Pintor-Tortolero J, Medina J, Duran M, Briceno J. Anorectal tumor as a debut form of visceral leishmaniasis. SURGERY. 2018; 164(6):1390-1391.
IF: 3,574 Q1
3. Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. LIVER TRANSPLANTATION. 2018; 24(2):192-203.
IF: 3,752 Q1

4. Arjona-Sanchez A, Rufian-Pena S, Artilles M, Sanchez-Hidalgo JM, Casado-Adam A, Cosano A, Thoelecke H, Ramnarine S, Garcilazo D, Briceno-Delgado J. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy. INTERNATIONAL JOURNAL OF HYPERTHERMIA. 2018; 34(5):570-577.
IF: 3,44 Q1

5. Arjona-Sanchez A, Rufian-Pena S, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience. WORLD JOURNAL OF SURGERY. 2018; 42(10):3120-3124.
IF: 2,766 Q1

SCIENTIFIC PRODUCTION





GC19: Artificial Vision Applications

<https://www.imibic.org/grupo/29>

ACTIVITY

- Nº ONGOING PROJECTS: 4 (public)
- Nº PROJECTS STARTING IN 2019: 1 (public)

TEAM

Medina	Carnicer	Rafael	R4
Muñoz	Salinas	Rafael	R3
Carmona	Poyato	Ángel	R3
Fernández	García	Nicolás Luis	R3
Garrido	Castro	Juan Luis	R3
Madrid	Cuevas	Francisco Jose	R3
Marin	Jimenez	Manuel Jesús	R3
Yeguas	Bolivar	Enrique	R3
Sarmadi		Hamid	R1
Romero	Ramirez	Francisco José	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - PAIDI TIC-161 Artificial Vision Applications (A.V.A)
- » **Competitive funding obtained for contracts:**
 - 1 I-PIFIS Contract (ISCIII)
- » **3 agreements with companies**

KEYWORDS

- Computer vision
- image segmentation
- pattern recognition
- 3D reconstruction
- augmented reality
- human recognition
- human pose estimation


HIGHLIGHTED PUBLICATIONS

1. Mondejar-Guerra V, Garrido-Jurado S, Munoz-Salinas R, Marin-Jimenez MJ, Medina-Carnicer R. Robust identification of fiducial markers in challenging conditions. EXPERT SYSTEMS WITH APPLICATIONS. 2018; 93:336-345.
IF: 3,768 Q1 D1
2. Munoz-Salinas R, Marin-Jimenez MJ, Yeguas-Bolivar E, Medina-Carnicer R. Mapping and localization from planar markers. PATTERN RECOGNITION. 2018; 73:158-171.
IF: 3,962 Q1
3. Romero-Ramirez FJ, Munoz-Salinas R, Medina-Carnicer R. Speeded up detection of squared fiducial markers. IMAGE AND VISION COMPUTING. 2018; 76:38-47.
IF: 2,159 Q1
4. Garrido-Castro JL, Curbelo R, Mazzucchelli R, Dominguez-Gonzalez ME, Gonzalez-Navas C, Robles BJJ, Zarco P, Mulero J, Cea-Calvo L, Arteaga MJ, Font-Ugalde P, Carmona L, Collantes-Estevez E. High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. JOURNAL OF RHEUMATOLOGY. 2018; 45(10):1383-1388.
IF: 3,47 Q2

5. Marin-Jimenez MJ, Romero-Ramirez FJ, Munoz-Salinas R, Medina-Carnicer R. 3D human pose estimation from depth maps using a deep combination of poses. JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION. 2018; 55:627-639.

IF: 1,836 Q2

SCIENTIFIC PRODUCTION





GC20: Genetics and behavioural diseases

<https://www.imibic.org/grupo/34>


ACTIVITY

- N° ONGOING PROJECTS: 2 (public)
- N° CLINICAL TRIALS: 1

TEAM

Ruiz	Rubio	Manuel	R4
Moriana	Elvira	Juan Antonio	R4
Alejandro	Duran	Encarna	R3
Alós	Cívico	Francisco José	R3
Antolí	Cabrera	Adoración	R3
Burgos	Marín	Rafael	R3
Gámez	Granados	Juan Carlos	R3
García	Torres	Francisco Mariano	R3
Guijarro	Granados	Teresa	R3
Martin	Borreguero	Pilar	R3
Moreno		Eliana	R3
Pérez	Dueñas	Carolina	R3
Romero	Balsera	María Auxiliadora	R3
Sánchez	Raya	M ^a Araceli	R3
Sánchez	Vázquez	Vicente	R3
Soto	Hidalgo	José Manuel	R3
Jurado	González	Francisco Javier	R1
Arriaga	Díaz	Valle	R1
Cuadrado	Hidalgo	Fátima	R1
Gálvez	Lara	Mario	R1
Rodríguez	Ramos	Ángel	R1
Vacas	Ruiz	Julia	R1
Venceslá	Martínez	José Fernando	CR
Espejo	Durán	Carmen	T
Moyano	Santiago	Álvaro	T
Velasco	Rodríguez	Judith	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - Excellence research and interdisciplinary Network for the diagnosis and promotion of youth issues, emotions and psychological well-being (MINECO PSI2015-70943-REDT). (Collaborator)
- » **2 agreements with companies**

KEYWORDS

- behaviour genetics
- autism spectrum disorder
- C. elegans
- oncology
- clinical psychology
- psycho-oncology
- psychological treatment
- primary care
- depression
- anxiety
- based-evidence psychology
- early attention
- developmental disorders
- neuropsychological alterations
- rare diseases
- developmental disability
- verbal behaviour
- cognitive behaviour

HIGHLIGHTED PUBLICATIONS

- García-Torres F, Castillo-Mayen R, Alos FJ. Psychoticism and employment status in breast cancer survivors. PSYCHO-ONCOLOGY. 2018; 27(1):359-361.
IF: 3,455 Q1 D1
- Galvez-Lara M, Corpas J, Moreno E, Vencesla JF, Sanchez-Raya A, Moriana JA. Psychological Treatments for Mental Disorders in Children and Adolescents: A Review of the Evidence of Leading International Organizations. CLINICAL CHILD AND FAMILY PSYCHOLOGY REVIEW. 2018; 21(3):366-387.
IF: 3,6 Q1
- Perez-Duenas C, Rivas MF, Oyediran OA, Garcia-Torres F. Induced Negative Mood Increases Dictator Game Giving. FRONTIERS IN PSYCHOLOGY. 2018; 9: Núm artículo 1542
IF: 2,089 Q2
- Diaz-Gonzalez MC, Duenas CP, Sanchez-Raya A, Moriana, JA, Vazquez VS. Mindfulness-based stress reduction in adolescents with mental disorders: A randomised clinical trial. PSICOTHEMA. 2018; 30(2):165-170.
IF: 1,516 Q2
- Osuna-Luque J, Rodriguez-Ramos A, Gamez-del-Estal MD, Ruiz-Rubio M. Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole. JOURNAL OF EXPERIMENTAL NEUROSCIENCE. 2018; 12: Núm artículo UNSP 1179069518798628
IF: 0





GC21: Metabolomics and identification of bioactive compounds

<https://www.imibic.org/grupo/48>

ACTIVITY

- N° ONGOING PROJECTS: 2 (public), 2 (public-private)
- N° THESIS: 1

TEAM

Priego	Capote	Feliciano	R4
Luque	de Castro	Maria Dolores	R4
Calderón	Santiago	Mónica	R2A
Ledesma	Escobar	Carlos Augusto	R2A
Delgado	Povedano	Mª Del Mar	R1
Díaz	Lozano	Azahara	R1
Castillo	Peinado	Laura De Los Santos	R1
López	Bascón	María Asunción	R1
Luque	Córdoba	Diego	R1
Mena	Bravo	Antonio	R1
Criado	Navarro	Inmaculada	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - CIBERFES - Cooperative Research Thematic Network on Aging and Frailty [link: <http://www.ciberfes.es/en>] (Collaborator)
 - Dr Priego Capote is the coordinator of the FQM-227 - Analytical Chemistry Research Group, of the Andalusian Plan for Research, Development and Innovation (PAIDI).
- » **International Projects: Interreg-Med Program. MED-1033**
- » **5 agreements with companies**

KEYWORDS

- metabolomics
- mass spectrometry
- targeted analysis
- untargeted analysis
- sample preparation
- clinical analysis
- agrofood
- bioactive compounds


HIGHLIGHTED PUBLICATIONS

1. Miho H, Diez CM, Mena-Bravo A, de Medina VS, Moral J, Melliou E, Magiatis P, Rallo L, Barranco D, Priego-Capote F. Cultivar influence on variability in olive oil phenolic profiles determined through an extensive germplasm survey. FOOD CHEMISTRY. 2018; 266:192-199.
IF: 4,946 Q1 D1
2. Ledesma-Escobar CA, Priego-Capote F, Robles-Olvera VJ, Luque de Castro MD. Targeted analysis of the concentration changes of phenolic compounds in Persian lime (*Citrus latifolia*) during fruit growth. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. 2018; 66(8):1813-1820.
IF: 3,412 Q1 D1
3. Delgado-Povedano MM, Calderon-Santiago M, Luque de Castro MD, Priego-Capote F. Metabolomics analysis of human sweat collected after moderate exercise. TALANTA. 2018; 177:47-65.
IF: 4,244 Q1
4. Lopez-Bascon MA, Calderon-Santiago M, Sanchez-Ceinos J, Fernandez-Vega A, Guzman-Ruiz R, Lopez-Miranda J, Malagon MM, Priego-Capote F. Influence of sample preparation on lipidomics analysis of polar lipids in adipose tissue. TALANTA 2018; 177:86-93.
IF: 4,244 Q1

5. Luque-Cordoba D, Calderon-Santiago M, Luque de Castro MD, Priego-Capote F. Study of sample preparation for determination of endocannabinoids and analogous compounds in human serum by LC-MS/MS in MRM mode. TALANTA 2018; 185:602-610.

IF: 4,244 Q1

SCIENTIFIC PRODUCTION





GC22: Epigenetics

<https://www.imibic.org/grupo/43>

ACTIVITY

- N° ONGOING PROJECTS: 3 (public)
- N° THESIS: 1

TEAM

Roldán	Arjona	Mª Teresa	R4
Rodríguez	Ariza	Rafael	R3
Córdoba	Cañero	Mª Dolores	R2
García	Ortiz	Mª Victoria	R2
Morales	Ruiz	Mª Teresa	R2
Parrilla	Doblas	Jara Teresa	R2
Barbado	García-Gil	Casimiro	R1
Devesa	Guerra	Iván	R1
Dorado	León	Macarena	R1
Lara	Amaro	Beatriz	T
Clemente	Vázquez	Lorena	T

ADDITIONAL INFORMATION

- » **Networks:**
 - Our group participates in the COST Action (CM1406) Epigenetic Chemical Biology (EPICHEMbio). <http://epichembio.eu/>
- » **3 agreements with companies.**

KEYWORDS

- Epigenetics
- DNA repair
- cancer
- DNA methylation
- DNA demethylation
- DNA glycosylases
- base excision repair

HIGHLIGHTED PUBLICATIONS

1. Barbado C, Cordoba-Canero D, Ariza RR, Roldan-Arjona T. Nonenzymatic release of N7-methylguanine channels repair of abasic sites into an AP endonuclease-independent pathway in Arabidopsis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018; 115(5):E916-E924.

IF: 9,504 Q1 D1

2. Morales-Ruiz T, Garcia-Ortiz MV, Devesa-Guerra I, Raya-Ruiz L, Tejedor JR, Bayon GF, Sierra MI, Fraga MF, Ariza RR, Roldan-Arjona T. DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase. EPIGENETICS. 2018; 13(1):95-107.

IF: 4,918 Q1


3. Morales-Ruiz T, Romero-Valenzuela AC, Vazquez-Grande VM, Roldan-Arjona T, Ariza RR, Cordoba-Cañero D. Monitoring base excision repair in Chlamydomonas reinhardtii cell extracts. DNA REPAIR. 2018; 65:34-41.

IF: 4,461 Q1

4. Martinez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jerez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibanez M, Sempere A, Sanz MA, Lo-Coco F, Sanchez-Garcia J. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. HAEMATOLOGICA. 2018; 103(9):E400-E403.

IF: 9,09 Q1 D1

SCIENTIFIC PRODUCTION





GC23: Metabolism in childhood

<https://www.imibic.org/grupo/50>

ACTIVITY

- Nº ONGOING PROJECTS: 7 (public)
- Nº PROJECTS STARTING IN 2019: 1 (public)
- Nº CLINICAL TRIALS : 11

TEAM

Gil	Campos	María Mercedes	R4
Antón	Gamero	Montserrat	R3
De la Torre	Aguilar	Mª Jose	R3
Flores	Rojas	Katherine	R3
Ibarra	De La Rosa	Ignacio	R3
López	Laso	Eduardo	R3
Mateos	Gonzalez	María Elena	R3
Pérez	Navero	Juan Luis	R3
Velasco	Jabalquinto	María José	R3
Ariza	Jiménez	Ana Belén	R2
Llorente	Cantarero	Francisco Jesús	R2
Gómez	Fernández	Antonio Rafael	R1
Jurado	Castro	José Manuel	R1
Moreno	Hidalgo	Carmen María	R1
Ordoñez	Díaz	María Dolores	R1
Rodríguez	Benítez	María Victoria	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - CIBEROBN <https://www.ciberobn.es/en>
 - CIBERER <https://www.ciberer.es/en>
 - PAIDI CTS-639 Scientific group
 - Spanish Pediatric Clinical Trials Network RECLIP <http://www.reclip.org/>
- » **International Projects:**
- » **ChiLTERN - PHC-18-2015-001**

KEYWORDS

- Autism
- children
- childhood
- metabolic syndrome
- obesity
- oncology
- physical activity
- pre-probiotics
- renal disease

HIGHLIGHTED PUBLICATIONS

1. Plaza-Díaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. NUTRIENTS. 2018; 10(1): Núm artículo 42
IF: 4,196 Q1
2. Lund AM, Borgwardt L, Cattaneo F, Ardigo D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tytki-Szymanska A, Lopez-Rodriguez M, Guillen-Navarro E, Dali CI, Heron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. JOURNAL OF INHERITED METABOLIC DISEASE. 2018; 41(6):1225-1233.
IF: 4,092 Q1
3. Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, Heron B, Geraci S, Ardigo D, Cattaneo F, Fogh J, Van den Hout JMH, Beck M, Jones SA, Tytki-Szymanska A, Haugsted U, Lund AM. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. JOURNAL OF INHERITED METABOLIC DISEASE. 2018; 41(6):1215-1223.
IF: 4,092 Q1

4. Tofe I, Ruiz-Gonzalez MD, Canete MD, Pino A, Rueda RL, Parraga MJ, Perez-Navero JL. Efficacy of Paracetamol in Closure of Ductus Arteriosus in Infants under 32 Weeks of Gestation. FRONTIERS IN PEDIATRICS. 2018; 6: Núm artículo 25
IF: 2,335 Q2
5. Gomez-Fernandez A, de la Torre-Aguilar MJ, Gil-Campos M, Flores-Rojas K, Cruz-Rico MD, Martin-Borreguero P, Perez-Navero JL. Children With Autism Spectrum Disorder With Regression Exhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without Such Regression. FRONTIERS IN PEDIATRICS. 2018; 6: Núm artículo 264
IF: 2,335 Q2

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL





GC24: Clinical and Molecular Microbiology

<https://www.imibic.org/grupo/44>

ACTIVITY

- N° ONGOING PROJECTS: 3 (public), 2 (private)
- N° PROJECTS STARTING IN 2019: 1 (public)
- N° CLINICAL TRIALS : 3

TEAM

Martínez	Martínez	Luis	R4
Egea	Miranda	María Del Pilar	R3
Gracia	Ahufinger	Irene	R3
Tejero	García	Rocío	R3
Pérez	Jiménez	Ana Belén	R3
Rodríguez	López	Fernando Carlos	R3
Ruiz	Martinez	Pilar	R3
Linares	Sicilia	María José	R3
Causse	Del Rio	Manuel	R1
Guzmán	Puche	Julia	R1
Marfil	Perez	Eduardo	R1
Gutiérrez	D'onofrio	Bruno	R1
Muñoz	De La Rosa	Montserrat	R1
Revuelta	Lozano	Francisca	R1
Sánchez	León	Irene	R1
Jenayah		Rim	R1
Gamal		Doaa	R1
Sánchez	Martínez	Guillermina	R1
Pedraza	Merino	Rosa	S
Elías	López	Cristina	T

ADDITIONAL INFORMATION

- » **Networks:**
 - Spanish Network for Research on Infectious Diseases (REIPI, <http://reipi.org>).
 - Andalusian Network For Clinical Research In Infectious Diseases.
- » **Competitive funding obtained for contracts:**
 - 1 Miguel Servet Contract (ISCIII)
- » **International Projects**
 - INSPIRE-2018-01- Study of the mechanisms of resistance to Ceftazidime-Avibactam in isolates of *Klebsiella pneumoniae* producing KPC-3 cultured from patients under Ceftazidime-Avibactam therapy
- » **3 agreements with companies.**

KEYWORDS

- Antimicrobial-resistance
- beta-lactamases
- aminoglycoside-modifying-enzymes
- methyl-transferases
- Qnr
- quinolones
- polymyxins
- carbapenems
- cephalosporins
- heteroresistance
- antibiogram
- susceptibility-testing
- molecular-typing
- enterobacteria
- Pseudomonas
- Acinetobacter

HIGHLIGHTED PUBLICATIONS


1. Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J. Risks of Infection and Mortality Among Patients Colonized With *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae*: Validation of Scores and Proposal for Management. *CLINICAL INFECTIOUS DISEASES*. 2018; 66(8):1204-1210.
IF: 9,117 Q1 D1
2. Amat T, Gutierrez-Pizarra A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant *Acinetobacter baumannii*. *CLINICAL MICROBIOLOGY AND INFECTION*. 2018; 24(6):630-634.
IF: 5,394 Q1 D1
3. Hamzaoui Z, Ocampo-Sosa A, Martinez MF, Landolsi S, Ferjani S, Maamar E, Saidani M, Slim A, Martinez-Martinez L, Boutiba-Ben Boubaker I. Role of association of *OmpK35* and *OmpK36* alteration and *bla(ESBL)* and/or *bla(AmpC)* genes in conferring carbapenem resistance among non-carbapenemase-producing *Klebsiella pneumoniae*. *INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS*. 2018; 52(6):898-905.
IF: 4,253 Q1
4. Aguirre-Quinonero A, del Molino ICP, de la Fuente CG, Sanjuan MC, Aguero J, Martinez-Martinez L. Phenotypic detection of clinical isolates of *Haemophilus influenzae* with altered penicillin-binding protein 3. *EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES*. 2018; 37(8):1475-1480.
IF: 2,537 Q2

5. Fernandez-Martinez M, del Castillo BR, Lecea-Cuello MJ, Rodriguez-Bano J, Pascual A, Martinez-Martinez L. Prevalence of Aminoglycoside-Modifying Enzymes in *Escherichia coli* and *Klebsiella pneumoniae* Producing Extended Spectrum -Lactamases Collected in Two Multicenter Studies in Spain. *MICROBIAL DRUG RESISTANCE*. 2018; 24(4):367-376.
IF: 2,344 Q3

MAIN RESULTS

- » **CLINICAL GUIDES:**
 - Aguado JM, Silva JT, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C, Martinez-Martinez L, Vidal E, Almenar L, Almirante B, Canton R, Carratala J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernandez J, Farinas MC, Gavalda J, Goyanes MJ, Gutierrez-Gutierrez B, Hernandez D, Len O, Lopez-Andujar R, Lopez-Medrano F, Martin-Davila P, Montejo M, Moreno A, Oliver A, Pascual A, Perez-Nadales E, Roman-Broto A, San-Juan R, Seron D, Sole-Jover A, Valerio M, Munoz P, Torre-Cisneros J. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. *TRANSPLANTATION REVIEWS*. 2018; 32(1):36-57 IF: 2,364 Q3

SCIENTIFIC PRODUCTION





GC25: Knowledge Discovery and Intelligent Systems in Biomedicine

<https://www.imibic.org/grupo/46>

ACTIVITY

- N° ONGOING PROJECTS: 1 (public)
- N° PATENTS: 1

TEAM

Ventura	Soto	Sebastián	R4
Cano	Rojas	Alberto	R3
García	Martínez	Carlos	R3
Gibaja	Galindo	Eva Lucrecia	R3
Luque	Rodríguez	María	R3
Romero	Morales	Cristóbal	R3
Romero	Salguero	José Raúl	R3
Zafra	Gómez	Amelia	R3
Luna	Ariza	Jose Maria	R2
Reyes	Pupo	Oscar Gabriel	R2
Barrón	Ortiz	Marco Antonio	R1
Delgado	Osuna	José Antonio	R1
Guerrero	Enamorado	Alain	R1
Luque	Guzmán	Carmen	R1
Moyano	Murillo	José María	R1
Pérez	Perdomo	Eduardo	R1
Ramírez	Quesada	Aurora	R1
Robles	Berumen	Hermes	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - Knowledge discovery and intelligent systems. (Big DADE)
 - Search Based Software Engineering, SBSE http://www.uco.es/investigacion/proyectos/SEBASNet/index.php?title=P%C3%A1gina_principal
- » **Competitive funding obtained for contracts:**
 - 1 I-PFIS Contract (ISCIII)
- » **1 agreement with companies**


KEYWORDS

- Biomedical data analysis
- big data
- data science
- data mining
- machine learning
- predictive models
- classification
- regression
- descriptive models
- association
- clusters

HIGHLIGHTED PUBLICATIONS

1. Luna JM, Padillo F, Pechenizkiy M, Ventura S. Apriori Versions Based on MapReduce for Mining Frequent Patterns on Big Data. IEEE TRANSACTIONS ON CYBERNETICS. 2018; 48(10):2851-2865.
IF: 8,803 Q1 D1
2. Luna JM, Pechenizkiy M, del Jesus MJ, Ventura S. Mining Context-Aware Association Rules Using Grammar-Based Genetic Programming. IEEE TRANSACTIONS ON CYBERNETICS. 2018; 48(11):3030-3044.
IF: 8,803 Q1 D1
3. Moyano JM, Gibaja EL, Cios KJ, Ventura S. Review of ensembles of multi-label classifiers: Models, experimental study and prospects. INFORMATION FUSION. 2018; 44:33-45.
IF: 6,639 Q1 D1
4. Gahete MD, del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alois-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Pérez-Martínez P, Castño JP, López-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBIOMEDICINE. 2018; 37:356-365.
IF: 6,183 Q1 D1
5. Gonzalez-Lopez J, Ventura S, Cano A. Distributed nearest neighbor classification for large-scale multi-label data on spark. FUTURE GENERATION COMPUTER SYSTEMS-THE INTERNATIONAL JOURNAL OF ESCIENCE. 2018; 87:66-82.
IF: 4,639 Q1 D1

SCIENTIFIC PRODUCTION





GC26: Clinical virology and zoonosis

<https://www.imibic.org/grupo/45>


ACTIVITY

- N° ONGOING PROJECTS: 4 (public)
- N° PROJECTS STARTING IN 2019: 2 (public)
- N° CLINICAL TRIALS : 11
- N° THESIS: 1 • N° PATENTS: 1

TEAM

Rivero	Roman	Antonio	R4
Rivero	Juarez	Antonio	R3C
Frias	Casas	Mario	R2
Brieva	Herrero	Teresa	R1
López	López	Pedro	R1
Machuca	Sánchez	Isabel	R1
Reyes	Torres	Inmaculada	R1
Camacho	Espejo	Angela	CR
Cabada	Añón	Teresa	ADM
Ruiz	Torres	Laura	T
Zafra	Soto	Ismael	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - AIDS Research Network (RIS, RD16/0025/0034)
- » **Competitive funding obtained for contracts:**
 - 1 Sara Borrel Contract (ISCIII)
 - 1 Miguel Servet Contract (ISCIII)
- » **International Projects:**
 - PARTNER II Project from The National Institute for Health Research (NIHR) England.PI: Tina Brunn (Copenhagen HIV Programme, University Copenhagen) PI: Nodo Córdoba: Antonio Rivero Juárez (Hospital Universitario Reina Sofía).
- » **14 agreements with companies**
- » **Agreement with Janssen CCB.0196.02**

KEYWORDS


- HIV
- HCV
- HEV
- infection
- AIDS
- ART
- CD4
- hepatitis
- pathogens
- fibrosis
- cirrhosis
- innate immunity
- pharmacogenomics
- viral reservoir
- zoonoses

HIGHLIGHTED PUBLICATIONS

- Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. CLINICAL MICROBIOLOGY AND INFECTION. 2018. 24(11)1218-1219.
IF: 6,425 Q1 D1
- Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, Amado LEM, Morillas RM, Fornis X, Acevedo JMP, Andrade RJ, Rivero A, Carrion JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang GL, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. GASTROENTEROLOGY. 2018. 155(4) 1120-1127.
IF: 20,773 Q1 D1
- Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. CLINICAL MICROBIOLOGY REVIEWS. 2018.31(2)-.
IF: 20,642 Q1 D1
- Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Rivalde MA, Brieva T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. ZOOSES AND PUBLIC HEALTH. 2018. 65 (5) 584-588.
IF: 2,688 Q1 D1
- Lopez-Lopez P, Rivalde MD, Frias M, Garcia-Bocanegra I, Brieva T, Caballero-Gomez J, Camacho A, Fernandez-Molera V, Machuca I, Gomez-Villamandos JC, Rivero A, Rivero-Juarez A. Risk factors associated with hepatitis E virus in pigs from different production systems. VETERINARY MICROBIOLOGY. 2018. 224 () 88-92.
IF: 2,525 Q1 D1

MAIN RESULTS

- » **CLINICAL GUIDES**
 - Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM.
 - Costs and cost-efficacy analysis of the 2017 GESIDA/ Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2018 May; 36(5): 268-276. doi: 10.1016/j.eimc.2017.04.002. Epub 2017 May 19. PMID: 28532596
IF: 1,707 Q3
 - AIDS Study Group GeSIDA of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan.
 - Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).
 - Enferm Infecc Microbiol Clin. 2018 May 11. pii: S0213-005X(18)30075-2. doi: 10.1016/j.eimc.2018.02.010. [Epub ahead of print] English, Spanish. PMID: 29759422
IF: 1,707 Q3



GC27: OncObesity and Metabolism

<https://www.imibic.org/grupo/52>

ACTIVITY


- N° ONGOING PROJECTS: 6 (public), 2 (private), 1 (public-private)
- N° PATENTS: 2

TEAM

Luque	Huertas	Raúl Miguel	R4
Gahete	Ortiz	Manuel David	R3C
León	González	Antonio José	R2
Del Río	Moreno	Mercedes	R1
Vázquez	Borrego	M ^a Carmen	R1
Jiménez	Vacas	Juan Manuel	R1
Alors	Pérez	Emilia M ^a	R1
Gómez	Gómez	Enrique	R1
Herrero	Aguayo	Vicente	R1
Sáez	Martínez	Prudencio	R1
López	Cánovas	Juan Luis	R1
Sánchez	Sánchez	Rafael	R1
Sánchez	Medianero	M ^a Teresa	R1
Toledano	Borrego	Álvaro	R1
López	López	Fernando	T
Montero	Hidalgo	Antonio Jesús	S
Lara	López	Araceli	S
Pérez	Gómez	Jesús Miguel	S

Note: Since 01/07/2018, the Researcher Elena M. Yubero Serrano has been associated with our research group through a competitive contract financed by the Scientific Foundation of the AECC: REF. INVES18057YUBE, with the title "NEW BIOMARKERS AND THERAPEUTIC TARGETS IN BREAST AND PROSTATE CANCER: MOLECULAR MECHANISMS IN THE PATHOLOGICAL INTERACTION BETWEEN OBESITY AND CANCER"

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - CIBERObn Physiopathology of Obesity and Nutrition. <https://www.ciberobn.es/en>
 - Spanish Society of Endocrinology and Nutrition. Area of Knowledge of Neuroendocrinology <http://www.seen.es/endocrinologia/neuroendocrinologia/presentacion.aspx>
 - Andalusian Society of Endocrinology, Diabetes and Nutrition. Area of Knowledge of Neuroendocrinology <https://www.saedyn.es/grupos-de-trabajo/neuroendocrinologia/>
 - ceiA3 - Agrifood Campus of International Excellence <http://www.ceia3.es/>
 - PAIDI BIO-139 Cellular and Molecular Endocrinology (Andalusian Plan for Research, Development and Innovation – PAIDI)
- » **Competitive funding obtained for contracts:**
 - 1 Miguel Servet Contract (ISCIII)
 - 1 Sara Borrel Contract (ISCIII)
 - 1 Río Hortega Contract (ISCIII)
 - 1 PFIS Contract (ISCIII)
- » **Acquisition of scientific-technical equipment:** polyvalent system of genomic analysis of last generation (EQC2018-005254-P). Ministry of Science, Innovation and Universities. Spanish Plan I+D+I 2017-2020 and European foundation for Regional development (FEDER)
- » **4 agreements with companies**

KEYWORDS

- Obesity
- cancer
- tumor pathologies
- prostate cancer
- brain tumors
- hepatocellular carcinoma
- pituitary tumors
- diabetes
- metabolic dysregulations
- adipose tissue
- inflammasome
- miRNAs
- senescence-associated secretory phenotype (SASP)
- extracellular vesicles
- splicing/spliceosome
- non-sense mediated mRNA decay
- heterogeneity
- diagnostic biomarkers
- prognostic biomarkers

HIGHLIGHTED PUBLICATIONS

1. Gahete MD, Del Río-Moreno M, Camargo A, Alcalá-Díaz JF, Alors-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Pérez-Martínez P, Castaño JP, López-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. *EBioMedicine* 2018, 3964(18):30479-1. **IF: 6,680 D1; Medicine, Research & Experimental area**
2. Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM. The pituitary gland is a novel major site of action of metformin in non-human primates: A potential path to expand and integrate its metabolic actions. *Cell Physiol Biochem* 2018, 49(4):1444-1459. **IF: 5,500 D1; Physiology area**

3. Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. *J Cell Mol Med* 2018, 22(11):5688-5697. **IF: 4,658 Q1; Medicine, Research & Experimental area**

4. Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Pérez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. *Clin Transl Gastroenterol* 2018, 9(10):196. **IF: 4,803 Q1; Medicine, Research & Experimental area**

5. Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. *Sci Rep* 2018, 8(1):6173. **IF: 4,011 Q1; Multidisciplinary Sciences area**





GE01: Neuroplasticity and Oxidative Stress

<https://www.imibic.org/grupo/35>

ACTIVITY

- Nº ONGOING PROJECTS: 2 (public), 1 (public-private)
- Nº CLINICAL TRIALS : 22

TEAM

Túnez	Fiñana	Isaac	R4
Bahamonde	Román	Carmen	R3
Cruz	Guerrero	Antonio	R3
Gascón	Luna	Félix	R3
Gómez	Chaparro	José Luis	R3
Jimena	Medina	Ignacio	R3
Lillo	Roldán	Rafael	R3
Luque	Carabot	Evelio	R3
Ochoa	Sepúlveda	Juan José	R3
Peña	Amaro	Jose	R3
Ruiz	Villen	Mª Concepción	R3
Agüera	Morales	Eduardo	R2
Ramírez	Rivera	Alberto	R2
Conde	Gavilán	Cristina	R1
Galván	Jurado	Alberto	R1
Valverde	Moyano	Roberto	R1
Giraldo	Polo	Ana Isabel	T
LaTorre	Luque	Manuel	T

ADDITIONAL INFORMATION

- » **Networks:**
 - Spanish Brain Stimulation Network (Red Española de Estimulación Cerebral)
 - PAIDI CTS-624 Neuroplasticity and oxidative stress
- » **1 International Projects**
 - PHC25-2015-001- ICT4Life - ICT services for Life Improvement for the Elderly. (EU)
- » **11 agreements with companies**


KEYWORDS

- Antioxidant systems
- Huntington's disease
- Multiple sclerosis
- Neurodegenerative diseases
- Neuroplasticity
- Oxidative stress
- Cell death
- Transcranial magnetic stimulation

HIGHLIGHTED PUBLICATIONS

1. Postigo-Alonso B, Galvao-Carmona A, Benitez I, Conde-Gavilan C, Jover A, Molina S, Pena-Toledo MA, Aguera E. Cognitive-motor interference during gait in patients with Multiple Sclerosis: a mixed methods Systematic Review. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2018. 94()126-148.
IF: 8,037 Q1 D1
2. Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunes I. Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. JOURNAL OF FUNCTIONAL FOODS. 2018. 42()281-288.
IF: 3,47 Q1
3. Medina-Fernandez FJ, Escribano BM, Padilla-del-Campo C, Drucker-Colin R, Pascual-Leone A, Tunes I. Transcranial magnetic stimulation as an antioxidant. FREE RADICAL RESEARCH. 2018. 52(4)381-389.
IF: 3,038 Q2
4. Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunes I. Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. BRAIN RESEARCH BULLETIN. 2018. 137()140-145.
IF: 3,44 Q2

SCIENTIFIC PRODUCTION





GEO2: Preventive Medicine and Public Health

<https://www.imibic.org/grupo/37>

ACTIVITY

- Nº CLINICAL TRIALS: 1

TEAM

Guzmán	Herrador	Bernardo R	R4
Barranco	Quintana	José Luis	R3
Díaz	Molina	Carmen	R3
Salcedo	Leal	M ^a Inmaculada	R3
Torcello	Gaspar	Ricardo	R3
Fernández	Martínez	Nicolás Francisco	CR
Gavilán	León	Francisco José	CR
Ortiz	González-Serna	Rocío	CR
Ruiz	Montero	Rafael	CR
Ayora	Torres	M ^a del Pilar	T
Coca	Baena	M ^a Teresa	T
Rodríguez	Torrónteras	Alejandro	T
González	Nebauer	Valeria	T
Díaz	Gavira	Concepción	T
Narbona	Rodríguez	Francisco Javier	T
Herrera	Tierno	Jesús	T
Romero	Muñoz	M ^a Jesús	T

ADDITIONAL INFORMATION

» Networks:

- Ongoing collaborations with other hospitals of our region and with scientific societies such as “Sociedad Andaluza de Medicina Preventiva y Salud Pública (SAMPSP) <https://www.sociedadandaluzapreventiva.com/> and “Sociedad Española de Medicina Preventiva y Salud Pública e higiene (SEMPSPH) <https://www.sempsph.com/>.

KEYWORDS

- Public Health
- healthcare associated infections
- vaccination
- vaccine uptake
- adherence

HIGHLIGHTED PUBLICATIONS

1. Sanchez-Hidalgo JM, Rufian-Pena S, Duran-Martinez M, Arjona-Sanchez A, Salcedo-Leal I, Lopez-Cillero P, Briceno-Delgado J. Risk factors of early recurrence in retroperitoneal liposarcoma. CIRUGIA ESPANOLA. 2018.96(9):568-576.

IF: 0,841 Q4

2. Ortega RL, Cortes BO, Serna ROG, Garcia VG, Hernandez BL. Changes in Hepatitis A epidemiological pattern in Andalusia: 2007-2017. REVISTA ESPANOLA DE SALUD PUBLICA. 2018.92()-.

IF: 0,635 Q4

SCIENTIFIC PRODUCTION



PAPERS





GE03: Inflammatory immune-mediated cutaneous diseases

<https://www.imibic.org/grupo/14>

ACTIVITY

- N° ONGOING PROJECTS: 2 (public)
- N° CLINICAL TRIALS : 13
- N° THESIS: 1

TEAM

Ruano	Ruiz	Juan	R4
Franco	García	Francisco	R3
Hernández	Romero	José Luis	R3
Gómez	García	Francisco	R2
González	Padilla	Marcelino	R2
Vélez	García-Nieto	Antonio	R2
Isla	Tejera	Beatriz	R2
Aguilar	Luque	Macarena	R1
Carmona	Fernández	Pedro Jesús	R1
Gay	Mimbrera	Jesús	R1
Gómez	Arias	Pedro Jesús	R1
Sanz	Cabanillas	Juan Luis	R1
Viguera	Guerra	Isabel	R1
Alcalde	Mellado	Patricia	S
Maestre	López	Beatriz	S
Montilla	López	Ana M ^a	S
Clemente	Milla	María del Carmen	Other
López	García	María	Other
López	González	Carmen	Other

ADDITIONAL INFORMATION

- » **Networks:**
 - Cochrane Skin group <https://skin.cochrane.org/>
 - Cochrane Methods Bias group <https://methods.cochrane.org/bias/home>
 - PAIDI CTS-1041 Scientific Group. Coordinator (PI) of the Group “New diagnostic and therapeutic methods in immunomediated inflammatory skin diseases” that belongs to the Andalusian Research Plan since March 2018 <https://sica2.cica.es/login.do>
 - Laboratory of Investigative Dermatology, The Rockefeller University, New York (EEUU) <http://lab.rockefeller.edu/krueger/>
 - Eczema center and the Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine Center at Mount Sinai New York (EEUU) <http://labs.icaahn.mssm.edu/guttmanlab/>
 - Dept. of Population Health Science and Policy, Dept. of Genetics and Genomics Science, Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine Center at Mount Sinai New York (EEUU) <https://icaahn.mssm.edu/about/departments/population-health>
- » **7 agreements with companies**
- » **We have created a spin off on data mining called info4CURE that has obtained the AENOR quality certificate as Joven Empresa Innovadora (EA0043).** <http://www.info4cure.org/>

KEYWORDS

- Immune-mediated skin diseases
- psoriasis
- atopic dermatitis
- vitiligo
- alopecia areata
- genetic polymorphisms
- biological therapies
- cell culture
- cold atmospheric plasma
- cost-efficiency analyses
- systematic reviews
- meta-analyses
- meta-epidemiology

HIGHLIGHTED PUBLICATIONS

1. Ruano J, Gomez-Garcia F, Gay-Mimbrera J, Aguilar-Luque M, Fernandez-Rueda JL, Fernandez-Chaichio J, Alcalde-Mellado P, Carmona-Fernandez PJ, Sanz-Cabanillas JL, Viguera-Guerra I, Franco-Garcia F, Cardenas-Aranzana M, Romero JLH, Gonzalez-Padilla M, Isla-Tejera B, Garcia-Nieto AV. Evaluating characteristics of PROSPERO records as predictors of eventual publication of non-Cochrane systematic reviews: a meta-epidemiological study protocol. SYSTEMATIC REVIEWS. 2018; 7: Núm artículo 43
IF: 6,754 Q1 D1
2. Ruano J, Aguilar-Luque M, Isla-Tejera B, Alcalde-Mellado P, Gay-Mimbrera J, Hernandez-Romero JL, Sanz-Cabanillas JL, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Gomez-Garcia F, Garcia-Nieto AV. Relationships between abstract features and methodological quality explained variations of social media activity derived from systematic reviews about psoriasis interventions. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2018; 101:35-43.
IF: 4,245 Q1

3. Gomez-Garcia F, Sanz-Cabanillas JL, Viguera-Guerra I, Isla-Tejera B, Nieto AVG, Ruano J. Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA. DERMATOLOGY AND THERAPY. 2018; 8(4):539-556.

IF: 3,620 Q1

4. Gomez-Garcia F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Romero JLH, Garcia-Nieto AV. A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety. DERMATOLOGY AND THERAPY. 2018; 8(2):195-202.


5. Ruano J, Aguilar-Luque M, Gomez-Garcia F, Mellado PA, Gay-Mimbrera J, Carmona-Fernandez PJ, Maestre-Lopez B, Sanz-Cabanillas JL, Romero JLH, Gonzalez-Padilla M, Garcia-Nieto AV, Isla-Tejera B. The differential impact of scientific quality, bibliometric factors, and social media activity on the influence of systematic reviews and meta-analyses about psoriasis. PLOS ONE. 2018; 13(1): Núm artículo e0191124

IF: 2,766 Q1

MAIN RESULTS

- » **CLINICAL GUIDES:**
 - Current Status of Multidisciplinary Care in Psoriatic Arthritis in Spain: NEXUS 2.0 Project. Queiro R, Coto P, Joven B, Rivera R, Navío Marco T, de la Cueva P, Alvarez Vega JL, Narváez Moreno B, Rodríguez Martínez FJ, Pardo Sánchez J, Feded Olmos C, Pujol C, Rodríguez J, Notario J, Pujol Busquets M, García Font M, Galindez E, Pérez Barrio S, Urruticoechea-Arana A, Hergueta M, López Montilla MD, Vélez García-Nieto A, Maceiras F, Rodríguez Pazos L, Rubio Romero E, Rodríguez Fernandez Freire L, Luelmo J, Gratacós J. Reumatol Clin 2018 Feb 26. [Epub ahead of print] English, Spanish. 10.1016/j.reuma.2018.01.010

SCIENTIFIC PRODUCTION





GE04: Applied Psychology

<https://www.imibic.org/grupo/36>

ACTIVITY

- Nº ONGOING PROJECTS: 3 (public), 2 (private)

TEAM

Luque	Salas	Bárbara	R4
Tabernero	Urbieto	Carmen	R3
Arenas	Moreno	Alicia	R3
Antolí	Cabrera	Adoración	R3
Castillo	Mayén	Rosario	R3
Cuadrado		Esther	R3
Moyano	Pacheco	Manuel	R3
Pérez	Dueñas	Carolina	R3
Rubio	García	Sebastián	R3
Gutiérrez	Domingo	Tamara	R1

ADDITIONAL INFORMATION

» **Networks:**

- PAIDI HUM-414 Gender, communication systems, beliefs and education (PAIDI research group)
- PAIDI HUM-928 Evidence – Based Psychology. Evaluation and design of effective psychological interventions (PAIDI research group)
- Incyl - Institute of Neurosciences of Castilla Y León. <https://institutoneurociencias.org/>


KEYWORDS

- Motivation
- self-efficacy
- aging
- Women
- positivity
- emotions
- diet
- cardiovascular disease
- cope with stress
- emotional self-regulation
- management training programs
- e-health

HIGHLIGHTED PUBLICATIONS

- Schumpe, B. M., Bélanger, J. J., Moyano, M., & Nisa, C. F. The role of sensation seeking in political violence: An extension to significance quest theory. *Journal of Personality and Social Psychology*. 2018.
IF: 5,733 Q1
- Garcia-Torres, F., Castillo-Mayen, R., & Alos, F. Psychoticism and employment status in breast cancer survivors. *Psycho-Oncology*. 2018. 27(1). 359-361.
IF: 3,455 Q1
- Cuadrado, E., Gutierrez-Domingo, T., Castillo-Mayen, R., Luque, B., Arenas, A., & Tabernero, C. The Self-Efficacy Scale for Adherence to the Mediterranean Diet (SESAMeD): A scale construction and validation. *Appetite*. 2018. 120. 6-15.
IF: 3,403 Q1
- Perez-Duenas, C., Rivas, M. F., Oyediran, O. A., & Garcia-Torres, F. Induced negative mood increases dictator game giving. *Frontiers in Psychology*. 2018. 9. (Art. Num: 1542)
IF: 2,089 Q2
- Lobato, R. M., Moya, M., Moyano, M., & Trujillo, H. M. (2018). From oppression to violence: The role of oppression, radicalism, identity, and cultural intelligence in violent disinhibition. *Frontiers in Psychology*. 2018. 9. (Art. Num: 1505).
IF: 2,089 Q2

SCIENTIFIC PRODUCTION





GE05: Urology and Sexual Medicine

<https://www.imibic.org/grupo/38>


ACTIVITY

- Nº ONGOING PROJECTS: 4 (public), 1 (private)
- Nº CLINICAL TRIALS : 6

TEAM

Requena	Tapia	María Jose	R4
Blanca	Pedregosa	Ana Maria	R2
Campos	Hernandez	Juan Pablo	R2
Carrasco	Valiente	Julia	R2
Rubio	Galisteo	Juan Manuel	R1
Sánchez	González	Álvaro	R1
Anglada	Curado	Francisco	CR
Márquez	López	Javier	CR
Prieto	Castro	Rafael	CR
Ruiz	García	Jesús	CR
Valero	Rosa	José	CR

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

» Networks:

- Life Length – a biotechnology-based company whose activity focuses on the commercialization of the TAT telomere measurement technique <https://lifelength.com/>
- CTS-172 –Group of Urological Pathology, pertaining to the Andalusian Plan for Research, Development and Innovation (PAIDI)

» 1 International Projects

- SMEInst-2017-01. ONCOCHECK. A simple blood test for prognosis and monitoring of patients undergoing cancer therapy. European Commission <http://www.oncocheck.eu/>

» 11 agreements with companies

KEYWORDS

- bladder cancer
- prostate cancer
- kidney transplantation
- biomarkers
- diagnosis
- prognosis
- predictive
- robotic laparoscopic surgery

HIGHLIGHTED PUBLICATIONS

1. Gómez Gómez, E., Valero Rosa, J., Carrasco Valiente, J., Triviño Tarradas, F., Anglada Curado, F., López Ruiz, D., Requena Tapia, M.J. New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.(2018) Urology, 121, pp. 198-199.

IF:2,3 Q2

2. Carrasco, J., Gómez, E., García, J.H., Valero, J., Sánchez, Á., Salamanca, J.J., Campos, J.P., Requena, M.J.Impact of the use of simulators on the mental workload and confidence in a digital rectal examination and bladder catheterization workshop [Article@Impacto del uso de simuladores sobre la carga mental y la confianza en un taller de tacto rectal y cateterización vesical en estudiantes] (2018) Archivos Espanoles de Urologia, 71 (6), pp. 537-542.

3. Carrasco Valiente, J., Ruiz García, J.M., Requena Tapia, M.J.Oligometastatic prostate cancer. Concept and implications [Article@Cáncer de próstata oligometastásico. Concepto e implicaciones] (2018) Archivos Espanoles de Urologia, 71 (3), pp. 239-246.

4. Sánchez-Hidalgo, J.M., Salamanca-Bustos, J.J., Arjona-Sánchez, Á., Campos-Hernández, J.P., Ruiz Rabelo, J., Rodríguez-Benot, A., Requena-Tapia, M.J., Briceño-Delgado, J. What Is the Influence of Both Risk Donor and Risk Receiver on Simultaneous Pancreas-Kidney Transplantation? (2018) Transplantation Proceedings, 50 (2), pp. 664-668.

IF: 0,806 Q4

5. Salamanca-Bustos, J.J., Gomez-Gomez, E., Campos-Hernández, J.P., Carrasco-Valiente, J., Ruiz-García, J., Márquez-López, F.J., Zurera-Tendero, L., Requena-Tapia, M.J. Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients (2018) Transplantation Proceedings, 50 (2), pp. 587-590.

IF: 0.806 Q4

MAIN RESULTS

» CLINICAL GUIDES

- Urolithiasis Integrated Assistance Process. Arrabal Martín Miguel, Barrero Candau Rafael, Campoy Martínez Pedro, Carnero Bueno José, Del Río Urenda Susana, Díaz Rodríguez Francisco, Dotor Gracia Marisa, Martínez Pérez Rocío, Merino López Javier, Moreno Jiménez Juan, Ocete Martín Carolina, Reina Ruiz Manuel Carlos, Ras Luna Javier, Serrano Galán, Francisco, Santos Rubio María Dolores. Colaborador: María José Requena Tapia, UGC de Urología. Hospital Universitario Reina Sofía, Córdoba. Revista, año, volumen, primera y última páginas): Junta De Andalucía. Consejería De Salud. 2013
- Benign Prostate Hypertrophy / Prostate Cancer: Integrated Care Process. Baena González Víctor, Bachiller Burgos Jaime, Benavides Orgaz Manuel, Carnero Bueno José, Cozar Olmo José Manuel, Del Río Urenda Susana, Dotor Gracia Marisa, Gutierrez Cozar Ana, Herruzo Cabrera Ismael, Hormigo Pozo Antonio, Linares Armada Ramón, Medina López Rafael, Mendes Vidal María José, Monzón Moreno Antonio, Ortiz Gordillo María José, Pérez Álvarez Pedro Pablo, Pozo Muñoz Francisco, Ras Luna Javier, Requena Tapia María José, Sanz Amores Reyes, Torrubia Romero Francisco, Villalobos Martín Juan Carlos
- Referencia bibliográfica (Revista, año, volumen, primera y última páginas): EDITA: Junta de Andalucía. Consejería de Salud, ISBN: 84-8486-032-9, deposito legal: se-8027-2011 maquetación: Publipartners
- Sexual Health Performance Guidelines. Ignacio Moncada Iribarren, Rafael Prieto Castro. (Revista, año, volumen, primera y última páginas): Depósito legal: M3294-2012. ISBN: 978-84-7989-695-9.





GA01: Lung Transplants. Thoracic Neoplasms

<https://www.imibic.org/grupo/15>

ACTIVITY

- Nº ONGOING PROJECTS: 1 (public), 2 private (1 of them as CO-IP)
- Nº CLINICAL TRIALS : 1

TEAM

Salvatierra	Velázquez	Ángel	R4
Algar	Algar	Francisco Javier	R3
Álvarez	Kindelán	Antonio	R3
Baamonde	Laborda	Carlos	R3
Cerezo	Madueño	Francisco	R3
González	García	Francisco Javier	R3
Herrera	Merchán	Antonio	R3
Moreno	Casado	Paula	R3C
Muñoz	Foss	Anna	R3
Robles	Arista	Juan Carlos	R3
Mendoza	Porcuna	Manuela	T

ADDITIONAL INFORMATION

» Networks:

- Spanish Society of Pneumology and Thoracic Surgery – SEPAR
- Association of pulmonology and thoracic surgery of the south - NEUMOSUR
- Spanish Society of Thoracic Surgery

KEYWORDS

- Lung preservation
- chronic rejection
- bronchiolitis obliterans. Endothelium
- inflammation
- oxidative stress
- proteomics
- genomics
- lung cancer
- biomarkers
- ECMO
- ex-vivo lung perfusion

HIGHLIGHTED PUBLICATIONS

1. Moreno P, Jimenez-Jimenez C, Garrido-Rodriguez M, Calderon-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra A, Munoz E, Calzado MA. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. MOLECULAR ONCOLOGY. 2018; 12(10):1778-1796.

IF: 5,264 Q1

2. Barrios JMV, Luna FS, Velazquez AS. Lung Re-Transplantation. The Opposite View Point. ARCHIVOS DE BRONCONEUMOLOGIA. 2018; 54(6):311-312.

IF: 2,633 Q2


3. Murillo DA, Cerezo F, Gauman HD, Gonzalez FJ, Munoz A, Moreno PM, Ceballos MJ, Salvatierra A. Left Single Lung Transplantation Through Left Anterolateral Thoracotomy With Longitudinal Partial Sternotomy (Hemiclamshell): An Innovative Surgical Resource. TRANSPLANTATION PROCEEDINGS. 2018; 50(2):661-663.

IF: 0,806 Q4

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL





GA02: Comprehensive Nursing Care. Multi-disciplinary Perspective

<https://www.imibic.org/grupo/58>

ACTIVITY

- Nº ONGOING PROJECTS: 2 (publics), 2 (private)

TEAM

Rodríguez	Borrego	Mª Aurora	R4
Carmona	Torres	Juan Manuel	R3
Gonçalves	Nitschke	Rosane	R3
López	Soto	Pablo Jesús	R3
Alanis	López	Joaquin	R3
Cobo	Cuenca	Ana Isabel	R3
Dios	Guerra	Caridad	R3
Guerra	Martín	Dolores	R3
Hidalgo	Lopezosa	Pedro	R3
Morales	Cané	Ignacio	R1
Rodríguez	Muñoz	Pedro Manuel	R1
Arévalo	Buitrado	Pedro	R1
Clapés	Roldán	Cristina	R1
González	Gáncedo	Jacob	R1
Jiménez	Ruz	Andrea	R1
López	Cerdá	Elena	R1
Bretones		José Miguel	R1
Cuevas	Pareja	Francisca	R1
Medina	Valverde	María José	R1
Moral	Arroyo	Juan Antonio	R1
Muñoz	Alonso	Adoración	R1
Redondo	Pedraza	Rosa	R1
Miñarro	Del Moral	Rosa	R1
Fernández	Rodríguez	Vicente	R1

ADDITIONAL INFORMATION

- » **Networks:**
- PAIDI CTS-666 scientific group

KEYWORDS

- Integral nursing care
- nursing care philosophy
- professional development of nursing professionals
- assessment of training methods in higher education
- nursing service management
- evidence-based nursing care
- health and disease
- disease experience
- health communication
- integral human being
- female nurses
- healthcare in older people
- aging-life quality
- fragility
- health and gender
- Habits of life: drug addiction
- ergo-dynamic

HIGHLIGHTED PUBLICATIONS

1. Carmona-Torres JM, Lopez-Soto PJ, Coimbra-Roca AI, Galvez-Rioja RM, Goergen T, Rodriguez-Borrego MA. Elder Abuse in a Developing Area in Bolivia. JOURNAL OF INTERPERSONAL VIOLENCE. 2018; 33(2):339-356. **IF: 3,063 Q1**
2. Manfredini R, Lamberti N, Manfredini F, Straudi S, Fabbian F, Rodríguez-Borrego MA, Basaglia N, Carmona-Torres JM, López-Soto PJ. Gender Differences in Outcomes Following a Pain-Free, Home-Based Exercise Program for Claudication. JOURNAL OF WOMENS HEALTH. 2018; Early Access. **IF: 2,009 Q1**
3. Carmona-Torres JM, Cobo-Cuenca AI, Recio-Andrade B, Laredo-Aguilera JA, Martins MM, Rodriguez-Borrego MA. Prevalence and factors associated with polypharmacy in the older people: 2006-2014. JOURNAL OF CLINICAL NURSING. 2018; 27(15-16):2942-2952. **IF: 1,757 Q1**

4. Cobo-Cuenca AI, Martin-Espinosa NM, Sampietro-Crespo A, Rodriguez-Borrego MA, Carmona-Torres JM. Sexual dysfunction in Spanish women with breast cancer. PLOS ONE. 2018; 13(8): Núm artículo e0203151 **IF: 2,766 Q2**

5. Manfredini R, Fabbian F, Cappadona R, Zucchi B, Lopez-Soto PJ, Rodriguez-Borrego MA. Attempted suicide as a trigger of Takotsubo syndrome: a minireview of available case reports. INTERNAL AND EMERGENCY MEDICINE. 2018; 13(4):629-631. **IF: 2,335 Q2**

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL





GA03: Pneumology

<https://www.imibic.org/grupo/10>

ACTIVITY

- N° ONGOING PROJECTS: 3 (private)
- N° CLINICAL TRIALS: 4
- N° THESIS: 1

TEAM

Jurado	Gámez	Bernabé	R4
Arenas	De Larriva	Marisol	R3
Cobos	Ceballos	María Jesús	R3
Feu	Collado	Nuria	R3
García	Gil	Francisco Luis	R3
Lama	Martínez	Rafael	R3
Pascual	Martínez	Natalia	R3
Redel	Montero	Javier	R3
Santos	Luna	Francisco	R3
Vaquero	Barrios	José Manuel	R3
Arenas	Vacas	Antonio Pablo	R2
Entrenas	Costa	Luis M	R2

ADDITIONAL INFORMATION

» Networks:

- Spanish Society of Pulmonology and Thoracic Surgery – SEPAR <https://www.separ.es/>
- Association of Pulmonology and Thoracic Surgery of the South - NEUMOSUR <https://www.neumosur.net/>
- EUROPEAN RESPIRATORY SOCIETY

» 3 agreements with companies

KEYWORDS

- Cancer
- hypoxemia
- cell damage
- chronic respiratory disease
- metabolomics
- proteomics
- telecare
- telemedicine
- respiratory therapies

HIGHLIGHTED PUBLICATIONS

1. Vaquero Barrios JM, Santos Luna F, Salvatierra Velázquez Á. Lung Re-Transplantation. The Opposite View Point. ARCHIVOS DE BRONCONEUMOLOGIA. 2018; 54(6):311-312.

IF: 2,633 Q2

2. Merino JS, de Torres LAP, Bardwell WA, Gomez RM, Villalobos AR, Collado NF, Ruiz-Moral R, Jurado-Gamez B. Impact of Positive Pressure Treatment of the Airway on Health-Related Quality of Life in Elderly Patients With Obstructive Sleep Apnea. BIOLOGICAL RESEARCH FOR NURSING. 2018; 20(4):452-461.

IF: 1,579 Q2

3. Ballesteros FM, Fernandez JJS, Barrios JMV, Montero JR, Ceballos MJC, Amarilla CE, Muriana AMP, Luna FS. Long-term Prognosis After Lung Transplantation: A Monocentric Study in 510 Patients. TRANSPLANTATION PROCEEDINGS. 2018; 50(2):658-660.

IF: 0,806 Q4

4. Martinez-Gonzalez C, Casanova C, de-Torres JP, Marin JM, de Lucas P, Fuster A, Cosio BG, Calle M, Peces-Barba G, Solanes I, Agüero R, Feu-Collado N, Alfageme I, Plaza AR, Balcells E, de Diego A, Royo MM, Moreno A, Casanovas AL, Galdiz JB, Golpe R, Bautista CL, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD A Prospective Analysis From the CHAIN Cohort. CHEST. 2018; 154(2):274-285.

IF: 7,652 Q1


5. Plaza V, Cosio BG, Entrenas LM, Olaguibel JM, de Llano LP, Quirce S. The Role of FENO in the Diagnosis and Control of Asthma. Expert Multidisciplinary Group Debate during the Asthma Meeting Point 2017. ARCHIVOS DE BRONCONEUMOLOGIA. 2018; 54(4):237-238.

IF: 2,633 Q2

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL





GA04: Endocrinology and Nutrition. Insulin Resistance, Diabetes and Metabolism

<https://www.imibic.org/grupo/17>

ACTIVITY

- N° ONGOING PROJECTS: 1 (private)
- N° CLINICAL TRIALS : 9
- N° PATENTS: 1

TEAM

Galvez	Moreno	Mª Angeles	R4
Calañas	Continente	Alfonso	R3
Molina	Puerta	Mª Jose	R3
Paniagua	Gonzalez	Juan Antonio	R3
Palomares	Ortega	Rafael	R3
Rebollo	Martín	Ángel	R1
Muñoz	Jiménez	Concepción	R1
Padillo	Cuenca	José Carlos	R1
Moreno	Moreno	Paloma	R1
Alhambra	Expósito	Rosa María	R1
Herrera	Martínez	Aura Dulcinea	Researcher Collaborator

ADDITIONAL INFORMATION

- » **Networks:**
 - PAIDI CTS-651 scientific
- » **2 agreements with companies**

KEYWORDS

- Insulin resistance
- β-pancreatic dysfunction
- prediabetes
- metabolic syndrome
- adipotoxicity
- adipose tissue
- inflammation
- oxidative stress
- gene expression
- metabolomics
- pituitary adenoma
- somatostatin receptors
- vitamin D
- metabolic syndrome
- neuroendocrine tumors
- bariatric surgery
- adipose tissue
- hormones
- diabetes mellitus
- fertility
- pregnancy

HIGHLIGHTED PUBLICATIONS

1. Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martinez-Fuentes AJ, Galvez-Moreno MA, Castano JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. 2018; 9:Núm artículo 196

IF: 4,621 Q1 D1

2. Alhambra-Exposito MR, Ibanez-Costa A, Moreno-Moreno P, Rivero-Cortes E, Vazquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado A, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castano JP, Galvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. SCIENTIFIC REPORTS. 2018; 8:Núm artículo 6173

IF: 4,122 Q1

3. Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. ENDOCRINE. 2018; 59(2):426-437.

IF: 3,179 Q2

4. Rebollo-Roman A, Barrera-Martin A, Alcantara-Laguna MD, Iglesias-Flores E, Canada-Sanz E, Padillo-Cuenca JC, Molina-Puertas MJ, Calanas-Continente A. Non-oropharyngeal dysphagia with frequent Emergency Room attendance. NUTRICION HOSPITALARIA. 2018; 35(4):996-998.

IF: 0,747 Q4

5. Exposito MRA, Herrera-Martinez AD, Garcia GM, Calvo ME, Serrano CMB, Moreno MAG. Early nutrition support therapy in patients with head-neck cancer. NUTRICION HOSPITALARIA. 2018; 35(3):505-510.

IF: 0,747 Q4

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
DECILE



PUBLICATIONS
IN FIRST
QUARTIL





GA05: Study of Growth. Endocrinology and Child Nutrition

<https://www.imibic.org/grupo/39>

ACTIVITY

- N° ONGOING PROJECTS: 2 (public), 1 (private),
- N° CLINICAL TRIALS : 7
- N° PATENTS: 1

TEAM

Cañete	Estrada	Ramón	R4
García	Martínez	Elena	R3
Jimenez	Reina	Luis	R3
Martos	Estepa	Rosario	R3
Parraga	Quiles	Mª Jose	R3
Tofe	Valera	Ines	R3
Torres	Borrego	Javier	R3
Valle	Jimenez	Miguel	R3
Vazquez	Rueda	Fernando	R3
Ruiz	Gonzalez	Mª Dolores	R3
Gómez	Guzman	Elena	R1
Cañete	Vazquez	Mª Dolores	T

ADDITIONAL INFORMATION

- » **Networks:**
 - CIBERobn <https://www.ciberobn.es/en>
 - PAIDI CTS-329 <http://www.uco.es/dptos/ciencias-morfo/investigacion/grupos/cts-329.html>
- » **1 International Projects:**
 - PHC18-2015-001.ALBINO - Effect of allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome. European Commission
- » **1 agreement contract with companies**


KEYWORDS

- Child obesity
- metabolic syndrome
- diet
- endothelium
- inflammation
- cardiovascular biomarkers
- gene expression
- proteomics
- intrauterine-growth-retardation (IUGR)
- growth hormone (GH)
- food allergy

HIGHLIGHTED PUBLICATIONS

- Ortea I, Ruiz-Sanchez I, Canete R, Caballero-Villarraso J, Canete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. JOURNAL OF PROTEOMICS. 2018; 175:105-113.
IF: 3,722 Q1
- Gomez-Guzman E, Canete MD, Valle-Mertos R, Canete R, Valle M, Jimenez-Reina L, Caballero-Villarraso J. Short-Term Evaluation of Left Ventricular Mass and Function in Children With Growth Hormone Deficiency After Replacement Treatment. FRONTIERS IN PEDIATRICS. 2018; 6:Núm artículo 174
IF: 2,335 Q2
- Castillo-Fernandez AL, Vazquez-Rueda F, Canete MD, Caballero-Villarraso J. Retroperitoneal gastric duplication mimicking a prenatal adrenal cyst. CONGENITAL ANOMALIES. 2018; 58(4):141-142.
IF: 1,149 Q3
- Hernandez MAT, Martinez EG, Marin MJA, Guzman EG. Tolvaptan in a pediatric cardiorenal syndrome. What is its role? ARCHIVOS ARGENTINOS DE PEDIATRIA. 2018; 116(2):E279-E282.
IF: 0,405 Q4

SCIENTIFIC PRODUCTION





GA06: Clinical Analysis

<https://www.imibic.org/grupo/19>

ACTIVITY

- Nº CLINICAL TRIALS: 1
- Nº PATENTS: 1

TEAM

Rodriguez	Cantalejo	Fernando	R4
Caballero	Villarraso	Javier	R3
Barcos	Martínez	Montserrat	R2
Espejo	Portero	Isabel	R2
Moyano	Gallego	Mª José	CR
Romero	Baldonado	Cristina	R1
Peña	García	Victoria	T

KEYWORDS

- Evidence-based medicine (EBM): systematic reviews of the literature
- bibliometric studies and economic evaluations
- point-of-care testing
- POCT
- programming

HIGHLIGHTED PUBLICATIONS

1. Garcia-Rios A, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista J, Marin C, Leon-Acuna A, Camargo A, Rodriguez-Cantalejo F, Blanco-Rojo R, Quintana-Navarro G, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J, Perez-Martinez P. Beneficial effect of CETP gene polymorphism in combination with a Mediterranean diet influencing lipid metabolism in metabolic syndrome patients: CORDIOPREV study. *CLINICAL NUTRITION*. 2018; 37(1):229-234.

IF: 5,496 Q1 D1

2. Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Rialde MA, Brieua T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. *ZOOZOSES AND PUBLIC HEALTH*. 2018; 65(5):584-588.

IF: 2,688 Q1 D1

3. Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcala-Diaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castano J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES*. 2018; 73(3):327-332.

IF: 4,902 Q1


4. Ortea I, Ruiz-Sanchez I, Canete R, Caballero-Villarraso J, Canete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. *JOURNAL OF PROTEOMICS*. 2018; 175:105-113.

IF: 3,722 Q1

5. Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunez I. Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. *JOURNAL OF FUNCTIONAL FOODS*. 2018; 42:281-288.

IF: 3,47 Q1

SCIENTIFIC PRODUCTION





GA07: Visual Quality

<https://www.imibic.org/grupo/20>

ACTIVITY

- N° ONGOING PROJECTS: 2 (public)
- N° CLINICAL TRIALS: 4

TEAM

Gallardo	Galera	José María	R4
García	Martín	Manuel	R3
Giménez	Gómez	Rafael	R3
Martín	Suárez	Eva M	R3
Sánchez	León	Ana María	R3
Gonzalez	Andrades	Miguel	R2
Naranjo	Bonilla	Pedro	R1
Giménez-Alme-nara	Amo	Francisco Javier	CR
Osuna	Jiménez	Inmaculada	T

ADDITIONAL INFORMATION

» Networks:

- OFTARED ISCIII (Eye Diseases: Prevention, early detection and treatment of prevalent, degenerative and chronic ocular pathology) <http://www.oftared.com/>
- Spanish Society of Ophthalmology <https://www.oftalmoseo.com/>
- European Society of Ophthalmology <https://soevision.org/>
- Andalusian Initiative for Advance Therapies <https://www.sspa.juntadeandalucia.es/terapiasavanzadas/index.php/en/>

KEYWORDS

- Ophthalmology
- cornea
- retina
- glaucoma
- tissue engineering
- regenerative medicine
- biomedical engineering
- reconstructive surgery
- drug delivery
- nanomedicine
- nanoparticles
- biomaterials

HIGHLIGHTED PUBLICATIONS

1. Cruzat A, Gonzalez-Andrades M, Mauris J, Abusamra D, Chidambaram P, Kenyon K, Chodosh J, Dohlman C, Argueso P. Colocalization Of Galectin-3 With CD147 Is Associated With Increased Gelatinolytic Activity In Ulcerating Human Corneas. IOVS. 2018;59:223-230.

IF: 3.303 Q1

2. Gonzalez-Andrades M, Sharifi R, Islam MM, Divoux T, Haist M, Paschalis EI, Gelfand L, Mamodaly S, Di Cecilia L, Cruzat A, Ulm FJ, Chodosh J, Delori F, Dohlman CH. Improving the practicality and safety of artificial corneas: Pre-assembly and gamma-rays sterilization of the Boston Keratoprosthesis. Ocul Surf. 2018;16:322-330.

IF: 4.38 Q1 D1


3. Martin-Suarez E, Galan A, Morgaz J, Guisado A, Gallardo JM, Gomez-Villamandos RJ. Comparison of central corneal thickness in dogs measured by ultrasound pachymetry and ultrasound biomicroscopy. VETERINARY JOURNAL. 2018; 232:13-14.

IF: 1,773 Q1

4. Dohlman CH, Cade F, Regatieri CV, Zhou C, Lei F, Crnej A, Harissi-Dagher M, Robert MC, Papaliodis GN, Chen D, Aquavella JV, Akpek EK, Aldave AJ, Sippel KC, D Amico DJ, Dohlman JG, Fagerholm P, Wang L, Shen LQ, González-Andrades M, Chodosh J, Kenyon KR, Foster CS, Pineda R, Melki S, Colby KA, Ciolino JB, Vavvas DG, Kinoshita S, Dana R, Paschalis EI. Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Cornea. 2018; 37(2):248-251.

IF: 2,01 Q2

SCIENTIFIC PRODUCTION





GA08: Radiology

<https://www.imibic.org/grupo/21>

ACTIVITY

- N° ONGOING PROJECTS: 1 (public)
- N° CLINICAL TRIALS: 1

TEAM

López	Ruiz	Daniel	R4
Álvarez	Benito	Marina	R3
Benito	Ysamat	Alberto	R3
Cano	Sánchez	Antonio	R3
Cara	García	María	R3
Delgado	Acosta	Fernando	R3
García	Ortega	María José	R3
García-Revilla	García	Jose	R3
Izquierdo	Palomares	Lucía Nuria	R3
Muñoz	Carrasco	Rafaela	R3
Roldán	Romero	Elisa	R3
Santos	Romero	Ana Luz	R3
Ysamat	Marfa	Roser	R3
Amate	Rivas	Cristina	T

ADDITIONAL INFORMATION

» **2 agreements with companies**

KEYWORDS

- Stem cells
- arterial ischemia of the lower limbs
- therapeutic angiogenesis
- neoplasms
- demyelinating diseases
- rheumatic diseases
- pathochrony
- radiological assessment of response to drugs
- diagnostic radiological scans
- therapeutic radiological scans

HIGHLIGHTED PUBLICATIONS

1. Martin SR, Povedano JLR, Garcia MC, Romero ALS, Garriguet MP, Benito MA. Prospective study aiming to compare 2D mammography and tomosynthesis plus synthesized mammography in terms of cancer detection and recall. From double reading of 2D mammography to single reading of tomosynthesis. EUROPEAN RADIOLOGY. 2018; 28(6):2484-2491.

IF: 4,027 Q1

2. Puente AB, Rodriguez FDB, Rey IB, Romero ER. Intracranial developmental venous anomaly: is it asymptomatic?. RADIOLOGIA. 2018; 60(6):512-516.

IF: 0

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL





GA09: Cardiovascular Pathology

<https://www.imibic.org/grupo/23>


ACTIVITY

- N° ONGOING PROJECTS: 1 (public international)
- N° CLINICAL TRIALS: 2

TEAM

Muñoz	Carvajal	Ignacio	R4
Arias	Dachary	Francisco Javier	R3
Blazquez	Ruiz	Maria Del Valle	R3
Casares	Mediavilla	Jaime Guillermo	R3
Chacón	Quevedo	Antonio	R3
Elias	Fuentes	Agustín	R3
Hervas	Sotomayor	Daniela	R3
Inga	Távora	Laura Isabel	R3
Jiménez	Castilla	Agustina	R3
Jurado	Morata	Aurea	R3
Moya	Gonzalez	Javier	R3
Ortega	Lopera	Bibian	R3
Pernía	Oreña	Isabel	R3
Sartor		Lucio	R3
Alados	Arboledas	Pedro Jose	R2
Merino	Cejas	Carlos Manuel	R2
Zurita	Martinez	Federico	R2
Conejero	Jurado	María Teresa	R2
Dominguez	Del Castillo	Jose Joaquin	R1
Fernández	Carbonell	Azahara	R1
Turegano	Cisneros	Jose María	R1
López	Romero	Rosalía	T
Riballo	Cortes	Raquel	T
Romero	Morales	Maria Del Carmen	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **Networks:**
 - On the website of the Reina Sofia Hospital / https://www.juntadeandalucia.es/servicioandaluzdesalud/hrs3/index.php?id=cirugia_cardiovascular
- » **1 International Projects:**
 - PM-12-2016-002.STARS - Empowering Patients by Professional Stress Avoidance and Recovery Services. European Commission H2020.
- » **2 agreements with companies**

KEYWORDS

- Cardiovascular
- cardiac surgery

HIGHLIGHTED PUBLICATIONS

1. Carbonell AF, Mediavilla JC, Guerrero ER, Carvajal IM. Defibrillator implantation to a patient with large vessel transposition and physiological correction of Senning. CIRUGIA CARDIOVASCULAR. 2018; 25(4):212-213.

IF: 0

2. Carbonell AF, Arboledas PA, Guerrero ER, Montilla ME, Carvajal IM. Usefulness of the “chimney” technique in the emergency treatment of abdominal aortic aneurysms with unfavorable anatomy. CIRUGIA CARDIOVASCULAR. 2018; 25(3):158-162.

IF: 0





GA10: Nuclear Medicine

<https://www.imibic.org/grupo/24>

ACTIVITY

- Nº CLINICAL TRIALS: 1

TEAM

Vallejo	Casas	Juan Antonio	R4
Albala	Gonzalez	Maria Dolores	R3
Benitez	Velasco	Ana	R3
Carmona	Asenjo	Elviria	R3
Maza	Muret	Fº Roberto	R3
Mena	Bares	Luisa Maria	R3
Moreno	Ortega	Estefanía	R3
Pacheco	Capote	Carmen	R3
Guiote	Moreno	María Victoria	R1
Márquez	Fernández	Juan	R1
Rodríguez	Cáceres	Esther	R1
Santos	Bueno	Antonio María	R1
Martín	Ruiz	Antonio	T
Moriana	Porrás	María del carmen	T
Rojas	Arroyo	Anahi	T
Zurera	Pareja	Rocío	T

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » 2 agreements with companies

KEYWORDS

- Nuclear medicine

HIGHLIGHTED PUBLICATIONS

1. Moreno MVG, Bares LMM, Bueno AMS, Cáceres ER, Casas JAV. A unusual pediatric case of focal nodular hyperplasia studied with Tc-99m-rnebrofenin. REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR. 2018; 37(3):178-180.





GA11: Learning and Artificial Neural Networks

<https://www.imibic.org/grupo/41>

ACTIVITY

- N° ONGOING PROJECTS: 3 (public), 1 (private)
- N° START UP/CREATE:i

TEAM

Hervás	Martínez	César	R4
Gutiérrez	Peña	Pedro A.	R3
Becerra	Alonso	David	R3
Carbonero	Ruz	Mariano	R3
De La Paz	Marín	Mónica	R3
Durán	Rosal	Antonio M	R3
Fernández	Caballero	Juan Carlos	R3
Fernández	Navarro	Francisco	R3
García	Alonso	Carlos	R3
Martínez	Estudillo	Alfonso Carlos	R3
Martínez	Estudillo	Francisco José	R3
Pérez	Ortiz	María	R3
Rodero	Cosano	Mª Luisa	R3
Sánchez	Monedero	Javier	R3
Salinas	Pérez	José A.	R3
Salcedo	Sanz	Sancho	R3
Torres	Jiménez	Mercedes	R3
Barbero	Gómez	Javier	R1
Dorado	Moreno	Manuel	R1
Guijo	Rubio	David	R1
Vargas	Yún	Víctor	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - DAMA Network
 - MAPAS Network

KEYWORDS

- Ordinal classification
- artificial neural networks
- processing of biomedical images
- time series segmentation
- regression models
- ordinal regression
- evolutionary computation

HIGHLIGHTED PUBLICATIONS

1. Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. LIVER TRANSPLANTATION. 2018; 24(2):192-203.

IF: 3,752 Q1

2. Duran-Rosal AM, Gutierrez PA, Martinez-Estudillo FJ, Hervas-Martinez C. Simultaneous optimisation of clustering quality and approximation error for time series segmentation. INFORMATION SCIENCES. 2018; 442:186-201.

IF: 4,305 Q1 D1

3. Sanchez-Monedero J, Perez-Ortiz M, Saez A, Gutierrez PA, Hervas-Martinez C. Partial order label decomposition approaches for melanoma diagnosis. APPLIED SOFT COMPUTING. 2018; 64:341-355.

IF: 3,907 Q1


4. Guijo-Rubio D, Gutierrez PA, Casanova-Mateo C, Sanz-Justo J, Salcedo-Sanz S, Hervas-Martinez C. Prediction of low-visibility events due to fog using ordinal classification. ATMOSPHERIC RESEARCH. 2018; 214:64-73.

IF: 3,817 Q1

5. Duran-Rosal AM, Gutierrez PA, Salcedo-Sanz S, Hervas-Martinez C. A statistically-driven Coral Reef Optimization algorithm for optimal size reduction of time series. APPLIED SOFT COMPUTING. 2018; 63:139-153.

IF: 3,907 Q1

SCIENTIFIC PRODUCTION





GA12: Severe Mental Illness-Health alerts

<https://www.imibic.org/grupo/56>

OH. Other Scientific Contributions from the Hospital Division

ACTIVITY

- N° ONGOING PROJECTS: 1 (public)
- N° CLINICAL TRIALS : 5

TEAM

Sarramea	Crespo	Fernando	R4
Alcalá	Partera	José Ángel	R3
Caro	Martos	Inmaculada	R3
Carrión	Expósito	Laura	R3
Chauca	Chauca	Geli Marie	R3
Del Pozo	Seseña	Gloria Isabel	R3
Feu		Nuria	R3
Gómez	Moreno	Cristina	R3
Gutiérrez	Rojas	Luis	R3
Jaén	Moreno	María José	R3
López	Carnerero	María Soledad	R3
Luque	Luque	Rogelio	R3
Martín	Pérez	Darío	R3
Montiel	López	Francisco Javier	R3
Osuna	Carmona	María Isabel	R3
Padilla	Obrero	Leonor	R3
Prada	Carrasco	Carmen	R3
Prados	Ojeda	Juan Luis	R3
Redondo		Justa	R3
Sánchez	Martínez	María Dolores	R3
Valdivia	Romero	Francisca	R3
Zurita	Gotor	Pilar	R3
Ruiz	Rull	Cristina Esther	R1

ADDITIONAL INFORMATION

- » **Networks:**
 - Mental Health on CIBERSAM (ISCIII) <https://www.cibersam.es/grupos/grupo-de-investigacion?id=14263>
 - CTS 550 PAIDI scientific group.
 - GETBA (Group for the Study of Bipolar Disorder in Andalusia)

KEYWORDS

- severe mental disorder
- schizophrenia
- bipolar disorder
- tobacco cessation
- mortality
- readiness to change
- chronic obstructive pulmonary disease
- screening

MAIN RESULTS

- » **CLINICAL GUIDES**

Anesthesia Unit

ADDITIONAL INFORMATION

- » **International Projects**
 - RELIEF - Recovering Life wellbeing through pain self-management techniques involving ICTs

ACTIVITY

- N° ONGOING PROJECTS: 2 (public)
- N° CLINICAL TRIALS : 1


Clinical Analysis Unit

SCIENTIFIC PRODUCTION



Dermatology Unit

SCIENTIFIC PRODUCTION




ACTIVITY

- » N° CLINICAL TRIALS : 1

Emergencies Unit

SCIENTIFIC PRODUCTION



ACTIVITY:

- » N° PATENTS: 1



General and Digestive Surgery Unit

SCIENTIFIC PRODUCTION



PAPERS

ACTIVITY:

» N° CLINICAL TRIALS : 1

Gynecology & Obstetrics Unit

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL

ACTIVITY

» N° CLINICAL TRIALS : 2

Gastroenterology Unit

SCIENTIFIC PRODUCTION



PAPERS

Maxillofacial surgery Unit

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL

Neurosurgery Unit

ACTIVITY:

- » N° ONGOING PROJECTS: 1 (public)
- » N° PATENTS: 2

Neurology Unit

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL

ACTIVITY:

» N° CLINICAL TRIALS : 5

Nursing Unit

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL

Internal Medicine Unit

SCIENTIFIC PRODUCTION



PAPERS



PUBLICATIONS
IN FIRST
QUARTIL

Onco-radiotherapy Unit

SCIENTIFIC PRODUCTION



PAPERS


ACTIVITY:

» N° CLINICAL TRIALS : 3



Pathological Anatomy Unit

SCIENTIFIC PRODUCTION



Pharmacy Unit

ACTIVITY:

- » N° CLINICAL TRIALS : 1
- » N° PATENTS: 1


Physical Medicine and Rehabilitation

ACTIVITY:

- » N° PROJECTS STARTING IN 2019: 1 (public)

Intensive Care Unit

SCIENTIFIC PRODUCTION



ADDITIONAL INFORMATION

- » **International Projects.**
 - PREPARE - Platform foR European Preparedness Against (Re-)emerging Epidemics
 - COMBACTE-MAGNET - Combatting bacterial resistance in Europe - molecules against Gram negative infections

ACTIVITY

- » N° ONGOING PROJECTS: 2 (public)

Quality Unit

ACTIVITY:

- » N° ONGOING PROJECTS: 1 (public)

Radiology Unit

SCIENTIFIC PRODUCTION




Services General Unit

SCIENTIFIC PRODUCTION



Traumatology Unit


SCIENTIFIC PRODUCTION



ACTIVITY

- » N° CLINICAL TRIALS : 1





INNOVATION
AND TRANSFER

The Reina Sofía Hospital has among its objectives to promote research and innovation among its health professionals. For this, it has the support of IMIBIC, which in its strategic plan includes these common objectives, where innovation is positioned as one of the cross-cutting and growth axes of HURS / IMIBIC. Even so, one of the indicators of innovation of the institute defined as the “No. of therapeutic / diagnostic alternatives or innovative cost effective solutions implemented” has remained underestimated in recent years (accounting annually for one or none) as there is no tool for your registration. Therefore, and taking into account that innovation is one of the three strategic lines of the ISCIII, (along with the internationalization and translation of research results), it was decided to prepare the general survey of innovations. Based on this study, altogether 91 innovations implemented during 2017 were identified and the type of innovations that were detected, including Organization and support, Information Technologies, Imaging, Materials and devices, and Biotechnology.

Bellow, it is shown the analysis of the obtained results:

Final result: 91 innovations detected only in one year, of which 13 are carried out jointly between different UGCs:

- » 77% innovations in healthcare organizations.
- » 9% ICT innovations.
- » 9% innovations in materials and devices.
- » 4% biotechnological innovations.
- » 1% innovations in imaging techniques.

The economic impact of these innovations for HURS has been estimated based on savings derived from fewer diagnostic tests, interventions, hospitalization days, the use of more effective treatments and a reorganization of the tasks of health personnel.

The impact for the patient is derived from the reduction in the number of trips, in the number of check-ups and days due to medical leave. An improvement in patient care has been detected with the use of personalized medicine, less invasive alternatives that reduce the possibility of complications, which results in an improvement in their quality of life.

As a conclusion from this result, we can say that:

- » The UGCs that most innovate are those of General and Digestive Surgery, followed by Internal Medicine, Radiodiagnosis, Radiation Oncology and Nuclear Medicine.
- » HURS is emerging as an innovative entity, with a clear trend towards personalized medicine, with innovations in place that improve patient care and diagnosis, with professionals with a clear innovative spirit and continuous improvement.

During 2018, several actions for the dissemination of the identification of potential interest results for the care activity have been carried out, including its presentation healthcare institutions and healthcare professionals in the IIS environment and others. A portfolio with products of interest for clinical practice, have been also developed. The most representative actions are:

- » The innovation survey has been presented to the General Manager of the Reina Sofía Hospital and sent to the XXI Congress of Hospitals (SEDISA) for its potential presentation as an oral communication.
- » Two projects have been presented in the Biospain investor's forum in September 2018.
- » Presentation at the Health Investment Forum organized by Canaan on November 26 in Madrid.

- » Presentation of projects to companies: CETEMET, Tecnalia,
- » Portfolio of technological offers updated on the FPS website.
- » Presentation of the portfolio of technological offers in the Innolabs December, 2018 forum.
- » Presentation to the Cajasur Foundation of the innovations detected in HURS

Other key activities carried out by the Innovation Unit in 2018 were:

1. IMIBIC is part of ITEMAS platform (Innovation Platform in Medical and Health Technologies) funded by the National Institute of Health Carlos III (ISCIII) which promotes innovation in health technologies as a key tool to provide sustainability to the National Health System since 2013 Innovation Unit actively participated in the ITEMAS' ISO 166.002:2014 Certification Work Group. Furthermore, the Innovation Unit also collaborated with ITEMAS in the organization of courses targeted to the IMIBIC research community. In 2018 IMIBIC concluded its participation the 2013 ITEMAS platform (PT13/0006), however IMIBIC's participation is still on going in the renewal of the following ITEMAS platform (PT17/0005).
2. The Innovation Unit passed successfully the re-accreditation of its management quality system ISO 166.002:2014 standard. This is the second re-accreditation that the unit completed without observations.
3. The Unit has maintained more than 100 meeting with basics and clinic researchers, in order to have its portfolio of innovations updated with the insights, innovative ideas and research results that could potentially be protected in terms of IP.

4. In order to maintain the contact with the industrial sector, the Unit had more than 100 meetings with national and international companies, presenting its portfolio of protected ideas for the purpose of looking for collaborations that trigger the acceleration of the inventions developed at IMIBIC.

5. The Innovation Unit's team attended various national and international conferences and fairs, with the main objective to establish links and collaboration with company representatives and other research centres. The most important ones were:

- » Transfiere Forum 14th-15th February, Malaga (Spain)
- » Convention ITEMAS 2018, 25th May, Madrid (Spain)
- » Final Pitch Caixaimpulse Grant, 7th September, Barcelona (Spain)
- » Horizon Europe-Universidad Menendez Pelayo (UIMP) 10th-12th September, Santander (Spain)
- » Innovation Day by Johnson and Johnson at CNIO 13th September, Madrid (Spain)
- » BIOSPAIN 2018 25th-27th September, Sevilla (Spain).
- » Public Procurement of Innovation in Andalusia, conference held at Biospain 2018, 27th September Sevilla (Spain)
- » ANECORM Congress 2018, 25th October, Sevilla (Spain)
- » Innolabs annual meeting 2018, 13th November, Madrid (Spain) 27th November, Madrid (Spain).
- » Farmaindustria Cooperation Farma-Biotech meeting 2018, 28th November, Madrid (Spain).
- » EIT Health Summit 2018 4th-5th December, Lodz (Poland)

6. The Innovation Unit participates in two Pre-Commercial Procurement (PCP) projects funded by the



European Commission H2020 program. The RELIEF project, which started in 2016, concerns chronic pain management, and the STARS project, stress reduction and measurement management (project started in 2017). RELIEF project has entered in its final phase and is expected to be finished at the end of 2019. STARS project began its Phase I at the end of 2018.

7. Two projects have been selected for funding in the “Desarrollo Tecnológico en Salud (DTS)” 2018 call launches by the ISCII.

8. The Innovation Unit has promoted the participation of different research groups of IMIBIC in public-private

collaboration via competitive calls. In 2018, 26 projects were submitted to different calls and from those, 6 has been selected for funding. The calls where they belong are: FIPSE (2 projects), CIEN (1 project), DTS (2 projects) and one in the Consejería de Salud innovation call

9. The Innovation Unit has established collaboration with technological and industrial networks, as well as with technological groups of other research entities.

10. In relation to activities to promote the creation of start-up companies, the Innovation Unit has advised 3 potential companies and is working very close with the researchers to promote the creation of star-ups and licenses for the exploitation of results.

As a result of all the activities described above, the following results were obtained:

EVOLUTION OF RESULTS								
	2011	2012	2013	2014	2015	2016	2017	2018
PATENTS	6	8	13	11	14	9	16	13
PCTs	2	3	3	4	7	6	6	3
LICENSES	0	4	4	2	2	0	2	2
COMPANIES	1	2	0	1	0	0	0	0


Industrial and intellectual property patents

During 2018, a total of 16 industrial/intellectual property registrations were applied for:

Title	Registry type	Owner Entity	Research Groups
IMIBIC	Trademark register	FIBICO	
Predictive model to predict the development of type 2 diabetes mellitus using miRNAs	Patent	UCO-SAS-CIBE-ROBN	GC09
Anti- eschar cranial support	Utility Model	SAS	Neurosurgery

Title	Registry type	Owner Entity	Research Groups
Modular equipment for patient extraction in vehicles	Patent	Hospital Infanta Margarita	Emergency
Predictive biomarkers of ectopic pregnancy	Patent	SAS, UCO, FUNDACIÓN IVI	GC10
Anti- eschar cranial support (second design)	Utility Model	SAS	Neurosurgery
Method for the diagnosis, prognosis and treatment of neuroendocrine tumours (NETs)	Patent	SAS, UCO	GC27, GC08
Method to predict the development of type diabetes mellitus	Patent	SAS, UCO	GC27,GC09 AND Bioinformatics Unit
Method of diagnosis of Hepatitis E (HEV)	Patent	SAS	GC03
Use of splicing factors as biomarkers for diagnosis, stratification and prediction of clinical evolution and / or therapeutic response in rheumatoid arthritis	Patent	SAS, UCO	GC05 y GC27 (OncObesity and Metabolism) (Systemic and chronic inflammatory autoimmune diseases of the locomotor system and connective tissue)
TTParmacy	Intellectual property registry	SAS,	Hospital pharmacy
Care of the chronic and acute wounds (HECROA APP)	Intellectual property registry	SAS	Intensive care
Biomarkers for the diagnosis of the hormone deficit of child growth. Procedure and kit	PCT	SAS,UCO	Proteomics , GA05, GA06
Use of GOAT enzyme levels as a marker of prostate cancer. “Ghrelin-O-acyl transferase (GOAT) and its uses”.	National Phase in Brazil	SAS,UCO	GC08/GC27
Use of GOAT enzyme levels as a marker of prostate cancer. “Ghrelin-O-acyl transferase (GOAT) and its uses”.	National Phase in US	SAS,UCO	GC08/GC27
Use of GOAT enzyme levels as a marker of prostate cancer. “Ghrelin-O-acyl transferase (GOAT) and its uses”.	European Patent	SAS,UCO	GC08/GC27





FACTS
& FIGURES

SPECIFIC OBJECTIVES OF THE COOPERATIVE SCIENTIFIC PLAN

Boost translational research in predictive medicine.

In 2018, the following precision medicine projects were applied for and awarded:

- Ghrelin-O-acil-Transferase (GOAT): A New Biomarker for the screening of prostate cancer: DTS18/00131. PI: Raúl García Luque, Justo P. Castaño Fuentes.
- MERLIN - hoMEcare aRm rehabiLtatioN, PI: Fernando Jesús Mayordomo Riera
- 3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions. PI: Eduardo Collantes. (*proceeds to Phase Two)

In 2018, the patent, miRNAs as biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF alpha, was licenced. IMIBIC Groups GC05.

In addition, an application was made for the project: IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018.

Develop high-quality collaborative research projects in the IMIBIC groups.

At the institutional level, the Fleximet project, funded by the Instituto de Salud Carlos III public research organization, was developed. During 2018, application was made for the project: IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018.

Boost collaborative translational research with results close to the market.

In the course of 2018 16 patents were applied for and 2 were licenced.

Consolidate collaboration between research groups, covering:

Promoting joint projects and publications involving IMIBIC groups, as stated in the Cooperative Scientific Plan.

Measurable Indicators

- No. of projects involving collaboration between IMIBIC groups: 60 projects were carried out involving IMIBIC groups in 2018.
- No. of joint publications between IMIBIC groups: 82 articles were published involving collaboration between IMIBIC groups in 2018.
- Others relating to collaborative translational research:
 - » Clinical practice guidelines involving the collaboration of more than one IMIBIC group: 3 sets of guidelines were published in collaboration with other IMIBIC groups in 2018.
 - » Patents involving the collaboration of more than one IMIBIC group: 3 patents were applied for in collaboration with other IMIBIC groups in 2018.
 - » Activate dynamic actions, joint meetings, courses, mobility, etc. between groups in the Institute, as defined in the Training Plan:


Measurable Indicators

- » Intramural seminars: a total of 8 intramural seminars were held
- Improve communication and interaction between internal stakeholders and their commitment to the organization. These internal communication mechanisms in the IMIBIC are included in the Corporate Communication and Corporate Social Responsibility Plan.


Measurable Indicators

- » Draw up an Internal Communication Plan: A start was made on drawing up the Internal Communication Plan in 2018.

NUMBER OF GROUPS PER PROGRAM




NUMBER OF RESEARCH GROUPS PER PROGRAM




RESULTS OF ACTIVITIES PER PROGRAMS


PROGRAM 1




PROGRAM 2




PROGRAM 3



PROGRAM 4



PROGRAM 5




Legend

- Yellow:** Papers in 2018
- Blue:** Ongoing Projects in 2018
- Dark Blue:** Industrial and intellectual property patents request in 2018
- Red:** Ongoing Clinical Trials in 2018



PUBLICATIONS

In 2018, our researchers have contributed to society with 493 scientific documents published, only **459** have been considered documents published in scholarly journals indexed in the ISI Web of Science with quartil (Q1, Q2, Q3 & Q4).



PUBLICATION OUTPUT AND INDICATORS IN 2018

	Output	%D1	%Q1	%Q2
Original articles	374	21%	56%	25%
Reviews	44	23%	41%	30%
Editorial	19	5%	32%	11%
Letters	22	14%	50%	14%

Output

Total number of documents published in scholarly journals indexed in the ISI Web of Science with quartil.

% Q1 % of publications published in journals ranked in the first quartile (top 25%) of their category as ordered by the 2017 Journal Citation Reports.

% D1 % of publications published in journals ranked in the first decile (top 10%) of their category as ordered by the 2017 Journal Citation Reports.

Evol. OF PUBLICATIONS PER Q1 & D1




FIGURE LEGEND

All type of journal publication were taken into consideration. %Q1: % of publications published in journals ranked in the first quartile (top 25%) of their category as ordered by the 2017 Journal Citation

Evol. OF NUMBER OF PUBLICATION PER PROGRAM





FIGURE LEGEND

All documents were taken into consideration. Publications have been counted many times will apper for each program, so the sum of the documents per program is higher than the total.

NUMBER OF THE TOTAL NUMBER OF PUBLICATIONS IN 2018




DISTRIBUTION OF NATIONAL AND INTERNATIONAL JOURNALS

	NO. OF PUBLICATIONS
Original Articles in international journals	335
Original Articles in national journals	39
Reviews in international journals	39
Reviews in national journals	5
Editorial in International Journal	9
Editorial in national journal	10
Letters in international journals	9
Letters in national journals	13
TOTAL	459

INTERNATIONAL


186 International Research centres collaborating with IMIBIC



DISTRIBUTION OF AFFILIATION OF THE AUTHORS COLLABORATIONS


Affiliation of the authors pertains to	Nr of publications
International Groups	186
National Groups	173
Local Groups	100
	459
IMIBIC Groups	82

NUMBER OF CITATION PER CATEGORY ESI



Citation per article, calculated by Clarivate Analytics' Essential Science Indicators (ESI) database


OPEN SCIENCE



NUMBER OF CLINICAL GUIDES, CONSENSUS AND PROTOCOLS DOCUMENTS

IMBIC'S impact in society, it is worth mentioning that year our researchers participate in the elaboration of international clinical guides. These guidelines have a remarkable impact in patients' care and medical practice.

	Output	%D1	%Q1	%Q2
Clinical Guides and Consensus	25	12%	12%	28%




Total number of Clinical Practice Guidelines and Consensus Documents published in 2018 scholarly journals indexed in the ISI Web of Science with quartil.

These documents have been counted previously according to its type of journal publication: articles and reviews


RESEARCH PROJECT & NETWORKS

Our researchers have been developing competitive projects, 153 initiated their activity during the year. This external funding supports research projects, fellowship and networks. The European Regional Development Fund (ERDF) co-funds many of these activities.


INTERNATIONAL



NATIONAL



REGIONAL



ONGOING PROJECTS IN 2018

	No. of ongoing projects
National	
Publics	
Institute Carlos III Health (ISCIII)	59
<i>Fellowship</i>	21
Ministry of Economy and Competitiveness (MINECO)	24
<i>Fellowship</i>	14
Ministry of Education, Culture and Sport (MECD)	-
<i>Fellowship</i>	2
Interconecta (FEDER FUNDS)	2
Privates	
Private Funding	20
<i>Fellowship</i>	5
Regional	
Publics	
Regional Ministry of Health and Social Policy (CISPS)	29
<i>Fellowship</i>	2
Regional Ministry of Economy, Innovation, Science and Employment (CEICE).	7
<i>Fellowship</i>	2
Andalusian Progress and Health Foundation (FPS).	11
Andalusian Health Service (SAS)	14
<i>Fellowship</i>	
Privates	
Private Funding	1
International	
Publics	
European Commission	14
<i>Fellowship</i>	1
Other agency public	2
Privates	
Private Funding	6


GRANTED PROJECTS IN 2018

	No. of granted projects
National	
Publics	
Institute Carlos III Health (ISCIII)	14
<i>Fellowship</i>	8
Ministry of Economy and Competitiveness(MINECO)	-
<i>Fellowship</i>	1
Privates	
Private Funding	6
<i>Fellowship</i>	1
Regional	
Publics	
FIBICO. Research Programme	8
<i>Fellowship</i>	3
Andalusian Progress and Health Foundation (FPS)	3
<i>Fellowship</i>	2
International	
Publics	
European Commission	1
Privates	
Private Funding	4


These tables classifies our active and **new competitive projects/networks/human resources** obtained in 2018 by funding agency. Additionally, the funding institutions are differings in public and **private**

ONGOING PROJECTS COLLABORATION BETWEEN OUR TEAMS

Our researchers have been working in **60 active projects competitive** in 2018. Information classified per program.




CLINICAL TRIALS BY RESEARCH PROGRAM IN 2018



CLINICAL TRIALS


The adjacent graphics summarize the number of active clinical trials in 2018. In 2018, 161 new clinical trials were opened and overall, there were 496 active clinical trials. Most of these clinical trials correspond to phase III (48%).

ONGOING CLINICAL TRIALS IN 2018



CLINICAL TRIALS CLASSIFIED ACCORDING TO PROMOTER IN 2018

PROMOTER	Number of Trials	Percentage
INDUSTRY	359	72%
OTHER ENTITIES	120	24%
FIBICO	17	3%
TOTAL	496	100%



By scientific areas, most of the trials are national company performed in the area of oncology, rheumatology, digestive, hematology, infections diseases, Internal Medicine



INNOVATION

During 2018, 16 patent applications were filed (13 priority patents and 3 PCTs). Besides, 2 new license agreements were signed with local and international companies.


EVOLUTION OF PATENTS

Year	Priority patents National & international	Extensions PCTS & entry in national phases	Licenses
2013	13	3	4
2014	11	4	2
2015	14	7	2
2016	9	6	0
2017	10	5	2
2018	13	3	2

EVOLUTION OF START-UP OR SPIN-OFF COMPANIES CREATED

2013	1
	Start-ups or spin-off created
2014	1
	Start-ups or spin-off created
2015	0
	Start-ups or spin-off created
2016	0
	Start-ups or spin-off created
2017	0
	Start-ups or spin-off created
2018	0
	Start-ups or spin-off created

% OF PATENTES COLLABORATION BETWEEN OUR TEAMS





COMMUNICATIONS
AND PUBLIC
ENGAGEMENT

PRESS

PRESS RELEASES: 307

MEDIA APPEARANCES: 355

EVENTS ORGANISED: 9

ACTIVITIES ORGANISED: 152

- **TALKS:** 103
- **VISITS:** 49

SCIENTIFIC CULTURE

Number of people visiting IMIBIC: 1183

Number of people who come from: 707

» El Imibic capta 9,6 millones en 2017 y supera las 200 investigaciones
https://www.diariocordoba.com/noticias/temadia/imibic-capta-9-6-millones-2017-supera-200-investigaciones_1237967.html

» El Reina Sofía Córdoba y el IMIBIC coordinan un ensayo internacional para tratar tumores hepáticos malignos en niños
<https://www.europapress.es/esandalucia/cordoba/noticia-reina-sofia-cordoba-imibic-coordinan-ensayo-internacional-tratar-tumores-hepaticos-malignos-ninos-20180723180419.html>

» Álvaro Granados del Río se incorpora como nuevo gerente del IMIBIC
<https://cordopolis.es/2018/07/27/alvaro-granados-del-rio-se-incorpora-como-nuevo-gerente-del-imibic/>

» La investigadora de IMIBIC Córdoba, Elena Yubero, premiada por la Asociación Española Contra el Cáncer
<https://cordobabuenasnoticias.com/2018/09/24/la-investigadora-de-imibic-cordoba-elena-yubero-premiada-por-la-asociacion-espanola-contra-el-cancer/>

» El IMIBIC, el Hospital Reina Sofía y la Fundación Cajasur desarrollan un test para prevenir la demencia
<https://www.europapress.es/esandalucia/cordoba/noticia-imibic-hospital-reina-sofia-fundacion-cajasur-desarrollan-test-prevenir-demencia-20180918152118.html>



ENERO- MARZO

JULIO-SEPTIEMBRE

OCTUBRE-DICIEMBRE

Reina Sofía e Imibic participan en un ensayo clínico internacional sobre un nuevo medicamento para el glaucoma
<https://www.europapress.es/esandalucia/cordoba/noticia-reina-sofia-imibic-participan-ensayo-clinico-internacional-nuevo-medicamento-glaucoma-20180105130655.html>

IMIBIC coordina una guía internacional sobre el Síndrome Metabólico
https://www.diariocordoba.com/noticias/cordobalocal/imibic-coordina-guia-internacional-sindrome-metabolico_1197976.html

El investigador del IMIBIC y la UCO, Rafael Pineda, recibe una EARLY CAREER GRANT de la Sociedad de Endocrinología de Reino Unido
<http://biotech-spain.com/es/articles/el-investigador-del-imibic-y-la-uco-rafael-pineda-recibe-una-early-career-grant-de-la-sociedad-de-endocrinolog-a-de-reino-unido/>

» Diez años de Investigación Médica en el IMIBIC
<https://cordopolis.es/2018/04/26/diez-anos-de-investigacion-medica-en-el-imibic/>

» La Medicina Personalizada de Precisión consolida su camino
https://www.diariodesevilla.es/salud/Medicina-Personalizada-Precision-consolida-camino_0_1246975897.html

» El Imibic reúne a 200 investigadores en las jornadas de jóvenes científicos
https://www.eldiadecordoba.es/cordoba/Imibic-investigadores-jornadas-jovenes-cientificos_0_1250575025.html

» La UE aprueba el Proyecto STARS en el que participan el Hospital Universitario Reina Sofía y el IMIBIC
<https://www.europapress.es/esandalucia/cordoba/noticia-ue-aprueba-proyecto-stars-participan-hospital-universitario-reina-sofia-imibic-20180629182901.html>

» IMIBIC y Roche reconocen las mejores ideas innovadoras en Biomedicina
<https://www.20minutos.es/noticia/3369857/0/imibic-roche-reconocen-mejores-ideas-innovadoras-biomedicina/>

» El Imibic aumenta su actividad investigadora y producción científica en su décimo aniversario
<https://www.20minutos.es/noticia/3453674/0/imibic-aumenta-su-actividad-investigadora-produccion-cientifica-su-decimo-aniversario/>

» El cirujano Álvaro Arjona representa a España en Europa para investigar cáncer peritoneal
<http://www.cordobahoy.es/articulo/la-ciudad/cirujano-alvaro-arjona-representa-espana-plataforma-europea-investigar-cancer-peritoneal/20180927173129049332.html>

» El IMIBIC premia con su Lección Maimónides a Mariano Barbacid y a los mejores trabajos de investigación de 2018
<https://www.imibic.org/noticia/151>

» Reconocimiento a Mariano Barbacid
https://www.diariocordoba.com/noticias/cordobalocal/reconocimiento-mariano-barbacid_1271073.html


» Susana Díaz destaca la investigación de «vanguardia» llevada a cabo por el Imibic
https://www.diariocordoba.com/noticias/cordobalocal/susana-diaz-destaca-investigacion-vanguardia-llevada-cabo-imibic_1271075.html

SOCIAL MEDIA

TWITTER: 3907


FACEBOOK: 2709

LINKEDIN: 1366



GOALS FOR 2019

	OBJECTIVES FOR 2019
1. To promote and consolidate human resource integration in the institution (See Plan 1. To promote and consolidate human resource integration in the institution (See Integration Plan _ OE.1 actions 10,11 and 13)	1. Promote and consolidate human resource integration in the institution (See Plan 1. Promote and consolidate human resource integration in the institution (See Integration Plan _ OE.1 actions 10,11 and 13)
2. To develop strategies to increase the quality and number of scientific publications and the leadership of IMIBIC researchers in this area.	≥ 50 articles in the top decile
3. To promote and improve clinical research at the IMIBIC by increasing the development, quality and efficiency of independent clinical research projects.	To implement a New Clinical Research Plan
4. To promote and improve the self-sustainability of the IMIBIC via optimization of internal resource management, attraction of more European and competitive public funding and by fostering partnerships with the business world.	Core funding ≥ 2.2 million euros Revenue from private/public activity ≥ 53.5%
5. Development of a strategy for the incorporation of new university and clinical groups, and to promote those that already exist.	2 new groups (at least one emerging group) 1 promoted group
6. To increase recruitment of talented researchers and promote their professional development.	Active human resources funded through competitive calls > 50
7. To foster, define and consolidate international alliances and partnerships	Apply for 30 projects
8. To promote and increase the protection of intellectual property generated and the transfer of technology to the business community	>20% of patents exploited
9. To guarantee the quality of service provided by the central biomedical research support unit (UCAIB) and management units of the Institute and to stimulate innovation through transversal collaboration.	User satisfaction ≥ 85%
11. To develop and implement an action plan to promote research in primary care and nursing.	Active projects > 6



ANNEXED

LIST OF PUBLICATIONS

	IMBIC GROUPS/RUPO
Burgos AMC, Torres-Borrego J, Teran ABM, Corzo JL, Garcia BE, Pacheco RR, Aguilar CM, Davila I. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. <i>PEDIATRIC ALLERGY AND IMMUNOLOGY</i> . 2018. 29(4):369-374. DOI:10.1111/pai.12866. ;IF:4,137 DQ1 D1	GC01
IMBIC Groups.GA05 ;GC01	
Pera A, Caserta S, Albanese F, Blowers P, Morrow G, Terrazzini N, Smith HE, Rajkumar C, Reus B, Msonda JR, Verboom M, Hallensleben M, Blasczyk R, Davies KA, Kern F. CD28 (null) pro-atherogenic CD4 T-cells explain the link between CMV infection and an increased risk of cardiovascular death. <i>THERANOSTICS</i> . 2018. 8(16):4509-4519. DOI:10.7150/thno.27428. ;IF:8,537 DQ1 D1	GC01
IMBIC Groups.GC01 ;	
Rodrigues-Santos P, Lopez-Sejas N, Almeida JS, Ruzickova L, Couceiro P, Alves V, Campos C, Alonso C, Tarazona R, Freitas-Tavares P, Solana R, Santos-Rosa M. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. <i>FRONTIERS IN IMMUNOLOGY</i> . 2018. 9(.)-. DOI:10.3389/fimmu.2018.02587. ;IF:5,511 Q1	GC01
IMBIC Groups.GC01 ;	
Schiener M, Hilger C, Eberlein B, Pascal M, Kuehn A, Revets D, Planchon S, Pietsch G, Serrano P, Moreno-Aguilar C, de la Roca F, Biedermann T, Darsow U, Schmidt-Weber CB, Ollert M, Blank S. The high molecular weight dipeptidyl peptidase IV Pol d 3 is a major allergen of <i>Polistes dominulus</i> venom. <i>SCIENTIFIC REPORTS</i> . 2018. 8(.)-. DOI:10.1038/s41598-018-19666-7. ;IF:4,122 Q1	GC01
IMBIC Groups.GC01 ;	
Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pre-transplant CD8+IFNG + response. <i>ANTIVIRAL RESEARCH</i> . 2018. 155(.)97-105. DOI:10.1016/j.antiviral.2018.05.006. ;IF:4,307 Q1	GC01
IMBIC Groups.GC03 ;GC02 ;GC07 ;GC01	
Frias M, Rivero-Juarez A, Rodriguez-Cano D, Camacho A, Lopez-Lopez P, Rialde MA, Manzanares-Martin B, Brieva T, Machuca I, Rivero A. HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. <i>SCIENTIFIC REPORTS</i> . 2018. 8(.)-. DOI:10.1038/s41598-017-17531-7. ;IF:4,122 Q1	GC01
IMBIC Groups.GC26 ;GC01	
Misra MK, Augusto DG, Martin GM, Nemat-Gorgani N, Sauter J, Hofmann JA, Traherne JA, Gonzalez-Quezada B, Gorodezky C, Bultitude WP, Marin W, Vierra-Green C, Anderson KM, Balas A, Caro-Oleas JL, Cisneros E, Colucci F, Dandekar R, Elfishawi SM, Fernandez-Vina MA, Fouda M, Gonzalez-Fernandez R, Grosser A, Herrero-Mata MJ, Hollenbach SQ, Marsh SGE, Mentzer A, Middleton D, Moffett A, Moreno-Hidalgo MA, Mossallam GI, Nakimuli A, Oksenberg JR, Oppenheimer SJ, Parham P, Petzl-Erler ML, Planelles D, Sanchez-Garcia F, Sanchez-Gordo F, Schmidt AH, Trowsdale J, Vargas LB, Vicario JL, Vilches C, Norman PJ, Hollenbach JA. Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop. <i>HUMAN IMMUNOLOGY</i> . 2018. 79(12):825-833. DOI:10.1016/j.humimm.2018.10.003. ;IF:1,994 Q4	GC01
IMBIC Groups.GC01 ;	
Antolin-Amerigo D, Ruiz-Leon B, Boni E, Alfaya-Arias T, Alvarez-Mon M, Barbarroja-Escudero J, Gonzalez-de-Olano D, Moreno-Aguilar C, Rodriguez-Rodriguez M, Sanchez-Gonzalez MJ, Sanchez-Morillas L, Vega-Castro A. Component-resolved diagnosis in hymenoptera allergy. <i>ALLERGOLOGIA ET IMMUNOPATHOLOGIA</i> . 2018. 46(3):253-262. DOI:10.1016/j.aller.2017.05.003. ;IF:1,644 Q4	GC01
IMBIC Groups.GC01 ;	
Torrijos EG, Gonzalez-Mendiola R, Alvarado M, Avila R, Prieto-Garcia A, Valbuena T, Borja J, Infante S, Lopez MP, Marchan E, Prieto P, Moro M, Rosado A, Saiz V, Somoza ML, Uriel O, Vazquez A, Mur P, Poza-Guedes P, Bartra J. Eosinophilic Esophagitis: Review and Update. <i>FRONTIERS IN MEDICINE</i> . 2018. 5(.)-. DOI:10.3389/fmed.2018.00247. ;IF:0 NO Q	GC01
IMBIC Groups.GC01 ;	
Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Biron IA, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Shitrit ABG, Gutierrez A, Doherty GA, Fernandez-Salazar L, Cadilla JM, Huguet JM, O'Toole A, Stasi E, Marcos NM, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Palomares MDL, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkoval L, Iade B, Lissner D, Bradley IF, Roman ALS, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, de Carpi FJM, Gisbert JP. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>AMERICAN JOURNAL OF GASTROENTEROLOGY</i> . 2018. 113(3):396-403. DOI:10.1038/ajg.2017.501. ;IF:10,231 DQ1 D1	GC02
IMBIC Groups.GC02	

Gonzalez R, Molina-Ruiz FJ, Barcena JA, Padilla CA, Muntane J. Regulation of Cell Survival, Apoptosis, and Epithelial-to-Mesenchymal Transition by Nitric Oxide-Dependent Post-Translational Modifications. <i>ANTIOXIDANTS & REDOX SIGNALING</i> . 2018. 29(13):1312-1332. DOI:10.1089/ars.2017.7072. ;IF:6,53 DQ1 D1	GC02
IMBIC Groups.GC02	
Ordas I, Domenech E, Manosa M, Garcia-Sanchez V, Iglesias-Flores E, Rodriguez-Moranta F, Marquez L, Merino O, Fernandez-Baneres F, Gomollon F, Vera M, Gutierrez A, L Lao J, Gisbert JP, Aguas M, Arias L, Rodriguez-Lago I, Munoz C, Alcaide N, Calvet X, Rodriguez C, Montoro MA, Garcia S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panes J, Esteve M. Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry. <i>AMERICAN JOURNAL OF GASTROENTEROLOGY</i> . 2018. 113(7):1009-1016. DOI:10.1038/s41395-018-0057-0. ;IF:10,231 DQ1 D1	GC02
IMBIC Groups.GC02	
Manzardo C, Londono MC, Castells L, Testillano M, Montero JL, Penafiel J, Subirana M, Moreno A, Aguilera V, Gonzalez-Dieguez ML, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Sousa JM, Suarez F, Serrano T, Herrero JI, Jimenez M, Fernandez JR, Gimenez C, del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>AMERICAN JOURNAL OF TRANSPLANTATION</i> . 2018. 18(10):2513-2522. DOI:10.1111/ajt.14996. ;IF:6,493 DQ1 D1	GC02
IMBIC Groups.GC02	
Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernandez M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas A, Figueruela B, Fornis X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmeron J, Romero-Gomez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>JOURNAL OF HEPATOLOGY</i> . 2018. 68(5):940-948. DOI:10.1016/j.jhep.2017.12.019. ;IF:14,911 DQ1 D1	GC02
IMBIC Groups.GC02	
Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, Garcia-Sanchez V, Luisa De Castro M, Martin-Cardona A, Aldegue X, Minguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargallo A, Gonzalez-Muñoz C, Pérez Calle JL, Garcia-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, Garcia-Lopez S, Piqueras M, Hinojosa E, Arjol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>ALIMENTARY PHARMACOLOGY & THERAPEUTICS</i> . 2018. 48(8):839-851. DOI:10.1111/apt.14930. ;IF:7,357 DQ1 D1	GC02
IMBIC Groups.GC02	
Rodriguez-Peralvarez M, Guerrero M, Barrera L, Ferrin G, Alamo JM, Ayllon MD, Artacho GS, Montero JL, Briceno J, Bernal C, Padillo J, Marin-Gomez LM, Pascasio JM, Poyato A, Gomez-Bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>TRANSPLANTATION</i> . 2018. 102(12):2056-2064. DOI:10.1097/TP.0000000000002270. ;IF:3,96 DQ1 D1	GC02
IMBIC Groups.GC02 ;GC18	
Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> . 2018. 24(11):1218-1219. DOI:10.1016/j.cmi.2018.06.030. ;IF:5,394 DQ1 D1	GC02
IMBIC Groups.GC26 ;GC03 ;Anatomía Patológica ;GC02 ;GC18	
Fernandez-Fernandez S, Bobo-Jimenez V, Requejo-Aguilar R, Gonzalez-Fernandez S, Resch M, Carabias-Carrasco M, Ros J, Almeida A, Bolanos JP. Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function. <i>REDOX BIOLOGY</i> . 2018. 19(.)52-61. DOI:10.1016/j.redox.2018.08.003. ;IF:7,126 Q1	GC02
IMBIC Groups.GC02	
Frontinan-Rubio J, Santiago-Mora RM, Nieva-Velasco CM, Ferrin G, Martinez-Gonzalez A, Gomez MV, Moreno M, Ariza J, Lozano E, Arjona-Gutierrez J, Gil-Agudo A, De la Mata M, Pesic M, Peinado JR, Villalba JM, Perez-Romasanta L, Perez-Garcia VM, Alcaín FJ, Duran-Prado M. Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. <i>RADIOTHERAPY AND ONCOLOGY</i> . 2018. 128(2):236-244. DOI:10.1016/j.radonc.2018.04.033. ;IF:4,942 Q1	GC02
IMBIC Groups.GC02	
Domenech E, Panes J, Hinojosa J, Anese V, Magro F, Sturmiolo GC, Bossa F, Fernandez F, Gonzalez-Conde B, Garcia-Sanchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>JOURNAL OF CROHNS & COLITIS</i> . 2018. 12(6):687-694. DOI:10.1093/ecco-icc/ijy023. ;IF:6,637 Q1	GC02
IMBIC Groups.GC02	



Taxonera C, Ponferrada A, Riestra S, Bermejo F, Saro C, Martin-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, Lopez-Serrano P, Barrio J, Suarez C, Iglesias E, Arguelles-Arias F, Ferrer I, Marin-Jimenez I, Hernandez-Camba A, Bastida G, Van Domselaar M, Martinez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes O, Merino O, Alba C, Gisberty JP, Martin-Rodriguez MD, Botella B, Carpio D, Ceballos D, Verdejo C, Morales I, Legido J, Penate M, Chaparro M, Algaba A, de Francisco R. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>JOURNAL OF CROHNS & COLITIS</i> .2018.12.(11).1270-1279.DOI:10.1093/ecco-jcc/jjy104.;IF:6,637 Q1	GC02
IMIBIC Groups.GC02	
Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. <i>ANTIVIRAL RESEARCH</i> .2018.155.(.97-105.DOI:10.1016/j.antiviral.2018.05.006.;IF:4,307 Q1	GC02
IMIBIC Groups.GC03 ;GC02 ;GC07; GC01	
Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. <i>LIVER TRANSPLANTATION</i> .2018.24.(2).192-203. DOI:10.1002/lt.24870.;IF:3,752 Q1	GC02
IMIBIC Groups.GC18 ;GC02 ;GA11	
Garcia-Planella E, Manosa M, Chaparro M, Beltran B, Barreiro-de-Acosta M, Gordillo J, Ricart E, Bermejo F, Garcia-Sanchez V, Piqueras M, Liao J, Gisbert JP, Cabre E, Domenech E. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY</i> .2018.53.(2).152-157.DOI:10.1080/00365521.2017.1410219.;IF:2,629 Q3	GC02
IMIBIC Groups.GC02	
Ciria R, Navarro E, Sanchez-Frias M, Gallardo AB, Medina J, Ayllon MD, Gomez-Luque I, Ruiz-Rabelo J, Luque A, de la Mata M, Rufian S, Lopez-Cillero P, Briceno J. Preliminary results from the use of intraoperative real-time biliary oxygen monitoring in liver transplantation. <i>CLINICAL TRANSPLANTATION</i> .2018.32.(12).-.DOI:10.1111/ctr.13433.;IF:1,518 Q3	GC02
IMIBIC Groups.GC18 ;GC02 ;Anatomía Patológica	
Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. <i>MEDICINA CLINICA</i> .2018.150.(1).1-7.DOI:10.1016/j.medcli.2017.04.015.;IF:1,168 Q3	GC02
IMIBIC Groups.GC02 ;GC06	
Rebollo-Roman A, Barrera-Martin A, Alcantara-Laguna MD, Iglesias-Flores E, Canada-Sanz E, Padillo-Cuenca JC, Molina-Puertas MJ, Calanas-Continente A. Non-opharyngeal dysphagia with frequent Emergency Room attendance. <i>NUTRICION HOSPITALARIA</i> .2018.35.(4).996-998.DOI:10.20960/nh.1933.;IF:0,845 Q4	GC02
IMIBIC Groups.GA04 ;GC02 ;Salud Mental	
Rodriguez-Lago I, Benitez JM, Garcia-Sanchez V, Gutierrez A, Sempere L, Ginard D, Barreiro-de Acosta M, Cabriada JL. Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients' point of view. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> .2018.41.(7).423-431.DOI:10.1016/j.gastrohep.2018.04.007.;IF:1,078 Q4	GC02
IMIBIC Groups.GC02	
Aller R, Fernandez-Rodriguez C, Iacono O, Banares R, Abad J, Carrion JA, Garcia-Monzon C, Caballeria J, Berenguer M, Rodriguez-Peralvarez M, Miranda JL, Vilar-Gomez E, Crespo J, Garcia-Cortes M, Reig M, Navarro JM, Gallego R, Genesca J, Arias-Loste MT, Pareja MJ, Albillos A, Muntane J, Jorquera F, Sola E, Hernandez-Guerra M, Rojo MA, Salmeron J, Caballeria L, Diago M, Molina E, Bataller R, Romero-Gomez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> .2018.41.(5).328-349. DOI:10.1016/j.gastrohep.2017.12.003.;IF:1,078 Q4	GC02
IMIBIC Groups.GC02 ;GC09	
Alayon CG, Crespo CP, Pedrosa SM, Benitez J, Flores E, Rodriguez I, Medina R, Garcia-Sanchez V. Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> .2018.41.(1).22-29.DOI:10.1016/j.gastrohep.2017.07.011.;IF:1,078 Q4	GC02
IMIBIC Groups.GC02	
Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(.2S10-S20.DOI:10.1016/j.cmi.2017.12.025.;IF:5,394 DQ1 D1	GC03
IMIBIC Groups.GC03	
Clemente WT, Mourao PHO, Lopez-Medrano F, Schwartz BS, Garcia-Donoso C, Torre-Cisneros J. Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors. <i>TRANSPLANTATION</i> .2018.102.(2).2S8-S15.DOI:10.1097/TP.0000000000002018.;IF:3,96 DQ1 D1	GC03
IMIBIC Groups.GC03	



Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Romero P, Aydillo T, Danziger-Isakov L, Limaye AP, Carratala J, Munoz P, Montejo M, Lopez-Medrano F, Farinas MC, Gavalda J, Moreno A, Levi M, Fortun J, Torre-Cisneros J, Englund JA, Natori Y, Husain S, Reid G, Sharma TS, Humar A.A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. <i>CLINICAL INFECTIOUS DISEASES</i> .2018.67.(9).1322-1329. DOI:10.1093/cid/ciy294.;IF:9,117 DQ1 D1	GC03
IMIBIC Groups.GC03	
Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, Lopez-Velez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourao PHO, Kotton CN, Aguado JM. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. <i>TRANSPLANTATION</i> .2018.102.(2).193-208.DOI:10.1097/TP.0000000000002027.;IF:3,96 DQ1 D1	GC03
IMIBIC Groups.GC03	
Torre-Cisneros J, Natera C, Mesa F, Triki M, Rodriguez Bano J. Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study. <i>EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES</i> .2018.37.(1).51-56.DOI:10.1007/s10096-017-3100-y.;IF:2,537 Q2	GC03
IMIBIC Groups.GC03	
Guirao-Arrabal E, Torre-Cisneros J. Tuberculin skin test, Interferon gamma release assays or just chest x-ray to study latent tuberculosis before solid organ transplantation?. <i>TRANSPLANT INFECTIOUS DISEASE</i> .2018.20.(4).-.DOI:10.1111/tid.12920.;IF:1,869 Q3	GC03
IMIBIC Groups.GC03	
Serrano-Alonso M, Guillen-Grima F, Martin-Moreno P, Rabago G, Manrique J, Garcia-del-Barrio M, Reina G, Torre-Cisneros J, Fernandez-Alonso M, Herrero JI. Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation. <i>TRANSPLANT INFECTIOUS DISEASE</i> .2018.20.(3).-.DOI:10.1111/tid.12873.;IF:1,869 Q3	GC03
IMIBIC Groups.GC03	
Silva JT, Torre-Cisneros J, Aguado JM. Invasive aspergillosis in solid organ transplantation. <i>REVISTA IBEROAMERICANA DE MICROLOGIA</i> .2018.35.(4).206-209.DOI:10.1016/j.riam.2018.05.002.;IF:0,989 Q4	GC03
IMIBIC Groups.GC03	
Amat T, Gutierrez-Pizarra A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(6).630-634.DOI:10.1016/j.cmi.2017.09.016.;IF:5,394 DQ1 D1	GC03
IMIBIC Groups.GC03 ;GC24 ;GC26	
Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J. Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. <i>CLINICAL INFECTIOUS DISEASES</i> .2018.66.(8).1204-1210. DOI:10.1093/cid/cix991.;IF:9,117 DQ1 D1	GC03
IMIBIC Groups.GC03 ;GC24	
Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(11).1218-1219.DOI:10.1016/j.cmi.2018.06.030.;IF:5,394 DQ1 D1	GC03
IMIBIC Groups.GC26 ;GC03 ;Anatomía Patológica; GC02 ;GC18	
Merchante N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, Macias J, Miralles P, Jimenez-Sousa MA, Mancebo M, Perez-Latorre L, Pineda-Tenor D, Berenguer J, Resino S, Pineda JA. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>JOURNAL OF VIRAL HEPATITIS</i> .2018.25.(2).180-186.DOI:10.1111/jvh.12769.;IF:4,237 Q1	GC03
IMIBIC Groups.GC03 ;GC26	
Rivero-Juarez A, Camacho A, Brieva T, Frias M, Lopez-Lopez P, Rialde MA, Machuca I, Caston JJ, Martinez-Peinado A, Rivero A. Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. <i>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</i> .2018.78.(4).437-440.DOI:10.1097/QAI.0000000000001691.;IF:4,116 Q1	GC03
IMIBIC Groups.GC26 ;GC03	
Aguado JM, Silva JT, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C, Martinez-Martinez L, Vidal E, Almenar L, Almirante B, Canton R, Carratala J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernandez J, Farinas MC, Gavalda J, Goyanes MJ, Gutierrez-Gutierrez B, Hernandez D, Len O, Lopez-Andujar R, Lopez-Medrano F, Martin-Davila P, Montejo M, Moreno A, Oliver A, Pascual A, Perez-Nadales E, Roman-Broto A, San-Juan R, Seron D, Sole-Jover A, Valerio M, Munoz P, Torre-Cisneros J. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIP recommendations. <i>TRANSPLANTATION REVIEWS</i> .2018.32.(1).36-57. DOI:10.1016/j.tre.2017.07.001.;IF:2,364 Q3	GC03
IMIBIC Groups.GC24 ;GC03	



Machuca I, Vidal E, de la Torre-Cisneros J, Rivero-Roman A. Tuberculosis in immunosuppressed patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018. 36. (6). 366-374. DOI:10.1016/j.eimc.2017.10.009.;IF:1,707 Q3	GC03	Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sanchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Munoz E. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. SCIENTIFIC REPORTS. 2018. 8. (.)-. DOI:10.1038/s41598-018-34259-0.;IF:4,122 Q1	GC04
IMIBIC Groups.GC26 ;GC03		IMIBIC Groups.GC04 ;GC10	
Aguado R, Paez-Vega A, Aguera ML, Montejo M, Guirado L, Fortun J, Suarez-Benjumea A, Len O, Farinas MC, de Gracia C, Hernandez D, Cobos-Ceballos MJ, Torre-Cisneros J, Cantisan S. Lack of evidence of association between IFNG and IL28B polymorphisms and QuantIFERON-CMV test results in seropositive transplant patients. HUMAN IMMUNOLOGY. 2018. 79. (6). 499-505. DOI:10.1016/j.humimm.2018.03.009.;IF:1,994 Q4	GC03	Jimenez-Jimenez C, Lara-Chica M, Palomares B, Collado JA, Lopez-Mirand J, Munoz E, Calzado MA. Effect of N-acyl-dopamines on beta cell differentiation and wound healing in diabetic mice. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. 2018. 1865. (11)A. 1539-1551. DOI:10.1016/j.bbamcr.2018.08.008.;IF:4,651 Q1	GC04
IMIBIC Groups.GC03 ;GC07		IMIBIC Groups.GC09 ;GC04	
Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. ANTIVIRAL RESEARCH. 2018. 155. (.)97-105. DOI:10.1016/j.antiviral.2018.05.006.;IF:4,307 Q1	GC03	Luesma MJ, Cantarero I, Castiella T, Sanchez-Cano AI, Iruzueta P, Junquera C. Ultrastructural and immunohistochemical study of phenotypic switch in gastrointestinal smooth muscle cells. MICROSCOPY RESEARCH AND TECHNIQUE. 2018. 81. (11). 1233-1240. DOI:10.1002/jemt.23126.;IF:1,087 Q3	GC04
IMIBIC Groups.GC03 ;GC02 ;GC07 ;GC01		IMIBIC Groups.GC04	
Minassi A, Rogati F, Cruz C, Prados ME, Galera N, Jinenez C, Appendino G, Bellido ML, Calzado MA, Caprioglio D, Munoz E. Triterpenoid Hydroxamates as HIF Prolyl Hydroxylase Inhibitors. JOURNAL OF NATURAL PRODUCTS. 2018. 81. (10). 2235-2243. DOI:10.1021/acs.jnatprod.8b00514.;IF:3,885 DQ1 D1	GC04	Pollastro F, Caprioglio D, Del Prete D, Rogati F, Minassi A, Tagliatalata-Scafati O, Munoz E, Appendino G. Cannabichromene. NATURAL PRODUCT COMMUNICATIONS. 2018. 13. (9). 1189-1194. DOI:10.1002/npc.1189.;IF:8,9 Q4	GC04
IMIBIC Groups.GC04		IMIBIC Groups.GC04	
del Rio C, Cantarero I, Palomares B, Gomez-Canas M, Fernandez-Ruiz J, Pavicic C, Garcia-Martin A, Bellido ML, Ortega-Castro R, Perez-Sanchez C, Lopez-Pedrerera C, Appendino G, Calzado MA, Munoz E. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR gamma- and CB2 receptor-dependent pathways. BRITISH JOURNAL OF PHARMACOLOGY. 2018. 175. (19). 3813-3831. DOI:10.1111/bph.14450.;IF:6,81 DQ1 D1	GC04	Appel K, Munoz E, Navarrete C, Cruz-Teno C, Biller A, Thiemann E. Immunomodulatory and Inhibitory Effect of Immulina (R), and Immunoges (R) in the Ig-E Mediated Activation of RBL-2H3 Cells. A New Role in Allergic Inflammatory Responses. PLANTS-BASEL. 2018. 7. (1).-. DOI:10.3390/plants7010013.;IF:0 NO Q	GC04
IMIBIC Groups.GC04 ;GC05		IMIBIC Groups.GC04	
Moreno P, Jimenez-Jimenez C, Garrido-Rodriguez M, Calderon-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra A, Munoz E, Calzado MA. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. MOLECULAR ONCOLOGY. 2018. 12. (10). 1778-1796. DOI:10.1002/1878-0261.12369.;IF:5,264 Q1	GC04	del Rio C, Cantarero I, Palomares B, Gomez-Canas M, Fernandez-Ruiz J, Pavicic C, Garcia-Martin A, Bellido ML, Ortega-Castro R, Perez-Sanchez C, Lopez-Pedrerera C, Appendino G, Calzado MA, Munoz E. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR gamma- and CB2 receptor-dependent pathways. BRITISH JOURNAL OF PHARMACOLOGY. 2018. 175. (19). 3813-3831. DOI:10.1111/bph.14450.;IF:6,81 DQ1 D1	GC05
IMIBIC Groups.GA01 ;GC04 ;GC21		IMIBIC Groups.GC04 ;GC05	
Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jimenez-Jimenez C, Mestre L, Feliu A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Munoz E. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. JOURNAL OF NEUROINFLAMMATION. 2018. 15. (.)-. DOI:10.1186/s12974-018-1103-y.;IF:5,193 Q1	GC04	Cecchi I, de la Rosa IA, Menegatti E, Roccatello D, Collantes-Estevez E, Lopez-Pedrerera C, Barbarroja N. Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. AUTOIMMUNITY REVIEWS. 2018. 17. (11). 1138-1149. DOI:10.1016/j.autrev.2018.06.006.;IF:8,745 DQ1 D1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05	
Garcia-Martin A, Garrido-Rodriguez M, Navarrete C, del Rio C, Bellido ML, Appendino G, Calzado MA, Munoz E. EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. BIOCHEMICAL PHARMACOLOGY. 2018. 157. (.)304-313. DOI:10.1016/j.bcp.2018.07.047.;IF:4,235 Q1	GC04	Martin-Variillas JL, Calvo-Rio V, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Garfella MH, Pascual EV, Martinez-Costa L, Sellas-Fernandez A, Cordero-Coma M, Diaz-Llopis M, Gallego R, Salom D, Ortego N, Garcia-Serrano JL, Callejas-Rubio JL, Herreras JM, Garcia-Aparicio A, Maiz O, Blanco A, Torre I, Diaz-Valle D, Pato E, Aurrecochea E, Caracul MA, Gamero F, Minguez E, Carrasco-Cubero C, Olive A, Vazquez J, Ruiz-Moreno O, Manero J, Munoz-Fernandez S, Martinez MG, Rubio-Romero E, de Miera FJTS, Longo FJL, Nolla JM, Revenga M, Gonzalez-Vela C, Loricera J, Atienza-Mateo B, Demetrio-Pablo R, Hernandez JL, Gonzalez-Gay MA, Blanco R. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behcet's Disease. OPHTHALMOLOGY. 2018. 125. (9). 1444-1451. DOI:10.1016/j.ophtha.2018.02.020.;IF:7,479 DQ1 D1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05	
del Rio C, Millan E, Garcia V, Appendino G, DeMesa J, Munoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. BIOCHEMICAL PHARMACOLOGY. 2018. 157. (.)122-133. DOI:10.1016/j.bcp.2018.08.022.;IF:4,235 Q1	GC04	Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, Luque-Tevar M, Ruiz-Limon P, Barbarroja N, Jimenez-Gomez Y, Abalos-Aguilera MC, Collantes-Estevez E, Seguí P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martinez C, Gonzalez-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, Lopez-Pedrerera C. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. HAEMATOLOGICA. 2018. 103. (5). 908-918. DOI:10.3324/haematol.2017.184416.;IF:9,09 DQ1 D1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05 ;Radiodiagnóstico ;GC16	
Garcia C, Gomez-Canas M, Burgaz S, Palomares B, Gomez-Galvez Y, Palomo-Garo C, Campo S, Ferrer-Hernandez J, Pavicic C, Navarrete C, Bellido ML, Garcia-Arencibia M, Pazos MR, Munoz E, Fernandez-Ruiz J. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR gamma receptor. JOURNAL OF NEUROINFLAMMATION. 2018. 15. (.)-. DOI:10.1186/s12974-018-1060-5.;IF:5,193 Q1	GC04	de la Rosa IA, Escudero-Contreras A, Rodriguez-Cuenca S, Ruiz-Ponce M, Jimenez-Gomez Y, Ruiz-Limon P, Perez-Sanchez C, Abalos-Aguilera MC, Cecchi I, Ortega R, Calvo J, Guzman-Ruiz R, Malagon MM, Collantes-Estevez E, Vidal-Puig A, Lopez-Pedrerera C, Barbarroja N. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. JOURNAL OF INTERNAL MEDICINE. 2018. 284. (1). 61-77. DOI:10.1111/joim.12743.;IF:6,754 DQ1 D1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05 ;GC11	
Nizet S, Munoz E, Fiebich BL, Abuja PM, Kashofer K, Zatloukal K, Tangermann S, Kenner L, Tschegg C, Nagl D, Scheichl L, Meisslitzer-Ruppitsch C, Freissmuth M, Berger T. Clinoptilolite in Dextran Sulphate Sodium-Induced Murine Colitis: Efficacy and Safety of a Microparticulate Preparation. INFLAMMATORY BOWEL DISEASES. 2018. 24. (1). 54-66. DOI:10.1093/ibd/izx042.;IF:4,347 Q1	GC04	Perez-Sanchez C, Font-Ugalde P, Ruiz-Limon P, Lopez-Pedrerera C, Castro-Villegas MC, Abalos-Aguilera MC, Barbarroja N, Arias-de la Rosa I, Lopez-Montilla MD, Escudero-Contreras A, Lopez-Medina C, Collantes-Estevez E, Jimenez-Gomez Y. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. HUMAN MOLECULAR GENETICS. 2018. 27. (5). 875-890. DOI:10.1093/hmg/ddy008.;IF:4,902 Q1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05	
Rodriguez-Cueto C, Santos-Garcia I, Garcia-Toscano L, Espejo-Porras F, Bellido M, Fernandez-Ruiz J, Munoz E, de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1(G93A) transgenic mice, an experimental model of amyotrophic lateral sclerosis. BIOCHEMICAL PHARMACOLOGY. 2018. 157. (.)217-226. DOI:10.1016/j.bcp.2018.07.049.;IF:4,235 Q1	GC04	Lopez-Medina C, Dougados M, Collantes-Estevez E, Molto A. Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. RHEUMATOLOGY. 2018. 57. (5). 880-890. DOI:10.1093/rheumatology/kex514.;IF:5,245 Q1	GC05
IMIBIC Groups.GC04		IMIBIC Groups.GC05	



Travez A, Rabanal-Ruiz Y, Lopez-Alcala J, Molero-Murillo L, Diaz-Ruiz A, Guzman-Ruiz R, Catalan V, Rodriguez A, Fruhbeck G, Tinahones FJ, Gasman S, Vitale N, Jimenez-Gomez Y, Malagon MM. The caveolae-associated coiled-coil protein, NECC2, regulates insulin signalling in Adipocytes. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2018.22.(11).5648-5661. DOI:10.1111/jcmm.13840.;IF:4,302 Q1	GC05
IMIBIC Groups.GC11 ;GC05	
Lopez-Medina C, Jimenez-Gomez Y, Molto A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Gutierrez J, Castro-Villegas MC, Collantes-Estevez E, Font-Ugalde P. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. JOINT BONE SPINE. 2018.85.(4).447-453. DOI:10.1016/j.jbspin.2017.07.006.;IF:3,304 Q2	GC05
IMIBIC Groups.GC05	
Lopez-Medina C, Molto A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2018.32.(2).241-253. DOI:10.1016/j.berh.2018.10.006.;IF:3,198 Q2	GC05
IMIBIC Groups.GC05	
Julia A, Lopez-Longo FJ, Venegas JJP, Bonas-Guarch S, Olive A, Andreu JL, Aguirre-Zamorano MA, Vela P, Nolla JM, de la Fuente JLM, Zea A, Pego-Reigosa JM, Freire M, Diez E, Rodriguez-Almaraz E, Carreira P, Blanco R, Taboada VM, Lopez-Lasanta M, Corbeto ML, Mercader JM, Torrents D, Absher D, Marsal S, Fernandez-Nebro A. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. ARTHRITIS RESEARCH & THERAPY. 2018.20.(.)-. DOI:10.1186/s13075-018-1604-1.;IF:4,269 Q2	GC05
IMIBIC Groups.GC05	
Tevar-Sanchez M, Navarro-Compan V, Aznar JJ, Linares LF, Castro MC, de Miguel E. Prevalence and characteristics associated with dactylitis in patients with early spondyloarthritis: results from the ESPERanza cohort. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018.36.(5).879-883. DOI:.;IF:3,201 Q2	GC05
IMIBIC Groups.GC05	
Moreno M, Gratacos J, Navarro-Compan V, de Miguel E, Font P, Clavaguera T, Linares LF, Joven B, Juanola X. Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritis). CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018.36.(6).1038-1042. DOI:.;IF:3,201 Q2	GC05
IMIBIC Groups.GC05	
Garrido-Castro JL, Curbelo R, Mazzucchelli R, Dominguez-Gonzalez ME, Gonzalez-Navas C, Robles B, Zarco P, Mulero J, Cea-Calvo L, Arteaga MJ, Font-Ugalde P, Carmona L, Collantes-Estevez E. High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. JOURNAL OF RHEUMATOLOGY. 2018.45.(10).1383-1388. DOI:10.3899/jrheum.170941.;IF:3,47 Q2	GC05
IMIBIC Groups.GC05 ;GC19	
Arevalo M, Masmitha JG, Moreno M, Calvet J, Orellana C, Ruiz D, Castro C, Carreto P, Larrosa M, Collantes E, Font P. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. ARTHRITIS RESEARCH & THERAPY. 2018.20.(.)-. DOI:10.1186/s13075-018-1724-7.;IF:4,269 Q2	GC05
IMIBIC Groups.GC05	
Lopez-Medina C, Garrido-Castro JL, Castro-Jimenez J, Gonzalez-Navas C, Calvo-Gutierrez J, Castro-Villegas MC, Ortega-Castro R, Escudero-Contreras A, Font-Ugalde P, Collantes-Estevez E. Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. CLINICAL RHEUMATOLOGY. 2018.37.(6).1581-1588. DOI:10.1007/s10067-018-4112-4.;IF:2,141 Q3	GC05
IMIBIC Groups.GC05 ;GC19	
Florez MT, Almodovar R, Perez FG, Cambron ABR, Carmona L, Manzanero MAP, Cantalapiedra JA, Urruticoechea-Arana A, Lozano CJR, Castro C, Fernandez-Carballido C, de Miguel E, Galindez E, Vega JLA, Alonso JCT, Linares LF, Moreno M, Navarro-Compan V, Juanola X, Zarco P. The E-JES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. RHEUMATOLOGY INTERNATIONAL. 2018.38.(7).1277-1284. DOI:10.1007/s00296-018-4049-6.;IF:1,952 Q4	GC05
IMIBIC Groups.GC05	
Munoz-Fernandez S, Oton-Sanchez T, Carmona L, Calvo-Alen J, Escudero A, Narvaez J, Heredia JMR, Yuste SR, Vela P, Valdes SL, Garcia AR, Baquero JL. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. RHEUMATOLOGY INTERNATIONAL. 2018.38.(12).2289-2296. DOI:10.1007/s00296-018-4152-8.;IF:1,952 Q4	GC05
IMIBIC Groups.GC05	
Gonzalez C, Rodriguez RC, Torre-Alonso JC, Collantes E, Castaneda S, Hernandez MV, Urruticoechea-Arana A, Nieto-Gonzalez JC, Garcia J, Abad MA, Ramirez J, Suarez C, Dalmau R, Martin-Arranz MD, Leon L, Hermosa JC, Obaya JC, Oton T, Carmona L. Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. REUMATOLOGIA CLINICA. 2018.14.(6).346-359. DOI:10.1016/j.reuma.2017.03.011.;IF:0 NO Q	GC05
IMIBIC Groups.GC05	

Molina JT, Alen JC, Ballina J, Belmonte MA, Blanco FJ, Caracuel MA, Carbonell J, Corominas H, Chamizo E, Hidalgo C, Ivorra JR, Marengo JL, Muelas JVM, Munoz-Fernandez S, Nolla JM, Perez T, Sanmarti R, Trenor P, Urrego C, Vidal J, de Salazar JRG. Recommendations for the use of parenteral methotrexate in rheumatic diseases. REUMATOLOGIA CLINICA. 2018.14.(3).142-149. DOI:10.1016/j.reuma.2016.12.001.;IF:0 NO Q	GC05
IMIBIC Groups.GC05	
Almodovar R, Alonso JCT, Batlle E, Castillo C, Collantes-Estevez E, de Miguel E, Gonzalez S, Gratacos J, Hernandez A, Juanola X, Linares LF, Moreno MJ, Moreno M, Navarro-Compan V, Lozano CR, Sanz J, Sellas A, Loza E, Zarco P. Development of a checklist for patients with axial spondyloarthritis and psoriatic arthritis in daily practice: ONLY TOOLS project. REUMATOLOGIA CLINICA. 2018.14.(3).155-159. DOI:10.1016/j.reuma.2016.12.003.;IF:0 NO Q	GC05
IMIBIC Groups.GC05	
Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018.29.(2).439-444. DOI:10.1093/annonc/mdx737.;IF:13,926 DQ1 D1	GC06
IMIBIC Groups.GC06	
De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. TRENDS IN IMMUNOLOGY. 2018.39.(9).748-763. DOI:10.1016/j.it.2018.07.001.;IF:14,188 DQ1 D1	GC06
IMIBIC Groups.GC06	
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. JOURNAL OF CLINICAL ONCOLOGY. 2018.36.(28).2826-2835. DOI:10.1200/JCO.2017.76.7863.;IF:26,303 DQ1 D1	GC06
IMIBIC Groups.GC06	
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018.110.(6).638-648. DOI:10.1093/jnci/djx253.;IF:11,238 DQ1 D1	GC06
IMIBIC Groups.GC06	
Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018.16.(.)-. DOI:10.1186/s12915-017-0472-5.;IF:5,77 DQ1 D1	GC06
IMIBIC Groups.GC06 ;Cirugía General y Digestiva	
Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018.101.(.)263-272. DOI:10.1016/j.ejca.2018.06.024.;IF:7,191 Q1	GC06
IMIBIC Groups.GC06	
Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018.23.(11).1271-e128. DOI:10.1634/theoncologist.2018-0316.;IF:5,306 Q1	GC06
IMIBIC Groups.GC06	
Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018.103.(.)205-213. DOI:10.1016/j.ejca.2018.08.020.;IF:7,191 Q1	GC06
IMIBIC Groups.GC06	
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018.91.(.)99-106. DOI:10.1016/j.ejca.2017.12.014.;IF:7,191 Q1	GC06
IMIBIC Groups.GC06	



García-Foncillas J, Taberero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muínelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>BRITISH JOURNAL OF CANCER</i> .2018.119.(12).1464-1470. DOI:10.1038/s41416-018-0293-5.;IF:5,922 Q1	GC06	Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG in the detection of recurrent ovarian cancer. <i>MEDICINA CLINICA</i> .2018.151.(3).97-102. DOI:10.1016/j.medcli.2017.11.019.;IF:1,168 Q3	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC06	
Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. <i>PLOS ONE</i> .2018.13.(4).- DOI:10.1371/journal.pone.0194844.;IF:2,766 Q1	GC06	Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. <i>CLINICAL & TRANSLATIONAL ONCOLOGY</i> .2018.20.(10).1337-1344. DOI:10.1007/s12094-018-1865-9.;IF:2,392 Q3	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC06	
Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Taberero J, Giral J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>TARGETED ONCOLOGY</i> .2018.13.(1).69-78. DOI:10.1007/s11523-017-0536-z.;IF:3,877 Q2	GC06	Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C. SEOM clinical guideline for treatment of kidney cancer (2017). <i>CLINICAL & TRANSLATIONAL ONCOLOGY</i> .2018.20.(1).47-56. DOI:10.1007/s12094-017-1765-4.;IF:2,392 Q3	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC06	
Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. <i>CLINICAL COLORECTAL CANCER</i> .2018.17.(2).E323-E329. DOI:10.1016/j.clcc.2018.02.004.;IF:3,861 Q2	GC06	Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernandez S, Leon L, del Alba AG, Lainez N, Esteban E, Reyes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. <i>FUTURE ONCOLOGY</i> .2018.14.(1).41-50. DOI:10.2217/fon-2017-0297.;IF:2,369 Q3	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC06	
Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilard EA. Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. <i>MEDICINE</i> .2018.97.(17).- DOI:10.1097/MD.000000000010098.;IF:2,028 Q2	GC06	García-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. <i>MEDICINA CLINICA</i> .2018.150.(1).1-7. DOI:10.1016/j.medcli.2017.04.015.;IF:1,168 Q3	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC02 ;GC06	
Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Arta A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC CANCER</i> .2018.18.(.).- DOI:10.1186/s12885-018-4004-7.;IF:3,288 Q2	GC06	Esteban I, Vilario M, Adrover E, Angulo A, Carrasco E, Gadea N, Sanchez A, Ocana T, Llort G, Jover R, Cubiella J, Servitja S, Herraiz M, Cid L, Martinez S, Oruezabal-Moreno MJ, Garau I, Khorrami S, Herreros-de-Tejada A, Morales R, Cano JM, Serrano R, Lopez-Ceballos MH, Gonzalez-Santiago S, Juan-Fita MJ, Alonso-Cerezo C, Casas A, Grana B, Teule A, Alba E, Anton A, Guillen-Ponce C, Sanchez-Heras AB, Ales-Martinez JE, Brunet J, Balaguer F, Balmana J. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. <i>PSYCHO-ONCOLOGY</i> .2018.27.(6).1530-1537. DOI:10.1002/pon.4686.;IF:3,455 DQ1 D1	GC06
IMIBIC Groups.GC06		IMIBIC Groups.GC06	
Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Linares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. <i>EXPERT OPINION ON DRUG SAFETY</i> .2018.17.(6).573-579. DOI:10.1080/14740338.2017.1330410.;IF:3,156 Q2	GC06	Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suner M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, de Cordoba SR. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. <i>KIDNEY INTERNATIONAL</i> .2018.93.(2).450-459. DOI:10.1016/j.kint.2017.06.022.;IF:8,429 DQ1 D1	GC07
IMIBIC Groups.GC06		IMIBIC Groups.GC07	
Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>CLINICAL GENITOURINARY CANCER</i> .2018.16.(6).E1133-E1139. DOI:10.1016/j.clgc.2018.07.013.;IF:2,539 Q2	GC06	Ayasreh N, Bullich G, Miquel R, Furlano M, Ruiz P, Lorente L, Valero O, Garcia-Gonzalez MA, Arhda N, Garin I, Martinez V, Perez-Gomez V, Fulladosa X, Arroyo D, Martinez-Vea A, Espinosa M, Ballarin J, Ars E, Torra R. Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1. <i>AMERICAN JOURNAL OF KIDNEY DISEASES</i> .2018.72.(3).411-418. DOI:10.1053/j.ajkd.2018.03.019.;IF:7,129 DQ1 D1	GC07
IMIBIC Groups.GC06		IMIBIC Groups.GC07	
Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. <i>BMC CANCER</i> .2018.18.(.).- DOI:10.1186/s12885-018-4096-0.;IF:3,288 Q2	GC06	Rodelo-Haad C, Aguera ML, Ortega R, Martinez-Lopez A, Navarro MD, Rodriguez-Benot A, Aljama P. Lithium-associated nephropathy in the renal allograft. <i>KIDNEY INTERNATIONAL</i> .2018.93.(1).273-273. DOI:10.1016/j.kint.2017.08.032.;IF:8,429 DQ1 D1	GC07
IMIBIC Groups.GC18 ;GC06 ;Anatomía Patológica		IMIBIC Groups.GC07 ;Anatomía Patológica	
Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. <i>CLINICAL & TRANSLATIONAL ONCOLOGY</i> .2018.20.(5).613-618. DOI:10.1007/s12094-017-1756-5.;IF:2,392 Q3	GC06	Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. <i>ANTIVIRAL RESEARCH</i> .2018.155.(.).97-105. DOI:10.1016/j.antiviral.2018.05.006.;IF:4,307 Q1	GC07
IMIBIC Groups.GC06		IMIBIC Grups.GC03 ;GC02 ;GC07; GC01	
Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. <i>BMC PHARMACOLOGY & TOXICOLOGY</i> .2018.19.(.).- DOI:10.1186/s40360-018-0264-8.;IF:1,865 Q3	GC06	Varas J, Ramos R, Aljama P, Perez-Garcia R, Moreso F, Pinedo M, Merello JI, Stuard S, Canaud B, Martin-Malo A. Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. <i>NEPHROLOGY DIALYSIS TRANSPLANTATION</i> .2018.33.(1).160-170. DOI:10.1093/ndt/gfx209.;IF:4,6 Q1	GC07
IMIBIC Groups.GC06		IMIBIC Groups.GC07	



Lopez-Lopez I, Rodelo-Haad C, Aguera ML, Cabello-Jabalquinto R, Esquivias-Motta E, Navarro MD, Aljama P, Rodriguez-Benot A. Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males. PLOS ONE. 2018.13.(9).-. DOI:10.1371/journal.pone.0202589.;IF:2,766 Q1	GC07
IMIBIC Groups.GC07	
Helve J, Kramer A, Abad-Diez JM, Couchoud C, de Arriba G, de Meester J, Evans M, Glaudet F, Gronhagen-Riska C, Heaf JG, Lezaic V, Nordio M, Pals-son R, Pechter U, Resic H, Santamaria R, de Pablos CS, Massy ZA, Zurriaga O, Jager KJ, Finne P. Factors associating with differences in the incidence of renal replacement therapy among elderly: data from the ERA-EDTA Registry. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2018.33.(8).1428-1435. DOI:10.1093/ndt/gfy056.;IF:4,6 Q1	GC07
IMIBIC Groups.GC07	
Perez-Garcia R, Varas J, Cives A, Martin-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2018.33.(4).690-699. DOI:10.1093/ndt/gfx269.;IF:4,6 Q1	GC07
IMIBIC Groups.GC07	
Rodelo-Haad C, Rodriguez-Ortiz ME, Martin-Malo A, de Mier MVPR, Aguera ML, Munoz-Castaneda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodrigue M. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLOS ONE. 2018.13.(8).-. DOI:10.1371/journal.pone.0201537.;IF:2,766 Q1	GC07
IMIBIC Groups.GC07 ;GC13	
Santamaria R, Diaz-Tocados JM, de Mier MVPR, Robles A, Salmeron-Rodriguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Munoz-Castaneda JR, Martin-Malo A, Aljama P, Rodriguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. SCIENTIFIC REPORTS. 2018.8.(.).-. DOI:10.1038/s41598-018-32065-2.;IF:4,122 Q1	GC07
IMIBIC Groups.GC07 ;GC13 ;GC14 ;GC13	
del Pino MD, Andres A, Bernabeu AA, de Juan-Rivera J, Fernandez E, Diaz JDG, Hernandez D, Luno J, Fernandez IM, Paniagua J, de la Pazk MP, Rodriguez-Perez JC, Santamaria R, Torra R, Ambros JT, Vidau P, Torregrosa JV. Fabry Nephropathy: An Evidence-Based Narrative Review. KIDNEY & BLOOD PRESSURE RESEARCH. 2018.43.(2).406-421. DOI:10.1159/000488121.;IF:3,02 Q2	GC07
IMIBIC Groups.GC07	
Arjona-Sanchez A, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Rabelo JR, Salamanca-Bustos JJ, Rodriguez-Benot A, Campos-Hernandez P, Briceno-Delgado J. Intraoperative Heparinization During Simultaneous Pancreas-Kidney Transplantation: Is It Really Necessary?. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).673-675. DOI:10.1016/j.transproceed.2017.09.055.;IF:0,806 Q4	GC07
IMIBIC Groups.GC18 ;GE05 ;GC07	
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ruiz-Rabelo J, Salamanca-Bustos JJ, Rodriguez-Benot A, Marquez-Lopez FJ, Briceno-Delgado J. Pancreas Donor Hypermagnesemia: Is it Really a Risk Factor for Simultaneous Pancreas-kidney Transplantation?. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).676-678. DOI:10.1016/j.transproceed.2017.09.050.;IF:0,806 Q4	GC07
IMIBIC Groups.GC18 ;GE05 ;GC07	
Sanchez-Hidalgo JM, Salamanca-Bustos JJ, Arjona-Sanchez A, Campos-Hernandez JP, Rabelo JR, Rodriguez-Benot A, Requena-Tapia MJ, Briceno-Delgado J. What Is the Influence of Both Risk Donor and Risk Receiver on Simultaneous Pancreas-Kidney Transplantation?. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).664-668. DOI:10.1016/j.transproceed.2017.09.065.;IF:0,806 Q4	GC07
IMIBIC Groups.GC18 ;GE05 ;GC07	
Aguado R, Paez-Vega A, Aguera ML, Montejo M, Guirado L, Fortun J, Suarez-Benjumea A, Len O, Farinas MC, de Gracia C, Hernandez D, Cobos-Ceballos MJ, Torre-Cisneros J, Cantisan S. Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients. HUMAN IMMUNOLOGY. 2018.79.(6).499-505. DOI:10.1016/j.humimm.2018.03.009.;IF:1,994 Q4	GC07
IMIBIC Groups.GC03 ;GC07	
Rodelo-Haad C, Esquivias-Motta E, Aguera ML, Aljama P, Rodriguez-Benot A. 24-Hour Proteinuria Versus Spot Protein-Creatinine Ratio for Kidney Transplant Management in Clinical Practice. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).560-564. DOI:10.1016/j.transproceed.2017.09.071.;IF:0,806 Q4	GC07
IMIBIC Groups.GC07	
Gorostidi M, Sanchez-Martinez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamaria R, del Pino MD, Guallar-Castillon P, de Alvaro F, Rodriguez-Artalejo F, Banegas JR. Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors. NEPHROLOGIA. 2018.38.(6).606-615. DOI:10.1016/j.nefro.2018.04.004.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07	



Caluillo-Arbizu J, Perez-Valdivia MA, Gentil-Govantes MA, Castro-de-la-Nuezd P, Mazuecos-Blanca A, Rodriguez-Benot A, Gracia-Guindo MC, Borrego-Utiel F, Cabello-Diaz M, Bedoya-Perez R, Alonso-Gil M, Salgueira-Lazo M, Roa-Romero LM. Does the Kidney Donor Profile Index (KDPI) predict graft and patient survival in a Spanish population?. NEPHROLOGIA. 2018.38.(6).587-595. DOI:10.1016/j.nefro.2018.06.009.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07	
Soriano ML, Rodriguez-Benot A, Valcarcel M. Nanotechnological foundations of a "new" Nephrology. NEPHROLOGIA. 2018.38.(4).368-378. DOI:10.1016/j.nefro.2018.02.007.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07	
Sanjuan JB, Navarro-Gonzalez JF, Arenas MD, Torregrosa JV, Menendez JT, de Francisco ALM, Gonzalez-Parra E, Cora MJL, Alvarez JES, Martin-Malo A, Vila PM, Bajo MA, Santos ID. Pharmacological interactions of phosphate binders. NEPHROLOGIA. 2018.38.(6).573-578. DOI:10.1016/j.nefro.2018.05.003.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07	
Martinez MSA, Ruiz CR, Sanchez RS, Salas RO, Andreu ML, Garcia PA, Hernandez ME. C3 deposits worsens the prognosis in type III extracapillary glomerulonephritis. NEPHROLOGIA. 2018.38.(2).213-219. DOI:10.1016/j.nefro.2017.08.001.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07 ;Anatomía Patológica ;GC14	
Lopez RO, de Motta EE, Carmona A, Montemayor VG, Berdud I, Malo AM, Garcia PA. Correction of 25-OH-vitamin D deficiency improves control of secondary hyperparathyroidism and reduces the inflammation in stable haemodialysis patients. NEPHROLOGIA. 2018.38.(1).41-47. DOI:10.1016/j.nefro.2017.05.008.;IF:1,167 Q4	GC07
IMIBIC Groups.GC07	
de Mier MVPR, Aguera ML, Navarro MD, Rodriguez-Benot A, Aljama P. Prevalence and Survival of Cancer After Pancreas-Kidney Transplantation. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).669-672. DOI:10.1016/j.transproceed.2017.09.064.;IF:0,806 Q4	GC07
IMIBIC Groups.GC13 ;GC07	
de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, Pascual J, Aljama P. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients. KIDNEY INTERNATIONAL REPORTS. 2018.3.(2).374-384. DOI:10.1016/j.ekir.2017.11.001.;IF:0 NO Q	GC07
IMIBIC Groups.GC07	
Rodelo-Haad C, Gimenez RFD, Ortega R, Rodriguez M, Aljama P. Calcific arteriopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists. CLINICAL CASES IN MINERAL AND BONE METABOLISM. 2018.15.(1).85-88. DOI:10.1016/j.cmb.2017.11.001.;IF:0 NO Q	GC07
IMIBIC Groups.GC07 ;GC13 ;GC09 ;GC14	
Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castano JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. PHARMACOLOGICAL REVIEWS. 2018.70.(4).763-835. DOI:10.1124/pr.117.015388.;IF:18,964 DQ1 D1	GC08
IMIBIC Groups.GC08	
Ramiro-Ortega E, Bonilla-Palomares JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Alhambra-Exposito R, Sanchez MA. Nutritional intervention in acute heart failure patients with undernutrition and normal albuminemia: A subgroup analysis of PICNIC study. CLINICAL NUTRITION. 2018.37.(5).1762-1764. DOI:10.1016/j.clnu.2017.07.009.;IF:5,496 DQ1 D1	GC08
IMIBIC Groups.GC08 ;GC15	
Jimenez-Lucena R, Rangel-Zuniga OA, Alcalá-Díaz JF, Lopez-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castano JP, Ordoñas JM, Perez-Martinez P, Camargo A, Lopez-Miranda J. Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study. MOLECULAR THERAPY-NUCLEIC ACIDS. 2018.12.(1).146-157. DOI:10.1016/j.omtn.2018.05.002.;IF:5,66 DQ1 D1	GC08
IMIBIC Groups.GC09 ;GA06 ;GC08	
Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcalá-Díaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castano J, Ordoñas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2018.73.(3).327-332. DOI:10.1093/gerona/glw194.;IF:4,902 DQ1 D1	GC08
IMIBIC Groups.GC09 ;GA06 ;GC08	
Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, Alcalá-Díaz JF, Perez-Martinez P, Jimenez-Lucena R, Castano JP, Roche HM, Delgado-Lista J, Ordoñas JM, Camargo A, Lopez-Miranda J. Mediterranean Diet, Glucose Homeostasis, and Inflammation Genetic Variants: The CORDIOPREV Study. MOLECULAR NUTRITION & FOOD RESEARCH. 2018.62.(9).-. DOI:10.1002/mnfr.201700960.;IF:5,151 DQ1 D1	GC08
IMIBIC Groups.GC09 ;GC08	



Vazquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castano JP, Kineman RD, Luque RM. The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions. <i>CELLULAR PHYSIOLOGY AND BIOCHEMISTRY</i> .2018.49.(4).1444-1459.DOI:10.1159/000493448.;IF:5,5 DQ1 D1	GC08	Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceska R, Lopez-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation Insights From the FOURIER Trial. <i>JAMA CARDIOLOGY</i> .2018.3.(8).749-753.DOI:10.1001/jamacardio.2018.1533.;IF:10,133 DQ1 D1	GC09
IMIBIC Groups.GC27 ;GC08		IMIBIC Groups.GC09	
Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martinez-Fuentes AJ, Galvez-Moreno MA, Castano JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. <i>CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY</i> .2018.9.(.)-.DOI:10.1038/s41424-018-0058-8.;IF:4,621 DQ1 D1	GC08	Schroder H, Cardenas-Fuentes G, Martinez-Gonzalez MA, Corella D, Vioque J, Romaguera D, Martinez JA, Tinahones FJ, Miranda JL, Estruch R, Bueno-Cavanillas A, Aros F, Marcos A, Tur JA, Warnberg J, Serra-Majem L, Martin V, Vazquez C, Lapetra J, Pinto X, Vidal J, Daimiel L, Gaforio JJ, Matia-Martin P, Ros E, Castaner O, Lassale C, Ruiz-Canela M, Asensio EM, Basora J, Torres-Collado L, Garcia-Rios A, Abete I, Toledo E, Buil-Cosiales P, Bullo M, Goday A, Fito M, Salas-Salvado J. Effectiveness of the physical activity intervention program in the PREDIMED-Plus study: a randomized controlled trial. <i>INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY</i> .2018.15.(.)-.DOI:10.1186/s12966-018-0741-x.;IF:5,548 DQ1 D1	GC09
IMIBIC Groups.GC27 ;GC08 ;GA04; Anatomía Patológica ;Oncología Médica		IMIBIC Groups.GC09	
Gahete MD, del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alois-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martinez P, Castano JP, Lopez-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. <i>EBIOMEDICINE</i> .2018.37.(.)356-365.DOI:10.1016/j.ebiom.2018.10.056.;IF:6,183 DQ1 D1	GC08	Grandone E, Di Micco PP, Villani M, Colaizzo D, Fernandez-Capitan C, Del Toro J, Rosa V, Bura-Riviere A, Quere I, Blanco-Molina A, Margaglione M, Monreal M. Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. <i>THROMBOSIS AND HAEMOSTASIS</i> .2018.118.(11).1962-1968.DOI:10.1055/s-0038-1673402.;IF:4,952 DQ1 D1	GC09
IMIBIC Groups.GC27 ;GC25 ;GC08; GC09		IMIBIC Groups.GC09	
Rincon-Fernandez D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castano JP. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cell lines. <i>CARCINOGENESIS</i> .2018.39.(3).447-457. DOI:10.1093/carcin/bgx146.;IF:2,072 Q1	GC08	Garcia-Rios A, Alcalá-Díaz JF, Gomez-Delgado F, Delgado-Lista J, Marin C, Leon-Acuna A, Camargo A, Rodriguez-Cantalejo F, Blanco-Rojo R, Quintana-Navarro G, Ordoñas JM, Perez-Jimenez F, Lopez-Miranda J, Perez-Martinez P. Beneficial effect of CETP gene polymorphism in combination with a Mediterranean diet influencing lipid metabolism in metabolic syndrome patients: CORDIOPREV study. <i>CLINICAL NUTRITION</i> .2018.37.(1).229-234. DOI:10.1016/j.clnu.2016.12.011.;IF:5,496 DQ1 D1	GC09
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GC09 ;GA06	
Alhambra-Exposito MR, Ibanez-Costa A, Moreno-Moreno P, Rivero-Cortes E, Vazquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado A, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castano JP, Galvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. <i>SCIENTIFIC REPORTS</i> .2018.8.(.)-.DOI:10.1038/s41598-018-24260-y.;IF:4,122 Q1	GC08	Jimenez-Lucena R, Rangel-Zuniga OA, Alcalá-Díaz JF, Lopez-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castano JP, Ordoñas JM, Perez-Martinez P, Camargo A, Lopez-Miranda J. Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study. <i>MOLECULAR THERAPY-NUCLEIC ACIDS</i> .2018.12.(.)146-157.DOI:10.1016/j.omtn.2018.05.002.;IF:5,66 DQ1 D1	GC09
IMIBIC Groups.GC08 ;Radiodiagnóstico ;GA10; GA04 ;GC27		IMIBIC Groups.GC09 ;GA06 ;GC08	
Pedraza-Arevalo S, Gahete MD, Alors-Perez E, Luque RM, Castano JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. <i>REVIEWS IN ENDOCRINE & METABOLIC DISORDERS</i> .2018.19.(2)2.179-192.DOI:10.1007/s11154-018-9465-0.;IF:4,963 Q1	GC08	Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcalá-Díaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castano J, Ordoñas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. <i>JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES</i> .2018.73.(3).327-332.DOI:10.1093/gerona/glw194.;IF:4,902 DQ1 D1	GC09
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GC09 ;GA06 ;GC08	
Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortes E, Madrazo-Atutxa A, Japon MA, Luque RM, Castano JP, Cano DA, Soto-Moreno A. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. <i>JOURNAL OF CELLULAR AND MOLECULAR MEDICINE</i> .2018.22.(3).1640-1649.DOI:10.1111/jcmm.13440.;IF:4,302 Q1	GC08	Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, Alcalá-Díaz JF, Perez-Martinez P, Jimenez-Lucena R, Castano JP, Roche HM, Delgado-Lista J, Ordoñas JM, Camargo A, Lopez-Miranda J. Mediterranean Diet, Glucose Homeostasis, and Inflammation Genetic Variants: The CORDIOPREV Study. <i>MOLECULAR NUTRITION & FOOD RESEARCH</i> .2018.62.(9)-.DOI:10.1002/mnfr.201700960.;IF:5,151 DQ1 D1	GC09
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GC09 ;GC08	
Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. <i>JOURNAL OF CELLULAR AND MOLECULAR MEDICINE</i> .2018.22.(11).5688-5697.DOI:10.1111/jcmm.13845.;IF:4,302 Q1	GC08	Gahete MD, del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alois-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martinez P, Castano JP, Lopez-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. <i>EBIOMEDICINE</i> .2018.37.(.)356-365.DOI:10.1016/j.ebiom.2018.10.056.;IF:6,183 DQ1 D1	GC09
IMIBIC Groups.GC27 ;GC08 ;Ge05; GC09 ;U Innovación Metodología Imibic; Anatomía Patológica		IMIBIC Groups.GC27 ;GC25 ;GC08; GC09	
Vazquez-Borrego MC, Gahete MD, Martinez-Fuentes AJ, Fuentes-Fayos AC, Castano JP, Kineman RD, Luque RM. Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: Lessons from human and non-human primate models. <i>MOLECULAR AND CELLULAR ENDOCRINOLOGY</i> .2018.463.(C).4-22.DOI:10.1016/j.mce.2017.12.007.;IF:3,563 Q2	GC08	Gomez-Marin B, Gomez-Delgado F, Lopez-Moreno J, Alcalá-Díaz JF, Jimenez-Lucena R, Torres-Pena JD, Garcia-Rios A, Ortiz-Morales AM, Yubero-Serrano EM, Malagon MD, Lai CQ, Delgado-Lista J, Ordoñas JM, Lopez-Miranda J, Perez-Martinez P. Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial. <i>AMERICAN JOURNAL OF CLINICAL NUTRITION</i> .2018.108.(5).963-970.DOI:10.1093/ajcn/nqy144.;IF:6,549 DQ1 D1	GC09
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GC09 ;GC11	
Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. <i>ENDOCRINE</i> .2018.59.(2).426-437.DOI:10.1007/s12020-017-1482-3.;IF:3,179 Q2	GC08	Torres-Pena JD, Garcia-Rios A, Delgado-Casado N, Gomez-Luna P, Alcalá-Díaz JF, Yubero-Serrano EM, Gomez-Delgado F, Leon-Acuna A, Lopez-Moreno J, Camargo A, Tinahones FJ, Delgado-Lista J, Ordoñas JM, Perez-Martinez P, Lopez-Miranda J. Mediterranean diet improves endothelial function in patients with diabetes and prediabetes: A report from the CORDIOPREV study. <i>ATHEROSCLEROSIS</i> .2018.269.(.)50-56.DOI:10.1016/j.atherosclerosis.2017.12.012.;IF:4,467 Q1	GC09
IMIBIC Groups.GC08 ;GA04 ;Anatomía Patológica; GC14 ;Oncología Médica; GC27		IMIBIC Groups.GC09	
Lopez-Moreno J, Quintana-Navarro GM, Delgado-Lista J, Garcia-Rios A, Alcalá-Díaz JF, Gomez-Delgado F, Camargo A, Perez-Martinez P, Tinahones FJ, Striker GE, Perez-Jimenez F, Villalba JM, Lopez-Miranda J, Yubero-Serrano EM. Mediterranean Diet Supplemented With Coenzyme Q(10) Modulates the Postprandial Metabolism of Advanced Glycation End Products in Elderly Men and Women. <i>JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES</i> .2018.73.(3).340-346.DOI:10.1093/gerona/glw214.;IF:4,902 DQ1	GC09	Rosique-Esteban N, Papandreou C, Romaguera D, Warnberg J, Corella D, Martinez-Gonzalez MA, Diaz-Lopez A, Estruch R, Vioque J, Aros F, Garcia-Rios A, Bueno-Cavanillas A, Vidal J, Serra-Majem L, Sibai AA, Tinahones FJ, Martinez A, Ordoñas JM, Tur JA, Ellacuria MT, Sanllorente A, Pinto X, Buil-Cosiales P, Fernandez-Carrion R, Castaner O, Bullo M, Ruiz-Canela M, Garcia-de la Hera M, Perez-Farinos N, Baron-Lopez FJ, Colom A, Abete I, Ros E, Salas-Salvado J. Cross-sectional associations of objectively-measured sleep characteristics with obesity and type 2 diabetes in the PREDIMED-Plus trial. <i>SLEEP</i> .2018.41.(12)-.DOI:10.1093/sleep/zsy190.;IF:5,137 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	
D'Erasmus L, Minicocci I, Nicolucci A, Pintus P, Van Lennep JER, Masana L, Mata P, Sanchez-Hernandez RM, Prieto-Matos P, Real JT, Prieto-Matos P, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M. Autosomal Recessive Hypercholesterolemia Long-Term Cardiovascular Outcomes. <i>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY</i> .2018.71.(3).279-288.DOI:10.1016/j.jacc.2017.11.028.;IF:16,834 DQ1 D1	GC09	IMIBIC Groups.GC09	
IMIBIC Groups.GC09			



Sanchez-Hernandez RM, Prieto-Matos P, Civeira F, Lafuente EE, Vargas MF, Real JT, Goicoechea FG, Fuentes FJ, Pocovi M, Boronat M, Wagner AM, Masana L. Autosomal recessive hypercholesterolemia in Spain. <i>ATHEROSCLEROSIS</i> .2018.269.(1).1-5.DOI:10.1016/j.atherosclerosis.2017.12.006.;IF:4,467 Q1	GC09	Galilea-Zabalza I, Buil-Cosiales P, Salas-Salvado J, Toledo E, Ortega-Azorin C, Diez-Espino J, Vazquez-Ruiz Z, Zomeno MD, Vioque J, Martinez JA, Romaguera D, Perez-Farinós N, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Aros F, Tur JA, Tinahones F, Serra-Majem L, Marcos-Delgado A, Ortega-Calvo M, Vazquez C, Pinto X, Vidal J, Daimiel L, Delgado-Rodriguez M, Matia P, Corella D, Diaz-Lopez A, Babio N, Munoz MA, Fito M, Gonzalez-Palacios S, Abete I, Garcia-Rios A, Ros E, Martinez-Gonzalez MA. Mediterranean diet and quality of life: Baseline cross-sectional analysis of the PREDIMED-PLUS trial. <i>PLOS ONE</i> .2018.13.(6).-DOI:10.1371/journal.pone.0198974.;IF:2,766 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	
Cano-Ibanez N, Bueno-Cavanillas A, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Zomeno MD, Garcia-de-la-Hera M, Romaguera D, Martinez JA, Baron-Lopez FJ, Garcia-Rios A, Estruch R, Garcia-Molina L, Gomez AA, Tur JA, Tinahones F, Serra-Majem L, Cubelos-Fernandez N, Lapetra J, Vazquez C, Pinto X, Vidal J, Daimiel L, Juan Gaforio J, Matia P, Ros E, Diez-Espino J, Fernandez-Carrion R, Basora J, Fito M, Zazo JM, Colom A, Toledo E, Diaz-Lopez A, Munoz MA, Ruiz-Canela M, Gea A. Dietary Intake in Population with Metabolic Syndrome: Is the Prevalence of Inadequate Intake Influenced by Geographical Area? Cross-Sectional Analysis from PREDIMED-Plus Study. <i>NUTRIENTS</i> .2018.10.(11).-DOI:10.3390/nu10111661.;IF:4,196 Q1	GC09	Jimenez-Jimenez C, Lara-Chica M, Palomares B, Collado JA, Lopez-Miranda J, Munoz E, Calzado MA. Effect of N-acyl-dopamines on beta cell differentiation and wound healing in diabetic mice. <i>BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH</i> .2018.1865.(11).1539-1551. DOI:10.1016/j.bbamcr.2018.08.008.;IF:4,651 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;GC04	
Sanchez-Villegas A, Alvarez-Perez J, Toledo E, Salas-Salvado J, Ortega-Azorin C, Zomeno MD, Vioque J, Martinez JA, Romaguera D, Perez-Lopez J, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Aros F, Tur JA, Tinahones FJ, Lecea O, Martin V, Ortega-Calvo M, Vazquez C, Pinto X, Vidal J, Daimiel L, Delgado-Rodriguez M, Matia P, Corella D, Diaz-Lopez A, Babio N, Munoz MA, Fito M, de la Hera MG, Abete I, Garcia-Rios A, Ros E, Ruiz-Canela M, Martinez-Gonzalez MA, Izquierdo M, Serra-Majem L. Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial. <i>NUTRIENTS</i> .2018.10.(12).-DOI:10.3390/nu10122000.;IF:4,196 Q1	GC09	Roncero-Ramos I, Jimenez-Lucena R, Alcalá-Díaz JF, Vals-Delgado C, Arenas-Larriva AP, Rangel-Zuniga OA, Leon-Acuna A, Malagon MM, Delgado-Lista J, Perez-Martinez P, Ordovas JM, Camargo A, Lopez-Miranda J. Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes. <i>JOURNAL OF NUTRITIONAL BIOCHEMISTRY</i> .2018.62.(1).247-256.DOI:10.1016/j.jnutbio.2018.08.012.;IF:4,414 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;GC11	
Mallorqui-Bague N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvado J, Cuenca-Royo A, Vioque J, Romaguera D, Martinez JA, Warnberg J, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Alonso-Gomez A, Tur JA, Tinahones FJ, Serra-Majem L, Martin V, Lapetra J, Vazquez C, Pinto X, Vidal J, Daimiel L, Gaforio JJ, Matia P, Ros E, Granero R, Buil-Cosiales P, Barragan R, Bullo M, Castaner O, Garcia-de-la-Hera M, Yanez AM, Abete I, Garcia-Rios A, Ruiz-Canela M, Diaz-Lopez A, Jimenez-Murcia S, Martinez-Gonzalez MA, De la Torre R, Fernandez-Aranda F. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. <i>SCIENTIFIC REPORTS</i> .2018.8.(1).-DOI:10.1038/s41598-018-33843-8.;IF:4,122 Q1	GC09	Jimenez-Lucena R, Camargo A, Alcalá-Díaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Rangel-Zuniga OA, Lopez-Miranda J. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. <i>EXPERIMENTAL AND MOLECULAR MEDICINE</i> .2018.50.(1).-DOI:10.1038/s12276-018-0194-y.;IF:5,584 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;GC27	
Ramos-Molina B, Castellano-Castillo D, Alcaide-Torres J, Pastor O, Diaz RD, Salas-Salvado J, Lopez-Moreno J, Fernandez-Garcia JC, Macias-Gonzalez M, Cardona F, Tinahones FJ. Differential effects of restrictive and malabsorptive bariatric surgery procedures on the serum lipidome in obese subjects. <i>JOURNAL OF CLINICAL LIPIDOLOGY</i> .2018.12.(6).1502-1512.DOI:10.1016/j.jacl.2018.07.006.;IF:3,58 Q1	GC09	Santos-Marcos, JA; Rangel-Zuniga, OA; Jimenez-Lucena, R; Quintana-Navarro, GM; Garcia-Carpintero, S; Malagon, MM; Landa, BB; Tena-Sempere, M; Perez-Martinez, P; Lopez-Miranda, J; Perez-Jimenez, F; Camargo, A. Influence of gender and menopausal status on gut microbiota. <i>MATURITAS</i> .2018.116.(1).43-53.DOI:10.1016/j.maturitas.2018.07.008.;IF:3,315 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;GC10 ;GC11	
Grosjean F, Yubero-Serrano EM, Zheng F, Esposito V, Swamy S, Elliot SJ, Cai WJ, Vlassara H, Salem F, Striker GE. Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice. <i>PLOS ONE</i> .2018.13.(9).-DOI:10.1371/journal.pone.0204366.;IF:2,766 Q1	GC09	de Isla LP, Alonso R, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Miramontes JP, Fuentes F, de Diego JJG, Gonzalez-Estrada A, Mata N, Saltijeral A, Barreiro M, Tomas M, de Andres R, Argues R, Gotarredona MPS, Herrero SN, Palazon RJP, de Caralt TM, de Centi LAS, Zhilina S, Perez SE, Padro T, Mata P. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. <i>JOURNAL OF CLINICAL LIPIDOLOGY</i> .2018.12.(4).948-957.DOI:10.1016/j.jacl.2018.04.003.;IF:3,58 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;Radiodiagnóstico	
Brenner B, Bikdeli B, Tzoran I, Madridano O, Lopez-Reyes R, Surinach JM, Blanco-Molina A, Tufano A, Nunez JLL, Trujillo-Santos J, Monreal M. Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism. <i>AMERICAN JOURNAL OF MEDICINE</i> .2018.131.(9).1095-1103.DOI:10.1016/j.amjmed.2018.04.037.;IF:5,117 Q1	GC09	Lopez-Bascon MA, Calderon-Santiago M, Sanchez-Ceinos J, Fernandez-Vega A, Guzman-Ruiz R, Lopez-Miranda J, Malagon MM, Priego-Capote F. Influence of sample preparation on lipidomics analysis of polar lipids in adipose tissue. <i>TALANTA</i> .2018.177.(1).86-93.DOI:10.1016/j.talanta.2017.09.017.;IF:4,244 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC21 ;GC11 ;GC09	
Mari-Alfonso B, Simeon-Aznar CP, Guillen-Del Castillo A, Rubio-Rivas M, Trapiella-Martinez L, Todoli-Parra JA, Carballeira MR, Marin-Ballve A, Iniesta-Arandia N, Colunga-Arguelles D, Castillo-Palma MJ, Saez-Comet L, Egurbide-Arberas MV, Ortego-Centeno N, Freire M, Hitos JAV, Chamorro AJ, Madronero-Vuelta AB, Perales-Fraile I, Pla-Salas X, Fernandez-De-La-Puebla RA, Fonollosa-Pla V, Tolosa-Vilella C. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. <i>SEMINARS IN ARTHRITIS AND RHEUMATISM</i> .2018.47.(6).849-857.DOI:10.1016/j.semarthrit.2017.10.004.;IF:4,356 Q1	GC09	Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. <i>JOURNAL OF CELLULAR AND MOLECULAR MEDICINE</i> .2018.22.(11).5688-5697.DOI:10.1111/jcmm.13845.;IF:4,302 Q1	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC27 ;GC08 ;Ge05; GC09 ;U Innovación Metodología Imibic; Anatomía Patológica	
Mena-Sanchez G, Babio N, Martinez-Gonzalez MA, Corella D, Schroder H, Vioque J, Romaguera D, Martinez JA, Lopez-Miranda J, Estruch R, Warnberg J, Bueno-Cavanillas A, Serra-Majem L, Tur JA, Aros F, Tinahones FJ, Sanchez VM, Lapetra J, Pinto X, Vidal J, Vazquez C, Ordovas JM, Delgado-Rodriguez M, Matia-Martin R, Basora J, Buil-Cosiales R, Fernandez-Carrion R, Fito M, Salas-Salvado J. Fermented dairy products, diet quality, and cardio-metabolic profile of a Mediterranean cohort at high cardiovascular risk. <i>NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES</i> .2018.28.(10).1002-1011.DOI:10.1016/j.numecd.2018.05.006.;IF:3,318 Q1	GC09	Chivite D, Formiga F, Corbella X, Conde-Martel A, Aramburu O, Carrera M, Davila MF, Perez-Silvestre J, Manzano L, Montero-Perez-Barquero M. Basal functional status predicts one-year mortality after a heart failure hospitalization in elderly patients - The RICA prospective study. <i>INTERNATIONAL JOURNAL OF CARDIOLOGY</i> .2018.254.(1).182-188.DOI:10.1016/j.ijcard.2017.10.104.;IF:4,034 Q2	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	
Morales-Rull JL, Bielsa S, Conde-Martel A, Aramburu-Bodas O, Llacer P, Quesada MA, Suarez-Pedreira I, Manzano L, Barquero MMP, Porcel JM. Pleural effusions in acute decompensated heart failure: Prevalence and prognostic implications. <i>EUROPEAN JOURNAL OF INTERNAL MEDICINE</i> .2018.52.(1).49-53.DOI:10.1016/j.ejim.2018.02.004.;IF:3,282 Q1	GC09	Fernandez CS, Castilla-Guerra L, Hinojosa JC, Surinach JM, de Bilbao FA, Tamarit JJ, Diaz JLD, Hernandez JL, Pose A, Montero-Perez-Barquero M, Roquer J, Gallego J, Vivancos J, Mostaza JM. Satisfaction with oral anticoagulants in patients with atrial fibrillation. <i>PATIENT PREFERENCE AND ADHERENCE</i> .2018.12.(1).267-274.DOI:10.2147/PPA.S152109.;IF:1,733 Q2	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	
		Bikdeli B, Sharif-Kashani B, Bikdeli B, Valle R, Falga C, Riera-Mestre A, Mazzolai L, Verhamme P, Wells PS, Torrero JFSM, Lopez-Jimenez L, Monreal M. Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>SEMINARS IN THROMBOSIS AND HEMOSTASIS</i> .2018.44.(4).341-347.DOI:10.1055/s-0037-1621716.;IF:3,345 Q2	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	
		Moustafa F, Stehouwer A, Kamphuisen P, Sahuquillo JC, Samperiz A, Alfonso M, Pace F, Surinach JM, Blanco-Molina A, Mismetti P, Monreal M. Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. <i>THROMBOSIS RESEARCH</i> .2018.171.(1).74-80.DOI:10.1016/j.thromres.2018.09.049.;IF:2,779 Q2	GC09
IMIBIC Groups.GC09		IMIBIC Groups.GC09	



Lopez-Moreno J, Garcia-Carpintero S, Gomez-Delgado F, Jimenez-Lucena R, Vals-Delgado C, Alcalá-Díaz JF, Roncero-Ramos I, Rangel-Zuniga OA, Yubero-Serrano EM, Malagon MM, Ordovas JM, Perez-Martinez P, Lopez-Miranda J, Camargo A. Endotoxemia is modulated by quantity and quality of dietary fat in older adults. <i>EXPERIMENTAL GERONTOLOGY</i> . 2018. 109.(1).119-125. DOI:10.1016/j.exger.2017.11.006.;IF:3,224 Q2	GC09	Perez-Jimenez F, Pascual V, Meco JF, Martinez PP, Lista JD, Domenech M, Estruch R, Leon-Acuna A, Lopez-Miranda J, Sanchez-Ramos A, Ferrer CSI, Soler-Rivas C, Alberich RMS, Valdivielso P, Ros E. Document of recommendations of the SEA 2018. Lifestyle in cardiovascular prevention. <i>CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS</i> . 2018. 30.(6).280-310. DOI:10.1016/j.arteri.2018.06.005.;IF:0 NO Q	GC09
IMIBIC Groups.GC09 ;GC11		IMIBIC Groups.GC09	
Katsiki N, Kolovou G, Perez-Martinez P, Mikhailidis DP. Dyslipidaemia in the elderly: to treat or not to treat?. <i>EXPERT REVIEW OF CLINICAL PHARMACOLOGY</i> . 2018. 11.(3).259-278. DOI:10.1080/17512433.2018.1425138.;IF:2,758 Q2	GC09	Vazquez MJ, Toro CA, Castellano JM, Ruiz-Pino F, Roa J, Beiroa D, Heras V, Velasco I, Dieguez C, Pinilla L, Gaytan F, Nogueiras R, Bosch MA, Ronnekleiv OK, Lomniczi A, Ojeda SR, Tena-Sempere M. SIRT1 mediates obesity- and nutrient-dependent perturbation of pubertal timing by epigenetically controlling Kiss1 expression. <i>NATURE COMMUNICATIONS</i> . 2018. 9.(1). DOI:10.1038/s41467-018-06459-9.;IF:12,353 DQ1 D1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC10	
Romero-Saldana M, Tauler P, Vaquero-Abellan M, Lopez-Gonzalez AA, Fuentes-Jimenez FJ, Aguilo A, Alvarez-Fernandez C, Molina-Recio G, Bennisar-Veny M. Validation of a non-invasive method for the early detection of metabolic syndrome: a diagnostic accuracy test in a working population. <i>BMJ OPEN</i> . 2018. 8.(10). DOI:10.1136/bmjopen-2017-020476.;IF:2,413 Q2	GC09	Roa J, Barroso A, Ruiz-Pino F, Vazquez MJ, Seoane-Collazo P, Martinez-Sanchez N, Garcia-Galiano D, Ilhan T, Pineda R, Leon S, Manfredi-Lozano M, Heras V, Poutanen M, Castellano JM, Gaytan F, Dieguez C, Pinilla L, Lopez M, Tena-Sempere M. Metabolic regulation of female puberty via hypothalamic AMPK-kisspeptin signaling. <i>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA</i> . 2018. 115.(45). E10758-E10767. DOI:10.1073/pnas.1802053115.;IF:9,504 DQ1 D1	GC10
IMIBIC Groups.GC12 ;GC09		IMIBIC Groups.GC10	
Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Pena S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J. Gastrointestinal stromal tumors: a multidisciplinary challenge. <i>WORLD JOURNAL OF GASTROENTEROLOGY</i> . 2018. 24.(18).1925-1941. DOI:10.3748/wjg.v24.i18.1925.;IF:3,3 Q2	GC09	Manfredi-Lozano M, Roa J, Tena-Sempere M. Connecting metabolism and gonadal function: Novel central neuropeptide pathways involved in the metabolic control of puberty and fertility. <i>FRONTIERS IN NEUROENDOCRINOLOGY</i> . 2018. 48.(1).37-49. DOI:10.1016/j.yfrme.2017.07.008.;IF:6,875 DQ1 D1	GC10
IMIBIC Groups.GC18 ;GC09		IMIBIC Groups.GC10	
Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas O, Conde-Martel A, Arias-Jimenez JL, Llacer-Iborra P, Davila-Ramos MF, Cabanes-Hernandez Y, Manzano L, Montero-Perez-Barquero M. Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: Findings from the RICA Registry. <i>INTERNATIONAL JOURNAL OF CARDIOLOGY</i> . 2018. 255.(1).124-128. DOI:10.1016/j.ijcard.2017.07.101.;IF:4,034 Q2	GC09	Gaytan F, Morales C, Roa J, Tena-Sempere M. Changes in keratin 8/18 expression in human granulosa cell lineage are associated to cell death/survival events: potential implications for the maintenance of the ovarian reserve. <i>HUMAN REPRODUCTION</i> . 2018. 33.(4).680-689. DOI:10.1093/humrep/dey010.;IF:4,99 DQ1 D1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC10	
Garcia-Rios A, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. New diet trials and cardiovascular risk. <i>CURRENT OPINION IN CARDIOLOGY</i> . 2018. 33.(4).423-428. DOI:10.1097/HCO.0000000000000523.;IF:2,006 Q3	GC09	Seoane-Collazo P, Roa J, Rial-Pensado E, Linares-Pose L, Beiroa D, Ruiz-Pino F, Lopez-Gonzalez T, Morgan DA, Pardavila JA, Sanchez-Tapia MJ, Martinez-Sanchez N, Contreras C, Fidalgo M, Dieguez C, Coppari R, Rahmouni K, Nogueiras R, Tena-Sempere M, Lopez M. SF1-Specific AMPK alpha 1 Deletion Protects Against Diet-Induced Obesity. <i>DIABETES</i> . 2018. 67.(11).2213-2226. DOI:10.2337/db17-1538.;IF:7,273 DQ1 D1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC10	
Franco J, Formiga F, Cepeda J, Llacer P, Arevalo-Lorido J, Cerqueiro J, Gonzalez-Franco A, Epelde F, Manzano L, Perez-Barquero MM. Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction. <i>MEDICINA CLINICA</i> . 2018. 150.(10).376-382. DOI:10.1016/j.medcli.2017.06.065.;IF:1,168 Q3	GC09	Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sanchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Munoz E. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. <i>SCIENTIFIC REPORTS</i> . 2018. 8.(1). DOI:10.1038/s41598-018-34259-0.;IF:4,122 Q1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC04 ;GC10	
Pedro-Botet J, Ascaso JF, Barrios V, De la Sierra A, Escalada J, Millan J, Mostaza JM, Perez-Martinez P, Pinto X, Salas-Salvado J, Valdivielso P. COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY</i> . 2018. 11.(1).683-697. DOI:10.2147/DMSO.S165740.;IF:2,961 Q3	GC09	Santos-Marcos JA, Rangel-Zuniga OA, Jimenez-Lucena R, Quintana-Navarro GM, Garcia-Carpintero S, Malagon MM, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A. Influence of gender and menopausal status on gut microbiota. <i>MATURITAS</i> . 2018. 116.(1).43-53. DOI:10.1016/j.maturitas.2018.07.008.;IF:3,315 Q1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC09 ;GC10 ;GC11	
Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>CURRENT VASCULAR PHARMACOLOGY</i> . 2018. 16.(3).219-227. DOI:10.2174/157016115666170621075619.;IF:2,087 Q3	GC09	Leon S, Velasco I, Vazquez MJ, Barroso A, Beiroa D, Heras V, Ruiz-Pino F, Manfredi-Lozano M, Romero-Ruiz A, Sanchez-Garrido MA, Dieguez C, Pinilla L, Roa J, Nogueiras R, Tena-Sempere M. Sex-Biased Physiological Roles of NPFF1R, the Canonical Receptor of RFRP-3, in Food Intake and Metabolic Homeostasis Revealed by its Congenital Ablation in mice. <i>METABOLISM-CLINICAL AND EXPERIMENTAL</i> . 2018. 87.(1).87-97. DOI:10.1016/j.metabol.2018.07.003.;IF:5,963 Q1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC10	
Sanchez-Garcia ME, Ramirez-Lara I, Gomez-Delgado F, Yubero-Serrano EM, Leon-Acuna A, Marin C, Alcalá-Díaz JF, Camargo A, Lopez-Moreno J, Perez-Martinez P, Tinahones FJ, Ordovas JM, Caballero J, Blanco-Molina A, Lopez-Miranda J, Delgado-Lista J. Quantitative evaluation of capillaroscopic microvascular changes in patients with established coronary heart disease. <i>MEDICINA CLINICA</i> . 2018. 150.(4).131-137. DOI:10.1016/j.medcli.2017.06.068.;IF:1,168 Q3	GC09	Poutanen M, Tena-Sempere M. Animal Models for Human Endocrine Disorders Preface. <i>BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM</i> . 2018. 32.(3).215-218. DOI:10.1016/j.beem.2018.05.001.;IF:4,417 Q1	GC10
IMIBIC Groups.GC09 ;GA06		IMIBIC Groups.GC10	
Aller R, Fernandez-Rodriguez C, Iacono O, Banares R, Abad J, Carrion JA, Garcia-Monzon C, Caballeria J, Berenguer M, Rodriguez-Peralvarez M, Miranda JL, Vilar-Gomez E, Crespo J, Garcia-Cortes M, Reig M, Navarro JM, Gallego R, Genesca J, Arias-Loste MT, Pareja MJ, Albillos A, Muntane J, Jorquera F, Sola E, Hernandez-Guerra M, Rojo MA, Salmeron J, Caballeria L, Diago M, Molina E, Bataller R, Romero-Gomez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> . 2018. 41.(5).328-349. DOI:10.1016/j.gastrohep.2017.12.003.;IF:1,078 Q4	GC09	Franssen D, Tena-Sempere M. The kisspeptin receptor: A key G-protein-coupled receptor in the control of the reproductive axis. <i>BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM</i> . 2018. 32.(2).107-123. DOI:10.1016/j.beem.2018.01.005.;IF:4,417 Q1	GC10
IMIBIC Groups.GC02 ;GC09		IMIBIC Groups.GC10	
Lobo JL, Garcia-Fuertes JA, Trujillo-Santos J, Merah A, Blanco-Molina MA, Casado I, Hirmerova J, De Miguel J, Salgado E, Monreal M. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease. <i>EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY</i> . 2018. 30.(5).526-530. DOI:10.1097/MEG.0000000000001084.;IF:2,014 Q4	GC09	Gonzalez-Garcia I, Contreras C, Estevez-Salguero A, Ruiz-Pino F, Colsh B, Pensado I, Linares-Pose L, Rial-Pensado E, de Morentin PBM, Ferno J, Dieguez C, Nogueiras R, Le Stunff H, Magnan C, Tena-Sempere M, Lopez M. Estradiol Regulates Energy Balance by Ameliorating Hypothalamic Ceramide-Induced ER Stress. <i>CELL REPORTS</i> . 2018. 25.(2).413-423. DOI:10.1016/j.celrep.2018.09.38.;IF:8,032 Q1	GC10
IMIBIC Groups.GC09		IMIBIC Groups.GC10	
Rodelo-Haad C, Gimenez RFD, Ortega R, Rodriguez M, Aljama P. Calcific arteriopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists. <i>CLINICAL CASES IN MINERAL AND BONE METABOLISM</i> . 2018. 15.(1).85-88. DOI:10.1016/j.ccm.2017.07.005.;IF:3,961 Q2	GC09	Sanchez-Garrido MA, Ruiz-Pino F, Velasco I, Barroso A, Fernandois D, Heras V, Manfredi-Lozano M, Vazquez MJ, Castellano JM, Roa J, Pinilla L, Tena-Sempere M. Intergenerational Influence of Paternal Obesity on Metabolic and Reproductive Health Parameters of the Offspring: Male-Preferential Impact and Involvement of Kiss1-Mediated Pathways. <i>ENDOCRINOLOGY</i> . 2018. 159.(2).1005-1018. DOI:10.1210/en.2017-00705.;IF:3,961 Q2	GC10
IMIBIC Groups.GC07 ;GC13 ;GC09 ;GC14		IMIBIC Groups.GC10	



Roa J, Tena-Sempere M.Unique Features of a Unique Cell: The Wonder World of GnRH Neurons.ENDOCRINOLOGY.2018.159.(12).3895-3896. DOI:10.1210/en.2018-00870.;IF:3,961 Q2	GC10	Lopez-Bascon MA, Calderon-Santiago M, Sanchez-Ceinos J, Fernandez-Vega A, Guzman-Ruiz R, Lopez-Miranda J, Malagon MM, Priego-Capote F.Influence of sample preparation on lipidomics analysis of polar lipids in adipose tissue.TALANTA.2018.177.(.).86-93.DOI:10.1016/j.talanta.2017.09.017.;IF:4,244 Q1	GC11
IMIBIC Groups.GC10		IMIBIC Groups.GC21 ;GC11 ;GC09	
Gonzalez-Garcia I, de Morentin PBM, Estevez-Salguero A, Contreras C, Romero-Pico A, Ferno J, Nogueiras R, Dieguez C, Tena-Sempere M, Tovar S, Lopez M.mTOR signaling in the arcuate nucleus of the hypothalamus mediates the anorectic action of estradiol.JOURNAL OF ENDOCRINOLOGY.2018.238.(3).177-186.DOI:10.1530/JOE-18-0190.;IF:4,012 Q2	GC10	Lopez-Moreno J, Garcia-Carpintero S, Gomez-Delgado F, Jimenez-Lucena R, Vals-Delgado C, Alcalá-Díaz JF, Roncero-Ramos I, Rangel-Zuniga OA, Yubero-Serrano EM, Malagon MM, Ordoñas JM, Perez-Martinez P, Lopez-Miranda J, Camargo A.Endotoxemia is modulated by quantity and quality of dietary fat in older adults.EXPERIMENTAL GERONTOLOGY.2018.109.(.).119-125.DOI:10.1016/j.exger.2017.11.006.;IF:3,224 Q2	GC11
IMIBIC Groups.GC10		IMIBIC Groups.GC09 ;GC11	
Argente-Arizon P, Diaz F, Ros P, Barrios V, Tena-Sempere M, Garcia-Segura LM, Argente J, Chowen JA.The Hypothalamic Inflammatory/Gliosis Response to Neonatal Overnutrition Is Sex and Age Dependent.ENDOCRINOLOGY.2018.159.(1).368-387.DOI:10.1210/en.2017-00539.;IF:3,961 Q2	GC10	Albornos-Munoz L, Moreno-Casbas MT, Sanchez-Pablo C, Bays-Moneo A, Fernandez-Dominguez JC, Rich-Ruiz M, Gea-Sanchez M.Efficacy of the Otago Exercise Programme to reduce falls in community-dwelling adults aged 65-80 years old when delivered as group or individual training.JOURNAL OF ADVANCED NURSING.2018.74.(7).1700-1711.DOI:10.1111/jan.13583.;IF:2,267 DQ1 D1	GC12
IMIBIC Groups.GC10		IMIBIC Groups.GC12	
Argente-Arizon P, Castro-Gonzalez D, Diaz F, Fernandez-Gomez MJ, Sanchez-Garrido MA, Tena-Sempere M, Argente J, Chowen JA.Neonatal Overnutrition Increases Testicular Size and Expression of Luteinizing Hormone beta-Subunit in Peripubertal Male Rats.FRONTIERS IN ENDOCRINOLOGY.2018.9.(.).-DOI:10.3389/fendo.2018.00168.;IF:3,519 Q2	GC10	Martin-Rioboo E, de Torres LAP, Banegas JR, Lobos-Bejarano JM, Cuixart CB, Criado EIG, Martin-Carrillo P, Muro MMR, Cabello MIE, Galan AM.Knowledge, availability, and use of ambulatory and home blood pressure monitoring in primary care in Spain: the MAMPA study.JOURNAL OF HYPERTENSION.2018.36.(5).1051-1058.DOI:10.1097/HJH.0000000000001673.;IF:4,092 Q1	GC12
IMIBIC Groups.GC10		IMIBIC Groups.GC12	
Lehman MN, Coolen LM, Steiner RA, Neal-Perry G, Wang L, Moenter SM, Moore AM, Goodman RL, Yeo SH, Padilla SL, Kauffman AS, Garcia J, Kelly MJ, Clarkson J, Radovick S, Babwah AV, Leon S, Tena-Sempere M, Comninou AN, Seminara S, Dhillon WS, Levine J, Terasawa E, Negron A, Navarro VM, Herbison AE.The 3rd World Conference on Kisspeptin, "Kisspeptin 2017: Brain and Beyond": Unresolved questions, challenges and future directions for the field.JOURNAL OF NEUROENDOCRINOLOGY.2018.30.(5).-DOI:10.1111/jne.12600.;IF:3,392 Q2	GC10	Alonso JV, del Pozo FJF, Vaquero M, Islam IFA 48-Year-Old Woman Presenting With Syncope and Shortness of Breath.CHEST.2018.154.(2).E41-E43. DOI:10.1016/j.chest.2018.02.040.;IF:7,652 Q1	GC12
IMIBIC Groups.GC10		IMIBIC Groups.GC12	
Quinones M, Al-Massadi O, Figueira C, Bremser S, Gallego R, Torres-Leal L, Haddad-Tovolli R, Garcia-Caceres C, Hernandez-Bautista R, Lam BYH, Beiroa D, Sanchez-Rebordelo E, Senra A, Malagon JA, Valerio P, Fondevila MF, Ferno J, Malagon MM, Contreras R, Pfluger P, Bruning JC, Yeo G, Tschop M, Dieguez C, Lopez M, Claret M, Kloppenburg P, Sabio G, Nogueiras R.p53 in AgRP neurons is required for protection against diet-induced obesity via JNK1.NATURE COMMUNICATIONS.2018.9.(.).-DOI:10.1038/s41467-018-05711-6.;IF:12,353 DQ1 D1	GC11	Alonso JV, del Pozo FJF, Vaquero M, Islam I.Sepsis, fluid resuscitation and bedside echocardiography.QJM-AN INTERNATIONAL JOURNAL OF MEDICINE.2018.111.(1).51-52.DOI:10.1093/qjmed/hcx206.;IF:3,204 Q1	GC12
IMIBIC Groups.GC11		IMIBIC Groups.GC12	
Gomez-Marin B, Gomez-Delgado F, Lopez-Moreno J, Alcalá-Díaz JF, Jimenez-Lucena R, Torres-Pena JD, Garcia-Rios A, Ortiz-Morales AM, Yubero-Serrano EM, Malagon MD, Lai CQ, Delgado-Lista J, Ordoñas JM, Lopez-Miranda J, Perez-Martinez P.Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial.AMERICAN JOURNAL OF CLINICAL NUTRITION.2018.108.(5).963-970.DOI:10.1093/ajcn/nqy144.;IF:6,549 DQ1 D1	GC11	Alonso JV, del Pozo FJF, Alvarez MV, Carillo JDD, Llamas JC, Montes H.Sudden headache, lumbar puncture, and the diagnosis of subarachnoid hemorrhage in patients with a normal computed tomography scans.EMERGENCIAS.2018.30.(1).50-53.DOI:No consta.;IF:3,608 Q1	GC12
IMIBIC Groups.GC09 ;GC11		IMIBIC Groups.GC12 ;Urgencias Hosp Valle Pedroches	
de la Rosa IA, Escudero-Contreras A, Rodríguez-Cuenca S, Ruiz-Ponce M, Jimenez-Gomez Y, Ruiz-Limon P, Perez-Sanchez C, Abalos-Aguilera MC, Cecchi I, Ortega R, Calvo J, Guzman-Ruiz R, Malagon MM, Collantes-Estevez E, Vidal-Puig A, Lopez-Pedraza C, Barbarroja N.Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues.JOURNAL OF INTERNAL MEDICINE.2018.284.(1).61-77. DOI:10.1111/joim.12743.;IF:6,754 DQ1 D1	GC11	Merino JS, de Torres LAP, Bardwell WA, Gomez RM, Villalobos AR, Collado NF, Ruiz-Moral R, Jurado-Gamez B.Impact of Positive Pressure Treatment of the Airway on Health-Related Quality of Life in Elderly Patients With Obstructive Sleep Apnea.BIOLOGICAL RESEARCH FOR NURSING.2018.20.(4).452-461.DOI:10.1177/1099800418774633.;IF:1,579 Q2	GC12
IMIBIC Groups.GC05 ;GC11		IMIBIC Groups.Atención Primaria ;GC12 ;GA03	
Roncero-Ramos I, Jimenez-Lucena R, Alcalá-Díaz JF, Vals-Delgado C, Arenas-Larriva AP, Rangel-Zuniga OA, Leon-Acuna A, Malagon MM, Delgado-Lista J, Perez-Martinez P, Ordoñas JM, Camargo A, Lopez-Miranda J.Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes. JOURNAL OF NUTRITIONAL BIOCHEMISTRY.2018.62.(.).247-256.DOI:10.1016/j.jnutbio.2018.08.012.;IF:4,414 Q1	GC11	Serrano-Gemes G, Serrano-del-Rosal R, Rich-Ruiz M.Decision-making on the location of care of the elderly: protocol for a systematic review of qualitative studies.BMJ OPEN.2018.8.(10).-DOI:10.1136/bmjopen-2018-022411.;IF:2,413 Q2	GC12
IMIBIC Groups.GC09 ;GC11		IMIBIC Groups.GC12	
Santos-Marcos JA, Rangel-Zuniga OA, Jimenez-Lucena R, Quintana-Navarro, GM; Garcia-Carpintero, S; Malagon, MM; Landa, BB; Tena-Sempere, M; Perez-Martinez, P; Lopez-Miranda, J; Perez-Jimenez, F; Camargo, A.Influence of gender and menopausal status on gut microbiota.MATURITAS.2018.116.(.).43-53.DOI:10.1016/j.maturitas.2018.07.008.;IF:3,315 Q1	GC11	Romero-Saldana M, Tauler P, Vaquero-Abellan M, Lopez-Gonzalez AA, Fuentes-Jimenez FJ, Aguilo A, Alvarez-Fernandez C, Molina-Recio G, Bensusar-Veny M.Validation of a non-invasive method for the early detection of metabolic syndrome: a diagnostic accuracy test in a working population.BMJ OPEN.2018.8.(10).-DOI:10.1136/bmjopen-2017-020476.;IF:2,413 Q2	GC12
IMIBIC Groups.GC09 ;GC10 ;GC11		IMIBIC Groups.GC12 ;GC09	
Perez-Marin CC, Vizuete G, Vazquez-Martinez R, Galisteo JJ.Comparison of different cryopreservation methods for horse and donkey embryos.EQUINE VETERINARY JOURNAL.2018.50.(3).398-404.DOI:10.1111/evj.12777.;IF:2,022 Q1	GC11	Sanchez AR, de Torres LAP, Luna FS, Ruiz-Moral R.Prevalence of tobacco consumption among young physicians at a regional university hospital in southern Spain: a cross-sectional study.BMJ OPEN.2018.8.(2).-DOI:10.1136/bmjopen-2017-018728.;IF:2,413 Q2	GC12
IMIBIC Groups.GC11		IMIBIC Groups.GC12 ;GC12 ;GA03	
Travez A, Rabanal-Ruiz Y, Lopez-Alcala J, Molero-Murillo L, Diaz-Ruiz A, Guzman-Ruiz R, Catalan V, Rodriguez A, Fruhbeck G, Tinahones FJ, Gasman S, Vitale N, Jimenez-Gomez Y, Malagon MM.The caveolae-associated coiled-coil protein, NECC2, regulates insulin signalling in Adipocytes.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(11).5648-5661.DOI:10.1111/jcmm.13840.;IF:4,302 Q1	GC11	Diaz BM, de Larriva APA, Molina-Recio G, Moreno-Rojas R, de la Iglesia JM.Study of the nutritional status of patients over 65 years included in the home care program in an urban population.ATENCION PRIMARIA.2018.50.(2).88-95.DOI:10.1016/j.aprim.2017.02.006.;IF:1,148 Q3	GC12
IMIBIC Groups.GC11 ;GC05		IMIBIC Groups.Atención Primaria ;GC12	
		Delgado-Rodríguez E, Vaquero-Abellan M.Comments on Spanish translation and cross-cultural adaptation of the ARMS-scale.ATENCION PRIMARIA.2018.50.(9).568-569.DOI:10.1016/j.aprim.2017.11.012.;IF:1,148 Q3	GC12
		IMIBIC Groups.GC12	
		de Torres LAP, Garcia CE.What is the European Code against Cancer, who knows it and why it serves?.ATENCION PRIMARIA.2018.50.(2).71-73. DOI:10.1016/j.aprim.2017.08.002.;IF:1,148 Q3	GC12
		IMIBIC Groups.GC12	



Rioboo EM, Banegas JR, de Torres LAP, Bejarano JML. Diagnosis in blood hypertension: When the techniques do not are accessible in primary care and are also produced inequities. ATENCION PRIMARIA. 2018.50.(8).455-458. DOI:10.1016/j.aprim.2018.03.001. ;IF:1,148 Q3	GC12
IMIBIC Groups.GC12 ;Distrito Cordoba Guadalquivir	
Gutierrez-Aroca JB, Ruiz P, Vaquero M, Causse M, Casal M. Surveillance of Drug-Resistant Tuberculosis in Spain (2001-2015). MICROBIAL DRUG RESISTANCE. 2018.24.(6).839-843. DOI:10.1089/mdr.2017.0353. ;IF:2,344 Q3	GC12
IMIBIC Groups.GC24 ;GC12	
Alonso JV, del Pozo FJF, Van der Bergh E. Left calf haematoma mimicking deep vein thrombosis. BRITISH JOURNAL OF HOSPITAL MEDICINE. 2018.79.(10).590-591. DOI:10.12968/hmed.2018.79.10.590. ;IF:0,422 Q4	GC12
IMIBIC Groups.GC12	
Aparicio-Martinez P, Moreno AJP, Martinez-Jimenez MP, Mohedano RAE, Aguilera-Urena MJ, Pedros-Perez G, Vaquero-Abellan M. FROM BLACKBOARD TO SOCIAL NETWORKS: E-LEARNING BASED ON FACEBOOK AND ICT FOR TRANSVERSAL SUBJECTS OF SPANISH MASTERS. 12TH INTERNATIONAL TECHNOLOGY, EDUCATION AND DEVELOPMENT CONFERENCE (INTED). 2018..().2917-2925. DOI: ;IF:0 NO Q	GC12
IMIBIC Groups.GC12	
Alonso JV, del Pozo FJF, Alvarez MV. Short-term resolution of B-lines in thoracic ultrasound in acute pulmonary oedema after treatment. ARCHIVOS DE CARDIOLOGIA DE MEXICO. 2018.88.(3).247-250. DOI:10.1016/j.acmx.2018.03.001. ;IF:0 NO Q	GC12
IMIBIC Groups.GC12	
Rodelo-Haad C, Rodriguez-Ortiz ME, Martin-Malo A, de Mier MVPR, Aguera ML, Munoz-Castaneda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLOS ONE. 2018.13.(8).-. DOI:10.1371/journal.pone.0201537. ;IF:2,766 Q1	GC13
IMIBIC Groups.GC07 ;GC13	
Santamaria R, Diaz-Tocados JM, de Mier MVPR, Robles A, Salmeron-Rodriguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Munoz-Castaneda JR, Martin-Malo A, Aljama P, Rodriguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. SCIENTIFIC REPORTS. 2018.8.(.).-. DOI:10.1038/s41598-018-32065-2. ;IF:4,122 Q1	GC13
IMIBIC Groups.GC07 ;GC13 ;GC14 ;GC13	
Rodriguez-Ortiz ME, Pontillo C, Rodriguez M, Zurbig P, Mischak H, Ortiz A. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. SCIENTIFIC REPORTS. 2018.8.(.).-. DOI:10.1038/s41598-018-34386-8. ;IF:4,122 Q1	GC13
IMIBIC Groups.GC13	
Sanchez-Gonzalez C, Gonzalez-Casaus ML, Sellares VL, Albalade M, Torregrosa JV, Mas S, Ortiz A, Rodriguez M, Gonzalez-Parra E. Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. FRONTIERS IN PHYSIOLOGY. 2018.9.(.).-. DOI:10.3389/fphys.2018.01643. ;IF:3,394 Q1	GC13
IMIBIC Groups.GC13	
Rodriguez M, Aguilera-Tejero E. Energy-Dense Diets and Mineral Metabolism in the Context of Chronic Kidney Disease-Metabolic Bone Disease (CKD-MBD). NUTRIENTS. 2018.10.(12).-. DOI:10.3390/nu10121840. ;IF:4,196 Q1	GC13
IMIBIC Groups.GC13 ;GC13	
Pineda C, Rios R, Raya AI, Rodriguez M, Aguilera-Tejero E, Lopez I. Hypocaloric Diet Prevents the Decrease in FGF21 Elicited by High Phosphorus Intake. NUTRIENTS. 2018.10.(10).-. DOI:10.3390/nu10101496. ;IF:4,196 Q1	GC13
IMIBIC Groups.GC13 ;GC13	
Rios R, Pineda C, Lopez I, Munoz-Castaneda J, Rodriguez M, Aguilera-Tejero E, Raya AI. Phosphorus restriction does not prevent the increase in fibroblast growth factor 23 elicited by high fat diet. PLOS ONE. 2018.13.(6).-. DOI:10.1371/journal.pone.0198481. ;IF:2,766 Q1	GC13
IMIBIC Groups.GC13 ;GC13	
Munoz-Castaneda JR, de Mier MVPR, Rodriguez M, Rodriguez-Ortiz ME. Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2018.19.(3).-. DOI:10.3390/ijms19030664. ;IF:3,687 Q2	GC13
IMIBIC Groups.GC13	
de Mier MVPR, Aguera ML, Navarro MD, Rodriguez-Benot A, Aljama P. Prevalence and Survival of Cancer After Pancreas-Kidney Transplantation. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).669-672. DOI:10.1016/j.transproceed.2017.09.064. ;IF:0,806 Q4	GC13
IMIBIC Groups.GC13 ;GC07	

Rodelo-Haad C, Gimenez RFD, Ortega R, Rodriguez M, Aljama P. Calcific arteriopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists. CLINICAL CASES IN MINERAL AND BONE METABOLISM. 2018.15.(1).85-88. DOI: ;IF:0 NO Q	GC13
IMIBIC Groups.GC07 ;GC13 ;GC09 ;GC14	
Santamaria R, Diaz-Tocados JM, de Mier MVPR, Robles A, Salmeron-Rodriguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Munoz-Castaneda JR, Martin-Malo A, Aljama P, Rodriguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. SCIENTIFIC REPORTS. 2018.8.(.).-. DOI:10.1038/s41598-018-32065-2. ;IF:4,122 Q1	GC14
IMIBIC Groups.GC07 ;GC13 ;GC14 ;GC13	
Rubio-Navarro A, Sanchez-Nino MD, Guerrero-Hue M, Garcia-Caballero C, Gutierrez E, Yuste C, Sevillano A, Praga M, Egea J, Roman E, Cannata P, Ortega R, Cortegano I, de Andres B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. JOURNAL OF PATHOLOGY. 2018.244.(3).296-310. DOI:10.1002/path.5011. ;IF:6,253 Q1	GC14
IMIBIC Groups.GC14	
Garzon FB, Alvarez-Ossorio MP, Moreno MAR, Palanco VM, Arroyo CH, Conde JSDC. Coronary Flow Reserve and Ventricular Function Following Reperfusion Treatment in Patients With Revascularized Acute Anterior Myocardial Infarction. REVISTA ESPANOLA DE CARDIOLOGIA. 2018.71.(5).344-350. DOI:10.1016/j.recesp.2017.07.012. ;IF:5,166 Q1	GC14
IMIBIC Groups.GC15 ;GC14 ;Hematología	
Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. ENDOCRINE. 2018.59.(2).426-437. DOI:10.1007/s12020-017-1482-3. ;IF:3,179 Q2	GC14
IMIBIC Groups.GC08 ;GA04 ;Anatomía Patológica ;GC14 ;Oncología Médica ;GC27	
Martinez MSA, Ruiz CR, Sanchez RS, Salas RO, Andreu ML, Garcia PA, Hernandez ME. C3 deposits worsens the prognosis in type III extracapillary glomerulonephritis. NEFROLOGIA. 2018.38.(2).213-219. DOI:10.1016/j.nefro.2017.08.001. ;IF:1,167 Q4	GC14
IMIBIC Groups.GC07 ;Anatomía Patológica ;GC14	
Martin-Gomez MA, Caba-Molina M, Viciano-Martinez-Lage MJ, Ortega-Salas R, Sanchez-Crespo A, Soriano-Perez MJ, Gomez-Morales M. Collapsing glomerulonephritis with podocyte markers on hemophagocytic syndrome secondary to hepatosplenic T-cell lymphoma. BIOMEDICA. 2018.38.(4).-. DOI: ;IF:0,62 Q4	GC14
IMIBIC Groups.GC14	
Rodelo-Haad C, Gimenez RFD, Ortega R, Rodriguez M, Aljama P. Calcific arteriopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists. CLINICAL CASES IN MINERAL AND BONE METABOLISM. 2018.15.(1).85-88. DOI: ;IF:0 NO Q	GC14
IMIBIC Groups.GC07 ;GC13 ;GC09 ;GC14	
Ramiro-Ortega E, Bonilla-Palomos JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Alhambra-Exposito R, Sanchez MA. Nutritional intervention in acute heart failure patients with undernutrition and normalbuminemia: A subgroup analysis of PICNIC study. CLINICAL NUTRITION. 2018.37.(5).1762-1764. DOI:10.1016/j.clnu.2017.07.009. ;IF:5,496 DQ1 D1	GC15
IMIBIC Groups.GC08 ;GC15	
Ruiz JMM, Galderisi M, Buonauro A, Badano L, Aruta P, Swaans MJ, Sanchis L, Saraste A, Monaghan M, Theodoropoulos KC, Papitsas M, Liel-Cohen N, Kobal S, Bervar M, Berlot B, Filippatos G, Ikonomidis I, Katsanos S, Tanner FC, Cassani D, Faletta FF, Leo LA, Martinez A, Matabuena J, Grande-Trillo A, Alonso-Rodriguez D, Mesa D, Gonzalez-Alujas T, Sitges M, Carrasco-Chinchilla F, Li CH, Fernandez-Golfín C, Zamorano JL. Overview of mitral regurgitation in Europe: results from the European Registry of mitral regurgitation (EuMiClip). EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING. 2018.19.(5).503-507. DOI:10.1093/ehjci/ey011. ;IF:8,336 DQ1 D1	GC15
IMIBIC Groups.GC15	
Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia-Cubero J, Escribano-Subias P, San Roman JA, Borrás X, Alonso-Gomez A, Botas J, Crespo-Leiro MG, Velasco S, Bayes-Genis A, Lopez A, Munoz-Aguilera R, de Teresa E, Gonzalez-Juanatey JR, Evangelista A, Mombiola T, Gonzalez-Mansilla A, Elizaga J, Martin-Moreiras J, Gonzalez-Santos JM, Moreno-Escobar E, Fernandez-Aviles F. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. EUROPEAN HEART JOURNAL. 2018.39.(15).1255-1264. DOI:10.1093/eurheartj/ehx700. ;IF:23,425 DQ1 D1	GC15
IMIBIC Groups.GC15	
Alegre O, Formiga F, Lopez-Palop R, Marin F, Vidan MT, Martinez-Selles M, Carol A, Sionis A, Diez-Villanueva P, Aboal J, Palau-Vendrel A, Bueno H, Rivera AP, Sanchis J, Abu-Assi E, Corbi M, Castillo JC, Baneras J, Gonzalez-Salvado V, Cequier A, Ariza-Sole A. An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2018.19.(4).296-303. DOI:10.1016/j.jamda.2017.10.007. ;IF:5,325 DQ1 D1	GC15
IMIBIC Groups.GC15	



Esteve-Pastor MA, Rivera-Caravaca JM, Roldan-Rabadañ I, Roldan V, Muniz J, Rana-Miguez P, Ruiz-Ortiz M, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F.Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIA Registry.THROMBOSIS AND HAEMOSTASIS.2018.118.(2).279-287.DOI:10.1160/TH17-06-0416.;IF:4,952 DQ1 D1	GC15
IMIBIC Groups.GC15	
Bermejo J, Yotti R, Fernandez-Aviles F.The elephant in the room: reply.EUROPEAN HEART JOURNAL.2018.39.(36).3397-3397.DOI:10.1093/eurheartj/ehy241.;IF:23,425 DQ1 D1	GC15
IMIBIC Groups.GC15	
Barrios V, Escobar C, Cosin-Sales J, Bravo M, Saltijeral A, Ruiz-Ortiz M.Selection of the Best of 2017 in Clinical Cardiology. Continuum Healthcare Between Cardiology and Primary Care.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(1).59-59.DOI:10.1016/j.recesp.2017.09.017.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Escobar C, Cosin-Sales J, Barrios V, Bravo M, Saltijeral A, Ruiz-Ortiz M.Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelties. REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(1).60-60.DOI:10.1016/j.recesp.2017.09.018.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Ortiz MR, Muniz J, Miguez PR, Roldan I, Marin F, Esteve-Pastor MA, Cequier A, Martinez-Selles M, Bertomeu V, Anguita M.Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry.EUROPACE.2018.20.(10).1577-1583.DOI:10.1093/europace/eux316.;IF:5,231 Q1	GC15
IMIBIC Groups.GC15	
de Prado AP, Serrador A, Jimenez-Quevedo P, Gonzalez TB, Vazquez FF, Pan M.Selection of the Best of 2017 in Left Atrial Appendage Occlusion: Filling the Gap in Knowledge.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(3).225-227.DOI:10.1016/j.recesp.2017.10.016.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Pan M, Ojeda S, Jimenez-Quevedo P, Serrador A, Azzalini L, de Prado AP.Selection of the Best of 2017 on Percutaneous Treatment of Chronic Occlusions.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(3).221-223.DOI:10.1016/j.recesp.2017.10.017.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Hernandez JMD, Rumoroso JR, Ojeda S, Brugaletta S, Cascon JD, Ruisanchez C, Gila JS, Roa J, Tizon H, Gutierrez H, Larman M, Camareroa TG, Pinar E, Diaz JF, Pan M, Bueno MM, Oyonarte JM, Guerrero LR, Ble M, Paton RR, Arnold R, Echegaray K, de la Morena G, Sabate M.Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(5).327-334.DOI:10.1016/j.recesp.2017.03.021.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Solana-Gracia R, Rueda F, Betrian P, Gutierrez-Larraya F, del Cerro MJ, Pan M, Alcibar J, Coserria JF, Velasco JM, Zunzunegui JL.Pediatrics Spanish Registry of Percutaneous Melody Pulmonary Valve Implantation in Patients Younger Than 18 Years.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(4).283-290.DOI:10.1016/j.recesp.2017.07.005.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Vivas D, Roldan I, Ferrandis R, Marin F, Roldan V, Tello-Montoliu A, Ruiz-Nodar J, Gomez-Doblas J, Martin A, Llau J, Ramos-Gallo M, Munoz R, Arcelus J, Leyva F, Alberca F, Oliva R, Gomez A, Montero C, Arikans F, Ley L, Santos-Buesou E, Figuero E, Bujaldon A, Urbane J, Otero R, Hermida J, Egocheaga I, Llisterri J, Lobos J, Serrano A, Madridano O, Ferreira J, Cassinello C, Gomez-Luque A, Hidalgo F, Sierra P, Vera P, Arranza J, Palomo V, Guerrero A, Anguita M, Iniguez A.Peroperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEK, SEO, SEPA, SERVE', SECOT and AEU.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(7).553-564.DOI:10.1016/j.recesp.2018.01.001.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Barreiro-Perez M, Li CH, Mesa D, Fernandez-Golfin C, Lopez-Fernandez T, de Isla LP.Selection of the Best of 2017 in Cardiac Imaging and Structural Interventionism.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(2).125-126.DOI:10.1016/j.recesp.2017.10.003.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Jimenez-Quevedo P, Pan M, Serrador A, Gonzalo N, Del Trigo M, de Prado AP.Selection of the Best of 2017 in Interventional Cardiology: Revolution in the Study of Coronary Physiology and New Parameters.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(3).223-225.DOI:10.1016/j.recesp.2017.10.024.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Toro R, Blasco-Turrion S, Morales-Ponce FJ, Gonzalez P, Martinez-Cambor P, Lopez-Granados A, Brugada R, Campuzano O, Perez-Serra A, Longobardo FR, Mangas A, Llorente-Cortes V, de Gonzalo-Calvo D.Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy.JOURNAL OF MOLECULAR MEDICINE-JMM.2018.96.(8).845-856.DOI:10.1007/s00109-018-1666-1.;IF:4,938 Q1	GC15
IMIBIC Groups.GC15	

Esteve-Pastor MA, Rivera-Caravaca JM, Roldan-Rabadañ I, Roldan V, Muniz J, Rana-Miguez P, Ruiz-Ortiz M, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F.Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry.EUROPACE.2018.20.(9).1435-1441.DOI:10.1093/europace/eux314.;IF:5,231 Q1	GC15
IMIBIC Groups.GC15	
Rabadañ IR, Esteve-Pastor MA, Anguita-Sanchez M, Muniz J, Siles JC, Quesada MA, Ortiz MR, Marin F, Selles MM, Bertomeu V, Lip GYH, Fillat AC, Badimon L.Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIA Registry.EUROPEAN JOURNAL OF CLINICAL INVESTIGATION.2018.48.(5).-DOI:10.1111/eci.12910.;IF:3,086 Q1	GC15
IMIBIC Groups.GC15	
Ojeda S, Azzalini L, Chavarria J, Serra A, Hidalgo F, Benincasa S, Gheorghe LL, Diletti R, Romero M, Bellini B, Gutierrez A, de Lezo JS, Mazuelos F, Segura J, Carlino M, Colombo A, Pan M.One Versus 2-stent Strategy for the Treatment of Bifurcation Lesions in the Context of a Coronary Chronic Total Occlusion. A Multicenter Registry.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(6).432-439.DOI:10.1016/j.recesp.2017.08.017.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15	
Garzon FB, Alvarez-Ossorio MP, Moreno MAR, Palanco VM, Arroyo CH, Conde JSDC.Coronary Flow Reserve and Ventricular Function Following Regenerative Treatment in Patients With Revascularized Acute Anterior Myocardial Infarction.REVISTA ESPANOLA DE CARDIOLOGIA.2018.71.(5).344-350. DOI:10.1016/j.recesp.2017.07.012.;IF:5,166 Q1	GC15
IMIBIC Groups.GC15 ;GC14 ;Hematología	
Azzalini L, Ojeda S, Karatasakis A, Maeremans J, Tanabe M, La Manna A, Dautov R, Ybarra LF, Benincasa S, Bellini B, Candilio L, Demir OM, Hidalgo F, Karacsonyi J, Gravina G, Micciche E, D'Agosta G, Venuti G, Tamburino C, Pan M, Carlino M, Dens J, Brilakis ES, Colombo A, Rinfret S.Long-Term Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients Who Have Undergone Coronary Artery Bypass Grafting vs Those Who Have Not.CANADIAN JOURNAL OF CARDIOLOGY.2018.34.(3).310-318.DOI:10.1016/j.cjca.2017.12.016.;IF:4,524 Q2	GC15
IMIBIC Groups.GC15	
Mintz GS, Lefevre T, Lassen JF, Testa L, Pan M, Singh J, Stankovic G, Banning AP.Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club.EUROINTERVENTION.2018.14.(4).E467-E474.DOI:10.4244/EIJ-D-18-00194.;IF:4,417 Q2	GC15
IMIBIC Groups.GC15	
Lassen JF, Burzotta F, Banning AP, Lefevre T, Darremont O, Hildick-Smith D, Chieffo A, Pan M, Holm NR, Louvard Y, Stankovic G.Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club.EUROINTERVENTION.2018.13.(13).1540-1553.DOI:10.4244/EIJ-D-17-00622.;IF:4,417 Q2	GC15
IMIBIC Groups.GC15	
Burzotta F, Lassen JF, Banning AP, Lefevre T, Hildick-Smith D, Chieffo A, Darremont O, Pan M, Chatzizisis YS, Albiero R, Louvard Y, Stankovic G.Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club.EUROINTERVENTION.2018.14.(1).112-120.DOI:10.4244/EIJ-D-18-00357.;IF:4,417 Q2	GC15
IMIBIC Groups.GC15	
Azzalini L, Demir OM, Gasparini AL, Grancini L, La Manna A, Ojeda S, Benincasa S, Bellini B, Poletti E, Maccagni D, Soldi M, Lannetta L, Trabattoni D, Gravina G, Hidalgo F, Giannini F, Pan M, Tamburino C, Bartorelli AL, Reimers B, Godino C, Carlino M, Colombo A.Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry.INTERNAIONAL JOURNAL OF CARDIOLOGY.2018.258.(1).36-41.DOI:10.1016/j.ijcard.2018.01.115.;IF:4,034 Q2	GC15
IMIBIC Groups.GC15	
Barge-Caballero E, Almenar-Bonet L, Crespo-Leiro MG, Brossa-Loidi V, Rangel-Sousa D, Gomez-Bueno M, Farrero-Torres M, Diaz-Molina B, Delgado-Jimenez J, Martinez-Selles M, Lopez-Granados A, De-la-Fuente-Galan L, Gonzalez-Costello J, Garrido-Bravo IP, Blasco-Peiro T, Rabago-Juan-Aracil G, Gonzalez-Vilchez F.Preoperative Toxoplasma gondii serostatus does not affect long-term survival of cardiac transplant recipients. Analysis of the Spanish Heart Transplantation Registry.INTERNAIONAL JOURNAL OF CARDIOLOGY.2018.250.(1).183-187.DOI:10.1016/j.ijcard.2017.09.215.;IF:4,034 Q2	GC15
IMIBIC Groups.GC15	



Mates J, Mademont-Soler I, del Olmo B, Ferrer-Costa C, Coll M, Perez-Serra A, Pico F, Allegue C, Fernandez-Falgueras A, Alvarez P, Yotti R, Espinosa MA, Sarquella-Brugada G, Cesar S, Carro E, Brugada J, Arbelo E, Garcia-Pavia P, Borregan M, Tizzano E, Lopez-Granados A, Mazuelos F, de Bustamante AD, Darnaude MT, Gonzalez-Hevia JI, Diaz-Flores F, Trujillo F, Iglesias A, Fernandez-Aviles F, Campuzano O, Brugada R.Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice.EUROPEAN JOURNAL OF HUMAN GENETICS.2018.26.(7).1014-1025. DOI:10.1038/s41431-018-0119-1.;IF:3,636 Q2	GC15
IMIBIC Groups.GC15	
Azzalini L, Candilio L, Ojeda S, Dens J, La Manna A, Benincasa S, Bellini B, Hidalgo F, Chavarria J, Maeremans J, Gravina G, Micciche E, D'Agosta G, Venuti G, Tamburino C, Pan M, Carlino M, Colombo A.Impact of Incomplete Revascularization on Long-Term Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention.AMERICAN JOURNAL OF CARDIOLOGY.2018.121.(10).1138-1148.DOI:10.1016/j.amjcard.2018.01.033.;IF:3.171 Q2	GC15
IMIBIC Groups.GC15	
Azzalini L, Karatasakis A, Spratt JC, Tajti P, Riley RF, Ybarra LF, Schumacher SP, Benincasa S, Bellini B, Candilio L, Mitomo S, Henriksen P, Hidalgo F, Timmers L, Kraaijeveld AO, Agostoni P, Roy J, Ramsay DR, Weaver JC, Knaapen P, Nap A, Starcevic B, Ojeda S, Pan M, Alaswad K, Lombardi WL, Carlino M, Brilakis ES, Colombo A, Rinfret S, Mashayekhi K.Subadventitial stenting around occluded stents: A bailout technique to recanalize in-stent chronic total occlusions.CATHERETERIZATION AND CARDIOVASCULAR INTERVENTIONS.2018.92.(3).466-476.DOI:10.1002/ccd.27472.;IF:2,602 Q2	GC15
IMIBIC Groups.GC15	
Hidalgo F, Castillo JC, Anguita M.Facts and details: Ivabradine in acute decompensated heart failure.INTERNAIONAL JOURNAL OF CARDIOLOGY.2018.270.(1).202-202.DOI:10.1016/j.ijcard.2018.06.055.;IF:4,034 Q2	GC15
IMIBIC Groups.GC15	
Azzalini L, Ojeda S, Demir OM, Dens J, Tanabe M, La Manna A, Benincasa S, Bellini B, Poletti E, Maccagni D, Hidalgo F, Chavarria J, Maeremans J, Gravina G, Micciche E, D'Agosta G, Venuti G, Tamburino C, Pan M, Carlino M, Colombo A.Recanalization of Chronic Total Occlusions in Patients With vs Without Chronic Kidney Disease: The Impact of Contrast-Induced Acute Kidney Injury.CANADIAN JOURNAL OF CARDIOLOGY.2018.34.(10).1275-1282. DOI:10.1016/j.cjca.2018.07.012.;IF:4,524 Q2	GC15
IMIBIC Groups.GC15	
Bonilla-Palomas JL, Gamez-Lopez AL, Castillo-Dominguez JC, Moreno-Conde M, Lopez-Ibanez MC, Anguita-Sanchez M.Does nutritional intervention maintain its prognostic benefit in the long term for malnourished patients hospitalised for heart failure?.REVISTA CLINICA ESPANOLA.2018.218.(2).58-60.DOI:10.1016/j.rce.2017.10.005.;IF:1,184 Q3	GC15
IMIBIC Groups.GC15	
Montero-Perez FJ, Quero-Espinosa FB, Clemente-Millan MJ, Castro-Gimenez JA, de Burgos-Marin J, Romero-Moreno MA.Proposed clinical scale for the diagnosis of acute coronary syndrome in patients with an inconclusive electrocardiogram and myocardial injury biomarkers.REVISTA CLINICA ESPANOLA.2018.218.(2).49-57.DOI:10.1016/j.rce.2017.12.004.;IF:1,184 Q3	GC15
IMIBIC Groups.Urgencias ;GC15	
Granero VCL, Santos SF, Fernandez-Golfin C, Martin MP, Galarza JMD, Faletra FF, Swaans MJ, Lopez-Fernandez T, Mesa D, La Canna G, Garcia TE, Habib G, Monzonis AM, Gomez JLZ.Immediate improvement of left ventricular mechanics following transcatheter aortic valve replacement.CARDIOLOGY JOURNAL.2018.25.(4).487-494.DOI:10.5603/CJ.a2018.0066.;IF:1,339 Q4	GC15
IMIBIC Groups.GC15	
de Lezo JS, Martin P, Chavarria J.Acute coronary syndrome: an ideal scenario for direct Absorb implantation?.KARDIOLOGIA POLSKA.2018.76.(10).1416-1417.DOI:10.5603/KP.2018.0204.;IF:1,213 Q4	GC05
IMIBIC Groups.GC15	
Gutierrez-Barríos A, Ojeda S, Pan M, Alba M, Agarrado A, Oneto J.Dual-lumen catheter in coronary chronic occlusions.COR ET VASA.2018.60.(5).E482-E486.DOI:10.1016/j.crvasa.2017.08.007.;IF:0 NO Q	GC15
IMIBIC Groups.GC15	
Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, Luque-Tevar M, Ruiz-Limon P, Barbarroja N, Jimenez-Gomez Y, Abalos-Aguilera MC, Collantes-Estevez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martinez C, Gonzalez-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, Lopez-Pedraza C.Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome.HAEMATOLOGICA.2018.103.(5).908-918.DOI:10.3324/haematol.2017.184416.;IF:9,09 DQ1 D1	GC16
IMIBIC Groups.GC05 ;Radiodiagnóstico ;GC16	
Martinez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jerez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibanez M, Sempere A, Sanz MA, Lo-Coco F, Sanchez-Garcia J.Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes.HAEMATOLOGICA.2018.103.(9).E400-E403.DOI:10.3324/haematol.2018.188433.;IF:9,09 DQ1 D1	GC16
IMIBIC Groups.GC16 ;GC22	

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION.2018.24.(8).1754-1758. DOI:10.1016/j.bbmt.2018.03.025.;IF:4,484 Q1	GC16
IMIBIC Groups.GC16	
Sanchez-Garcia J, Falantes J, Perez AM, Hernandez-Mohedo F, Hermosin L, Torres-Sabariago A, Bailen A, Hernandez-Sanchez JM, Rodriguez MS, Casano FJ, Calderon C, Labrador M, Vahi M, Serrano J, Lumbleras E, Hernandez-Rivas JM.Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.LEUKEMIA & LYMPHO-MA.2018.59.(5).1095-1104.DOI:10.1080/10428194.2017.1366998.;IF:2,644 Q2	GC16
IMIBIC Groups.GC16	
de la Fuente FDA, Duran MS, Alvarez MA, Sanroman IL, Dios AM, Tamayo RR, Garcia R, Gonzalez MS, Prieto E, Barez A, Escalante F, Tejedor A, Ballesteros M, Cabanas V, Capote FJ, Couto C, Garzon S, Gonzalez-Pardo M, Manteca MVM.Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.SEMINARS IN HEMATOLOGY.2018.55.(4).189-196.DOI:10.1053/j.seminema-to1.2017.09.002.;IF:3,926 Q2	GC16
IMIBIC Groups.GC16	
Martinez-Cuadron D, Boluda B, Martinez P, Bergua J, Rodriguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salameo O, Cordon L, Sempere A, Jimenez-Ubieto A, Prieto-Delgado J, Diaz-Beya M, Garrido A, Benavente C, Perez-Simon JA, Moscardo F, Sanz MA, Montesinos P.A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.ANNALS OF HEMATOLOGY.2018.97.(5).763-772.DOI:10.1007/s00277-018-3229-5.;IF:2,845 Q2	GC16
IMIBIC Groups.GC16	
Serrano-Lopez J1, Nattamai K1, Pease NA1, Shephard MS1, Wellendorf AM1, Sertorio M1, Smith EA1, Geiger H1, Wells S1, Cancelas JA1, Privette Vinnedge LM2..Loss of DEK induces radioresistance of murine restricted hematopoietic progenitors.EXPERIMENTAL HEMATOLOGY.2018.59.(1).40-50. DOI:10.1016/j.exphem.2017.12.009.;IF:2,436 Q2	GC16
IMIBIC Groups.GC16	
Zhang C1, D'Alessandro A2, Wellendorf AM1, Mohmoud F3, Serrano-Lopez J1, Perentesis JP4, Komurov K1, Alexe G5,6, Stegmaier K5,6, Whitsett JA7, Grimes HL8, Cancelas JA1,3..KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.ONCOTARGET.2017..().-DOI:.;IF:3,45 Q2	GC16
IMIBIC Groups.GC16	
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.BLOOD ADVANCES.2018.2.(8).923-932.DOI:10.1182/bloodadvances.2018016121.;IF:0 NO Q	GC16
IMIBIC Groups.GC16	
Quesada-Gomez JM, Santiago-Mora R, Duran-Prado M, Dorado G, Pereira-Caro G, Moreno-Rojas JM, Casado-Diaz A. -Cryptoxanthin Inhibits Angiogenesis in Human Umbilical Vein Endothelial Cells ThroughRetinoic Acid Receptor.MOLECULAR NUTRITION & FOOD RESEARCH.2018.62.(2).- .DOI:10.1002/mnfr.201700489.;IF:5,151 DQ1 D1	GC17
IMIBIC Groups.GC17	
Roca-Ayats N, Ng PY, Garcia-Giralt N, Falco-Mascaro M, Cozar M, Abril JF, Gomez JMQ, Prieto-Alhambra D, Nogues X, Dunford JE, Russell RG, Baron R, Grinberg D, Balcells S, Diez-Perez A.Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types.JOURNAL OF BONE AND MINERAL RESEARCH.2018.33.(12).2091-2098.DOI:10.1002/jbmr.3580.;IF:6,314 DQ1 D1	GC17
IMIBIC Groups.GC17	
Quesada-Gomez JM, Bouillon R.Is calcifediol better than cholecalciferol for vitamin D supplementation?.OSTEOPOROSIS INTERNATIONAL.2018.29.(8).1697-1711.DOI:10.1007/s00198-018-4520-y.;IF:3,856 Q2 IMIBI	GC17
IMIBIC Groups.GC17	
Nogues X, Nolla JM, Casado E, Jodar E, Munoz-Torres M, Quesada-Gomez JM, Canals L, Balcells M, Lizan L.Spanish consensus on treat to target for osteoporosis.OSTEOPOROSIS INTERNATIONAL.2018.29.(2).489-499.DOI:10.1007/s00198-017-4310-y.;IF:3,856 Q2	GC17
IMIBIC Groups.GC17	
Navarro-Valverde C, Caballero-Villarraso J, Mata-Granados JM, Casado-Diaz A, Sosa-Henriquez M, Malouf-Sierra J, Nogues-Solan X, Rodriguez-Manas L, Cortes-Gil X, Delgadillo-Duarte J, Quesada-Gomez JM.High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women.CALCIFIED TISSUE INTERNATIONAL.2018.102.(6).651-656.DOI:10.1007/s00223-017-0379-8.;IF:3,293 Q2	GC17
IMIBIC Groups.GC17 ;GA06 ;GC17	



Navarro-Valverde C, Quesada-Gomez JM, Perez-Cano R, Fernandez-Palacin A, Pastor-Torres LF. Effect of calcifediol treatment on cardiovascular outcomes in patients with acute coronary syndrome and percutaneous revascularization. <i>MEDICINA CLINICA</i> . 2018. 151.(9).345-352. DOI:10.1016/j.medcli.2017.11.033.;IF:1,168 Q3	GC17	Gomez-Bravo MA, Apellaniz-Ruiz M, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, Pons JA, Bilbao I, Alamo JM, Millan O, Brunet M, Rodriguez-Antona C. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients. <i>PHARMACOGENETICS AND GENOMICS</i> . 2018. 28.(2).41-48. DOI:10.1097/FPC.0000000000000321.;IF:2,25 Q2	GC18
IMIBIC Groups.GC17		IMIBIC Groups.GC18	
Roca-Ayats N, Falco-Mascaro M, Garcia-Giralt N, Cozar M, Abril JF, Duesada-Gomez JM, Prieto-Alhambra D, Nogues X, Mellibovsky L, Diez-Perez A, Grinberg D, Balcells S. Genetic study of atypical femoral fractures using exome sequencing in three affected sisters and three unrelated patients. <i>REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL</i> . 2018. 10.(4).108-117. DOI:10.4321/S1889-836X2018000400002.;IF:0 NO Q	GC17	Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. <i>BMC CANCER</i> . 2018. 18.(.).-. DOI:10.1186/s12885-018-4096-0.;IF:3,288 Q2	GC18
IMIBIC Groups.GC17		IMIBIC Groups.GC18 ;GC06 ;Anatomía Patológica	
Abu Hilal M, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R, Aroori S, Belli G, Besselink M, Briceno J, Gayet B, D'Hondt M, Lesurtel M, Menon K, Lodge P, Rotellar F, Santoyo J, Scatton O, Soubrane O, Sutcliffe R, Van Dam R, White S, Halls MC, Cipriani F, Van der Poel M, Ciria R, Barkhatov L, Gomez-Luque Y, Ocana-Garcia S, Cook A, Buell J, Clavien PA, Dervenis C, Fusai G, Geller D, Lang HK, Primrose J, Taylor M, Van Gulik T, Wakabayashi G, Asbun H, Cherqui D. The Southampton Consensus Guidelines for Laparoscopic Liver Surgery From Indication to Implementation. <i>ANNALS OF SURGERY</i> . 2018. 268.(1).11-18. DOI:10.1097/SLA.0000000000002524.;IF:9,203 DQ1 D1	GC18	Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Pena S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J. Gastrointestinal stromal tumors: a multidisciplinary challenge. <i>WORLD JOURNAL OF GASTROENTEROLOGY</i> . 2018. 24.(18).1925-1941. DOI:10.3748/wjg.v24.i18.1925.;IF:3,3 Q2	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18 ;GC09	
Rodriguez-Peralvarez M, Guerrero M, Barrera L, Ferrin G, Alamo JM, Ayllon MD, Artacho GS, Montero JL, Briceno J, Bernal C, Padillo J, Marin-Gomez LM, Pascasio JM, Poyato A, Gomez-Bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>TRANSPLANTATION</i> . 2018. 102.(12).2056-2064. DOI:10.1097/TP.0000000000002270.;IF:3,96 DQ1 D1	GC18	Medina-Fernandez FJ, Escribano BM, Padilla-del-Campo C, Drucker-Colin R, Pascual-Leone A, Tunes I. Transcranial magnetic stimulation as an antioxidant. <i>FREE RADICAL RESEARCH</i> . 2018. 52.(4).381-389. DOI:10.1080/10715762.2018.1434313.;IF:3,038 Q2	GC18
IMIBIC Groups.GC02 ;GC18		IMIBIC Groups.GC18 ;GE01	
Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> . 2018. 24.(11).1218-1219. DOI:10.1016/j.cmi.2018.06.030.;IF:5,394 DQ1 D1	GC18	Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunes I. Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. <i>BRAIN RESEARCH BULLETIN</i> . 2018. 137.(.).140-145. DOI:10.1016/j.brainresbull.2017.11.018.;IF:3,44 Q2	GC18
IMIBIC Groups.GC26 ;GC03 ;Anatomía Patológica; GC02 ;GC18		IMIBIC Groups.GC18 ;GA06	
Garcilazo-Arismendi D, Goergen M, Azagra-Soria JS. Laparoscopic ultralow anterior resection with intersphincteric dissection and delayed coloanal anastomosis in the TaTME era - a video vignette. <i>COLORECTAL DISEASE</i> . 2018. 20.(8).733-734. DOI:10.1111/codi.14276.;IF:2,778 Q1	GC18	Gomez JJ. Challenges in childhood liver transplantation in innate errors of metabolism. <i>ANALES DE PEDIATRIA</i> . 2018. 88.(2).61-62. DOI:10.1016/j.anpedi.2017.12.006.;IF:1,318 Q3	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18	
Duran-Martinez M, Medina-Fernandez FJ, Martinez-Duenas JL, Diaz-Lopez C, Briceno-Delgado J. Endoanal resection of a giant villous adenoma in the middle rectum - a video vignette. <i>COLORECTAL DISEASE</i> . 2018. 20.(4).357-357. DOI:10.1111/codi.14032.;IF:2,788 Q1	GC18	Ciria R, Navarro E, Sanchez-Frias M, Gallardo AB, Medina J, Ayllon MD, Gomez-Luque I, Ruiz-Rabelo J, Luque A, de la Mata M, Rufian S, Lopez-Cillero P, Briceno J. Preliminary results from the use of intraoperative real-time biliary oxygen monitoring in liver transplantation. <i>CLINICAL TRANSPLANTATION</i> . 2018. 32.(12).-. DOI:10.1111/ctr.13433.;IF:1,518 Q3	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18 ;GC02 ;Anatomía Patológica	
Arjona-Sanchez A, Rufian-Pena S, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience. <i>WORLD JOURNAL OF SURGERY</i> . 2018. 42.(10).3120-3124. DOI:10.1007/s00268-018-4634-6.;IF:2,766 Q1	GC18	Arjona-Sanchez A, Rodriguez-Ortiz L, Rufian-Pena S, Sanchez-Hidalgo JM, Briceno-Delgado J. Laparoscopic approach in complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy by CO2 closed system in a low grade pseudomyxoma peritonei. <i>CIRUGIA ESPANOLA</i> . 2018. 96.(10).656-658. DOI:10.1016/j.ciresp.2018.03.013.;IF:0,841 Q4	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18	
Adam R, Karam V, Cailliez V, Grady JGO, Mirza D, Cherqui D, Klempnauer J, Salizzoni M, Pratschke J, Jamieson N, Hidalgo E, Paul A, Andujar RL, Lerut J, Fisher L, Boudjema K, Fondevila C, Soubrane O, Bachellier P, Pinna AD, Berlakovich G, Bennet W, Pinzani M, Schemmer P, Zieniewicz K, Romero CJ, De Simone P, Ericson BG, Schneeberger S, Wigmore SJ, Prous JF, Colledan M, Porte RJ, Yilmaz S, Azoulay D, Pirenne J, Line PD, Truncka P, Navarro F, Lopez AV, De Carlis L, Pena SR, Kochs E, Duvoux C. 2018 Annual Report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation. <i>TRANSPLANT INTERNATIONAL</i> . 2018. 31.(12).1293-1317. DOI:10.1111/tri.13358.;IF:3,196 Q1	GC18	Sanchez-Hidalgo JM, Rufian-Pena S, Duran-Martinez M, Arjona-Sanchez A, Salcedo-Leal I, Lopez-Cillero P, Briceno-Delgado J. Risk factors of early recurrence in retroperitoneal liposarcoma. <i>CIRUGIA ESPANOLA</i> . 2018. 96.(9).568-576. DOI:10.1016/j.ciresp.2018.06.002.;IF:0,841 Q4	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18	
Pintor-Tortolero J, Medina J, Duran M, Briceno J. Anorectal tumor as a debut form of visceral leishmaniasis. <i>SURGERY</i> . 2018. 164.(6).1390-1391. DOI:10.1016/j.surg.2018.08.010.;IF:3,574 Q1	GC18	Arjona-Sanchez A, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Rabelo JR, Salamanca-Bustos JJ, Rodriguez-Benot A, Campos-Hernandez P, Briceno-Delgado J. Intraoperative Heparinization During Simultaneous Pancreas-Kidney Transplantation: Is It Really Necessary?. <i>TRANSPLANTATION PROCEEDINGS</i> . 2018. 50.(2).673-675. DOI:10.1016/j.transproceed.2017.09.055.;IF:0,806 Q4	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18 ;GE05 ;GC07	
Arjona-Sanchez A, Rufian-Pena S, Artilles M, Sanchez-Hidalgo JM, Casado-Adam A, Cosano A, Thoelecke H, Ramnarine S, Garcilazo D, Briceno-Delgado J. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy. <i>INTERNATIONAL JOURNAL OF HYPERTHERMIA</i> . 2018. 34.(5).570-577. DOI:10.1080/02656736.2018.1423708.;IF:3,44 Q1	GC18	Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ruiz-Rabelo J, Salamanca-Bustos JJ, Rodriguez-Benot A, Marquez-Lopez FJ, Briceno-Delgado J. Pancreas Donor Hyponatremia: Is it Really a Risk Factor for Simultaneous Pancreas-kidney Transplantation?. <i>TRANSPLANTATION PROCEEDINGS</i> . 2018. 50.(2).676-678. DOI:10.1016/j.transproceed.2017.09.050.;IF:0,806 Q4	GC18
IMIBIC Groups.GC18		IMIBIC Groups.GC18 ;GE05 ;GC07	
Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. <i>LIVER TRANSPLANTATION</i> . 2018. 24.(2).192-203. DOI:10.1002/lt.24870.;IF:3,752 Q1	GC18	Sanchez-Hidalgo JM, Salamanca-Bustos JJ, Arjona-Sanchez A, Campos-Hernandez JP, Rabelo JR, Rodriguez-Benot A, Requena-Tapia MJ, Briceno-Delgado J. What Is the Influence of Both Risk Donor and Risk Receiver on Simultaneous Pancreas-Kidney Transplantation?. <i>TRANSPLANTATION PROCEEDINGS</i> . 2018. 50.(2).664-668. DOI:10.1016/j.transproceed.2017.09.065.;IF:0,806 Q4	GC18
IMIBIC Groups.GC18 ;GC02 ;GA11		IMIBIC Groups.GC18 ;GE05 ;GC07	
		Pardo F, Pons JA, Castells L, Colmenero J, Gomez MA, Llado L, Perez B, Prieto M, Briceno J. VI consensus document by the Spanish Liver Transplantation Society. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> . 2018. 41.(6).406-421. DOI:10.1016/j.gastrohep.2018.05.012.;IF:1,078 Q4	GC18
		IMIBIC Groups.GC18	



Pardo F, Pons JA, Castells L, Colmenero J, Gomez MA, Llado L, Perez B, Prieto M, Briceno J.VI consensus document by the Spanish Liver Transplantation Society.CIRUGIA ESPANOLA.2018.96.(6).326-341.DOI:10.1016/j.ciresp.2017.12.013.;IF:0,841 Q4	GC18	Diaz-Gonzalez MC, Duenas CP, Sanchez-Raya A, Elvira JAM, Vazquez VS.Mindfulness-based stress reduction in adolescents with mental disorders: A randomised clinical trial.PSICOTHEMA.2018.30.(2).165-170.DOI:10.7334/psicothema2017.259.;IF:1,516 Q2	GC20
IMIBIC Groups.GC18		IMIBIC Groups.GC20 ;Hospital Infanta Margarita Distrito Cordoba Sur Lucena ;GE04	
Dios-Barbeito S, Dominguez-Bastante M, Moreno-Navas A, Leon-Diaz FJ, Fundora-Suarez Y, Briceno-Delgado FJ, Pitarch-Martinez M, Gomez-Bravo MA.Multicentric Study of the Andalusian Experience in Polycystic Liver Disease as Indication for Liver Transplantation.TRANSPLANTATION PROCEEDINGS.2018.50.(2).613-616.DOI:10.1016/j.transproceed.2017.09.073.;IF:0,806 Q4	GC18	Gomez-Fernandez A, de la Torre-Aguilar MJ, Gil-Campos M, Flores-Rojas K, Cruz-Rico MD, Martin-Borreguero P, Perez-Navero JL.Children With Autism Spectrum Disorder With Regression Exhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without Such Regression.FRONTIERS IN PEDIATRICS.2018.6.(.)-.DOI:10.3389/fped.2018.00264.;IF:2,335 Q2	GC20
IMIBIC Groups.GC18		IMIBIC Groups.GC23 ;GC20	
Mondejar-Guerra V, Garrido-Jurado S, Munoz-Salinas R, Marin-Jimenez MJ, Medina-Carnicer R.Robust identification of fiducial markers in challenging conditions.EXPERT SYSTEMS WITH APPLICATIONS.2018.93.(.)336-345.DOI:10.1016/j.eswa.2017.10.032.;IF:3,768 DQ1 D1	GC19	Perez-Duenas C, Rivas MF, Oyediran OA, Garcia-Torres F.Induced Negative Mood Increases Dictator Game Giving.FRONTIERS IN PSYCHOLOGY.2018.9.(.)-.DOI:10.3389/fpsyg.2018.01542.;IF:2,089 Q2	GC20
IMIBIC Groups.GC19		IMIBIC Groups.GE04 ;GC20	
Munoz-Salinas R, Marin-Jimenez MJ, Yeguas-Bolivar E, Medina-Carnicer R.Mapping and localization from planar markers.PATTERN RECOGNITION.2018.73.(.)158-171.DOI:10.1016/j.patcog.2017.08.010.;IF:3,962 Q1	GC19	Osuna-Luque J, Rodriguez-Ramos A, Gamez-del-Estal MD, Ruiz-Rubio M.Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole.JOURNAL OF EXPERIMENTAL NEUROSCIENCE.2018.12.(.)-.DOI:10.1177/1179069518798628.;IF:0 NO Q	GC20
IMIBIC Groups.GC19		IMIBIC Groups.GC20	
Romero-Ramirez FJ, Munoz-Salinas R, Medina-Carnicer R.Speded up detection of squared fiducial markers.IMAGE AND VISION COMPUTING.2018.76.(.)38-47.DOI:10.1016/j.imavis.2018.05.004.;IF:2,159 Q1	GC19	Jimenez-Romero S, Carrasco-Salas P, Benitez-Burraco A.Language and Cognitive Impairment Associated with a Novel p.Cys63Arg Change in the MED13L Transcriptional Regulator.MOLECULAR SYNDROMOLOGY.2018.9.(2).83-91.DOI:10.1159/000485638.;IF:0 NO Q	GC20
IMIBIC Groups.GC19		IMIBIC Groups.GC20	
Garrido-Castro JL, Curbelo R, Mazzucchelli R, Dominguez-Gonzalez ME, Gonzalez-Navas C, Robles BJB, Zarco P, Mulero J, Cea-Calvo L, Arteaga MJ, Font-Ugalde P, Carmona L, Collantes-Estevez E.High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis.JOURNAL OF RHEUMATOLOGY.2018.45.(10).1383-1388.DOI:10.3899/jrheum.170941.;IF:3,47 Q2	GC19	Miho H, Diez CM, Mena-Bravo A, de Medina VS, Moral J, Melliou E, Magiatis P, Rallo L, Barranco D, Priego-Capote F.Cultivar influence on variability in olive oil phenolic profiles determined through an extensive germplasm survey.FOOD CHEMISTRY.2018.266.(.)192-199.DOI:10.1016/j.foodchem.2018.06.002.;IF:4,946 DQ1 D1	GC21
IMIBIC Groups.GC05 ;GC19		IMIBIC Groups.GC21	
Marin-Jimenez MJ, Romero-Ramirez FJ, Munoz-Salinas R, Medina-Carnicer R.3D human pose estimation from depth maps using a deep combination of poses.JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION.2018.55.(.)627-639.DOI:10.1016/j.jvcir.2018.07.010.;IF:1,836 Q2	GC19	Ledesma-Escobar CA, Priego-Capote F, Olvera VJR, de Castro MDL.Targeted Analysis of the Concentration Changes of Phenolic Compounds in Persian Lime (Citrus latifolia) during Fruit Growth.JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2018.66.(8).1813-1820.DOI:10.1021/acs.jafc.7b05535.;IF:3,412 DQ1 D1	GC21
IMIBIC Groups.GC19		IMIBIC Groups.GC21	
Lopez-Medina C, Garrido-Castro JL, Castro-Jimenez J, Gonzalez-Navas C, Calvo-Gutierrez J, Castro-Villegas MC, Ortega-Castro R, Escudero-Contreras A, Font-Ugalde P, Collantes-Estevez E.Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage.CLINICAL RHEUMATOLOGY.2018.37.(6).1581-1588.DOI:10.1007/s10067-018-4112-4.;IF:2,141 Q3	GC19	IMIBIC Groups.GC21	
IMIBIC Groups.GC05 ;GC19		Tsolakou A, Diamantakos IP, Kalaboki I, Mena-Bravo A, Priego-Capote F, Abdallah IM, Kaddoumi A, Melliou E, Magiatis P.Oleocanthic Acid, a Chemical Marker of Olive Oil Aging and Exposure to a High Storage Temperature with Potential Neuroprotective Activity.JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2018.66.(28).7337-7346.DOI:10.1021/acs.jafc.8b00561.;IF:3,412 DQ1 D1	GC21
IMIBIC Groups.GC05 ;GC19		IMIBIC Groups.GC21	
Cano A, Yeguas-Bolivar E, Munoz-Salinas R, Medina-Carnicer R, Ventura S.Parallelization strategies for markerless human motion capture.JOURNAL OF REAL-TIME IMAGE PROCESSING.2018.14.(2).453-467.DOI:10.1007/s11554-014-0467-1.;IF:1,574 Q3	GC19	Moreno P, Jimenez-Jimenez C, Garrido-Rodriguez M, Calderon-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra A, Munoz E, Calzado MA.Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.MOLECULAR ONCOLOGY.2018.12.(10).1778-1796.DOI:10.1002/1878-0261.12369.;IF:5,264 Q1	GC21
IMIBIC Groups.GC25 ;GC19		IMIBIC Groups.GA01 ;GC04 ;GC21	
Garcia-Torres F, Castillo-Mayen R, Alos FJ.Psychoticism and employment status in breast cancer survivors.PSYCHO-ONCOLOGY.2018.27.(1).359-361.DOI:10.1002/pon.4417.;IF:3,455 DQ1 D1	GC20	Delgado-Povedano MM, Calderon-Santiago M, de Castro MDL, Priego-Capote F.Metabolomics analysis of human sweat collected after moderate exercise.TALANTA.2018.177.(.)47-65.DOI:10.1016/j.talanta.2017.09.028.;IF:4,244 Q1	GC21
IMIBIC Groups.GC20 ;GE04		IMIBIC Groups.GC21	
Gonzalez-Blanch C, Medrano LA, Munoz-Navarro R, Ruiz-Rodriguez P, Moriana JA, Limonero JT, Schmitz F, Cano-Vindel A.Factor structure and measurement invariance across various demographic groups and over time for the PHQ-9 in primary care patients in Spain.PLOS ONE.2018.13.(2).-.DOI:10.1371/journal.pone.0193356.;IF:2,766 Q1	GC20	Luque-Cordoba D, Calderon-Santiago M, de Castro MDL, Priego-Capote F.Study of sample preparation for determination of endocannabinoids and analogous compounds in human serum by LC-MS/MS in MRM mode.TALANTA.2018.185.(.)602-610.DOI:10.1016/j.talanta.2018.04.033.;IF:4,244 Q1	GC21
IMIBIC Groups.GC20		IMIBIC Groups.GC21	
Galvez-Lara M, Corpas J, Moreno E, Vencesla JF, Sanchez-Raya A, Moriana JA.Psychological Treatments for Mental Disorders in Children and Adolescents: A Review of the Evidence of Leading International Organizations.CLINICAL CHILD AND FAMILY PSYCHOLOGY REVIEW.2018.21.(3).366-387.DOI:10.1007/s10567-018-0257-6.;IF:3,6 Q1	GC20	Arguello H, Estelle J, Zaldivar-Lopez S, Jimenez-Marin A, Carvajal A, Lopez-Bascon MA, Crispie F, O'Sullivan O, Cotter PD, Priego-Capote F, Morera L, Garrido JJ.Early Salmonella Typhimurium infection in pigs disrupts Microbiome composition and functionality principally at the ileum mucosa.SCIENTIFIC REPORTS.2018.8.(.)-.DOI:10.1038/s41598-018-26083-3.;IF:4,122 Q1	GC21
IMIBIC Groups.GC20 ;Salud Mental		IMIBIC Groups.GC21	
Gonzalez-Blanch C, Hernandez-de-Hita F, Munoz-Navarro R, Ruiz-Rodriguez P, Medrano LA, Moriana JA, Cano-Vindel A.Domain-specific associations between disability and depression, anxiety, and somatization in primary care patients.PSYCHIATRY RESEARCH.2018.269.(.)596-601.DOI:10.1016/j.psychres.2018.09.007.;IF:2,223 Q2	GC20	Lope V, Castello A, Mena-Bravo A, Amiano P, Aragones N, Fernandez-Villa T, Guevara M, Dierssen-Sotos T, Fernandez-Tardon G, Castano-Vinyals G, Marcos-Gragera R, Moreno V, Salas-Trejo D, Diaz-Santos M, Oribe M, Romieu I, Kogevinas M, Priego-Capote F, Perez-Gomez B, Pollan M.Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain).JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.2018.182.(.)4-13.DOI:10.1016/j.jsbmb.2018.04.005.;IF:4,095 Q1	GC21
IMIBIC Groups.GC20		IMIBIC Groups.GC21	



Rallo L, Diez CM, Morales-Sillero A, Miho H, Priego-Capote F, Rallo P. Quality of olives: A focus on agricultural preharvest factors. <i>SCIENTIA HORTICULTURAE</i> . 2018. 233. (.) 491-509. DOI:10.1016/j.scienta.2017.12.034.;IF:1,76 Q1	GC21	Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, Heron B, Geraci S, Ardigo D, Cattaneo F, Fogh J, Van den Hout JMH, Beck M, Jones SA, Tytki-Szymanska A, Haugsted U, Lund AM. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. <i>JOURNAL OF INHERITED METABOLIC DISEASE</i> . 2018. 41. (6). 1215-1223. DOI:10.1007/s10545-018-0185-0.;IF:4,092 Q1	GC23
IMIBIC Groups.GC21		IMIBIC Groups.GC23	
Lopez-Bascon MA, Calderon-Santiago M, Sanchez-Ceinos J, Fernandez-Vega A, Guzman-Ruiz R, Lopez-Miranda J, Malagon MM, Priego-Capote F. Influence of sample preparation on lipidomics analysis of polar lipids in adipose tissue. <i>TALANTA</i> . 2018. 177. (.) 86-93. DOI:10.1016/j.talanta.2017.09.017.;IF:4,244 Q1	GC21	Ruperez AI, Olza J, Gil-Campos M, Leis R, Bueno G, Aguilera CM, Gil A, Moreno LA. Cardiovascular risk biomarkers and metabolically unhealthy status in prepubertal children: Comparison of definitions. <i>NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES</i> . 2018. 28. (5). 524-530. DOI:10.1016/j.numecd.2018.02.006.;IF:3,318 Q2	GC23
IMIBIC Groups.GC21 ;GC11 ;GC09		IMIBIC Groups.GC23	
de Castro MDL, Priego-Capote F. The analytical process to search for metabolomics biomarkers. <i>JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS</i> . 2018. 147. (.) 341-349. DOI:10.1016/j.jpba.2017.06.073.;IF:2,831 Q2	GC21	Barja-Fernandez S, Aguilera CM, Martinez-Silva I, Vazquez R, Gil-Campos M, Olza J, Bedoya J, Cadarso-Suarez C, Gil A, Seoane LM, Leis R. 25-Hydroxyvitamin D levels of children are inversely related to adiposity assessed by body mass index. <i>JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY</i> . 2018. 74. (1). 111-118. DOI:10.1007/s13105-017-0581-1.;IF:2,736 Q2	GC23
IMIBIC Groups.GC21		IMIBIC Groups.GC23	
Garcia-Valverde MT, Ledesma-Escobar CA, Lucena R, Cardenas S. Tunable Polarity Carbon Fibers, a Holistic Approach to Environmental Protection. <i>MOLECULES</i> . 2018. 23. (5) -. DOI:10.3390/molecules23051026.;IF:3,098 Q2	GC21	Tofe I, Ruiz-Gonzalez MD, Canete MD, Pino A, Rueda RL, Parraga MJ, Perez-Navero JL. Efficacy of Paracetamol in Closure of Ductus Arteriosus in Infants under 32 Weeks of Gestation. <i>FRONTIERS IN PEDIATRICS</i> . 2018. 6. (.) -. DOI:10.3389/fped.2018.DDN5.;IF:2,335 Q2	GC23
IMIBIC Groups.GC21		IMIBIC Groups.GC23 ;GA05 ;Pediatria	
Jimenez-Munguia I, Calderon-Santiago M, Rodriguez-Franco A, Priego-Capote F, Rodriguez-Ortega MJ. Multi-omic profiling to assess the effect of iron starvation in <i>Streptococcus pneumoniae</i> TIGR4. <i>PEERJ</i> . 2018. 6. (.) -. DOI:10.7717/peerj.4966.;IF:2,118 Q2	GC21	Gomez-Fernandez A, de la Torre-Aguilar MJ, Gil-Campos M, Flores-Rojas K, Cruz-Rico MD, Martin-Borreguero P, Perez-Navero JL. Children With Autism Spectrum Disorder With Regression Exhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without Such Regression. <i>FRONTIERS IN PEDIATRICS</i> . 2018. 6. (.) -. DOI:10.3389/fped.2018.00264.;IF:2,335 Q2	GC23
IMIBIC Groups.GC21		IMIBIC Groups.GC23 ;GC20	
Ledesma-Escobar CA, Luque de Castro MD. Citrus coumarins and their healthy properties. In <i>Phytochemicals in Citrus. Applications in functional foods...</i> (.) -. DOI:.;IF:	GC21	Sancho AL, Atance EP, Martin MJR, Gil-Campos M, Trabazo RL, Curieses MPB, Lozano GB. Spanish collaborative study: Description of usual clinical practice in infant obesity. <i>ANALES DE PEDIATRIA</i> . 2018. 88. (6). 340-349. DOI:10.1016/j.anpedi.2017.07.008.;IF:1,318 Q3	GC23
IMIBIC Groups.GC21		IMIBIC Groups.GC23	
Martinez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jerez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibanez M, Sempere A, Sanz MA, Lo-Coco F, Sanchez-Garcia J. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. <i>HAEMATOLOGICA</i> . 2018. 103. (9). E400-E403. DOI:10.3324/haematol.2018.188433.;IF:9,09 DQ1 D1	GC22	Perez-Garcia C, Jimenez ABA, Lozano LC, Morano CD. Importance of the exhaustive anamnesis to an unexplained unilateral gynecomastia in a child. <i>ARCHIVOS ARGENTINOS DE PEDIATRIA</i> . 2018. 116. (5). E655-E658. DOI:10.5546/aap.2018.e655.;IF:0,405 Q4	GC23
IMIBIC Groups.GC16 ;GC22		IMIBIC Groups.GC23	
Barbado C, Cordoba-Canero D, Arizaa RR, Roldan-Arjona T. Nonenzymatic release of N7-methylguanine channels repair of abasic sites into an AP endonuclease-independent pathway in <i>Arabidopsis</i> . <i>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA</i> . 2018. 115. (5). E916-E924. DOI:10.1073/pnas.1719497115.;IF:9,504 DQ1 D1	GC22	Gascon-Jimenez FJ, Gallardo-Hernandez FL, Fernandez-Ramos JA, Aguilar-Quintero M, Camino-Leon R, Lopez-Laso E. Hereditary primary microcephaly of type 5. Not everything is Zika virus. <i>REVISTA DE NEUROLOGIA</i> . 2018. 66. (3). 101-102. DOI:No consta.;IF:0,601 Q4	GC23
IMIBIC Groups.GC22		IMIBIC Groups.GC23 ;Hospital Montilla ;Hospital Infanta Margarita Cabra	
Morales-Ruiz T, Garcia-Ortiz MV, Devesa-Guerra I, Raya-Ruiz L, Tejedor JR, Bayon GF, Sierra MI, Fraga MF, Ariza RR, Roldan-Arjona T. DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase. <i>EPIGENETICS</i> . 2018. 13. (1). 95-107. DOI:10.1080/15592294.2017.1414128.;IF:4,918 Q1	GC22	Sancho-Montero N, Fernandez-Ramos JA, Caballero-Rodriguez C, Camino-Leon R, Lopez-Laso E. Multiple cranial neuropathy: a case report of three paediatric patients. <i>REVISTA DE NEUROLOGIA</i> . 2018. 67. (8). 321-323. DOI:.;IF:0,601 Q4	GC23
IMIBIC Groups.GC22		IMIBIC Groups.GC23	
Morales-Ruiz T, Romero-Valenzuela AC, Vazquez-Grande VM, Roldan-Arjona T, Ariza RR, Cordoba-Canero D. Monitoring base excision repair in <i>Chlamydomonas reinhardtii</i> cell extracts. <i>DNA REPAIR</i> . 2018. 65. (.) 34-41. DOI:10.1016/j.dnarep.2018.02.011.;IF:4,461 Q1	GC22	Amat T, Gutierrez-Pizarra A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>CLINICAL MICROBIOLOGY AND INFECTION</i> . 2018. 24. (6). 630-634. DOI:10.1016/j.cmi.2017.09.016.;IF:5,394 DQ1 D1	GC24
IMIBIC Groups.GC22		IMIBIC Groups.GC03 ;GC24 ;GC26	
Patino, B (Patino, Belen)[1] ; Vazquez, C (Vazquez, Covadonga)[1] ; Manning, JM (Manning, James M.)[2] ; Roncero, MIG (Roncero, Maria Isabel G.)[3,4] ; Cordoba-Canero, D (Cordoba-Canero, Dolores)[3,4] ; Di Pietro, A (Di Pietro, Antonio)[3,4] ; Martinez-del-Pozo, A (Martinez-del-Pozo, Alvaro)[5] . Characterization of a novel cysteine-rich antifungal protein from <i>Fusarium graminearum</i> with activity against maize fungal pathogens. <i>INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY</i> . 2018. (.) -. DOI:.;IF:3,451 Q1	GC22	Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J. Risks of Infection and Mortality Among Patients Colonized With <i>Klebsiella pneumoniae</i> Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. <i>CLINICAL INFECTIOUS DISEASES</i> . 2018. 66. (8). 1204-1210. DOI:10.1093/cid/cix991.;IF:9,117 DQ1 D1	GC24
IMIBIC Groups.GC22		IMIBIC Groups.GC03 ;GC24	
Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. <i>NUTRIENTS</i> . 2018. 10. (1) -. DOI:10.3390/nu10010042.;IF:4,196 Q1	GC23	Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadiis J, Botterel F, Bustamante B, Chen YC, Chakrabarti A, Chowdhary A, Chryssanthou E, Cordoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Flörl C, Linares-Sicilia MJ, Martin-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM. Posaconazole MIC Distributions for <i>Aspergillus fumigatus</i> Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values. <i>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY</i> . 2018. 62. (4) -. DOI:10.1128/AAC.01916-17.;IF:4,255 Q1	GC24
IMIBIC Groups.GC23		IMIBIC Groups.GC24	
Lund AM, Borgwardt L, Cattaneo F, Ardigo D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tytki-Szymanska A, Lopez-Rodriguez M, Guillen-Navarro E, Dali CI, Heron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. <i>JOURNAL OF INHERITED METABOLIC DISEASE</i> . 2018. 41. (6). 1225-1233. DOI:10.1007/s10545-018-0175-2.;IF:4,092 Q1	GC23		
IMIBIC Groups.GC23			



Hamzaoui Z, Ocampo-Sosa A, Martinez MF, Landolsi S, Ferjani S, Maamar E, Saidani M, Slim A, Martinez-Martinez L, Boutiba-Ben Boubaker I. Role of association of OmpK35 and OmpK36 alteration and bla(ESBL) and/or bla(AmpC) genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2018.52.(6).898-905. DOI:10.1016/j.ijantimicag.2018.03.020.;IF:4,253 Q1	GC24	Aguado JM, Silva JT, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C, Martinez-Martinez L, Vidal E, Almenar L, Almirante B, Canton R, Carratala J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernandez J, Farinas MC, Gavalda J, Goyanes MJ, Gutierrez-Gutierrez B, Hernandez D, Len O, Lopez-Andujar R, Lopez-Medrano F, Martin-Davila P, Montejo M, Moreno A, Oliver A, Pascual A, Perez-Nadales E, Roman-Broto A, San-Juan R, Seron D, Sole-Jover A, Valerio M, Munoz P, Torre-Cisneros J. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIP recommendations. TRANSPLANTATION REVIEWS. 2018.32.(1).36-57. DOI:10.1016/j.ttre.2017.07.001.;IF:2,364 Q3	GC24
IMIBIC Groups.GC24		IMIBIC Groups.GC24 ;GC03	
Lopez M, Rueda A, Florido JP, Blasco L, Fernandez-Garcia L, Trastoy R, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Pascual A, Bou G, Tomas M. Evolution of the Quorum network and the mobilome (plasmids and bacteriophages) in clinical strains of Acinetobacter baumannii during a decade. SCIENTIFIC REPORTS. 2018.8.(.). DOI:10.1038/s41598-018-20847-7.;IF:4,122 Q1	GC24	Gutierrez-Aroca JB, Ruiz P, Vaquero M, Causse M, Casal M. Surveillance of Drug-Resistant Tuberculosis in Spain (2001-2015). MICROBIAL DRUG RESISTANCE. 2018.24.(6).839-843. DOI:10.1089/mdr.2017.0353.;IF:2,344 Q3	GC24
IMIBIC Groups.GC24		IMIBIC Groups.GC24 ;GC12	
Zboromyrska Y, Bosch J, Aramburu J, Cuadros J, Garcia-Riestra C, Guzman-Puche J, Martos CL, Loza E, Munoz-Algarra M, de Alegria CR, Sanchez-Hellin V, Vila JA multicentre study investigating parameters which influence direct bacterial identification from urine. PLOS ONE. 2018.13.(12). DOI:10.1371/journal.pone.0207822.;IF:2,766 Q1	GC24	Gutierrez-Aroca JB, Ruiz-Martinez P, Rodriguez-Ruiz L, Casal-Roman M. Distribution of hepatitis C genotypes in the city of Cordoba. REVISTA ESPANOLA DE QUIMIOTERAPIA. 2018.31.(2).164-165. DOI:10.1016/j.re.2017.07.001.;IF:0,605 Q4	GC24
IMIBIC Groups.GC24		IMIBIC Groups.GC24	
Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menendez O, Ayats J, Castro C, Garcia-Rodriguez J, Goterris-Bonet L, Ibanez-Martinez E, Linares-Sicilia MJ, Martin-Gomez MT, Martin-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Anza DV, Vinuelas J, Zapico MS, Cuenca-Estrella M. Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2018.62.(9). DOI:10.1128/AAC.00358-18.;IF:4,255 Q1	GC24	Luna JM, Padillo F, Pechenizkiy M, Ventura S. Apriori Versions Based on MapReduce for Mining Frequent Patterns on Big Data. IEEE TRANSACTIONS ON CYBERNETICS. 2018.48.(10).2851-2865. DOI:10.1109/TCYB.2017.2751081.;IF:8,803 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Garcia-Castillo M, Garcia-Fernandez S, Gomez-Gil R, Pitart C, Oviano M, Gracia-Ahufinger I, Diaz-Reganon J, Tato M, Canton R. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2018.51.(3).511-515. DOI:10.1016/j.ijantimicag.2018.01.011.;IF:4,253 Q1	GC24	Luna JM, Pechenizkiy M, del Jesus MJ, Ventura S. Mining Context-Aware Association Rules Using Grammar-Based Genetic Programming. IEEE TRANSACTIONS ON CYBERNETICS. 2018.48.(11).3030-3044. DOI:10.1109/TCYB.2017.2750919.;IF:8,803 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Aguirre-Quinonero A, del Molino ICP, de la Fuente CG, Sanjuan MC, Aguero J, Martinez-Martinez L. Phenotypic detection of clinical isolates of Haemophilus influenzae with altered penicillin-binding protein 3. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2018.37.(8).1475-1480. DOI:10.1007/s10096-018-3273-z.;IF:2,537 Q2	GC24	Moyano JM, Gibaja EL, Cios KJ, Ventura S. Review of ensembles of multi-label classifiers: Models, experimental study and prospects. INFORMATION FUSION. 2018.44.(.).33-45. DOI:10.1016/j.inffus.2017.12.001.;IF:6,639 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Fernandez-Garcia L, Ambroa A, Blasco L, Blierot I, Lopez M, Alvarez-Marin R, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Rodriguez-Bano J, Gamacho-Montero J, Cisneros JM, Pascual A, Pachon J, Bou G, Smani Y, Tomas M. Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A-baumannii. FRONTIERS IN MICROBIOLOGY. 2018.9.(.). DOI:10.3389/fmicb.2018.03105.;IF:4,019 Q2	GC24	Ramirez A, Romero JR, Ventura S. Interactive multi-objective evolutionary optimization of software architectures. INFORMATION SCIENCES. 2018.463.(.).92-109. DOI:10.1016/j.ins.2018.06.034.;IF:4,305 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Cerezales M, Ocampo-Sosa AA, Montes LA, Rios CD, Bustamante Z, Santos J, Martinez-Martinez L, Higgins PG, Gallego L. High Prevalence of Extensively Drug-resistant Acinetobacter baumannii at a Children Hospital in Bolivia. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2018.37.(11).1118-1123. DOI:10.1097/INF.0000000000001962.;IF:2,305 Q2	GC24	Reyes O, Fardoun HM, Ventura S. An ensemble-based method for the selection of instances in the multi-target regression problem. INTEGRATED COMPUTER-AIDED ENGINEERING. 2018.25.(4).305-320. DOI:10.3233/ICA-180581.;IF:3,667 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Fernandez-Martinez M, del Castillo BR, Lecea-Cuello MJ, Rodriguez-Bano J, Pascual A, Martinez-Martinez L. Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum Lactamases Collected in Two Multicenter Studies in Spain. MICROBIAL DRUG RESISTANCE. 2018.24.(4).367-376. DOI:10.1089/mdr.2017.0102.;IF:2,344 Q3	GC24	Gonzalez-Lopez J, Ventura S, Cano A. Distributed nearest neighbor classification for large-scale multi-label data on spark. FUTURE GENERATION COMPUTER SYSTEMS-THE INTERNATIONAL JOURNAL OF ESCIENCE. 2018.87.(.).66-82. DOI:10.1016/j.future.2018.04.094.;IF:4,639 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
Cercenado E, Canton R, Ramirez MG, Mansilla CA, Ahufinger IG, Ramirez MG, Alarcon JM. Procedures in Clinical Microbiology (number 15.(a), 2nd edition 2018). ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018.36.(9).603-603. DOI:10.1016/j.eimc.2018.06.010.;IF:1,717 Q3	GC24	Gahete MD, del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alois-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Pérez-Martínez P, Castano JP, López-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBIO MEDICINE. 2018.37.(.).356-365. DOI:10.1016/j.ebiom.2018.10.056.;IF:6,183 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC27 ;GC25 ;GC08 ;GC09	
Rodriguez-Lozano J, de Malet A, Cano ME, de la Rubia L, Wallmann R, Martinez-Martinez L, Calvo J. Antimicrobial susceptibility of microorganisms that cause urinary tract infections in pediatric patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018.36.(7).417-422. DOI:10.1016/j.eimc.2017.08.003.;IF:1,707 Q3	GC24	Padillo F, Luna JM, Herrera F, Ventura S. Mining association rules on Big Data through MapReduce genetic programming. INTEGRATED COMPUTER-AIDED ENGINEERING. 2018.25.(1).31-48. DOI:10.3233/ICA-170555.;IF:3,667 DQ1 D1	GC25
IMIBIC Groups.GC24		IMIBIC Groups.GC25	
		Reyes O, Altalhi AH, Ventura S. Statistical comparisons of active learning strategies over multiple datasets. KNOWLEDGE-BASED SYSTEMS. 2018.145.(.).274-288. DOI:10.1016/j.knosys.2018.01.033.;IF:4,396 Q1	GC25
		IMIBIC Groups.GC25	
		Melki G, Cano A, Ventura S. MIRSVM: Multi-instance support vector machine with bag representatives. PATTERN RECOGNITION. 2018.79.(.).228-241. DOI:10.1016/j.patcog.2018.02.007.;IF:3,962 Q1	GC25
		IMIBIC Groups.GC25	
		Reyes O, Morell C, Ventura S. Effective active learning strategy for multi-label learning. NEUROCOMPUTING. 2018.273.(.).494-508. DOI:10.1016/j.neucom.2017.08.001.;IF:3,241 Q1	GC25
		IMIBIC Groups.GC25	



Reyes O, Ventura S. Evolutionary Strategy to Perform Batch-Mode Active Learning on Multi-Label Data. <i>ACM TRANSACTIONS ON INTELLIGENT SYSTEMS AND TECHNOLOGY</i> .2018.9.(4).-DOI:10.1145/3161606.;IF:2,973 Q1	GC25	Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Risalde MA, Brieva T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. <i>ZOOZOOSES AND PUBLIC HEALTH</i> .2018.65.(5).584-588. DOI:10.1111/zph.12472.;IF:2,688 DQ1 D1	GC26
IMIBIC Groups.GC25		IMIBIC Groups.GC26 ;GA06	
Melki G, Kecman V, Ventura S, Cano A. OLLAWV: OnLine Learning Algorithm using Worst-Violators. <i>APPLIED SOFT COMPUTING</i> .2018.66.(.)384-393. DOI:10.1016/j.asoc.2018.02.040.;IF:3,907 Q1	GC25	Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(11).1218-1219. DOI:10.1016/j.cmi.2018.06.030.;IF:5,394 DQ1 D1	GC26
IMIBIC Groups.GC25		IMIBIC Groups.GC26 ;GC03 ;Anatomía Patológica; GC02 ;GC18	
Guerrero-Enamorado A, Morell C, Ventura S. A gene expression programming algorithm for discovering classification rules in the multi-objective space. <i>INTERNATIONAL JOURNAL OF COMPUTATIONAL INTELLIGENCE SYSTEMS</i> .2018.11.(1).540-559. DOI:.;IF:2 Q2	GC25	Merchante N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, Macias J, Miralles P, Jimenez-Sousa MA, Mancebo M, Perez-Latorre L, Pineda-Tenor D, Berenguer J, Resino S, Pineda JA. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>JOURNAL OF VIRAL HEPATITIS</i> .2018.25.(2).180-186. DOI:10.1111/jvh.12769.;IF:4,237 Q1	GC26
IMIBIC Groups.GC25		IMIBIC Groups.GC03 ;GC26	
Reyes O, Cano A, Fardoun HM, Ventura S. A locally weighted learning method based on a data gravitation model for multi-target regression. <i>INTERNATIONAL JOURNAL OF COMPUTATIONAL INTELLIGENCE SYSTEMS</i> .2018.11.(1).282-295. DOI:.;IF:2 Q2	GC25	Rivero-Juarez A, Risalde MA, Frias M, Garcia-Bocanegra I, Lopez-Lopez P, Cano-Terriza D, Camacho A, Jimenez-Ruiz S, Gomez-Villamandos JC, Rivero A. Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?. <i>BMC VETERINARY RESEARCH</i> .2018.14.(.)-. DOI:10.1186/s12917-018-1377-4.;IF:1,958 Q1	GC26
IMIBIC Groups.GC25		IMIBIC Groups.GC26	
Bogarin A, Cerezo R, Romero C. A survey on educational process mining. <i>WILEY INTERDISCIPLINARY REVIEWS-DATA MINING AND KNOWLEDGE DISCOVERY</i> .2018.8.(1).-DOI:10.1002/widm.1230.;IF:1,939 Q2	GC25	Cuyper L, Perez AB, Chueca N, Aldamiz-Echevarria T, Alados JC, Martinez-Sapina AM, Merino D, Pineda JA, Tellez F, Espinosa N, Salmeron J, Rivero-Juarez A, Vivancos MJ, Hontanon V, Vandamme AM, Garcia F. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelling by phylogenetic analysis. <i>PLOS ONE</i> .2018.13.(7).-DOI:10.1371/journal.pone.0201268.;IF:2,766 Q1	GC26
IMIBIC Groups.GC25		IMIBIC Groups.GC26	
Cano A, Yeguas-Bolivar E, Munoz-Salinas R, Medina-Carnicer R, Ventura S. Parallelization strategies for markerless human motion capture. <i>JOURNAL OF REAL-TIME IMAGE PROCESSING</i> .2018.14.(2).453-467. DOI:10.1007/s11554-014-0467-1.;IF:1,574 Q3	GC25	Roy A, Risalde MA, Bezos J, Casal C, Romero B, Sevilla I, Diez-Guerrero A, Rodriguez-Bertos A, Dominguez M, Garrido J, Gortazar C, Dominguez L. Response of goats to intramuscular vaccination with heat-killed <i>Mycobacterium bovis</i> and natural challenge. <i>COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES</i> .2018.60.(.)28-34. DOI:10.1016/j.cimid.2018.09.006.;IF:1,92 Q1	GC26
IMIBIC Groups.GC25 ;GC19		IMIBIC Groups.GC26	
Amat T, Gutierrez-Pizarra A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(6).630-634. DOI:10.1016/j.cmi.2017.09.016.;IF:5,394 DQ1 D1	GC26	Merchante N, Rodriguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, Garcia-Deltoro M, Rivero-Juarez A, Tellez F, Delgado-Fernandez M, Rios-Villegas MJ, Garcia MA, Vera-Mendez FJ, Ojeda-Burgos G, Lopez-Ruz MA, Metola L, Omar M, Aleman-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macias J, Pineda JA. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. <i>AIDS</i> .2018.32.(11).1423-1430. DOI:10.1097/QAD.0000000000001809.;IF:4,914 Q1	GC26
IMIBIC Groups.GC03 ;GC24 ;GC26		IMIBIC Groups.GC26	
Lopez-Lopez P, Risalde MD, Frias M, Garcia-Bocanegra I, Brieva T, Caballero-Gomez J, Camacho A, Fernandez-Molera V, Machuca I, Gomez-Villamandos JC, Rivero A, Rivero-Juarez A. Risk factors associated with hepatitis E virus in pigs from different production systems. <i>VETERINARY MICROBIOLOGY</i> .2018.224.(.)88-92. DOI:10.1016/j.vetmic.2018.08.020.;IF:2,525 DQ1 D1	GC26	Frias M, Rivero-Juarez A, Rodriguez-Cano D, Camacho A, Lopez-Lopez P, Risalde MA, Manzanares-Martin B, Brieva T, Machuca I, Rivero A. HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. <i>SCIENTIFIC REPORTS</i> .2018.8.(.)-. DOI:10.1038/s41598-017-17531-7.;IF:4,122 Q1	GC26
IMIBIC Groups.GC26		IMIBIC Groups.GC26 ;GC01	
Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, Amado LEM, Morillas RM, Forns X, Acevedo JMP, Andrade RJ, Rivero A, Carrion JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang GL, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>GASTROENTEROLOGY</i> .2018.155.(4).1120-1127. DOI:10.1053/j.gastro.2018.06.042.;IF:20,773 DQ1 D1	GC26	Rivero-Juarez A, Camacho A, Brieva T, Frias M, Lopez-Lopez P, Risalde MA, Machuca I, Caston JJ, Martinez-Peinado A, Rivero A. Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. <i>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</i> .2018.78.(4).437-440. DOI:10.1097/QAI.0000000000001691.;IF:4,116 Q1	GC26
IMIBIC Groups.GC26		IMIBIC Groups.GC26 ;GC03	
Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. <i>CLINICAL MICROBIOLOGY REVIEWS</i> .2018.31.(2).-DOI:10.1128/CMR.00079-17.;IF:20,642 DQ1 D1	GC26	Berenguer J, Jarrin I, Perez-Latorre L, Hontanon V, Vivancos MJ, Navarro J, Tellez MJ, Guardiola JM, Iribarren JA, Rivero-Juarez A, Marquez M, Artero A, Morano L, Santos I, Moreno J, Farinas MC, Galindo MJ, Hernando MA, Montero M, Cifuentes C, Domingo P, Sanz J, Dominguez L, Ferrero OL, De la Fuente B, Rodriguez C, Reus S, Hernandez-Quero J, Gaspar G, Perez-Martinez L, Garcia C, Force L, Veloso S, Losa JE, Vilaro J, Bernal E, Arponen S, Orti AJ, Chocarro A, Teira R, Alonso G, Silvarino R, Vegas A, Geijo P, Bisbe J, Esteban H, Gonzalez-Garcia J. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>OPEN FORUM INFECTIOUS DISEASES</i> .2018.5.(1).-DOI:10.1093/ofid/ofx258.;IF:3,24 Q2	GC26
IMIBIC Groups.GC26		IMIBIC Groups.GC26	
Perez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Marino A, Crespo M, Hernandez-Quero J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Perez-Molina JA. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. <i>JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY</i> .2018.73.(9).2444-2451. DOI:10.1093/jac/dky212.;IF:5,217 DQ1 D1	GC26	Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. <i>EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY</i> .2018.14.(9).901-910. DOI:10.1080/17425255.2018.1506765.;IF:3,151 Q2	GC26
IMIBIC Groups.GC26		IMIBIC Groups.GC26	
Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Villalobos M, Omar M, Rincon P, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Palacios R, Gomez-Vidal MA, Macias J, Pineda JA. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY</i> .2018.73.(9).2435-2443. DOI:10.1093/jac/dky234.;IF:5,217 DQ1 D1	GC26	Frias M, Lopez-Lopez P, Rivero A, Rivero-Juarez A. Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure. <i>BIOMED RESEARCH INTERNATIONAL</i> .2018.(.)-. DOI:10.1155/2018/9098535;9098535.;IF:2,583 Q2	GC26
IMIBIC Groups.GC26		IMIBIC Groups.GC26	



Frias M, Rivero-Juarez A, Lopez-Lopez P, Rivero A.Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.PHARMACOGENOMICS.2018.19.(12).979-995.DOI:10.2217/pgs-2018-0046.;IF:2,302 Q3	GC26	Jimenez-Lucena R, Camargo A, Alcalá-Díaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Rangel-Zuniga OA, Lopez-Miranda J.A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. EXPERIMENTAL AND MOLECULAR MEDICINE.2018.50.(.).-DOI:10.1038/s12276-018-0194-y.;IF:5,584 Q1	GC27
IMIBIC Groups.GC26		IMIBIC Groups.GC09 ;GC27	
Rivero A, Perez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lazaro P, Lopez-Aldeguer J, Lozano F, Martinez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM.Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA.2018.36.(5).268-276.DOI:10.1016/j.eimc.2017.04.002.;IF:1,707 Q3	GC26	Coelho MCA, Vasquez ML, Wildemberg LE, Vazquez-Borrego MC, Bitana L, Camacho AHD, Silva D, Ogino LL, Ventura N, Chimelli L, Luque RM, Kasuki L, Gadelha MR.Molecular evidence and clinical importance of beta-arrestins expression in patients with acromegaly.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(4).2110-2116.DOI:10.1111/jcmm.13427.;IF:4,302 Q1	GC27
IMIBIC Groups.GC26		IMIBIC Groups.GC27	
Rivero A, Polo R, Aldeguer JL, Lozano F, Antela A, Arribas JR, Asensi V, Berenguer J, Blanco JR, Casado JL, Clotet B, Crespo M, Domingo P, Duenas C, Gatell JM, Gomez-Sirvent JL, Gonzalez-Garcia J, Iribarren JA, de Quiros JCLB, Cortes LFL, Losa JE, Mallolas J, Marino A, Martinez E, Miro JM, Moreno S, Palacios R, Pasquau J, Pineda JA, Podzamczar D, Portilla J, Poveda E, Pulido F, Rubio R, Santos J, Moreno JS, Sanz JS, Tellez MJ, de la Torre J, Tuset M, Molina JAP.Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017).ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA.2018.36.(7).435-445. DOI:10.1016/j.eimc.2017.04.001.;IF:1,707 Q3	GC26	Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM.Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(11).5688-5697.DOI:10.1111/jcmm.13845.;IF:4,302 Q1	GC27
IMIBIC Groups.GC26		IMIBIC Groups.GC27 ;GC08 ;GE05; GC09 ;U Innovación Metodología Imibic; Anatomía Patológica	
Machuca I, Vidal E, de la Torre-Cisneros J, Rivero-Roman A.Tuberculosis in immunosuppressed patients.ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA.2018.36.(6).366-374.DOI:10.1016/j.eimc.2017.10.009.;IF:1,707 Q3	GC26	Vazquez-Borrego MC, Gahete MD, Martinez-Fuentes AJ, Fuentes-Fayos AC, Castano JP, Kineman RD, Luque RM.Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: Lessons from human and non-human primate models.MOLECULAR AND CELLULAR ENDOCRINOLOGY.2018.463.(C).4-22.DOI:10.1016/j.mce.2017.12.007.;IF:3,563 Q2	GC27
IMIBIC Groups.GC26 ;GC03		IMIBIC Groups.GC08 ;GC27	
Pineda JA, Rivero-Juarez A, de los Santos I, Collado A, Merino D, Morano-Amado LE, Rios MJ, Perez-Perez M, Tellez F, Palacios R, Perez AB, Mancebo M, Rivero A, Macias J.Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.HIV CLINICAL TRIALS.2018.19.(1).23-30.DOI:10.1080/15284336.2018.1436637.;IF:1,379 Q4	GC26	Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP.Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.ENDOCRINE.2018.59.(2).426-437.DOI:10.1007/s12020-017-1482-3.;IF:3,179 Q2	GC27
IMIBIC Groups.GC26		IMIBIC Groups.GC08 ;GA04 ;Anatomía Patológica; GC14 ;Oncología Medica; GC27	
Leon-Gonzalez AJ, Navarro I, Acero N, Mingarro DM, Martin-Cordero C.Genus Retama: a review on traditional uses, phytochemistry, and pharmacological activities.PHYTOCHEMISTRY REVIEWS.2018.17.(4)SI.701-731.DOI:10.1007/s11101-018-9555-3.;IF:3,875 DQ1 D1	GC27	Luque RM, Kineman RD.Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin.JOURNAL OF ENDOCRINOLOGY.2018.237.(3).217-227.DOI:10.1530/JOE-18-0135.;IF:4,012 Q2	GC27
IMIBIC Groups.GC27		IMIBIC Groups.GC27	
Vazquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castano JP, Kineman RD, Luque RM.The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions.CELLULAR PHYSIOLOGY AND BIOCHEMISTRY.2018.49.(4).1444-1459.DOI:10.1159/000493448.;IF:5,5 DQ1 D1	GC27	Cordoba-Chacon J, Sarmiento-Cabral A, del Rio-Moreno M, Diaz-Ruiz A, Subbaiah PV, Kineman RD.Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.ENDOCRINOLOGY.2018.159.(11).3761-3774.DOI:10.1210/en.2018-00669.;IF:3,961 Q2	GC27
IMIBIC Groups.GC27 ;GC08		IMIBIC Groups.GC27	
Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martinez-Fuentes AJ, Galvez-Moreno MA, Castano JP, Luque RM.Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY.2018.9.(.).-DOI:10.1038/s41424-018-0058-8.;IF:4,621 DQ1 D1	GC27	Gomez EG, Rosa JV, Valiente JC, Tarradas FT, Curado FA, Ruiz DL, Tapia MJR.New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.UROLOGY.2018.121.(.).198-199.DOI:10.1016/j.urology.2017.08.027.;IF:2,3 Q2	GC27
IMIBIC Groups.GC27 ;GC08 ;GA04; Anatomía Patológica ;Oncología Médica		IMIBIC Groups.GC27 ;GE05 ;GA08	
Gahete MD, del Rio-Moreno M, Camargo A, Alcalá-Díaz JF, Alois-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martinez P, Castano JP, Lopez-Miranda J, Luque RM.Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study.EBIOMEDICINE.2018.37.(.).356-365.DOI:10.1016/j.ebiom.2018.10.056.;IF:6,183 DQ1 D1	GC27	Salamanca-Bustos JJ, Gomez-Gomez E, Campos-Hernandez JP, Carrasco-Valiente J, Ruiz-Garcia J, Marquez-Lopez FJ, Zurera-Tendero L, Requena-Tapia MJ.Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients.TRANSPLANTATION PROCEEDINGS.2018.50.(2).587-590.DOI:10.1016/j.transproceed.2017.09.048.;IF:0,806 Q4	GC27
IMIBIC Groups.GC27 ;GC25 ;GC08; GC09		IMIBIC Groups.GE05 ;GC27 ;Radiodiagnóstico	
Rincon-Fernandez D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castano JP.In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.CARCINOGENESIS.2018.39.(3).447-457. DOI:10.1093/carcin/bgx146.;IF:2,072 Q1	GC27	Postigo-Alonso B, Galvao-Carmona A, Benitez I, Conde-Gavilan C, Jover A, Molina S, Pena-Toledo MA, Aguera E.Cognitive-motor interference during gait in patients with Multiple Sclerosis: a mixed methods Systematic Review.NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS.2018.94.(.).126-148.DOI:10.1016/j.neubiorev.2018.08.016.;IF:8,037 DQ1 D1	GE01
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GE01 ;Neurología	
Alhambra-Exposito MR, Ibanez-Costa A, Moreno-Moreno P, Rivero-Cortes E, Vazquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado A, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castano JP, Galvez MA, Luque RM.Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.SCIENTIFIC REPORTS.2018.8.(.).-DOI:10.1038/s41598-018-24260-y.;IF:4,122 Q1	GC27	Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunes I.Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects.JOURNAL OF FUNCTIONAL FOODS.2018.42.(.).281-288.DOI:10.1016/j.jff.2017.12.068.;IF:3,47 Q1	GE01
IMIBIC Groups.GC08 ;Radiodiagnóstico ;GA10; GA04 ;GC27		IMIBIC Groups.GE03 ;GA06 ;GE01;	
Pedraza-Arevalo S, Gahete MD, Alors-Perez E, Luque RM, Castano JP.Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS.2018.19.(2).179-192.DOI:10.1007/s11154-018-9465-0.;IF:4,963 Q1	GC27	Medina-Fernandez FJ, Escribano BM, Padilla-del-Campo C, Drucker-Colin R, Pascual-Leone A, Tunes I.Transcranial magnetic stimulation as an antioxidant.FREE RADICAL RESEARCH.2018.52.(4).381-389.DOI:10.1080/10715762.2018.1434313.; IF:3,038 Q2	GE01
IMIBIC Groups.GC08 ;GC27		IMIBIC Groups.GC18 ;GE01	
Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortes E, Madrazo-Atutxa A, Japon MA, Luque RM, Castano JP, Cano DA, Soto-Moreno A.Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(3).1640-1649.DOI:10.1111/jcmm.13440.;IF:4,302 Q1	GC27		
IMIBIC Groups.GC08 ;GC27			



Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunez I. Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. BRAIN RESEARCH BULLETIN. 2018. 137. (.) .140-145. DOI:10.1016/j.brainresbu-ll.2017.11.018.;IF:3,44 Q2	GE01
IMIBIC Groups.GC18 ;GE01 ;GA06;	
Maya-Lopez M, Mireles-Garcia MV, Ramirez-Toledo M, Colin-Gonzalez AL, Galvan-Arzate S, Tunez I, Santamaria A. Thallium-Induced Toxicity in Rat Brain Crude Synaptosomal/Mitochondrial Fractions is Sensitive to Anti-excitatory and Antioxidant Agents. NEUROTOXICITY RESEARCH. 2018. 33. (3). 634-640. DOI:10.1007/s12640-017-9863-1.;IF:3,186 Q2	GE01
IMIBIC Groups.GE01 ;	
Dircio-Bautista M, Colin-Gonzalez A, Aguilera G, Maya-Lopez M, Villeda-Hernandez J, Galvan-Arzate S, Garcia E, Tunez I, Santamaria A. The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum. NEUROTOXICITY RESEARCH. 2018. 33. (4). 837-845. DOI:10.1007/s12640-017-9836-4.;IF:3,186 Q2	GE01
IMIBIC Groups.GE01 ;	
Balius R, Alomar X, Pedret C, Blasi M, Rodas G, Pruna R, Pena-Amaro J, Fernandez-Jaen T. Role of the Extracellular Matrix in Muscle Injuries: Histoarchitectural Considerations for Muscle Injuries. ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE. 2018. 6. (9).-. DOI:10.1177/2325967118795863.;IF:0 NO Q	GE01
IMIBIC Groups.GE01 ;	
Sanchez-Hidalgo JM, Rufian-Pena S, Duran-Martinez M, Arjona-Sanchez A, Salcedo-Leal I, Lopez-Cillero P, Briceno-Delgado J. Risk factors of early recurrence in retroperitoneal liposarcoma. CIRUGIA ESPANOLA. 2018. 96. (9). 568-576. DOI:10.1016/j.ciresp.2018.06.002.;IF:0,841 Q4	GE02
IMIBIC Groups.GC18 ;GE02	
Ortega RL, Cortes BO, Serna ROG, Garcia VG, Hernandez BL. Changes in Hepatitis A epidemiological pattern in Andalusia: 2007-2017. REVISTA ESPANOLA DE SALUD PUBLICA. 2018. 92. (.) .-. DOI:.;IF:0,635 Q4	GE02
IMIBIC Groups.GE02 ;	
Descalzo MA, Carretero G, Ferrandiz C, Rivera R, Dauden E, Gomez-Garcia FJ, de la Cueva P, Herrera-Ceballos E, Belinchon I, Lopez-Esteban JL, Alsina M, Sanchez-Carazo JL, Ferran M, Baniandres O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Munoz-Santos C, Garcia-Doval I. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2018. 78. (4). 798-800. DOI:10.1016/j.jaad.2017.10.051.;IF:6,898 DQ1 D1	GE03
IMIBIC Groups.GE03 ;	
Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gomez-Garcia FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the UK and Republic of Ireland. BRITISH JOURNAL OF DERMATOLOGY. 2018. 179. (4). 863-871. DOI:10.1111/bjd.16715.;IF:6,129 DQ1 D1	GE03
IMIBIC Groups.GE03 ;	
Ruano J, Gomez-Garcia F, Gay-Mimbrera J, Aguilar-Luque M, Fernandez-Rueda JL, Fernandez-Chaichio J, Alcalde-Mellado P, Carmona-Fernandez PJ, Sanz-Cabanillas JL, Viguera-Guerra I, Franco-Garcia F, Cardenas-Aranzana M, Romero JLH, Gonzalez-Padilla M, Isla-Tejera B, Garcia-Nieto AV. Evaluating characteristics of PROSPERO records as predictors of eventual publication of non-Cochrane systematic reviews: a meta-epidemiological study protocol. SYSTEMATIC REVIEWS. 2018. 7. (.) .-. DOI:10.1186/s13643-018-0709-6.;IF:6,754 DQ1 D1	GE03
IMIBIC Groups.GE03 ;GE03	
Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunez I. Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. JOURNAL OF FUNCTIONAL FOODS. 2018. 42. (.) .281-288. DOI:10.1016/j.jff.2017.12.068.;IF:3,47 Q1	GE03
IMIBIC Groups.GE03 ;GA06 ;GE01;	

Ruano J, Aguilar-Luque M, Isla-Tejera B, Alcalde-Mellado P, Gay-Mimbrera J, Hernandez-Romero JL, Sanz-Cabanillas JL, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Gomez-Garcia F, Garcia-Nieto AV. Relationships between abstract features and methodological quality explained variations of social media activity derived from systematic reviews about psoriasis interventions. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2018. 101. (.) .35-43. DOI:10.1016/j.jclinepi.2018.05.015.;IF:4,245 Q1	GE03
IMIBIC Groups.GE03 ;GE03	
Ruano J, Aguilar-Luque M, Gomez-Garcia F, Mellado PA, Gay-Mimbrera J, Carmona-Fernandez PJ, Maestre-Lopez B, Sanz-Cabanillas JL, Romero JLH, Gonzalez-Padilla M, Garcia-Nieto AV, Isla-Tejera B. The differential impact of scientific quality, bibliometric factors, and social media activity on the influence of systematic reviews and meta-analyses about psoriasis. PLOS ONE. 2018. 13. (1).-. DOI:10.1371/journal.pone.0191124.;IF:2,766 Q1	GE03
IMIBIC Groups.GE03 ;GE03	
Gomez-Garcia F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Romero JLH, Garcia-Nieto AV. A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety. DERMATOLOGY AND THERAPY. 2018. 8. (2). 195-202. DOI:10.1007/s13555-018-0235-4.;IF:0 NO Q	GE03
IMIBIC Groups.GE03 ;	
Hernandez GC, Ferrandiz C, Diaz RR, Tello ED, de la Cueva-Dobao P, Gomez-Garcia FJ, Herrera-Ceballos E, Romero IB, Lopez-Esteban JL, Gibert MA, Sanchez-Carazo JL, Farres MF, Quesada AG, Carrillo JMC, Llamas-Velasco M, Fernandez MVM, Genao DR, Santos CM, Garcia-Doval I, Descalzo MA. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016. ACTAS DERMATO-SIFILIOGRAFICAS. 2018. 109. (7). 617-623. DOI:10.1016/j.ad.2018.04.004.;IF:0 NO Q	GE03
IMIBIC Groups.GE03 ;	
Gomez-Garcia F, Sanz-Cabanillas JL, Viguera-Guerra I, Isla-Tejera B, Nieto AVG, Ruano J. Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA. DERMATOLOGY AND THERAPY. 2018. 8. (4). 539-556. DOI:10.1007/s13555-018-0269-7.;IF:0 NO Q	GE03
IMIBIC Groups.GE03 ;GE03	
Garcia-Torres F, Castillo-Mayen R, Alos FJ. Psychoticism and employment status in breast cancer survivors. PSYCHO-ONCOLOGY. 2018. 27. (1). 359-361. DOI:10.1002/pon.4417.;IF:3,455 DQ1	GE04
IMIBIC Groups.GC20 ;GE04	
Diaz-Gonzalez MC, Duenas CP, Sanchez-Raya A, Elvira JAM, Vazquez VS. Mindfulness-based stress reduction in adolescents with mental disorders: A randomised clinical trial. PSICOTHEMA. 2018. 30. (2). 165-170. DOI:10.7334/psicotema2017.259.;IF:1,516 Q2	GE04
IMIBIC Groups.GC20 ;Hospital Infanta Margarita Distrito Cordoba Sur Lucena ;GE04;	
Cuadrado E, Gutierrez-Domingo T, Castillo-Mayen R, Luque B, Arenas A, Tabereroa C. The Self-Efficacy Scale for Adherence to the Mediterranean Diet (SESAMeD): A scale construction and validation. APPETITE. 2018. 120. (.) .6-15. DOI:10.1016/j.appet.2017.08.015.;IF:3,174 Q2	GE04
IMIBIC Groups.GE04 ;	
Perez-Duenas C, Rivas MF, Oyediran OA, Garcia-Torres F. Induced Negative Mood Increases Dictator Game Giving. FRONTIERS IN PSYCHOLOGY. 2018. 9. (.) .-. DOI:10.3389/fpsyg.2018.01542.;IF:2,089 Q2	GE04
IMIBIC Groups.GE04 ;GC20	
Lobato, R. M., Moya, M., Moyano, M., & Trujillo, H. M. From Oppression to Violence: The Role of Oppression, Radicalism, Identity, and Cultural Intelligence in Violent Disinhibition. FRONTIERS MEDIA SA. 2018. (.) .-. DOI:.;IF:2,089 Q2	GE04
IMIBIC Groups.GE04 ;	
Di Marco, D., Arenas, A., Giorgi, G., Arcangeli, G., & Mucci, N. (2018). Be friendly, stay well: the effects of job resources on well-being in a discriminatory work environment. FRONTIERS MEDIA SA. 2018. (.) .-. DOI:.;IF:2,089 Q2	GE04
IMIBIC Groups.GE04 ;	



Di Marco, D., Martínez-Corts, I., Arenas, A., & Gamero, N. (2018)..Spanish validation of the shorter version of the Workplace Incivility Scale: An employment status invariant measure.FRONTIERS MEDIA SA.2018..().-DOI:.;IF:2,089 Q2	GE04
IMIBIC Groups.GE04 ;	
Abad-Merino S, Dovidio JF, Taberner C, Gonzalez I.The systematic study of how subtle forms of bias related to prosocial behavior operate in racial and gender relations.THEORY & PSYCHOLOGY.2018.28.(1).104-121.DOI:10.1177/0959354317745588.;IF:0,816 Q3	GE04
IMIBIC Groups.GE04 ;	
Agudo CD, Salas BL, Farre AF.Strategies of life in the fourth age: Women living alone.PRISMA SOCIAL.2018..(21).1-27. DOI:.;IF:0 NO Q	GE04
IMIBIC Groups.GE04 ;	
Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM.Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(11).5688-5697.DOI:10.1111/jcmm.13845.;IF:4,302 Q1	GE05
IMIBIC Groups.GC27 ;GC08 ;Ge05; GC09 ;U Innovación Metodología Imibic; Anatomía Patológica; ;	
Gomez EG, Rosa JV, Valiente JC, Tarradas FT, Curado FA, Ruiz DL, Tapia MJR.New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.UROLOGY.2018.121.(.).198-199.DOI:10.1016/j.urology.2017.08.027.;IF:2,3 Q2	GE05
IMIBIC Groups.GC27 ;GE05 ;GA08;	
Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R.The Identification of Immunological Biomarkers in Kidney Cancers.FRONTIERS IN ONCOLOGY.2018.8.(.).-DOI:10.3389/fonc.2018.00456.;IF:4,416 Q2	GE05
IMIBIC Groups.GE05 ;	
Volavsek M, Blanca A, Montironi R, Cheng L, Raspollini MR, Vau N, Fonseca J, Pierconti F, Lopez-Beltran A.Digital versus light microscopy assessment of surgical margin status after radical prostatectomy.VIRCHOWS ARCHIV.2018.472.(3).451-460. DOI:10.1007/s00428-018-2296-2.;IF:2,936 Q2	GE05
IMIBIC Groups.GE05 ;	
Arjona-Sanchez A, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Rabelo JR, Salamanca-Bustos JJ, Rodriguez-Benot A, Campos-Hernandez P, Briceno-Delgado J.Intraoperative Heparinization During Simultaneous Pancreas-Kidney Transplantation: Is It Really Necessary?.TRANSPLANTATION PROCEEDINGS.2018.50.(2).673-675.DOI:10.1016/j.transproceed.2017.09.055.;IF:0,806 Q4	GE05
IMIBIC Groups.GC18 ;GE05 ;GC07;	
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ruiz-Rabelo J, Salamanca-Bustos JJ, Rodriguez-Benot A, Marquez-Lopez FJ, Briceno-Delgado J.Pancreas Donor Hypernatremia: Is it Really a Risk Factor for Simultaneous Pancreas-kidney Transplantation?.TRANSPLANTATION PROCEEDINGS.2018.50.(2).676-678.DOI:10.1016/j.transproceed.2017.09.050.;IF:0,806 Q4	GE05
IMIBIC Groups.GC18 ;GE05 ;GC07;	
Sanchez-Hidalgo JM, Salamanca-Bustos JJ, Arjona-Sanchez A, Campos-Hernandez JP, Rabelo JR, Rodriguez-Benot A, Requena-Tapia MJ, Briceno-Delgado J.What Is the Influence of Both Risk Donor and Risk Receiver on Simultaneous Pancreas-Kidney Transplantation?.TRANSPLANTATION PROCEEDINGS.2018.50.(2).664-668.DOI:10.1016/j.transproceed.2017.09.065.;IF:0,806 Q4	GE05
IMIBIC Groups.GC18 ;GE05 ;GC07;	
Zamorano-Leon JJ, Segura A, Lahera V, Rodriguez-Pardo JM, Prieto R, Puigvert A, Farre AJL.Relationship Between Erectile Dysfunction, Diabetes and Dyslipidemia in Hypertensive-Treated Men.UROLOGY JOURNAL.2018.15.(6).370-375.DOI:.;IF:0,88 Q4	GE05
IMIBIC Groups.GE05 ;	



Puigvert AM, Prieto R, Garcia F.Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities.REVISTA INTERNACIONAL DE ANDROLOGIA.2018.16.(1).28-33.DOI:10.1016/j.androl.2017.02.007.;IF:0,096 Q4	GE05
IMIBIC Groups.GE05 ;	
Salamanca-Bustos JJ, Gomez-Gomez E, Campos-Hernandez JP, Carrasco-Valiente J, Ruiz-Garcia J, Marquez-Lopez FJ, Zureta-Tendero L, Requena-Tapia MJ.Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients.TRANSPLANTATION PROCEEDINGS.2018.50.(2).587-590.DOI:10.1016/j.transproceed.2017.09.048.;IF:0,806 Q4	GE05
IMIBIC Groups.GE05 ;GC27 ;Radiodiagnóstico;	
Carrasco, J ; Gomez, E ; Garcia, JH ; Valero, J; Sanchez, A ; Salamanca, JJ; Campos, JP; Requena, MJ .Impact of the use of simulators on the mental workload and confidence in a digital rectal examination and bladder catheterization workshop. ARCHIVOS ESPANOLES DE UROLOGIA.2018.(6):537-542.;IF:0,465 Q4	GE05
IMIBIC Groups.GE05 ;	
Valiente, JC; Garcia, JMR ; Tapia, MJR .Oligometastatic prostate cancer. Concept and implications.ARCHIVOS ESPANOLES DE UROLOGIA.201871(3):239-246.;IF:0,465 Q4	GE05
IMIBIC Groups.GE05 ;	
Moreno P, Jimenez-Jimenez C, Garrido-Rodriguez M, Calderon-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra A, Munoz E, Calzado MA.Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.MOLECULAR ONCOLOGY.2018.12.(10).1778-1796.DOI:10.1002/1878-0261.12369.;IF:5,264 Q1	GA01
IMIBIC Groups.GA01 ;GC04 ;GC21;	
Barrios JMV, Luna FS, Velazquez AS.Lung Re-Transplantation. The Opposite View Point.ARCHIVOS DE BRONCONEUMOLOGIA.2018.54.(6).311-312. DOI:10.1016/j.arbres.2018.04.001.;IF:2,633 Q2	GA01
IMIBIC Groups.GA03 ;GA01	
Murillo DA, Cerezo F, Gauman HD, Gonzalez FJ, Munoz A, Moreno PM, Ceballos MJ, Salvatierra A.Left Single Lung Transplantation Through Left Anterolateral Thoracotomy With Longitudinal Partial Sternotomy (Hemiclamshell): An Innovative Surgical Resource.TRANSPLANTATION PROCEEDINGS.2018.50.(2).661-663.DOI:10.1016/j.transproceed.2017.09.049.;IF:0,806 Q4	GA01
IMIBIC Groups.GA01 ;Neumología	
Cobo-Cuenca AI, Martin-Espinosa NM, Sampietro-Crespo A, Rodriguez-Borrego MA, Carmona-Torres JM.Sexual dysfunction in Spanish women with breast cancer.PLOS ONE.2018.13.(8).-DOI:10.1371/journal.pone.0203151.;IF:2,766 Q1	GA02
IMIBIC Groups.GA02 ;	
Carmona-Torres JM, Lopez-Soto PJ, Coimbra-Roca AI, Galvez-Rioja RM, Goergen T, Rodriguez-Borrego MA.Elder Abuse in a Developing Area in Bolivia. JOURNAL OF INTERPERSONAL VIOLENCE.2018.33.(2).339-356.DOI:10.1177/0886260515608803.;IF:2,443 Q1	GA02
IMIBIC Groups.GA02 ;	
Manfredini R, Lamberti N, Manfredini F, Straudi S, Fabbian F, Borrego MAR, Basaglia N, Torres JMC, Soto PJL.Gender Differences in Outcomes Following a Pain-Free, Home-Based Exercise Program for Claudication.JOURNAL OF WOMENS HEALTH.2018..().-DOI:10.1089/jwh.2018.7113.;IF:2,097 Q1	GA02
IMIBIC Groups.GA02 ;	
Cobo-Cuenca AI, Rodriguez-Borrego MA, Hidalgo-Lopezosa P, Rodriguez-Munoz PM, Martins M, Carmona-Torres JM.Prevalence and determinants in cytology testing for cervical cancer screening in Spain (2006-14).EUROPEAN JOURNAL OF PUBLIC HEALTH.2018.28.(3).410-415.DOI:10.1093/eurpub/cky015.;IF:2,782 Q2	GA02
IMIBIC Groups.GA02 ;	
Manfredini R, Fabbian F, Cappadona R, Zucchi B, Lopez-Soto PJ, Rodriguez-Borrego MA.Attempted suicide as a trigger of Takotsubo syndrome: a minireview of available case reports.INTERNAL AND EMERGENCY MEDICINE.2018.13.(4).629-631. DOI:10.1007/s11739-018-1812-3.;IF:2,453 Q2	GA02
IMIBIC Groups.GA02 ;	
Hidalgo-Lopezosa P, Cobo-Cuenca AI, Carmona-Torres JM, Luque-Carrillo P, Rodriguez-Munoz PM, Rodriguez-Borrego MA.Factors associated with late fetal mortality.ARCHIVES OF GYNECOLOGY AND OBSTETRICS.2018.297.(6).1415-1420.DOI:10.1007/s00404-018-4726-4.;IF:2,236 Q2	GA02
IMIBIC Groups.GA02 ;	



Fabbian F, De Giorgi A, Boari B, Misurati E, Gallerani M, Cappadona R, Cultrera R, Manfredini R, Borrego MAR, Lopez-Soto PJ. Infections and internal medicine patients Could a comorbidity score predict in-hospital mortality?. MEDICINE. 2018.97.(42).-DOI:10.1097/MD.00000000000012818.;IF:2,028 Q2	GA02
IMIBIC Groups.GA02 ;	
Carmona-Torres JM, Cobo-Cuenca AI, Recio-Andrade B, Laredo-Aguilera JA, Martins MM, Rodriguez-Borrego MA. Prevalence and factors associated with polypharmacy in the older people: 2006-2014. JOURNAL OF CLINICAL NURSING. 2018.27.(15-16).2942-2952.DOI:10.1111/jocn.14371.;IF:1,635 Q2	GA02
IMIBIC Groups.GA02 ;	
Carrnona-Torres JM, Recio-Andrade B, Rodriguez-Borrego MA. Violence committed by intimate partners of physicians, nurses and nursing assistants. INTERNATIONAL NURSING REVIEW. 2018.65.(3).441-449.DOI:.;IF:1,496 Q2	GA02
IMIBIC Groups.GA02 ;	
Lopez-Soto PJ, Garcia-Arcos A, Fabbian F, Manfredini R, Rodriguez-Borrego MA. Falls Suffered by Elderly People From the Perspective of Health Care Personnel: A Qualitative Study. CLINICAL NURSING RESEARCH. 2018.27.(6).675-691.DOI:10.1177/1054773817705532.;IF:1,466 Q2	GA02
IMIBIC Groups.GA02 ;	
Carmona-Torres JM, Cobo-Cuenca AI, Martin-Espinosa NM, Piriz-Campos RM, Laredo-Aguilera JA, Rodriguez-Borrego MA. Prevalence in the performance of mammographies in Spain: Analysis by Communities 2006-2014 and influencing factors. ATENCION PRIMARIA. 2018.50.(4).228-237.DOI:10.1016/j.aprim.2017.03.007.;IF:1,148 Q3	GA02
IMIBIC Groups.GA02 ;	
Manfredini R, Fabbian F, De Giorgi A, Cappadona R, Zucchi B, Storari A, Borrego MAR, Torres JMC, Soto PJL. Takotsubo syndrome and dialysis: an uncommon association?. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2018.46.(11).4399-4406.DOI:10.1177/0300060518794249.;IF:1,023 Q4	ga02
IMIBIC Groups.ga02 ;	
Lopez-Soto PJ, Bretones-Garcia JM, Arroyo-Garcia V, Garcia-Ruiz M, Sanchez-Ossorio E, Rodriguez-Borrego MA. Occipital Neuralgia: a noninvasive therapeutic approach. REVISTA LATINO-AMERICANA DE ENFERMAGEM. 2018.26.(.)-.DOI:10.1590/1518-8345.2621.3067.;IF:0,712 Q4	GA02
IMIBIC Groups.GA02 ;	
Araujo MD, Caldevilla NN, Maciel C, Malheiro F, Rodriguez-Borrego MA, Lopez-Soto PJ. Record of the circumstances of falls in the community: perspective in the Iberian Peninsula. REVISTA LATINO-AMERICANA DE ENFERMAGEM. 2018.26.(.)-.DOI:10.1590/1518-8345.2373.2977.;IF:0,712 Q4	GA02
IMIBIC Groups.GA02 ;	
Martinez-Gonzalez C, Casanova C, de-Torres JP, Marin JM, de Lucas P, Fuster A, Cosio BG, Calle M, Peces-Barba G, Solanes I, Agüero R, Feu-Collado N, Alfageme I, Plaza AR, Balcells E, de Diego A, Royo MM, Moreno A, Casanovas AL, Galdiz JB, Golpe R, Bautista CL, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD A Prospective Analysis From the CHAIN Cohort. CHEST. 2018.154.(2).274-285.DOI:10.1016/j.chest.2018.02.007.;IF:7,652 Q1	GA03
IMIBIC Groups.GA03 ;	
Merino JS, de Torres LAP, Bardwell WA, Gomez RM, Villalobos AR, Collado NF, Ruiz-Moral R, Jurado-Gamez B. Impact of Positive Pressure Treatment of the Airway on Health-Related Quality of Life in Elderly Patients With Obstructive Sleep Apnea. BIOLOGICAL RESEARCH FOR NURSING. 2018.20.(4).452-461.DOI:10.1177/1099800418774633.;IF:1,579 Q2	GA03
IMIBIC Groups.Atención Primaria ;GC12 ;GA03;	
Plaza V, Cosio BG, Entrenas LM, Olaguibel JM, de Llano LP, Quirce S. The Role of FENO in the Diagnosis and Control of Asthma. Expert Multidisciplinary Group Debate during the Asthma Meeting Point 2017. ARCHIVOS DE BRONCONEUMOLOGIA. 2018.54.(4).237-238.DOI:10.1016/j.arbres.2017.09.016.;IF:2,633 Q2	GA03
IMIBIC Groups.GA03 ;	
Sanchez AR, de Torres LAP, Luna FS, Ruiz-Moral R. Prevalence of tobacco consumption among young physicians at a regional university hospital in southern Spain: a cross-sectional study. BMJ OPEN. 2018.8.(2).-DOI:10.1136/bmjopen-2017-018728.;IF:2,413 Q2	GA03
IMIBIC Groups.GC12 ;GC12 ;GA03;	
Barrios JMV, Luna FS, Velazquez AS. Lung Re-Transplantation. The Opposite View Point. ARCHIVOS DE BRONCONEUMOLOGIA. 2018.54.(6).311-312.DOI:10.1016/j.arbres.2018.04.001.;IF:2,633 Q2	GA03
IMIBIC Groups.GA03 ;GA01	



Ballesteros FM, Fernandez JJS, Barrios JMV, Montero JR, Ceballos MJC, Amarilla CE, Muriana AMP, Luna FS. Long-term Prognosis After Lung Transplantation: A Monocentric Study in 510 Patients. TRANSPLANTATION PROCEEDINGS. 2018.50.(2).658-660.DOI:10.1016/j.transproceed.2017.09.061.;IF:0,806 Q4	GA03
IMIBIC Groups.GA03 ;Cardiología	
Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martinez-Fuentes AJ, Galvez-Moreno MA, Castano JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. 2018.9.(.)-.DOI:10.1038/s41424-018-0058-8.;IF:4,621 DQ1 D1	GA04
IMIBIC Groups.GC27 ;GC08 ;GA04; Anatomía Patológica ;Oncología Médica; ;	
Alhambra-Exposito MR, Ibanez-Costa A, Moreno-Moreno P, Rivero-Cortes E, Vazquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado A, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castano JP, Galvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. SCIENTIFIC REPORTS. 2018.8.(.)-.DOI:10.1038/s41598-018-24260-y.;IF:4,122 Q1	GA04
IMIBIC Groups.GC08 ;Radiodiagnóstico ;GA10; GA04 ;GC27; ;	
Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. ENDOCRINE. 2018.59.(2).426-437.DOI:10.1007/s12020-017-1482-3.;IF:3,179 Q2	GA04
IMIBIC Groups.GC08 ;GA04 ;Anatomía Patológica; GC14 ;Oncología Médica; gc27; ;	
Rebollo-Roman A, Barrera-Martin A, Alcantara-Laguna MD, Iglesias-Flores E, Canada-Sanz E, Padillo-Cuenca JC, Molina-Puertas MJ, Calanas-Continente A. Non-orpharyngeal dysphagia with frequent Emergency Room attendance. NUTRICION HOSPITALARIA. 2018.35.(4).996-998.DOI:10.20960/nh.1933.;IF:0,845 Q4	GA04
IMIBIC Groups.GA04 ;GC02 ;Salud Mental;	
Exposito MRA, Herrera-Martinez AD, Garcia GM, Calvo ME, Serrano CMB, Moreno MAG. Early nutrition support therapy in patients with head-neck cancer. NUTRICION HOSPITALARIA. 2018.35.(3).505-510.DOI:10.20960/nh.1560.;IF:0,747 Q4	GA04
IMIBIC Groups.GA04 ;Oncología Radioterápica	
Herrera-Martinez AD, Ortega RP, Opazo RB, Moreno-Moreno P, Puerta MJM, Galvez-Moreno MA. Hyperlipidemia during gestational diabetes and its relation with maternal and offspring complications. NUTRICION HOSPITALARIA. 2018.35.(3).698-706.DOI:10.20960/nh.1539.;IF:0,747 Q4	GA04
IMIBIC Groups.GA04 ;	
Bernabeu I, Aller J, Alvarez-Escola C, Fajardo-Montanana C, Galvez-Moreno A, Guillin-Amarelle C, Semsilo G. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus. ENDOCRINOLOGIA DIABETES Y NUTRICION. 2018.65.(5).297-305.DOI:10.1016/j.endinu.2018.01.008.;IF:0 NO Q	GA04
IMIBIC Groups.GA04 ;	
Burgos AMC, Torres-Borrego J, Teran ABM, Corzo JL, Garcia BE, Pacheco RR, Aguilar CM, Davila I. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. PEDIATRIC ALLERGY AND IMMUNOLOGY. 2018.29.(4).369-374.DOI:10.1111/pai.12866.;IF:4,137 DQ1 D1	GA05
IMIBIC Groups.GA05 ;GC01	
Ortea I, Ruiz-Sanchez I, Canete R, Caballero-Villarraso J, Canete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. JOURNAL OF PROTEOMICS. 2018.175.(.)105-113.DOI:10.1016/j.jprot.2018.01.003.;IF:3,722 Q1	GA05
IMIBIC Groups.Unidad Proteómica Imibic ;GA05 ;GA06;	
Tortajada-Girbes M, Bousquet R, Bosque M, Martinez JJC, Ibanez MD, Moreira A, Nieto A, Plaza AM, Rivas C, Requena G, Sanchez-Solis M, Tabar A, Torres-Borrego J, Zapatero L. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. EXPERT REVIEW OF RESPIRATORY MEDICINE. 2018.12.(9).745-754.DOI:10.1080/17476348.2018.1507740.;IF:2,607 Q2	GA05
IMIBIC Groups.GA05 ;	
Gomez-Guzman E, Canete MD, Valle-Mertos R, Canete R, Valle M, Jimenez-Reina L, Caballero-Villarraso J. Short-Term Evaluation of Left Ventricular Mass and Function in Children With Growth Hormone Deficiency After Replacement Treatment. FRONTIERS IN PEDIATRICS. 2018.6.(.)-.DOI:10.3389/fped.2018.00174.;IF:2,335 Q2	GA05
IMIBIC Groups.GA05 ;GA05 ;GA06;	
Tofe I, Ruiz-Gonzalez MD, Canete MD, Pino A, Rueda RL, Parraga MJ, Perez-Navero JL. Efficacy of Paracetamol in Closure of Ductus Arteriosus in Infants under 32 Weeks of Gestation. FRONTIERS IN PEDIATRICS. 2018.6.(.)-.DOI:10.3389/fred.2018.DDN5.;IF:2,335 Q2	GA05
IMIBIC Groups.GC23 ;GA05 ;Pediatria;	



Castillo-Fernandez AL, Vazquez-Rueda F, Canete MD, Caballero-Villarraso J.Retroperitoneal gastric duplication mimicking a prenatal adrenal cyst.CONGENITAL ANOMALIES.2018.58.(4).141-142.DOI:10.1111/cga.12244.;IF:1,149 Q3	GA05
IMIBIC Groups.GA05 ;GA06	
Hernandez MAT, Martinez EG, Marin MJA, Guzman EG.Tolvaptan in a pediatric cardiorenal syndrome. What is its role?.ARCHIVOS ARGENTINOS DE PEDIATRIA.2018.116.(2).E279-E282.DOI:10.5546/aap.2018.e279.;IF:0,405 Q4	GA05
IMIBIC Groups.GA05 ;Pediatria	
Guendiaín M, Montes R, Lopez-Belmonte G, Martín-Matillas M, Castellote AI, Martín-Bautista E, Martí A, Martínez JA, Moreno L, Garagorri JM, Warnberg J, Caballero J, Marcos A, Lopez-Sabater MC, Campoy C.Changes in plasma fatty acid composition are associated with improvements in obesity and related metabolic disorders: A therapeutic approach to overweight adolescents.CLINICAL NUTRITION.2018.37.(1).149-156.DOI:10.1016/j.clnu.2016.11.006.;IF:5,496 DQ1 D1	GA06
IMIBIC Groups.GA06 ;	
García-Ríos A, Alcalá-Díaz JF, Gómez-Delgado F, Delgado-Lista J, Marín C, León-Acuna A, Camargo A, Rodríguez-Cantalejo F, Blanco-Rojo R, Quintana-Navarro G, Ordoñas JM, Pérez-Jiménez F, López-Miranda J, Pérez-Martínez P.Beneficial effect of CETP gene polymorphism in combination with a Mediterranean diet influencing lipid metabolism in metabolic syndrome patients: CORDIOPREV study.CLINICAL NUTRITION.2018.37.(1).229-234. DOI:10.1016/j.clnu.2016.12.011.;IF:5,496 DQ1 D1	GA06
IMIBIC Groups.GC09 ;GA06	
Jiménez-Lucena R, Rangel-Zuniga OA, Alcalá-Díaz JF, López-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castano JP, Ordoñas JM, Pérez-Martínez P, Camargo A, López-Miranda J.Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary HeartDisease Patients from the CORDIOPREV Study.MOLECULAR THERAPY-NUCLEIC ACIDS.2018.12.(.).146-157. DOI:10.1016/j.omtn.2018.05.002.;IF:5,66 DQ1 D1	GA06
IMIBIC Groups.GC09 ;GA06 ;GC08;	
Gómez-Delgado F, Delgado-Lista J, López-Moreno J, Rangel-Zuniga OA, Alcalá-Díaz JF, León-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, García-Ríos A, Caballero J, Castano J, Ordoñas JM, López-Miranda J, Pérez-Martínez P.Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study.JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES.2018.73.(3).327-332.DOI:10.1093/gerona/glw194.;IF:4,902 DQ1 D1	GA06
IMIBIC Groups.GC09 ;GA06 ;GC08;	
Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Rivalde MA, Brieva T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A.Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection.ZOOZOSES AND PUBLIC HEALTH.2018.65.(5).584-588. DOI:10.1111/zph.12472.;IF:2,688 DQ1 D1	GA06
IMIBIC Groups.GC26 ;GA06	
Escribano BM, Agüera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, García-Maceira FI, Santamaría A, Túniz I.Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects.JOURNAL OF FUNCTIONAL FOODS.2018.42.(.).281-288.DOI:10.1016/j.jff.2017.12.068.;IF:3,47 Q1	GA06
IMIBIC Groups.GE03 ;GA06 ;GE01;	
Ortea I, Ruiz-Sánchez I, Canete R, Caballero-Villarraso J, Canete MD.Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection.JOURNAL OF PROTEOMICS.2018.175.(.).105-113.DOI:10.1016/j.jprot.2018.01.003.;IF:3,722 Q1	GA06
IMIBIC Groups.Unidad Proteómica Imibic ;GA05 ;GA06;	
Gomez-Guzman E, Canete MD, Valle-Mertos R, Canete R, Valle M, Jimenez-Reina L, Caballero-Villarraso J.Short-Term Evaluation of Left Ventricular Mass and Function in Children With Growth Hormone Deficiency After Replacement Treatment.FRONTIERS IN PEDIATRICS.2018.6.(.).DOI:10.3389/fped.2018.00174.;IF:2,335 Q2	GA06
IMIBIC Groups.GA05 ;GA05 ;GA06;	
Navarro-Valverde C, Caballero-Villarraso J, Mata-Granados JM, Casado-Díaz A, Sosa-Henriquez M, Malouf-Sierra J, Nogues-Solan X, Rodríguez-Manas L, Cortes-Gil X, Delgadillo-Duarte J, Quesada-Gómez JM.High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women.CALCIFIED TISSUE INTERNATIONAL.2018.102.(6).651-656.DOI:10.1007/s00223-017-0379-8.;IF:3,293 Q2	GA06
IMIBIC Groups.GC17 ;GA06 ;GC17;	
Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Túniz I.Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis.BRAIN RESEARCH BULLETIN.2018.137.(.).140-145.DOI:10.1016/j.brainresbull.2017.11.018.;IF:3,44 Q2	GA06
IMIBIC Groups.GC18 ;GE01 ;GA06;	

Castillo-Fernandez AL, Vazquez-Rueda F, Canete MD, Caballero-Villarraso J.Retroperitoneal gastric duplication mimicking a prenatal adrenal cyst.CONGENITAL ANOMALIES.2018.58.(4).141-142.DOI:10.1111/cga.12244.;IF:1,149 Q3	GA06
IMIBIC Groups.GA05 ;GA06	
Sanchez-Garcia ME, Ramirez-Lara I, Gomez-Delgado F, Yubero-Serrano EM, Leon-Acuna A, Marin C, Alcalá-Díaz JF, Camargo A, Lopez-Moreno J, Perez-Martinez P, Tinahones FJ, Ordoñas JM, Caballero J, Blanco-Molina A, Lopez-Miranda J, Delgado-Lista J.Quantitative evaluation of capillaroscopic microvascular changes in patients with established coronary heart disease.MEDICINA CLINICA.2018. 150(4):131-137. doi: 10.1016/j.medcli.2017.06.068. 137.DOI:10.1016/j.medcli.2017.06.068.;IF:1,168 Q3	GA06
IMIBIC Groups.GC09 ;GA06	
Gonzalez-Andrades M, Sharifi R, Islam MM, Divoux T, Haist M, Paschalis EI, Gelfand L, Mamodaly S, Di Cecilia L, Cruzat A, Ulm FJ, Chodosh J, Delori F, Dohlman CH. .Improving the practicality and safety of artificial corneas: Pre-assembly and gamma-rays sterilization of the Boston Keratoprosthesis. 2018Jul(3):322-330. doi: 10.1016/j.jtos.2018.04.002.IF:4,38 DQ1 d1	GA07
IMIBIC Groups.GA07 ;	
Martin-Suarez E, Galan A, Morgaz J, Guisado A, Gallardo JM, Gomez-Villamandos RJ.Comparison of central corneal thickness in dogs measured by ultrasound pachymetry and ultrasound biomicroscopy.VETERINARY JOURNAL.2018.232.13-14.DOI:10.1016/j.tvjl.2017.12.003.;IF:1,773 Q1	GA07
IMIBIC Groups.GA07 ;	
Cruzat A, Gonzalez-Andrades M, Mauris J, AbuSamra DB, Chidambaram P, Kenyon KR, Chodosh J, Dohlman CH, Argüeso P.Colocalization Of Galectin-3 With CD147 Is Associated With Increased Gelatinolytic Activity In Ulcerating Human Corneas.2018.;IF:3,303 Q1	GA07
IMIBIC Groups.GA07 ;	
Dohlman CH, Cade F, Regatieri CV, Zhou C, Lei F, Crnej A, Harissi-Dagher M, Robert MC, Papaliodis GN, Chen D, Aquavella JV, Akpek EK, Aldave AJ, Sippel KC, D Amico DJ, Dohlman JG, Fagerholm P, Wang L, Shen LQ, González-Andrades M, Chodosh J, Kenyon KR, Foster CS, Pineda R, Melki S, Colby KA, Ciolino JB, Vavvas DG, Kinoshita S, Dana R, Paschalis EI..Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities..2018.IF:2,01 Q2	GA07
IMIBIC Groups.GA07 ;	
Martin SR, Povedano JLR, Garcia MC, Romero ALS, Garriguet MP, Benito MA.Prospective study aiming to compare 2D mammography and tomosynthesis plus synthesized mammography in terms of cancer detection and recall. From double reading of 2D mammography to single reading of tomosynthesis.EUROPEAN RADIOLOGY.2018.28.(6).2484-2491.DOI:10.1007/s00330-017-5219-8.;IF:4,027 Q1	GA08
IMIBIC Groups.GA08 ;	
Gomez EG, Rosa JV, Valiente JC, Tarradas FT, Curado FA, Ruiz DL, Tapia MJR.New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.UROLOGY.2018.121.(.).198-199.DOI:10.1016/j.urology.2017.08.027.;IF:2,3 Q2	GA08
IMIBIC Groups.GC27 ;GE05 ;GA08;	
Puente AB, Rodríguez FDB, Rey IB, Romero ER.Intracranial developmental venous anomaly: is it asymptomatic?.RADIOLOGIA.2018.60.(6).512-516. DOI:10.1016/j.rx.2018.02.004.;IF:0 NO Q	GA08
IMIBIC Groups.GA08 ;	
Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez JL, Gonzalez-Costello J, Segovia-Cubero J, Castel-Lavilla MA, Delgado-Jimenez J, Garrido-Bravo IP, Rangel-Sousa D, Martinez-Selles M, De la Fuente-Galan L, Rabago-Juan-Aracil G, Sanz-Julve M, Hervas-Sotomayor D, Mirabet-Perez S, Muniz J, Crespo-Leiro MG.Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry.EUROPEAN JOURNAL OF HEART FAILURE.2018.20.(1).178-186.DOI:10.1002/ehf.956.;IF:10,683 DQ1 D1	GA09
IMIBIC Groups.GA09 ;	
Carbonell AF, Mediavilla JC, Guerrero ER, Carvajal IM.Defibrillator implantation to a patient with large vessel transposition and physiological correction of Senning.CIRUGIA CARDIOVASCULAR.2018.25.(4).212-213.DOI:10.1016/j.circv.2017.12.037.;IF:0 NO Q	GA09
IMIBIC Groups.GA09 ;Atención Primaria Lucena	
Rodriguez-Caulo EA, Adsuar A, Parody G, Ferreira A, Dachary JA, Rodriguez-Mora F, Barquero JM, Garrido JM, Muñoz-Carvajal I, Melero JM.Long-term follow-up of aortic valve replacement with biological or mechanical prosthesis in middle-aged patients. initial results of a multicentre study.CIRUGIA CARDIOVASCULAR.2018.25.(4).178-185.DOI:10.1016/j.circv.2018.05.003.;IF:0 NO Q	GA09
IMIBIC Groups.GA09 ;	
Carbonell AF, Arboledas PA, Guerrero ER, Montilla ME, Carvajal IM.Usefulness of the "chimney" technique in the emergency treatment of abdominal aortic aneurysms with unfavorable anatomy.CIRUGIA CARDIOVASCULAR.2018.25.(3).158-162.DOI:10.1016/j.circv.2017.12.039.;IF:0 NO Q	GA09



IMIBIC Groups.GA09 ;Atención Primaria. Distrito Cordoba Sur Lucena ;Radiodiagnóstico;	
Alhambra-Exposito MR, Ibanez-Costa A, Moreno-Moreno P, Rivero-Cortes E, Vazquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado A, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castano JP, Galvez MA, Luque RM.Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.SCIENTIFIC REPORTS.2018.8.(.).-DOI:10.1038/s41598-018-24260-y.;IF:4,122 Q1	GA10
IMIBIC Groups.GC08 ;Radiodiagnóstico ;GA10; GA04 ;GC27; ; ;	
Moreno MVG, Bares LMM, Bueno AMS, Caceres ER, Casas JAV.A unusual pediatric case of focal nodular hyperplasia studied with Tc-99m-rnebrofenin. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR.2018.37.(3).178-180.DOI:10.1016/j.rem.2017.05.005.;IF:1,202 Q4	GA10
IMIBIC Groups.Ga10 ;Informatica HURS	
Redel-Macias MD, Hervas-Martinez C, Gutierrez PA, Pinzi S, Cubero-Atienza AJ, Dorado MP.Computational models to predict noise emissions of a diesel engine fueled with saturated and monounsaturated fatty acid methyl esters.ENERGY.2018.144.(.).110-119.DOI:10.1016/j.energy.2017.11.143.;IF:4,968 DQ1 D1	GA11
IMIBIC Groups.GA11 ;	
Duran-Rosal AM, Gutierrez PA, Martinez-Estudillo FJ, Hervas-Martinez C.Simultaneous optimisation of clustering quality and approximation error for time series segmentation.INFORMATION SCIENCES.2018.442.(.).186-201.DOI:10.1016/j.ins.2018.02.041.;IF:4,305 DQ1 D1	GA11
IMIBIC Groups.GA11 ;	
Fernandez JC, Cruz-Ramirez M, Hervas-Martinez C.Sensitivity versus accuracy in ensemble models of Artificial Neural Networks from Multi-objective Evolutionary Algorithms.NEURAL COMPUTING & APPLICATIONS.2018.30.(1).289-305.DOI:10.1007/s00521-016-2781-y.;IF:4,213 Q1	GA11
IMIBIC Groups.GA11 ;	
Fernandez-Navarro F, de la Cruz MA, Gutierrez PA, Castano A, Hervas-Martinez C.Time series forecasting by recurrent product unit neural networks. NEURAL COMPUTING & APPLICATIONS.2018.29.(3).779-791.DOI:10.1007/s00521-016-2494-2.;IF:4,213 Q1	GA11
IMIBIC Groups.GA11 ;	
Duran-Rosal AM, Gutierrez PA, Salcedo-Sanz S, Hervas-Martinez C.A statistically-driven Coral Reef Optimization algorithm for optimal size reduction of time series.APPLIED SOFT COMPUTING.2018.63.(.).139-153.DOI:10.1016/j.asoc.2017.11.037.;IF:3,907 Q1	GA11
IMIBIC Groups.GA11 ;	
Duran-Rosal AM, Fernandez JC, Casanova-Mateo C, Sanz-Justo J, Salcedo-Sanz S, Hervas-Martinez C.Efficient fog prediction with multi-objective evolutionary neural networks.APPLIED SOFT COMPUTING.2018.70.(.).347-358.DOI:10.1016/j.asoc.2018.05.035.;IF:3,907 Q1	GA11
IMIBIC Groups.GA11 ;	
Sanchez-Monedero J, Perez-Ortiz M, Saez A, Gutierrez PA, Hervas-Martinez C.Partial order label decomposition approaches for melanoma diagnosis. APPLIED SOFT COMPUTING.2018.64.(.).341-355.DOI:10.1016/j.asoc.2017.11.042.;IF:3,907 Q1	GA11
IMIBIC Groups.GA11 ;	
Guijo-Rubio D, Gutierrez PA, Casanova-Mateo C, Sanz-Justo J, Salcedo-Sanz S, Hervas-Martinez C.Prediction of low-visibility events due to fog using ordinal classification.ATMOSPHERIC RESEARCH.2018.214.(.).64-73.DOI:10.1016/j.atmosres.2018.07.017.;IF:3,817 Q1	GA11
IMIBIC Groups.GA11 ;	
Perez-Barea JJ, Fernandez-Navarro F, Montero-Simo MJ, Araque-Padilla R.A socially responsible consumption index based on non-linear dimensionality reduction and global sensitivity analysis.APPLIED SOFT COMPUTING.2018.69.(.).599-609.DOI:10.1016/j.asoc.2018.04.059.;IF:3,907 Q1	GA11
IMIBIC Groups.GA11 ;	
Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J.Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation.LIVER TRANSPLANTATION.2018.24.(2).192-203. DOI:10.1002/lt.24870.;IF:3,752 Q1	GA11
IMIBIC Groups.GC18 ;GC02 ;GA11;	
Chung YJ, Salvador-Carulla L, Salinas-Perez JA, Uriarte-Uriarte JJ, Iruin-Sanz A, Garcia-Alonso CR.Use of the self-organising map network (SOMNet) as a decision support system for regional mental health planning.HEALTH RESEARCH POLICY AND SYSTEMS.2018.16.(.).-DOI:10.1186/s12961-018-0308-y.;IF:2,179 Q2	GA11
IMIBIC Groups.GA11 ;	

Del Pozo-Antunez JJ, Ariza-Montes A, Fernandez-Navarro F, Molina-Sanchez H.Effect of a Job Demand-Control-Social Support Model on Accounting Professionals' Health Perception.INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH.2018.15.(11).-DOI:10.3390/ijer-ph15112437.;IF:2,145 Q2	GA11
IMIBIC Groups.GA11 ;	
Fernandez-Arias D, Lopez-Martin M, Montero-Romero T, Martinez-Estudillo F, Fernandez-Navarro F.Financial Soundness Prediction Using a Multi-classification Model: Evidence from Current Financial Crisis in OECD Banks.COMPUTATIONAL ECONOMICS.2018.52.(1).275-297.DOI:10.1007/s10614-017-9676-6.;IF:1,038 Q3	GA11
IMIBIC Groups.GA11 ;	
Ortea I, Gonzalez-Fernandez MJ, Ramos-Bueno RP, Guil-Guerrero JL.Proteomics Study Reveals That Docosahexaenoic and Arachidonic Acids Exert Different In Vitro Anticancer Activities in Colorectal Cancer Cells.JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2018.66(24).6003-ap2. IF:3,412 DQ1 Imibic Groups:Core Facilities Proteomics	Core Facilities Proteomics
Fernandez AF, Bayon GF, Sierra MI, Urduinguio RG, Torano E, Garcia MG, Carella A, Lopez V, Santamarina P, Perez RF, Belmonte T, Tejedor JR, Cobo I, Menendez P, Mangas C, Ferrero C, Rodrigo L, Astudillo A, Ortea I, Diaz SC, Rodriguez-Gonzalez P, Alonso JIG, Mollejo M, Melendez B, Dominguez G, Bonilla F, Fraga MF.Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. HUMAN MOLECULAR GENETICS.2018.27(17).3046-ap2. IF:4,902 Q1 Imibic Groups: Core Facilities Proteomics	Core Facilities Proteomics
Ortea I, Ruiz-Sanchez I, Canete R, Caballero-Villarraso J, Canete MD.Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection.JOURNAL OF PROTEOMICS.2018.175(1).105-ap2. IF:3,722 Q1 Imibic Groups: Core Facilities Proteomics ;GA05 ;GA06; ; ; ;	Core Facilities Proteomics

	OH Groups
Benitez-Burraco A, Barcos-Martinez M, Espejo-Portero I, Fernandez-Urquiza M, Torres-Ruiz R, Rodriguez-Perales S, Jimenez-Romero MS.Narrowing the Genetic Causes of Language Dysfunction in the 1q21.1 Microduplication Syndrome. FRONTIERS IN PEDIATRICS.2018.6(1).-ap2. IF:2,335 Q2	Clinical Analysis Unit
Imibic Groups: Clinical Analysis Unit	
Miguel-Gomez L, Rodrigues-Barata AR, Molina-Ruiz A, Martorell-Calatayud A, Fernandez-Crehuet P, Grimalt R, Barco D, Arias-Santiago S, Serrano-Falcon C, Camacho FM, Saceda-Corralo D, Jaen-Olasolo P, Vano-Galvan S.Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY.2018.79(5).878-Z2. IF:6,898 DQ1D1	Dermatology Unit
Imibic Groups:Dermatology Unit	
Fernandez-Crehuet P, Gomez-Arias PJ, Ruiz-Villaverde R.Doctor, my armpit hair has turned yellow! Malodorous yellowish axillary hair in an adolescent patient.AUSTRALIAN JOURNAL OF GENERAL PRACTICE.2018.47(9).607-Z2. IF:0 NO Q	Dermatology Unit
Imibic Groups:Dermatology Unit	
Vallejo RS.Imiquimoid 5%: In Pursuit of New Treatment Regimens for Actinic Keratosis.ACTAS DERMO-SIFILIOGRAFICAS.2018.109(3).200-Z2. IF:0 NO Q	Dermatology Unit
Imibic Groups:Dermatology Unit	
Saceda-Corralo D, Fernandez-Crehuet P, Fonda-Pascual P, Pindado-Ortega C, Moreno-Arrones OM, Vano-Galvan S.Clinical Description of Frontal Fibrosing Alopecia with Concomitant Lichen Planopilaris.SKIN APPENDAGE DISORDERS.2018.4(2).105-Z2. IF:0 NO Q	Dermatology Unit
Imibic Groups:Dermatology Unit	
Lopez-Estebarez JL, de la Cueva-Dobao P, Fraga CD, Gutierrez MG, Guerra EG, Sanchez JM, Romero IB.Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.ACTAS DERMO-SIFILIOGRAFICAS.2018.109(7).631-Z2. IF:0 NO Q	Dermatology Unit
Imibic Groups:Dermatology Unit	



Buendia-Eisman A, Arias-Santiago S, Molina-Leyva A, Gilaberte Y, Fernandez-Crehuet P, Husein-EIAhmed H, Viera-Ramirez A, Fernandez-Penas P, Taberner R, Descalzo MA, Garcia-Doval I. Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project. <i>ACTAS DERMATO-SIFILIOGRAFICAS</i> .2018.109(5).416-22. IF:0 NO Q	Dermatology Unit	Russo A, Falcone M, Gutierrez-Gutierrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa R, Gasch O, Gozalo M, Pitout J, Akova M, Pena C, Cisneros JM, Hernandez-Torres A, Farcomeni A, Prim N, Origun J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Perez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh RR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodriguez-Bano J, Venditti M. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. <i>INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS</i> .2018.52(5).577-22. IF:4,253 Q1	Intensive Care Unit
Imibic Groups: Dermatology Unit		Imibic Groups: Intensive Care Unit	
del Olmo RO, Salido-Vallejo R. Ingenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice. <i>JOURNAL OF DERMATOLOGICAL TREATMENT</i> .2018.29(4).393-22. IF:2,144 Q2	Dermatology Unit	Ferron FR, Simon JMS. Trigger reverse identification in critical care setting. <i>MEDICINA INTENSIVA</i> .2018.42(6).391-22. IF:1,755 Q4	Intensive Care Unit
Imibic Groups: Dermatology Unit		Imibic Groups: Intensive Care Unit	
Ruiz-Villaverde R, Pereyra-Rodriguez JJ, Hernandez-Montoya C, Galan-Gutierrez M, Alcantara-Luna S, Lara-Jimenez MA. Omalizumab for the treatment of chronic spontaneous urticaria in daily clinical practice in South Spain. <i>DERMATOLOGIC THERAPY</i> .2018.31(5).-22. IF:1,563 Q3	Dermatology Unit	Sanchez PC, Serrano MTG, Simon JMS. Spontaneous multivisceral cholesterol crystal embolism presenting as livedo reticularis. <i>MEDICINA INTENSIVA</i> .2018.42(4).E4-22. IF:1,755 Q4	Intensive Care Unit
Imibic Groups: Dermatology Unit		Imibic Groups: Intensive Care Unit; pathological anatomy Unit	
Fernandez-Crehuet P, Ruiz-Villaverde R. Dress Syndrome Induced by Telaprevir: A Potentially Fatal Adverse Event in Chronic Hepatitis C Therapy. <i>CUTIS</i> .2018.102(5).E4-22. IF:1,167 Q4	Dermatology Unit	Santesteban-Espejo A, Campos F, Martin-Piedra L, Durand-Herrera D, Moral-Munoz JA, Campos A, Martin-Piedra MA. Global Tissue Engineering Trends: A Scientometric and Evolutionary Study. <i>TISSUE ENGINEERING PART A</i> .2018.24(1).19-22. IF:3,508 Q2	Internal Medicine Unit
Imibic Groups: Dermatology Unit		Imibic Groups: Internal Medicine	
Feito-Rodriguez M, Sanchez-Orta A, De Lucas R, Lopez-Gutierrez JC, Ruiz-Bravo E, Baselga E, Victoria AM, Hernandez-Martin A, Campos-Dominguez M, Frohner BB, Garnacho-Saucedo G, Casano AV, Villa AV, Bernabeu-Wittel J, Kutzner H, Requena L. Congenital tufted angioma: A multicenter retrospective study of 30 cases. <i>PEDIATRIC DERMATOLOGY</i> .2018.35(6).808-22. IF:1,041 Q4	Dermatology Unit	del-Pino-Casado R, Lopez-Martinez C, Serrano-Ortega N, Pastor-Bravo MD, Parra-Anguita L. Obligation and negative consequences in primary caregivers of dependent older relatives. <i>PLOS ONE</i> .2018.13(9).-22. IF:2,766 Q1	Internal Medicine Unit
Imibic Groups: Dermatology Unit		Imibic Groups: Internal Medicine Unit, Nursing Unit	
Alonso L, Nieto L, Carugno J. Hysteroscopic Removal of Retained Products of Conception Implanted Over a Focal Area of Adenomyosis: A Case Report. <i>JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY</i> .2018.25(3).382-22. IF:3,061 Q1	Gynecology & Obstetrics Unit	Dominguez C, Pozo-Rosich P, Torres-Ferrus M, Hernandez-Beltran N, Jurado-Cobo C, Gonzalez-Oria C, Santos S, Monzon MJ, Latorre G, Alvaro LC, Gago A, Gallego M, Medrano V, Huerta M, Garcia-Alhama J, Belvis R, Leira Y, Leira R. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. <i>EUROPEAN JOURNAL OF NEUROLOGY</i> .2018.25(2).411-22. IF:4,621 Q1	Neurology Unit
Imibic Groups: Gynecology & Obstetrics Unit		Imibic Groups: Neurology Unit	
Larino-Noia J, de-la-Iglesia D, Iglesias-Garcia J, Macias M, Lopez-Martin A, Legaz ML, Vila J, Reyes A, Abdulkader I, Dominguez-Munoz JE. Endoscopic ultrasound cytologic brushing vs endoscopic ultrasound - fine needle aspiration for cytological diagnosis of cystic pancreatic lesions. A multicenter, randomized open-label trial. <i>REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS</i> .2018.110(8).478-22. IF:1,632 Q4	Gastroenterology Unit	Sanchez JJR, Calzado RR, Sanchez MR. Efficiency in nursing prescription in Andalusia. A step back in the health system after annulment by Royal Decree. <i>ATENCION PRIMARIA</i> .2018.50(5).299-ap2. IF:1,148 Q3	Nursing Unit
Imibic Groups: Gastroenterology Unit		Imibic Groups: Nursing Unit	
Mearin F, Lanas A, Bujanda L, Canelles P, Cotter J, Hervas A, de Argila CM, Montoro M, Gisbert JP. Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> .2018.41(1).63-22. IF:1,078 Q4	Gastroenterology Unit	del-Pino-Casado R, Lopez-Martinez C, Serrano-Ortega N, Pastor-Bravo MD, Parra-Anguita L. Obligation and negative consequences in primary caregivers of dependent older relatives. <i>PLOS ONE</i> .2018.13(9).-ap2. IF:2,766 Q1	Nursing Unit
Imibic Groups: Gastroenterology Unit		Imibic Groups: Internal Medicine Unit, Nursing Unit	
Valenciano CML, Concejo FB, Serrano EM, Bocos JM, Martinez-Moneo E, Rodriguez EP, Gonzalez MF, Del Pozo-Garcia A, Martin AH, Barba EL, Pena MLO, De-Madaria E. Prevalence of exocrine pancreatic insufficiency in patients with chronic pancreatitis without follow-up. <i>PANCR-EVOL Study</i> . <i>GASTROENTEROLOGIA Y HEPATOLOGIA</i> .2018.41(2).77-22. IF:1,078 Q4	Gastroenterology Unit	Exposito MRA, Herrera-Martinez AD, Garcia GM, Calvo ME, Serrano CMB, Moreno MAG. Early nutrition support therapy in patients with head-neck cancer. <i>NUTRICION HOSPITALARIA</i> .2018.35(3).505-ap2. IF:0,747 Q4	Onco-radiotherapy Unit
Imibic Groups: Gastroenterology Unit		Imibic Groups: GA04 ; onco. Radio Unit	
Garnacho-Montero J, Diaz-Martin A, Canton-Bulnes L, Ramirez P, Sierra R, Arias-Verdu D, Rodriguez-Delgado M, Loza-Vazquez A, Rodriguez-Gomez J, Gordon M, Estella A, Garcia-Garmendia JL. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study*. <i>CRITICAL CARE MEDICINE</i> .2018.46(3).384-22. IF:6,63 Q1	Intensive Care Unit	Rodelo-Haad C, Aguera ML, Ortega R, Martinez-Lopez A, Navarro MD, Rodriguez-Benot A, Aljama P. Lithium-associated nephropathy in the renal allograft. <i>KIDNEY INTERNATIONAL</i> .2018.93.(1).273-273. DOI:10.1016/j.kint.2017.08.032. IF:8,429 DQ1 D1	pathological anatomy Unit
Imibic Groups: Intensive Care Unit		IMIBIC Groups: GC07 ; pathological anatomy Unit	
		Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. <i>BMC BIOLOGY</i> .2018.16.(1).-DOI:10.1186/s12915-017-0472-5. IF:5,77 DQ1 D1	Pathological anatomy Unit
		IMIBIC Groups: GC06 ; Cirugía General y Digestiva, pathological anatomy Unit	
		Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. <i>CLINICAL MICROBIOLOGY AND INFECTION</i> .2018.24.(11).1218-1219. DOI:10.1016/j.cmi.2018.06.030. IF:5,394 DQ1 D1	Pathological anatomy Unit
		IMIBIC Groups: GC26 ; GC03 ; pathological anatomy Unit; GC02 ; GC18	



Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martinez-Fuentes AJ, Galvez-Moreno MA, Castano JP, Luque RM.Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY.2018.9.(.)-.DOI:10.1038/s41424-018-0058-8.;IF:4,621 DQ1 D1	Pathological anatomy Unit
IMIBIC Groups.GC27 ;GC08 ;GA04; Gc06, pathological anatomy Unit	
Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM.Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018.22.(11).5688-5697.DOI:10.1111/jcmm.13845.;IF:4,302 Q1	Pathological anatomy Unit
IMIBIC Groups.GC27 ;GC08 ;Ge05; GC09 ; pathological anatomy Unit	
Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP.Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.ENDOCRINE.2018.59.(2).426-437.DOI:10.1007/s12020-017-1482-3.;IF:3,179 Q2	Pathological anatomy Unit
IMIBIC Groups.GC08 ;GA04 ; pathological anatomy Unit; GC14 ;gc06; gc27; ;	
Oulego-Erroz I, Gonzalez-Cortes R, Garcia-Soler P, Balaguer-Gargallo M, Frias-Perez M, Mayordomo-Colunga J, Llorente-de-la-Fuente A, Santos-Herraiz P, Menendez-Suso JJ, Sanchez-Porras M, Palanca-Arias D, Clavero-Rubio C, Holanda-Pena MS, Renter-Valdovinos L, Fernandez-De-Miguel S, Rodriguez-Nunez A.Ultrasound-guided or landmark techniques for central venous catheter placement in critically ill children.INTENSIVE CARE MEDICINE.2018.44(1).61-Z2. IF:15,008 DQ1	Pediatric Surgery Unit
Imibic Groups: Pediatric Surgery Unit	
Perez JJG, Moreno BJ, Salas MR.Aetiology, outcomes and prognostic indicators of paediatric acute liver failure.ANALES DE PEDIATRIA.2018.88(2).63-Z2. IF:1,318 Q3	Pediatric Surgery Unit
Imibic Groups: Pediatric Surgery Unit	
Benitez-Burraco A, Barcos-Martinez M, Espejo-Portero I, Fernandez-Urquiza M, Torres-Ruiz R, Rodriguez-Perales S, Jimenez-Romero MS.Narrowing the Genetic Causes of Language Dysfunction in the 1q21.1 Microduplication Syndrome.FRONTIERS IN PEDIATRICS.2018.6().-ap2. IF:2,335 Q2	Clinical Analysis Unit
Imibic Groups: Clinical Analysis Unit	
Montilla MEP, Galera SL, Herrero JJE, Sastoque JM, Tendero LZ.Diagnostic performance of imaging-guided core needle biopsy of the mesentery and peritoneum.RADIOLOGIA.2018.60(2).128-Z2. IF:0 NO Q	Radiology Unit
Imibic Groups: Radiology Unit	
Lombardo S, Espejo JJ, Perez-Montilla ME, Zurera LJ, Gonzalez-Galilea A.The keys to successful TIPS in patients with portal vein thrombosis and cavernous transformation.RADIOLOGIA.2018.60(2).94-Z2. IF:0 NO Q	Radiology Unit
Imibic Groups: Radiology Unit ;Gastro Unit	
Dantas AG, Alonso DA, Sanchez-Miguel PA, Sanchez CD.Factors Dancers Associate with their Body Dissatisfaction.BODY IMAGE.2018.25(4).40-Z2. IF:3,595 DQ1D1	Psychiatric Unit
Imibic Groups: Psychiatric Unit	
Guzman-Parra J, Rivas F, Strohmaier J, Forstner A, Streit F, Auburger G, Propping P, Orozco-Diaz G, Gonzalez MJ, Gil-Flores S, Cabaleiro-Fabeiro FJ, del Rio-Noriega F, Perez-Perez F, Haro-Gonzalez J, de Diego-Otero Y, Romero-Sanchiz P, Moreno-Kustner B, Cichon S, Nothen MM, Rietschel M, Mayoral F.The Andalusian Bipolar Family (ABiF) Study: Protocol and sample description.REVISTA DE PSIQUIATRIA Y SALUD MENTAL.2018.11(4).199-Z2. IF:2,233 Q2	Psychiatric Unit
Imibic Groups: Psychiatric Unit	
Montero-Perez FJ, Quero-Espinosa FB.Hand gestures in chest pain of coronary origim.REVISTA CLINICA ESPANOLA.2018.218(4).211-ap2. IF:1,184 Q3	Emergencies Unit
Imibic Groups: Emergencies Unit	

Montero-Perez FJ, Quero-Espinosa FB, Clemente-Millan MJ, Castro-Gimenez JA, de Burgos-Marin J, Romero-Moreno MA.Proposed clinical scale for the diagnosis of acute coronary syndrome in patients with an inconclusive electrocardiogram and myocardial injury biomarkers.REVISTA CLINICA ESPANOLA.2018.218(2).49-ap2. IF:1,184 Q3	Emergencies Unit
Imibic Groups: Emergencies Unit;GC15	
Moreno JS, de Hita JLG, Bueno MH.Inclusion of Environmental Criteria in the Public Procurement Processes by the Andalusian Healthcare Service.REVISTA DE SALUD AMBIENTAL.2018.18(2).110-Z2. IF:0 NO Q	SSG Unit
Imibic Groups: SSG Unit	
Prieto-Alhambra D, Reyes C, Sainz MS, Gonzalez-Macias J, Delgado LG, Bouzon CA, Ganan SM, Miedes DM, Vaquero-Cervino E, Bardaji MFB, Herrando LE, Baztan FB, Ferrer BL, Perez-Coto I, Bueno GA, Mora-Fernandez J, Donate TE, Blasco JMI, Aguado-Maestro I, Saez-Lopez P, Domenech MS, Climent-Peris V, Rodriguez AD, Sardinias HK, Gomez OT, Serra JT, Caeiro-Rey JR, Cano IA, Carsi MB, Etxebarria-Foronda I, Hernandez JDA, Solis JR, Suau OT, Nogues X, Herrera A, Diez-Perez A.In-hospital care, complications, and 4-month mortality following a hip or proximal femur fracture: the Spanish registry of osteoporotic femur fractures prospective cohort study.ARCHIVES OF OSTEOPOROSIS.2018.13(1).-ap2. IF:2,382 Q2	Traumatology Unit
Imibic Groups: Traumatology Unit	
Izquierdo-Fernandez A, Minarro JC, Carpintero-Lluch R, Estevez-Torres EM, Carpintero-Benitez P.Reverse shoulder arthroplasty in obese patients: analysis of functionality in the medium-term.ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY.2018.138(1).1-ap2. IF:1,967 Q2	Traumatology Unit
Imibic Groups:Traumatology Unit	

LIST OF ONGOING PROJECTS, NETWORKS & FELLOWSHIPS

PROJECTS & NETWORKS	IMIBIC GROUP
CARMEN MORENO AGUILAR;Anafilaxia por picaduras de insectos. Búsqueda de biomarcado;Funding Agency: SOCIEDAD ANDALUZA DE ALERGOLOGÍA E INMUNOLOGÍA CLÍNICA;Reference: alergosur16	GC01
CARMEN MORENO AGUILAR;Papel del microbioma en las enfermedades alérgicas por Prote;Funding Agency: SOCIEDAD ANDALUZA DE ALERGOLOGÍA E INMUNOLOGÍA CLÍNICA;Reference: alergosur17_001	GC01
MARIA BERTA RUIZ LEON;Papel del Microbioma en las Enfermedades Alérgicas Por Prote;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0119-2016	GC01
CARMEN MORENO AGUILAR;Anafilaxia por picaduras de insectos. Búsqueda de biomarcado;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/02170	GC01
CORONA ALONSO DIAZ;Implicaciones de la inmunosenescencia en el diseño de protoc;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01615	GC01
CARMEN MORENO AGUILAR;Asma, Reacciones Adversas y Alérgicas (ARADYAL);Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0006/0018	GC01
CARMEN MORENO AGUILAR;Anafilaxia por picaduras de insectos. ;Funding Agency: SOCIEDAD ESPAÑOLA DE ALERGOLOGÍA E INMUNOLOGÍA CLINICA;Reference: SEAIC_15	GC01
PILAR SERRANO DELGADO;Identificación de biomarcadores en pacientes alérgicos a ven;Funding Agency: CONSEJERÍA DE SALUD;Reference: PC-0278-2017	GC01
JOSÉ ANTONIO BÁRCENA RUIZ;Función de las peroxirredoxinas en la homeostasis celular co;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2016-80006-P	GC02
JOSÉ ANTONIO BÁRCENA RUIZ;Antitumor activity of nitric oxide: regulation of sorafenib;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-6264	GC02



MANUEL DE LA MATA GARCÍA;IMPORTANCIA DE LA ACTIVACIÓN DEL SISTEMA INMUNE PARA ELIMINA;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/01469	GC02	NURIA BARBARROJA PUERTO;Estudio de los mecanismos epigeneticos involucrados en el de;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01316	GC05
MARÍA DEL VALLE GARCÍA SÁNCHEZ;Marcadores Proteomicos de respuesta a infliximab biosimilare;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01352	GC02	EDUARDO COLLANTES ESTEVEZ;Red de Investigación en Inflamación y Enfermedades Reumática;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0012/0015	GC05
PATRICIA AGUILAR MELERO;Marcadores Proteómicos de Respuesta A Fármacos Anti-Tnf en ;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0199-2013	GC02	ENRIQUE ARANDA AGUILAR;CIBER-ONC ONCOLOGIA TUMORES DIGESTIVOS;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CB16/12/00349	GC06
MANUEL DE LA MATA GARCÍA;CONVENIO COLABORACION ENTRE CIBEREHD E INSTITUCIÓN;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MCI.CIBEREHD	GC02	ENRIQUE ARANDA AGUILAR;VARIACIONES GENÉTICAS ASOCIADAS A HIPERTENSIÓN Y TROMBOSIS C;Funding Agency: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER;Reference: AECC14/002	GC06
JULIAN CARLOS DE LA TORRE CISNEROS;COMBACTE-NET;Funding Agency: COMISIÓN EUROPEA;Reference: IMI-2012-001	GC03	JUAN RAFAEL DE LA HABA RODRÍGUEZ;Perfil epigenético en pacientes oncológicos con incrementos ;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/00516	GC06
JULIAN CARLOS DE LA TORRE CISNEROS;COMBACTE-CARE;Funding Agency: COMISIÓN EUROPEA;Reference: IMI-2013-001	GC03	SILVIA GUIL LUNA;Efecto Antitumoral de la Inmunoterapia Mediante Bloqueo de ;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0150-2017	GC06
JUAN JOSE CASTON OSORIO;CAVICOR;Funding Agency: PFIZER, S.A;Reference: INSPIRE-2018-02	GC03	LAURA MARIA LÓPEZ SANCHEZ;Estudio proteomico para la identificacion de nuevos biomarca;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0268-2014	GC06
JULIAN CARLOS DE LA TORRE CISNEROS;Ensayo clínico de suspensión de la profilaxis con valgancicil;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/00402	GC03	ENRIQUE ARANDA AGUILAR;Asociación entre inmunidad antitumoral, el sistema renina-an;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01271	GC06
SARA CANTISAN BOHORQUEZ;Impacto de la ausencia de respuesta T CD8+ CMV-específica en;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01419	GC03	ANTONIO RODRÍGUEZ ARIZA;Las relaciones entre óxido nítrico y subtipos moleculares en;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01508	GC06
JULIAN CARLOS DE LA TORRE CISNEROS;Estudio de la cinetica de la inmunidad T CD8+;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0294-2014	GC03	ENRIQUE ARANDA AGUILAR;;Funding Agency: ;Reference: INTER.0003/1	GC06
JULIAN CARLOS DE LA TORRE CISNEROS;Premio - Julián de la Torre Cisneros- Fundación Senefro;Funding Agency: SOCIEDAD ESPAÑOLA DE NEFROLOGÍA;Reference: PFS.002	GC03	SAGRARIO SORIANO CABRERA;Papel de Fgf3 en la Progresión del Daño Vascular Asociado A;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0136-2016	GC07
ELENA PÉREZ NADALES;La carga bacteriana como factor de riesgo de colonización, d;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01631	GC03	ALEJANDRO MARTÍN MALO;INTELIGENCIA ARTIFICIAL: UNA NUEVA ALTERNATIVA PARA ANALIZAR;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0311-2014	GC07
JULIAN CARLOS DE LA TORRE CISNEROS;RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0016/0008	GC03	PEDRO ALJAMA GARCÍA;Actividad inflamatoria mediada por la interacción de CD14+CD;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01785	GC07
EDUARDO MUÑOZ BLANCO;Identificación de nuevas funciones y substratos de la proteí;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SAF2016-75228-R.	GC04	ALEJANDRO MARTÍN MALO;Mecanismos moleculares implicados en los procesos de adhesió;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01785	GC07
EDUARDO MUÑOZ BLANCO;ESTUDIO DEL MECANISMO DE ACCION DEL VCE-004.8, UN DERIVADO Q;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SAF2017-87701-R	GC04	PEDRO ALJAMA GARCÍA;Red de Investigacion Renal REDINRENKidney Research Network;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0009/0034	GC07
EDUARDO MUÑOZ BLANCO;Desarroll preclínico de VCE-003.2 para el tratamiento de la;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: RTC-2015-3364-1	GC04	MARIA SAGRARIO SORIANO CABRERA;Papel modulador de micropartículas endoteliales ;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-7352	GC07
NURIA BARBARROJA PUERTO;CP15/00158PROYECMOCHILA Miguel Servet I BARBARROJA_COLLANTES;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CP15/00158	GC05	JUSTO PASTOR CASTAÑO FUENTES;Alteraciones de la maquinaria de splicing alternativo en cán;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2016-80360-R.	GC08
ROSARIO LOPEZ PEDRERA;MECANISMOS CELULARES Y MOLECULARES ;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-7940	GC05	ANTONIO JESÚS MARTÍNEZ FUENTES;Presencia y acciones antitumorales del sistema KISS-1/KISS1-;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0077-2016	GC08
EDUARDO COLLANTES ESTEVEZ;PRECISESADS;Funding Agency: COMISIÓN EUROPEA;Reference: IMI/0002	GC05	JOSE LOPEZ MIRANDA;EFECTO DE UNA DIETA MEDITERRANEA RICA EN ACEITE DE OLIVA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: AGL2015-67896-P	GC09
EDUARDO COLLANTES ESTEVEZ;Can Inertial Movement Sensors (IMUs) provide a valid and rel;Funding Agency: FOUNDATION FOR RESEARCH IN RHEUMATOLOGY;Reference: FOREUM-2015-001	GC05	ANTONIO CAMARGO GARCÍA;CONTRATOS MIGUEL SERVET TIPO I 2014;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MSCP14/00114	GC09
ROSARIO LOPEZ PEDRERA;Estudio de los mecanismos de aterotrombosis en enfermedades ;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01333	GC05	JOSE LOPEZ MIRANDA;Análisis nutrigenómico del efecto de una dieta mediterránea ;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: P11-CVI-7450	GC09
YOLANDA JIMÉNEZ GÓMEZ;Nuevos Mecanismos de Regulación Génica Post-Transcripcional;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0139-2017	GC05	JOSE LOPEZ MIRANDA;Fatty Acid Metabolism - Interlinking Diet with Cardiometabol;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: ERA-HDHL BioNH 2016-001	GC09
MARIA ANGELES AGUIRRE ZAMORANO;Identificacion y Caracterizacion de Nuevos Biomarcadores Co;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0285-2017	GC05	ANTONIO GARCÍA RIOS;PREDIMED+DM: Efecto de una dieta mediterránea hipocalórica y;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/00618	GC09
FRANCISCO ALBURQUERQUE SENDÍN;Evaluación Clinimétrica de Los Sensores Inerciales de Movim;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0324-2017	GC05		



CARMEN MARÍN HINOJOSA;Identificación de nuevos biomarcadores terapéuticos en la pr;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/00733	GC09	ROCÍO GUZMÁN RUIZ;Identificación de biomarcadores y factores predictores de re;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0159-2016	GC11
FRANCISCO JAVIER DELGADO LISTA;POWER2DM - Predictive model-based decision support for diabe;Funding Agency: COMISIÓN EUROPEA;Reference: PHC28-2015-001	GC09	MARIA DEL MAR MALAGÓN POYATO;Caracterización de componentes extracelulares e intracelular;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2016-76711-R	GC11
FRANCISCO PÉREZ JIMÉNEZ;La Dieta Mediterránea asociada a probióticos mejora la capac;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01777	GC09	MARIA DEL MAR MALAGÓN POYATO;Red Temática de Investigación sobre plasticidad adiposa y su;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2015-70454-REDT	GC11
YOLANDA ALMADEN PEÑA;Influencia del Metabolismo Mineral sobre la disfunción endot;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01024	GC09	MARIA DEL MAR MALAGÓN POYATO;.Integración de plataformas para la identificación de dianas;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: rtc-2016-4589-1	GC11-GC04
ANTONIO GARCÍA RIOS;PREDIMED+DM: Efecto de una pérdida de peso con dieta mediter;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01183	GC09	LUIS ANGEL PÉRULA DE TORRES;EFECTO SOBRE LA CALIDAD DE VIDA DEL TRATAMIENTO CON DISPOSIT;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0025-2015	GC12
FRANCISCO FUENTES JIMÉNEZ;Determinación de nuevas variables predictoras de enfermedad;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01320	GC09	MARIA DEL CARMEN ARIAS BLANCO;UTILIDAD DE LA TELEDERMATOSCOPIA EN EL DIAGNOSTICO DE LESION;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0067-2016-AP	GC12
JOSE LOPEZ MIRANDA;EARLY PREDICTORS AND CAUSES OF LOSS OF PHENOTYPIC FLEXIBILIT;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PIE14/00005	GC09	MARIA DEL PILAR CARRERA GONZALEZ;Adaptación y Validación de la Versión Española de la Pain A;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0357-2017	GC12
CARMEN MARÍA HARO MARISCAL;Herramienta de Diagnóstico Precoz de Cáncer Colorrectal Basa;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0156-2016	GC09	MANUEL RICH RUÍZ;Eficacia del Programa de Ejercicios de Otago aplicado de for;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01520	GC12
FRANCISCO PÉREZ JIMÉNEZ;FORMALIZACIÓN DE ACUERDO COMPENZACIÓN ECONÓMICA;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MCI.CIBEROBN	GC09	CARLOS PERULA DE TORRES;Efectividad de Una Intervención No Farmacológica Multicompon;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: AP-0079-2016	GC12
JOSE LOPEZ MIRANDA;Proyecto de Investigación Prof. Dr. Miguel Vilardell;Funding Agency: FUNDACION ESPAÑOLA DE MEDICINA INTERNA;Reference: MVILARDELL_01_2018	GC09	ANTONIO HIDALGO REQUENA;;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: AP-0140-2017	GC12
JOSE LOPEZ MIRANDA;EARLY PREDICTORS AND CAUSES OF LOSS OF PHENOTYPIC FLEXIBILIT;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PIE14/00031	GC09	ANA MARIA ROLDÁN VILLALOBOS;;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: AP-0155-2018	GC12
ELENA M YUBERO SERRANO;Efecto del Consumo de Dos Modelos de Dieta en el Desarrollo;Funding Agency: CONSEJERÍA DE SALUD;Reference: PC-0283-2017	GC09	JUAN MARIANO RODRÍGUEZ PORTILLO;Influencia de la excreción urinaria de fósforo sobre la prog;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/00638	GC13
ELENA M YUBERO SERRANO;Efectos de dos modelos de dieta cardiovasculares sobre la r;Funding Agency: SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS;Reference: FEA2018/01	GC09	Mª ENCARNACIÓN RODRÍGUEZ ORTIZ;Caracterización de Los Cambios en Wnt Inducidos Por Magnesio;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0154-2017	GC13
MARIA SOLEDAD AVENDAÑO HERRADOR;Papel fisiopatológico, pronóstico y diagnóstico de los miRNA;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0370-2016	GC10	JUAN MARIANO RODRÍGUEZ PORTILLO;Caracterización de los cambios en Wnt inducidos por Mg y esc;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01010	GC13
MANUEL TENA SEMPERE;Análisis del papel de las kisspeptinas como elemento clave e;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2014-57581-P	GC10	JUAN RAFAEL MUÑOZ CASTAÑEDA;NUEVA TERAPIA PARA EL TRATAMIENTO DE LA OSTEOARTROSIS DEGENE;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: DTS16/00061	GC13
MANUEL TENA SEMPERE;"KISSPEPTINAS Y PUBERTAD - NUEVOS ASPECTOS FISIOLÓGICOS E IM;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2017-83934-P	GC10	Mª SAGRARIO CAÑADILLAS LÓPEZ;Efecto de la hipoxia sobre el potencial regenerativo de Célu;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/00087	GC14
JUAN CASTELLANO RODRIGUEZ;Hipogonadismo inducido por sobrepeso como principal factor e;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SAF2014-56995-JIN	GC10	INMACULADA CONCEPCIÓN HERRERA ARROYO;DESARROLLO PRE-CLINICO DE UN NUEVO MEDICAMENTO DE TERAPIA CE;Funding Agency: CONSEJERÍA DE SALUD;Reference: SALUD-201600073092-TRA	GC14
JUAN ROA RIVAS;PROYECTO MOOCHILA M Servet Juan Roa;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CP15/00047	GC10	JUANA SERRANO LOPEZ;ANALISIS DE EXPRESION GENICA EN PLATAFORMA NANOSTRING Y DE M;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0364-2016	GC16
MANUEL TENA SEMPERE;MicroRNAs y Salud Reproductiva: Estudios mecanísticos y tras;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: FQM1943	GC10	CARMEN MARTÍNEZ LOSADA;BECA FUNDACION ANDALUZA PARA EL ESTUDIO Y TRATAMIENTO DE LAS;Funding Agency: ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA;Reference: AAHH2016_001	GC16
MANUEL TENA SEMPERE;FidiPro;Funding Agency: ACADEMY OF FINLAND;Reference: FidiPro-2014-001	GC10	CARMEN MARTÍNEZ LOSADA;JORNADAS DE INVESTIGACIÓN EN HEMATOLOGÍA EN ANDALUCÍA;Funding Agency: ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA;Reference: AAHH2017_001	GC16
VIOLETA HERAS DOMINGUEZ;Novel role of central ceramide signaling in mediating obesit;Funding Agency: EUROPEAN SOCIETY OF ENDOCRINOLOGY;Reference: ESE-2018-01	GC10	JOSE MANUEL QUESADA GÓMEZ;Efecto de la PTH(1-34) y Vitamina D3 en la movilización de c;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01857	GC17
JUAN ROA RIVAS;Pubertad y riesgo metabólico en niños obesos: Alteraciones e;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01243	GC10	JOSE MANUEL QUESADA GÓMEZ;CIBER-BIMINI Fisiopatología del Sistema Endocrino de la v;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CB16/10/00501	GC17
PINEDA REYES, R. ;Society for Endocrinology Early Career Grant for Rafael Pineda Reyes;Funding Agency: SOCIETY FOR ENDOCRINOLOGY;Reference: Sfe-ECG-2017-001	GC10	ANTONIO CASADO DÍAZ;Efecto de la PTH(1-34) y Vitamina D3 en la movilización y ac;Funding Agency: FUNDACIÓN ESPAÑOLA DE INVESTIGACIÓN ÓSEA Y DEL METABOLISMO MINERAL;Reference: FEIOMM2016_001	GC17



RUBÉN CIRIA BRU;MECANISMOS DE REACONDICIONAMIENTO DEL INJERTO HEPATICO ESTEA;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/01559	GC18	LUIS MARTÍNEZ MARTÍNEZ;Importancia de la selección de mutantes estables y de varian;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/02241	GC24
FRANCISCO JAVIER BRICEÑO DELGADO;VALIDACION EXTERNA DE UN MODELO DE EMPAREJAMIENTO DONANTEES.;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01570	GC18	LUIS MARTÍNEZ MARTÍNEZ;BECA 2016 PARA LA INVESTIGACIÓN DE LA SOCIEDAD ANDALUZA DE T;Funding Agency: SOCIEDAD ANDALUZA DE TRASPLANTES DE ÓRGANOS Y TEJIDOS;Reference: SATOT_2016_001	GC24
FRANCISCO JAVIER BRICEÑO DELGADO;VALIDACION EXTERNA DE UN MODELO DE EMPAREJAMIENTO DONANTE-RE;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0312-2014	GC18	LUIS MARTÍNEZ MARTÍNEZ;Study of the mechanisms of resistance to Ceftazidime-Avibact;Funding Agency: PFIZER, S.A;Reference: INSPIRE-2018-01	GC24
ÁLVARO ARJONA SÁNCHEZ;EuroPMP;Funding Agency: COMISIÓN EUROPEA;Reference: OC-2017-1-17101	GC18	SEBASTIAN VENTURA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: TIN2017	GC25
RUBÉN CIRIA BRU;RESCATE DE INJERTOS DESCARTADOS PARA TRASPLANTE HEPÁTICO MED;Funding Agency: FUNDACIÓN MUTUA MADRILEÑA;Reference: FMM-14-002	GC18	ANTONIO RIVERO ROMAN;Cohorte de seguimiento de pacientes con infección crónica;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI15/01017	GC26
JUAN LUIS GARRIDO CASTRO;Desarrollo y Validación del Uso de Sensores Inerciales Aplic;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0079-2016	GC19	ANTONIO RIVERO JUAREZ;IMPACTO DE LA INFECCION AGUDA POR VIRUS DE HEPATITIS E EN PA;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/01297	GC26
RAFAEL MEDINA CARNICER;VOLUMETRIC MEASURING SYSTEM;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: RTC-2016-5661-1_01	GC19	MANUEL MARIO FRIAS CASAS;Optimización del Diagnóstico Molecular de la Infección Por ;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0477-2017	GC26
RAFAEL MUÑOZ SALINAS;Sistema de vision para la localizacion y mapeado fusionando ;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: TIN2016-75279-P	GC19	ANTONIO RIVERO ROMAN;RED ESPAÑOLA DE INVESTIGACION EN SIDA (RIS);Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0025/0034	GC26
MARIA ARACELI SANCHEZ RAYA;Aplicación Móvil E Informática para la Detección, Diagnostic;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0072-2016	GC20	ANTONIO RIVERO;PARTNER II;Funding Agency: ;Reference: PARTNER II	GC26. NODE
JUAN ANTONIO MORIANA ELVIRA;Tratamientos psicológicos breves basados en la evidencia par;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: Psi2014-56368-r	GC20	ELENA M YUBERO SERRANO;NEW BIOMARKERS AND THERAPEUTIC TARGETS IN BREAST AND PROSTAT;Funding Agency: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER;Reference: AECC 2018/01	GC27
FELICIANO PRIEGO CAPOTE;ARISTOIL;Funding Agency: COMISIÓN EUROPEA;Reference: MED-1033	GC21	RAUL MIGUEL LUQUE HUERTAS;Nuevos mecanismos moleculares en la interacción patológica e;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/00264	GC27
FELICIANO PRIEGO CAPOTE;Desarrollo de estrategias para la mejora de la detección por;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: CTQ2015-68813-R	GC21	MANUEL DAVID GAHETE ORTIZ;Implicación de nuevos factores moleculares y endocrino-metab;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/02287	GC27
DAVID CALVO MALLON;Funding Agency: CDTI Feder Interconecta. ;Reference: ITC-20161265	GC21	MANUEL DAVID GAHETE ORTIZ;PROYECTO MOOCHILA MServer Manuel David Gahete;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CP15/00156	GC27
FELICIANO PRIEGO CAPOTE; Desarrollo de grasas avanzadas GR2020. ;Funding Agency: CDTI Feder Interconecta. ;Reference: ITC-20151323	GC21	RAUL MIGUEL LUQUE HUERTAS;Ghrelin-O-acil transferasa (GOAT): nuevo biomarcador para e;Funding Agency: FUNDACIÓN PARA LA INNOVACIÓN Y LA PROSPECTIVA EN SALUD EN ESPAÑA;Reference: FIPSE-3188-2017	GC27
Mª TERESA ROLDÁN ARJONA;Reparacion del ADN por escision de bases: del mantenimiento ;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BFU2016-80728-P	GC22	RAUL MIGUEL LUQUE HUERTAS;GOAT (Ghrelin-O-acil transferase): new biomarker for prostat;Funding Agency: FUNDACIÓN LA CAIXA;Reference: CAIXAIMPULSE_003	GC27
Mª TERESA ROLDÁN ARJONA;Epigenetic Chemical Biology;Funding Agency: COMISIÓN EUROPEA;Reference: COST-2014-002	GC22	RAUL MIGUEL LUQUE HUERTAS;Therapeutic opportunities for somatostatin, ghrelin and their receptors in pituitary pathologies: identification of new molecular targets and contribution of splicing mechanisms. ;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-1406	GC27
Mª TERESA ROLDÁN;CVI-7576 ;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CVI-7576	GC22	EDUARDO AGÜERA MORALES;ICT4Life - ICT services for Life Improvement for the Elderly;Funding Agency: COMISIÓN EUROPEA;Reference: PHC25-2015-001	GE01
MARÍA DOLORES ORDOÑEZ DÍAZ;Proyecto Lactoprem: Ensayo Clínico Controlado Aleatorizado p;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0323-2016	GC23	EDUARDO AGÜERA MORALES;Red Española de Esclerosis Múltiple;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0015/0026	GE01
MARIA ELENA MATEOS GONZALEZ;Children's Liver Tumour European Research Network;Funding Agency: COMISIÓN EUROPEA;Reference: PHC-18-2015-001	GC23	ISAAC TÚNEZ FIÑANA;DESARROLLO DE FARMACOS FRENTE A CELULAS MADRES TUMORALES;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: RTC-2015-3386-1_1	GE01
MONTSERRAT ANTON GAMERO;Creación de Un Sistema de Apoyo A la Toma de Decisiones Clí;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0385-2016	GC23	JUAN RUANO RUIZ;Proyecto Éaco: Desarrollo y Validación de Un Instrumento Te;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0316-2017	GE03
MARIA MERCEDES GIL CAMPOS;CIBER DE MARIA MERCEDES GIL CAMPOS;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CB15/00131	GC23	JUAN RUANO RUIZ;Ensayo clínico aleatorizado y multicéntrico para evaluar, en;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: ICI14/00136	GE03
JUAN LUIS PEREZ NAVERO.;EUCLIDS -Thegeneticbasis of meningococcal and otherlifethreateningbacterialinfections of childhood;Funding Agency: COMISIÓN EUROPEA;Reference: Perez Navero JL. EUCLIDS -Thegeneticbasis of meningococcal and otherlifethreateningbacterialinfections of childhood. Funding Agency: EuropeanCommission. Reference: OPI2010/200	GC23 NODE	MARIA DEL CARMEN TABERNERO URBIETA;La influencia de la autoeficacia y otras variables motivacio;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PSI2014-58609-R	GE04
IRENE GRACIA AHUFINGER;Estudio de las modificaciones epigenéticas inducidas por el ;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/01225	GC24	ALICIA ARENAS MORENO.;Análisis de indicadores fisiológicos y factores psicosociales en la salud laboral de profesionales sanitarios (SALPRO).;Funding Agency: Consejería de Salud de la Junta de Andalucía;Reference: PI-0098-2018	GE04
LUIS MARTÍNEZ MARTÍNEZ;Heterorresistencia y persistencia en Klebsiella pneumoniae R;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI14/01911	GC24		



JULIA CARRASCO VALIENTE;Patrones Asistenciales de Cáncer de Próstata en Andalucía y;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0126-2016	GE05
MARÍA JOSÉ REQUENA TAPIA;ONCOCHECK;Funding Agency: COMISIÓN EUROPEA;Reference: SMEInst-2017-01	GE05
MARÍA JOSÉ REQUENA TAPIA;Identificación de un panel de biomarcadores moleculares con;Funding Agency: ASOCIACIÓN ESPAÑOLA DE UROLOGÍA;Reference: FIU16/001	GE05
ANTONIO LÓPEZ BELTRÁN;Desarrollo de un perfil de expresión génica con valor pronós;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI17/01981	GE05 CO-IP
PAULA MORENO CASADO;Utilidad de la perfusión pulmonar ex-vivo para optimizar los;Funding Agency: FUNDACIÓN MUTUA MADRILEÑA;Reference: FMM16_002	GA01
PAULA MORENO CASADO;Impacto del oxigenador de membrana extracorporeo sobre el i;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: PI-0296-2014	GA01
Mª AURORA RODRÍGUEZ BORREGO;Violencia, perpetrada por la pareja íntima, en profesionales;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI13/01253	GA02
PABLO JESUS LOPEZ SOTO;Cronopreención en las Caídas Intrahospitalarias de Persona;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0360-2017	GA02
BERNABÉ JURADO GÁMEZ;BECA NEUMOSUR Nº 10/2016;Funding Agency: NEUMOSUR;Reference: Neumosur16_01	GA03
MARÍA NURIA FEU COLLADO;Proyecto nº 6/2014;Funding Agency: FUNDACION NEUMOSUR;Reference: Proyecto Neumosur 6	GA03
BERNABÉ JURADO GÁMEZ.;Discovery of diagnostic biomarkers in non-invasive samples using next-generation proteomics.;-Funding Agency: FUNDACION NEUMOSUR;Reference: 1/2018	GA03
INES Mª TOFÉ VALERA;BECA AYUDA INVESTIGACIÓN AEP 2017;Funding Agency: ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA DE ATENCIÓN PRIMARIA;Reference: AEP/2017	GA05
INES Mª TOFÉ VALERA;ALBINO;Funding Agency: COMISIÓN EUROPEA;Reference: PHC-18-2015-002	GA05
JOSÉ MARÍA GALLARDO GALERA;Prevención, detección precoz, tratamiento y rehabilitación d;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: RD16/0008/0018	GA07
JOSÉ MARÍA GALLARDO GALERA;MEJORA DEL BIENESTAR Y LA SEGURIDAD DEL PACIENTE EN LOS PROC;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: RTC-2016-5149_001	GA07
JOSÉ GARCÍA-REVILLO GARCÍA;Estudio y Desarrollo de Un Método de Medición de la Angiogé;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0452-2017	GA08
IGNACIO MUÑOZ CARVAJAL;STARS-Empowering Patients by Professional Stress Avoidance a;Funding Agency: COMISIÓN EUROPEA;Reference: PM-12-2016-002	GA09
CÉSAR HERVÁS MARTÍNEZ;ORDINAL CLASSIFICATION AND PREDICTION ALGORITHMS IN RENAWABL;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: TIN2014-54583-C2-1-R	GA11
CÉSAR HERVÁS-MARTÍNEZ AND PEDRO ANTONIO GUTIÉRREZ.;Hybrid Algorithms combining Machine-Learning and meta-hEurisTics for ordinal classification and prediction (HAMLET).;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: TIN2017-85887-C2-1-P.	GA11
PEDRO ANTONIO GUTIÉRREZ.;Learning Machines for Singular Problems and Applications (MAPAS).;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: TIN2017-90567-REDT.	GA11
FERNANDO SARRAMEA CRESPO;Eficacia para la cesación tabáquica en el enfermo con trasto;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: PI16/00802	GA12
INMACULADA HERRADOR MONTIEL;RECOVERING LIFE WELLBEING THROUGH PAIN SELF-MANAGEMENT TECHN;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: PHC-27-2015-001	ANESTHESIA UNIT

LOURDES FERNÁNDEZ DELGADO;Incidencia de angioedema bradiginérgico en pacientes con dol;Funding Agency: SOCIEDAD ANDALUZA DE ALERGOLOGÍA E INMUNOLOGÍA CLÍNICA;Reference: alergosur17_002	INMUNOLOGY & ALLERGY UNIT
RAFAEL LEÓN LÓPEZ;PREPARE;Funding Agency: COMISIÓN EUROPEA;Reference: HEALTH.2013.2.3.3-1	INTENSIVE CARE UNIT
RAFAEL LEÓN LÓPEZ;COMBACTE-MAGNET;Funding Agency: COMISIÓN EUROPEA;Reference: IMI-2014-01	INTENSIVE CARE UNIT
JUAN SOLIVERA VELA;Diagnóstico y Pronóstico Postquirúrgico Personalizado de Gli;Funding Agency: CONSEJERÍA DE SALUD;Reference: PI-0143-2016	NEUROSURGERY UNIT
MANUEL JIMBER DEL RIO;Mejora de la Seguridad del Paciente en Base A la Introducci;Funding Agency: CONSEJERÍA DE SALUD;Reference: PIN-0483-2017	QUALITY UNIT

FELLOWSHIPS	IMIBIC GROUP
CARMEN MORENO AGUILAR;S0169_Intensificación_Carmen Moreno Aguilar;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0169	GC01
MANUEL DE LA MATA GARCÍA;S0186-Intensificación-Manuel de la Mata;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0186	GC02
SARA CANTISAN BOHORQUEZ;CP17/00096-Miguel Servet-Sara Cantisan Bohorquez;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CP17/00096	GC03
JULIAN CARLOS DE LA TORRE CISNEROS;S0111 CONTRATO DE LARGA DURACION SAS 2015 JULIAN DE LA TORR;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0111	GC03
BELEN PALOMARES CAÑERO;CONTRATOS I-PFIS: Belen Palomares Cañero _ Eduardo Muñoz;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: IFI15/00022	GC04
RAFAELA ORTEGA CASTRO;CM15/00211 RIO HORTEGA: RAFAELA ORTEGA _ EDUARDO COLLANTES;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CM15/00211	GC05
NURIA BARBARROJA PUERTO;MSCP15/00158 Miguel Servet I _ NURIA BARBARROJA ;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MSCP15/00158	GC05
CARLOS PÉREZ SANCHEZ;Extensión Financiación Contrato Carlos Pérez Sánchez PI Exce;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-7940-RRHH-2017	GC05
EDUARDO COLLANTES ESTEVEZ;S0298-Intensificación-Eduardo Collantes;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0298	GC05
ALEJANDRO IBAÑEZ COSTA;Juan de la Cierva-Alejandro Ibanez Costa;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SFJC1600I030825XV1	GC05
SILVIA GUIL LUNA;AYUDA JOSE CASTILLEJOS SILVIA GUIL;Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL;Reference: JC2017/01	GC06



ANTONIO RODRÍGUEZ ARIZA;Renovación Nicolas Monardes Conv 2012: Antonio Rodriguez Ari;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: RC-0002-2016	GC06	JOAQUIN SÁNCHEZ GARCÍA;Becas de Investigación FEHH Convocatoria 2015-2016;Funding Agency: SOCIEDAD ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA;Reference: FEHH15_001	GC16
ENRIQUE ARANDA AGUILAR;S0172-Intensificación-Enrique Aranda;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0172	GC06	JOSE MANUEL QUESADA GÓMEZ;S0303_Intensificación_ Jose Manuel Quesada;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0303	GC17
SILVIA GUIL LUNA;SFJC1400I022254XV0 AYUDAS JUAN DE LA CIERVA - FORMACIÓN 2014;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SFJC1400I022254XV0	GC06	ÁLVARO ARJONA SÁNCHEZ;Beca AEC: Estudio multicéntrico, randomizado, para evaluar e;Funding Agency: ASOCIACION ESPAÑOLA DE CIRUJANOS;Reference: AEC001/18	GC18
SILVIA GUIL LUNA;JUAN DE LA CIERVA INCO-SILVIA GUIL LUNA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SIJC1600I029786XV0	GC06	HAMID SARMADI ;CONTRATOS I-PFIS 2016: SARMADI NASSER, HAMID;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: IFI16/00033	GC19
ANDRÉS CARMONA MUÑOZ;Ampliación Contratación Andrés Carmona PI Excelencia Convoca;Funding Agency: CONSEJERÍA DE CONOCIMIENTO, INVESTIGACIÓN Y UNIVERSIDADES;Reference: CTS-7352-RRHH-2017	GC07	EDUARDO PEREZ PERDOMO;IFI17/00015-iPFIS-Eduardo Pérez Perdomo;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: IFI17/00015	GC25
SERGIO PEDRAZA AREVALO;AYUDA DEL PROGRAMA DE FORMACIÓN DE PROFESORADO UNIVERSITARIO;Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL;Reference: FPU14	GC08	JOSÉ ANTONIO DELGADO OSUNA;Desarrollo de Modelos Predictivos Aplicados A Cáncer Colorr;Funding Agency: CONSEJERÍA DE SALUD;Reference: EF-0312-2017	GC25
JOSE LOPEZ MIRANDA;BES-2013-062614 AYUDAS PARA CONTRATOS PREDOCTORALES J.lopez;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BES-2013-062614	GC09	ANTONIO RIVERO JUAREZ;RH-0024-2013 Estudio hepatitis viricas en..Antonio Rivero J ;Funding Agency: CONSEJERÍA DE SALUD;Reference: RH-0024-2013	GC26
CRISTINA VALS DELGADO;BES-2016-077476 AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: BES-2016-077476	GC09	MARIA DE LOS ANGELES RISALDE MOYA;Sara Borrel Mª Angeles Risalde_Antonio Rivero;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CD16/00209	GC26
IRENE RONCERO RAMOS;Sara Borrel-Irene Roncero Ramos;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CD16/00047	GC09	ANTONIO JOSE LEON GONZALEZ;Sara Borrell ANTONIO JOSE LEON _ Raul Luque;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CD16/00092	GC27
MAGDALENA PEREZ CARDELO;FI17/00081-PFIS-Magdalena Pérez Cardelo;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: FI17/00081	GC09	ENRIQUE GOMEZ GOMEZ;Rio Hortega: Enrique Gomez _ Raul Luque;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CM16/00180	GC27
PABLO PÉREZ MARTÍNEZ;INT15/00097 INTENSIFICACION PABLO PEREZ MARTINEZ;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: INT15/00097	GC09	EMILIA MARIA ALORS PEREZ;FI17/00282-PFIS-Emilia Alors Pérez;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: FI17/00282	GC27
YOLANDA ALMADEN PEÑA;Renovación Nicolás Monardes Conv 2012: Yolanda Almadén;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: RC-0001-2016	GC09	MANUEL DAVID GAHETE ORTIZ;Miguel Servet I - Manuel David Gahete _ Justo;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MSCP15/00156	GC27
SILVIA DE LA CRUZ ARES;JCF-Silvia de la Cruz-GC09 Nutrigenomica;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: SFJC700I0163V0	GC09	MARINA ALVAREZ BENITO;ESTABILIZACIÓN ISCIII-SAS GEMMA ROJO;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: I3SNS-EST2013	GA08
AURA DULCINEA HERRERA MARTÍNEZ;Rio Hortega_ Aura Dulcinea_ AES2017;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CM17/00104	GC10	MARINA ALVAREZ BENITO;INTENSIFICACIONES ANDALUCIA;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: I3SNS-INT2013	GA08
MARIA SOLEDAD AVENDAÑO HERRADOR;Sara Borrell_ Maria Soledad Avendaño_ AES2017;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: CD17/00251	GC10	IGNACIO ORTEA GARCÍA;Estancia formativa para el aprendizaje de la aplicación de t;Funding Agency: SOCIEDAD ESPAÑOLA PROTEOMICA;Reference: SeProt17_01	CORE FACILITIES
JUAN ROA RIVAS;Miguel Servet I - Juan Roa _ Tena;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: MSCP15/00047	GC10	IGNACIO ORTEA GARCÍA;Vinculación de Técnicos a Estructuras Comunes de Apoyo a la;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0067-2018	CORE FACILITIES
MANUEL TENA SEMPERE;Overweight-induced Hypogonadism as major factor for the gene;Funding Agency: COMISIÓN EUROPEA;Reference: MSCA-EF-2014-002	GC10	MARÍA ESTHER PERALBO SANTAELLA;Vinculación de Técnicos a Estructuras Comunes de Apoyo a la;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0100	CORE FACILITIES
RAFAEL PINEDA REYES;Tecnico de apoyo: VETERINARIO;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2014-10043-I	GC10	JOSE MIGUEL GUZMÁN DE DAMAS;TECNICOS PROMOCION EMPLEO JOVEN:PROTEOMICA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PEJ-2014-A-86856-2	CORE FACILITIES
JUAN RAFAEL MUÑOZ CASTAÑEDA;S0024 VINCULACION DE INVESTIGADORES_JUAN MUÑOZ;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0024	GC13	ANABEL POZO SALAS;Personal Técnico Apoyo MINECO: Animalario (Anabel Pozo);Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2015-11077-I	CORE FACILITIES
ROSARIO JIMENEZ MORENO;S0137 Convocatoria SAS Técnicos de Apoyo: Rosario Jiménez (I);Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0137	GC14	GEMA GARCÍA JURADO;Técnicos de apoyo 2015 (GEMA GARCIA JURADO);Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2015-11242-I	CORE FACILITIES
INMACULADA CONCEPCIÓN HERRERA ARROYO;DESARROLLO PRE-CLINICO DE UN NUEVO MEDICAMENTO DE TERAPIA CE;Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD;Reference: OH-0014-2018	GC14		
FRANCISCO JOSE HIDALGO LESMES;Becas de la Sección de Hemodinámica y Cardiología Intervenci;Funding Agency: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA;Reference: BECA.SEC.01/17	GC15		
FRANCISCO JOSE HIDALGO LESMES;Becas de la Sección de Hemodinámica y Cardiología Intervenci;Funding Agency: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA;Reference: BECA.SEC.02/17	GC15		



ANTONIA SÁNCHEZ ARROYO;Personal Técnico Apoyo MINECO: Isotopos (Antonia Sanchez);Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2015-11745-I	CORE FACILITIES
JOSE MIGUEL GUZMÁN DE DAMAS;Renovación técnicos.Área de Proteómica;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: S0016-1	CORE FACILITIES
JOSE MIGUEL GUZMÁN DE DAMAS;TECNICOS PROMOCION EMPLEO JOVEN:TECNICO DE GESTION;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PEJ-2014-A-90798	CORE FACILITIES
JOSE MIGUEL GUZMÁN DE DAMAS;AYUDAS PERSONAL TÉCNICO DE APOYO;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2013-8703-I	CORE FACILITIES
HELENA MOLINA ABRIL;Tecnico de apoyo: IMAGEN MEDICA;Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA;Reference: PTA2014-10046-I	CORE FACILITIES
Management Contracts in Health Research;Funding Agency: INSTITUTO DE SALUD CARLOS III;Reference: GIS17/00037	MANAGEMENT STAFF
GEMMA ROJO MARTINEZ;Renovación Nicolás Monardes Conv 2012: Gemma Rojo;Funding Agency: SERVICIO ANDALUZ DE SALUD;Reference: RC-0006-2016 (FIB)	MANAGEMENT STAFF

LIST OF FINANCED PROJECTS, NETWORKS & FELLOWSHIPS

PROJECTS & NETWORKS	IMIBIC GROUP
ALEJANDRA PERA ROJAS.Papel De Las Células Inmunes Pro-Inflamatorias En La Estenosis De La Válvula Aórtica (Cipyeva).. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0324-2018-FIB	GC01
CARMEN MORENO AGUILAR.Estudio de la discontinuación de la inmunoterapia con veneno de abeja. ¿Persiste la protección?. INSTITUTO DE SALUD CARLOS III.PI18/00313	GC01
MANUEL DE LA MATA GARCÍA.LIBERACIÓN DE CÉLULAS TUMORALES CIRCULANTES TRAS LA ABLACIÓN LOCAL DEL HEPATOCARCINOMA.INSTITUTO DE SALUD CARLOS III.PI18/01736	GC02
JUAN JOSE CASTON OSORIO.CAVICOR - Impact of the treatment with ceftazidime/avibactam vs best available therapy on mortality of patients with infections caused by carbapenem-resistant Enterobacteriaceae.PFIZER, S.A.INSPIRE-2018-02	GC03
JULIAN CARLOS DE LA TORRE CISNEROS.ENSAYO CLÍNICO DE EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE PROFILAXIS DE DURACIÓN REDUCIDA SEGUIDA DE PROFILAXIS INMUNOGUIADA EN RECEPTORES DE TRANSPLANTE PULMONAR (ESTUDIO CYTOCOR).INSTITUTO DE SALUD CARLOS III.PI18/00099	GC03
SARA CANTISAN BOHORQUEZ.IMPLantación de la monitorización de la Inmunidad Celular frente a Citomegalovirus en la práctica clínica para mejorar el control de la infección por este virus en el Trasplante de Órgano Sólido (IMPLICI-TOS).FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PIN-0541-2018-FIB	GC03
EDUARDO COLLANTES ESTEVEZ.Desarrollo y validación del uso de sensores inerciales aplicados a la metrología de pacientes con espondiloartritis axial..INSTITUTO DE SALUD CARLOS III.DTS18/00046	GC05
ROSARIO LOPEZ PEDRERA.Identificación de la heterogeneidad molecular asociada a la enfermedad cardiovascular, la evolución clínica y la respuesta terapéutica en patologías autoinmunes sistémicas..INSTITUTO DE SALUD CARLOS III.PI18/00837	GC05
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Caracterización molecular del cáncer de mama gestacional..INSTITUTO DE SALUD CARLOS III.PI18/00817	GC06

CRISTINA MORALES ESTEVEZ.ANÁLISIS DE LA COMBINACIÓN IN VITRO DE TRASTUZUMAB Y LIRILUMAB EN CÁNCER DE MAMA. IMPLICACIÓN DE LOS PROCESOS DE SPLICING ALTERNATIVO.SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA. SEOM18/01	Gc06
FATIMA GUERRERO PAVON.Bioingeniería Regenerativa: Modelo in vitro de recellularización de un scaffold renal con células mesenquimales..FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0268-2018-FIB	GC07
RAUL MIGUEL LUQUE HUERTAS.Ghrelin-O-acil-Transferasa (GOAT): Nuevo biomarcador para el Screening del Cáncer de Próstata..INSTITUTO DE SALUD CARLOS III.DTS18/00131	GC08
RAUL MIGUEL LUQUE HUERTAS.Ghrelin-O-acil transferasa (GOAT): nuevo biomarcador para el cáncer de próstata.FUNDACIÓN PARA LA INNOVACIÓN Y LA PROSPECTIVA EN SALUD EN ESPAÑA.FIPSE-3188-2017	GC08
ELENA M YUBERO SERRANO.NEW BIOMARKERS AND THERAPEUTIC TARGETS IN BREAST AND PROSTATE CANCER: MOLECULAR MECHANISMS IN THE PATHOLOGICAL INTERACTION BETWEEN OBESITY AND CANCER.ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER.AECC 2018/01	GC09
ELENA M YUBERO SERRANO.Efectos de dos modelos de dieta cardiovasculares sobre la reducción de los niveles de productos finales de glicación avanzada y su utilidad como marcador de arteriosclerosis carotídea en pacientes con enfermedad coronaria.. SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS.FEA2018/01	GC09
JOSE LOPEZ MIRANDA.Proyecto de Investigación Prof. Dr. Miguel Vilardell.FUNDACION ESPAÑOLA DE MEDICINA INTERNA. MVILARDELL_01_2018	GC09
IRENE RONCERO RAMOS.Papel de la célula alfa en el desarrollo de diabetes mellitus tipo 2 en personas de edad avanzada. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0107-2018-FIB	GC09
ELENA M YUBERO SERRANO.INFLUENCIA DE LA OBESIDAD EN LA EVOLUCIÓN DE LA NEFROPATÍA DIABÉTICA. CONSUMO DE DOS MODELOS DE DIETA CARDIOSALUDABLES COMO ESTRATÉGICA TERAPÉUTICA EN EL DESARROLLO DE LA ENFERMEDAD.INSTITUTO DE SALUD CARLOS III.PI18/01822	GC09
MIGUEL ÁNGEL SANCHEZ-GARRIDO NOGUERAS.Efectos Del Tratamiento Con Glp-1 Sobre La Función Gonadal Masculina En Condiciones De Diabetes: Análisis Mecánicos E Implicaciones Terapéuticas Para El Hipogonadismo Asociado A Enfermedad Metabólica..FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0358-2018-FIB	GC10
RAFAEL PINEDA REYES.Society for Endocrinology Early Career Grant for Rafael Pineda Reyes.SOCIETY FOR ENDOCRINOLOGY. SfE-ECG-2017-001	GC10
VIOLETA HERAS DOMINGUEZ.Novel role of central ceramide signaling in mediating obesity-induced precocious puberty.EUROPEAN SOCIETY OF ENDOCRINOLOGY. ESE-2018-01	GC10
ANTONIO HIDALGO REQUENA.Efectividad de la Intervención Educativa Frente Al Autoaprendizaje por Documentación en el Paciente Epoc.FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD.AP-0140-2017	GC12
ANA MARIA ROLDÁN VILLALOBOS.PROYECTO MINDUDD. Eficacia de Un Programa de Entrenamiento en Mindfulness y en Autocompasión de 4 Sesiones Frente Al de 8 Sesiones para Reducir el Estrés Laboral y el Burnout en Profesionales de Medicina y Enfermería Familiar y Comunitaria: Un Ensayo C.FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD.AP-0155-2018	GC12
JUAN RAFAEL MUÑOZ CASTAÑEDA.Estudios básicos y clínicos acerca de la disfunción vascular inducida por altos niveles de FGF23 en pacientes urémicos..INSTITUTO DE SALUD CARLOS III.PI18/00138	GC13
INMACULADA CONCEPCIÓN HERRERA ARROYO.desarrollo pre-clinico de un nuevo medicamento de terapia celular génica constituido por linfocitos t alogénicos con expresión inducible de receptor antigénico quimérico (car) anti cd-19 para el tratamiento de neoplasias b refractarias.FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD.OH-0014-2018	GC14
INMACULADA CONCEPCIÓN HERRERA ARROYO.Desarrollo preclínico de CAR-T anti CD19 universales con subpoblaciones predeterminadas de memoria y efectores y expresión inducible del CAR..INSTITUTO DE SALUD CARLOS III.PI18/01610	GC14
MANUEL PAN ÁLVAREZ-OSSORIO.valoración mediante ratio de presión instantánea del compromiso funcional del ramo lateral tras la implantación de stent en el vaso principal en lesiones coronarias en bifurcación.INSTITUTO DE SALUD CARLOS III. PI18/00750	GC15
JOSE MANUEL QUESADA GÓMEZ.caracterización de exosomas derivados de msc y su efecto combinado con 25 hidroxivitamina d3 e inhibidores de la dpp4 sobre la cicatrización en diabéticos de úlceras cutáneas.INSTITUTO DE SALUD CARLOS III. PI18/01659	GC17
ÁLVARO ARJONA SÁNCHEZ.EuroPMP - European Network on Pseudomyxoma Peritonei.COMISIÓN EUROPEA.OC-2017-1-17101	GC18



ÁLVARO ARJONA SÁNCHEZ. Estudio multicéntrico, randomizado, para evaluar el efecto adyuvante de la quimioterapia intraoperatoria intraperitoneal en hipertermia (HIPEC) con Mitomicina C asociada a cirugía frente a cirugía sola en el carcinoma colorrectal localmente. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0424-2018-FIB	GC18
MARIA MERCEDES GIL CAMPOS. MEDITERRANEAN LIFESTYLE IN PEDIATRIC OBESITY PREVENTION: MELI-POP. INSTITUTO DE SALUD CARLOS III.PI18/00930	GC23
LUIS MARTÍNEZ MARTÍNEZ. Study of the mechanisms of resistance to Ceftazidime-Avibactam in isolates of Klebsiella pneumoniae producing KPC-3 cultured from patients under Ceftazidime-Avibactam therapy. PFIZER, S.A. INSPIRE-2018-01	GC24
Mª DOLORES FERNÁNDEZ GARCÍA. Miguel Servet Projects. INSTITUTO DE SALUD CARLOS III .LACP18/00067	GC24
ANTONIO RIVERO JUAREZ. Biología molecular del virus de la hepatitis e. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.EF-0003-2018-FIB	GC26
ANTONIO RIVERO JUAREZ. Miguel Servet Projects. INSTITUTO DE SALUD CARLOS III .LACP18/00111	GC26
ANTONIO RIVERO ROMAN. evaluación de la influencia de la enfermedad hepática grasa no alcohólica sobre eventos clínicos y mortalidad de los pacientes infectados por vih. INSTITUTO DE SALUD CARLOS III.PI18/01270	GC26
IGNACIO ORTEA GARCÍA. Descubrimiento De Biomarcadores De Diagnóstico De Cáncer De Pulmón En Muestras No Invasivas (Espito) Utilizando Proteómica De Próxima Generación.. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA.PI-0321-2018-FIB	CORE FACILITATE PROTEOMIC

FELLOWSHIPS	IMIBIC GROUP
JORGE RODRIGUEZ GOMEZ. Contratos Río Hortega . INSTITUTO DE SALUD CARLOS III. CM18/00227	GC03
SILVIA GUIL LUNA. Estancia Silvia Guil Canada. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA. EF-0239-2018-FIB	GC06
MARIA VICTORIA PENDON RUIZ DE MIER. Río Hortega _ MªVictoria Pendon _ AES2018_CM18/00250. INSTITUTO DE SALUD CARLOS III. CM18/00250	GC07
SILVIA DE LA CRUZ ARES. Contratos Sara Borrell. INSTITUTO DE SALUD CARLOS III. CD18/00104	GC09
SILVIA DE LA CRUZ ARES. JCF-Silvia de la Cruz-GC09 Nutrigenómica. MINISTERIO DE ECONOMIA Y EMPRESA. SFJ-C70010163V0	GC09
ÁLVARO ARJONA SÁNCHEZ. Beca AEC: Estudio multicéntrico, randomizado, para evaluar el efecto adyuvante de la quimioterapia intraoperatoria intraperitoneal en hipertermia (HIPEC) con Mitomicina C asociada a cirugía frente a cirugía sola en el carcinoma colorrectal localmente avan. ASOCIACIÓN ESPAÑOLA DE CIRUJANOS. AEC001/18	GC18
MARÍA DOLORES FERNÁNDEZ GARCÍA. Contratos Miguel Servet i. INSTITUTO DE SALUD CARLOS III. CP18/00067	GC24
MANUEL MARIO FRIAS CASAS. CONTRATOS SARA BORRELL. INSTITUTO DE SALUD CARLOS III. CD18/00091	GC26
ANTONIO RIVERO JUAREZ. CONTRATOS MIGUEL SERVET - ANTONIO RIVERO JUÁREZ. INSTITUTO DE SALUD CARLOS III. CP18/00111	GC26
ANTONIO RIVERO JUAREZ. Estudio HepE-CoRIS. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA. PP18/07	GC26
MACARENA AGUILAR LUQUE. Comparación De Las Revisiones Sistemáticas Publicadas Con Su Protocolo Registrado En Prospero.. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA. EF-0399-2018-FIB	GE03
JESÚS GAY MIMBRERA. Elucidación Del Perfil Molecular Del Cuero Cabelludo De Pacientes Con Alopecia Frontal Fibrosante. FIBICO. FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA. EF-0400-2018-FIB	GE03
MARÍA ESTHER PERALBO SANTAELLA. Vinculación de Técnicos a Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos aprobados en la Convocatoria 2013. SERVICIO ANDALUZ DE SALUD. S0100	CORE FACILITIES MICRO.

IGNACIO ORTEA GARCÍA. Vinculación de Técnicos a Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos aprobados en la Convocatoria 2013.. SERVICIO ANDALUZ DE SALUD. S0067-2018	CORE FACILITIES PROT.
--	-----------------------

LIST OF CLINICAL TRIALS

	IMIBIC GROUPS
CARMEN MORENO AGUILAR. Análisis De Los Perfiles De Sensibilización Mediante Prueba Cutánea, Determinación De Ige Frente A Extracto Completo Y Diagnóstico Molecular En Pacientes Con Enfermedad Alérgica Respiratoria Por Sensibilización A Pólenes. Implicaciones Diagnósticas Y Tera. Reference:3070	GC01
CARMEN MORENO AGUILAR. Efecto De La Medicación Antihipertensiva En La Gravedad De La Anafilaxia Y Efectos Secundarios Durante La Inmunoterapia A Veneno De Insectos Himenópteros. Eadoas.. Reference:2739	GC01
CARMEN MORENO AGUILAR. Anafilaxia Por Picaduras De Insectos . Búsqueda De Biomarcadores De Respuesta Precoc A La Inmunoterapia Con Veneno De Himenóptero. Reference:3031	GC01
EVA IGLESIAS FLORES. Estudio Multicéntrico De Fase Ii/Iii, Aleatorizado, Doble Ciego Y Controlado Con Placebo, Para Evaluar La Seguridad Y La Eficacia Del Tratamiento De Inducción Con Bi 655130 En Pacientes Con Colitis Ulcerosa Activa De Moderada A Grave Que No Han Respondido. Reference:/3776	GC02
EVA IGLESIAS FLORES. Estudio Preliminar De Eficacia De Bi 655130 Como Tratamiento Adicional En Pacientes Con Colitis Ulcerosa Activa De Leve A Moderada Durante El Tratamiento Con Inhibidores De Tnf.. Reference:/3718	GC02
EVA IGLESIAS FLORES. Ensayo Abierto Y A Largo Plazo De La Seguridad Del Tratamiento Con Bi 655130 En Pacientes Con Colitis Ulcerosa Activa Moderada O Grave Que Han Finalizado Ensayos Anteriores De Bi 655130. Reference:/3973	GC02
JOSE LUIS MONTERO ALVAREZ. Estudio De Fase 2, Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad De Enzalutamida En Sujetos Con Carcinoma Hepatocelular Avanzado. Reference:/2952	GC02
MANUEL LUÍS RODRÍGUEZ PERÁLVAREZ. Estudio En Fase Ii, Multicéntrico Y Abierto, Para Investigar La Eficacia, La Seguridad Y La Farmacocinética Del Anticuerpo Monoclonal Anti-Pd-1, Bgb-A317, En Pacientes Con Carcinoma Hepatocelular Irresecable Tratado Anteriormente. Reference:/3826	GC02
JOSE LUIS MONTERO ALVAREZ. Estudio En Fase Iii, Aleatorizado Y Doble Ciego De Nivolumab Adyuvante Frente A Placebo Para Participantes Con Carcinoma Hepatocelular Que Presentan Un Riesgo Alto De Recaída Después De La Resección O La Ablación Hepática Con Intención Curativa [Evaluació. Reference:/3749	GC02
EVA IGLESIAS FLORES. Eficacia De Los Bolos Intravenosos De Corticoides Más Tratamiento Con Corticoides Orales En Comparación Con Corticoides Orales En Monoterapia Para El Tratamiento De La Colitis Ulcerosa Moderada: Ensayo Clínico Multicéntrico Y Aleatorizado. Estudio Cecum. Reference:/3872	GC02
JOSE MANUEL BENITEZ CANTERO. Estudio De Estrategias De Mantenimiento Comparando Práctica Clínica Habitual Frente A Treat To Target En Pacientes Con Enfermedad De Crohn Tratados Con Ustekinumab. Reference:/3414	GC02
JOSE MANUEL BENITEZ CANTERO. An Open-Label, Randomized, Parallel-Group, Phase I Study To Evaluate Pharmacokinetics, Efficacy And Safety Between Subcutaneous Ct-P13 And Intravenous Ct-P13 In Patients With Active Crohn'S Disease Active Ulcerative Colitis. Reference:/3527	GC02
ENRIQUE FRAGA RIVAS. A Study Of Safety, Tolerability, And Clinical Activity Of Medi4736 And Tremelimumab Administered As Monotherapy And In Combination To Subjects With Unresectable Hepatocellular Carcinoma.. Reference:0257/15	GC02
SANDRA MARIN PEDROSA. Estudio Multicéntrico De Fase Iii Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad Del Etrolizumab Como Tratamiento De Inducción Y Mantenimiento En Pacientes Con Enfermedad De Crohn Activa De Moderada A Grave. Reference:/3907	GC02
SANDRA MARIN PEDROSA. Estudio Abierto De Extensión Y Supervisión De La Seguridad De Pacientes Con Enfermedad De Crohn Con Actividad De Moderada A Grave Previamente Inscritos En El Protocolo De Fase Iii Con Etrolizumab, Ga29144. Reference:/3908	GC02



MARÍA DEL VALLE GARCÍA SÁNCHEZ.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Investigate The Efficacy And Safety Of Mongsersen (Ged-0301) For The Treatment Of Subjects With Active Crohn'S Disease.. Reference:/3002	GC02	ANTONIO POYATO GONZÁLEZ.Blood Sample Collection To Evaluate Biomarkers For Hepatocellular Carcinoma.Referen- ce:4000	GC02
MARÍA DEL VALLE GARCÍA SÁNCHEZ.A Phase 3, Long-Term Active Treatment Extension Study Of Mongsersen (Ged-0301) In Subjects With Crohn'S Disease.Reference:/3024	GC02	JOSE MANUEL BENITEZ CANTERO.Eii Cáncer E Infecciones Graves En Europa: I-Care..Reference:3006	GC02
JOSE MANUEL BENITEZ CANTERO.Suspensión Del Tratamiento Anti-Tnf En Pacientes Con Enfermedad Inflamatoria Intestinal: Ensayo Clínico Multicéntrico, Prospectivo Y Aleatorizado.Reference:/3182	GC02	JOSE MANUEL BENITEZ CANTERO.Estudio Prospectivo Y Multicentrico Sobre La Epidemiología Y Características Ómicas De La Enfermedad Inflamatoria Intestinal De Reciente Diagnostico En España.Reference:3354	GC02
JOSE LUIS MONTERO ALVAREZ.Estudio Clínico Multicéntrico De Fase Ii Para Evaluar La Seguridad Y La Eficacia Preliminar De Dos Regímenes Posológicos De Hepastem En Pacientes Con Insuficiencia Hepática Crónica Agudizada.Reference:/3862	GC02	EVA IGLESIAS FLORES.An Observational Prospective Long-Term Exposure Registry Of Adult Patients With Moderate To Severe Ulcerative Colitis.Reference:3594	GC02
EVA IGLESIAS FLORES.Estudio De Inducción En Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, De Grupos Paralelos Y Controlado Con Placebo Sobre Mirikizumab En Pacientes Con Fracaso Convencional Y Biológico Con Colitis Ulcerosa Activa De Moderada A Grave. Lucent 1.Reference:/3938	GC02	JOSE MANUEL BENITEZ CANTERO.Análisis De La Efectividad Y Seguridad Del Switch De Infliximab Original A Biosimilar En Los Pacientes Con Enfermedad Inflamatoria Intestinal.Reference:3646	GC02
EVA IGLESIAS FLORES.Estudio De Mantenimiento En Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, De Grupos Paralelos, Controlado Con Placebo Sobre Mirikizumab En Pacientes Con Colitis Ulcerosa Activa De Moderada A Grave. Lucent 2.Reference:/3939	GC02	JOSE MANUEL BENITEZ CANTERO.A Post-Authorization Safety Of Golimumab In Uc Using Spanish Eneida Registry. Reference:3531	GC02
JOSE MANUEL BENITEZ CANTERO.Estudio Multicéntrico, Doble Ciego, Controlado Con Placebo Para Evaluar La Seguridad Y Eficacia De Abt 494 Para El Tratamiento De Inducción Y Mantenimiento En Pacientes Con Colitis Ulcerosa De Moderada A Grave.Reference:/3588	GC02	MANUEL LUÍS RODRÍGUEZ PERÁLVAREZ.Evaluación Funcional Del Paciente Cirrótico Candidato A Trasplante Hepático. Reference:4071	GC02
ENRIQUE FRAGA RIVAS.Estudio Abierto Y Multicéntrico Para Evaluar Los Resultados A Largo Plazo Con Abt-450/Ritonavir/ Abt-267 (Abt-450/R/Abt-267) Y Abt-333 Con O Sin Ribavirina (Rbv) En Adultos Con Infección Crónica Por El Virus De La Hepatitis C (Vhc) De Genotipo 1(Topaz-I).Reference:0249/14	GC02	JOSE MANUEL BENITEZ CANTERO.Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents In Patients With Ulcerative Colitis Or Crohn'S Disease..Reference:3355	GC02
JOSE MANUEL BENITEZ CANTERO.Estudio Fase 3 Multicéntrico, De Extensión Abierta, Para Evaluar La Seguridad Y Eficacia A Largo Plazo De Abt-494 En Pacientes Con Colitis Ulcerosa.Reference:/3589	GC02	EVA IGLESIAS FLORES.Efecto Del Automanejo Con Dosis Flexibles En Pacientes Con Colitis Ulcerosa Tratados Con Ácido 5- Aminosalicílico (5-Asa): Estudio Observacional Controlado (Estudio Asaflex).Reference:3657	GC02
JOSE LUIS MONTERO ALVAREZ.Estudio Abierto Y De Un Solo Grupo Para Evaluar La Eficacia Y La Seguridad De Glecaprevir (Gle)/Pibrentasvir (Pib) En Pacientes Con Infección Crónica Por El Virus De La Hepatitis C (Vhc) De Genotipo 1, 2, 4, 5 O 6 Y Cirrosis Compensada No Tratados Previam.Reference:/3561	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.A Multicenter, Randomized, Open-Label Clinical Study Of S-649266 Or Best Available Therapy For The Treatment Of Severe Infections Caused By Carbapenem-Resistant Gram-Negative Pathogens. Reference:/3406	GC03
JOSE MANUEL BENITEZ CANTERO.Estudio En Fase 2A, Multicéntrico, Aleatorizado, Comparativo Con Placebo, Con Enmascaramiento Doble Y Grupos Paralelos, Para Evaluar La Seguridad Y La Eficacia De La Administración Oral De Prv-6527 (Jnj-40346527), Un Inhibidor Del Receptor Del Factor 1 Es.Reference:/3751	GC02	JUAN JOSE CASTON OSORIO.Ensayo Clínico De Fase Iii, Aleatorizado, Doble Ciego Y Controlado Con Fármaco De Comparación Activo Para Evaluar La Seguridad, La Tolerabilidad Y La Eficacia De Imipenem/Cilastatina/Relebactam (Mk-7655A) En Comparación Con Piperacilina/Tazobactam En Suje.Reference:/3581	GC03
JOSE MANUEL BENITEZ CANTERO.Estudio De Inducción N.º 2: Estudio De Fase 3, Multicéntrico, Aleatorizado, Con Enmascaramiento Doble Y Comparativo Con Placebo, En El Que Se Evalúa Ozanimod Por Vía Oral Como Tratamiento De Inducción Para La Enfermedad De Crohn Activa De Moderada A Grave.Reference:/3866	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.Estudio Comparativo En Fase Iii, Prospectivo, Aleatorizado, Multicéntrico, Abierto Pero Enmascarado Para El Evaluador Principal Y De Grupos Paralelos Para Determinar La Eficacia, Seguridad Y Tolerabilidad De Aztreonam-Avibactam (Atm-Avi) +/- Metronidazol .Reference:/3829	GC03
JOSE MANUEL BENITEZ CANTERO.Estudio De Fase 3, Multicéntrico, Aleatorizado, Con Enmascaramiento Doble Y Comparativo Con Placebo, En El Que Se Evalúa Ozanimod Por Vía Oral Como Tratamiento De Mantenimiento Para La Enfermedad De Crohn Activa De Moderada A Grave.Reference:/3867	GC02	ANGELA MARIA CANO YUSTE.Estudio Comparativo, Aleatorizado, Doble Ciego, Multicéntrico, De La Seguridad, Tolerabilidad, Eficacia Y Farmacocinética De Cf-301 Frente A Placebo Agregado Al Tratamiento Antibacteriano De Referencia Para El Tratamiento De Pacientes Adultos Que Padecen .Reference:/3585	GC03
JOSE MANUEL BENITEZ CANTERO.Estudio De Ampliación De Fase 3, Multicéntrico, Sin Enmascaramiento En El Que Se Evalúa Ozanimod Por Vía Oral Para La Enfermedad De Crohn Activa De Moderada A Grave.Reference:/3874	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.Ensayo Clínico De Eficacia Y Seguridad De La Combinación De Profilaxis De Duración Reducida Seguida De Profilaxis Inmunoguiada En Receptores De Trasplante Pulmonar.Reference:/4027	GC03
EVA IGLESIAS FLORES.A Phase 3B, Randomized, Contrtrolled, Multicenter Study With Oral Ferric Maltol (Feraccru) Or Intravenous Iron (Fcm), For The Treatment Of Iron Deficiency Anemia In Subjects With Inflammatory Bowel Disease..Reference:0311/15	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.Ensayo Clínico De Suspensión De La Profilaxis Con Valganciclovir En Trasplantedos Renales Cmv-Seropositivo Que Mantienen La Inmunidad Celular Cd8+Cmv-Específica Tras Recibir Timoglobulina.. Reference:0298/15	GC03
EVA IGLESIAS FLORES.Registro No Intervencionista A Largo Plazo Para Evaluar La Seguridad Y La Eficacia De Humira (Adalimumab) En Pacientes Con Colitis Ulcerosa Moderadamente Activa Y Muy Activa (Legacy).Reference:2315	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.Ensayo De Eficacia, Inmunogenicidad Y Seguridad De La Vacuna De Toxoides De Clostridium Difficile En Sujetos En Riesgo De Desarrollar Infección Por C. Difficile Protection, Immune Response, And Safety Study Of Clostridium Difficile Toxoid Vaccine In Subje.Reference:0062/15	GC03
JOSE LUIS MONTERO ALVAREZ.Refine: Estudio Observacional De Regorafenib En Carcinoma Hepatocelular.Referen- ce:/3943	GC02	JUAN JOSE CASTON OSORIO.Ensayo Clínico Aleatorizado, Multicéntrico, Abierto, Controlado, En Fase Iii, Para Demostrar La No Inferioridad Del Tratamiento Antibiótico Dirigido De Espectro Reducido Frente Al Tratamiento De Amplio Espectro Con Un Betalactámico Antipseudomónico En El.Reference:/3786	GC03
JOSE LUIS MONTERO ALVAREZ.Manejo De Pacientes Con Carcinoma Hepatocelular Irreseccable (Chci) Tras Confirmación Radiológica De La Enfermedad A La Primera Linea De Tratamiento Sistemico.Reference:3659	GC02	ANGELA MARIA CANO YUSTE.Estudio De Fase Iib, Comparativo, Multicéntrico, Aleatorizado, Doble Ciego, Para Evaluar La Eficacia Y Seguridad De Vis410 Por Vía Intravenosa Administrado Junto Con Osetamivir (Tamiflu®) En Comparación Con Osetamivir En Monoterapia En Adultos Hospitali.Reference:/3521	GC03
JOSE LUIS MONTERO ALVAREZ.Efectividad De Envarsus En La Prevención Del Rechazo Del Trasplante De Hígado: Estudio Post-Autorización Observacional Prospectivo En Condicones De Práctica Clínica Habitual.Reference:3391	GC02	JULIAN CARLOS DE LA TORRE CISNEROS.Advanced Understandign Of Staphylococcus Aureus Infections In Europe- Surgical Site Infections (Aspire-Ssi).Reference:3723	GC03
		JULIAN CARLOS DE LA TORRE CISNEROS.Current European Practice Patterns Of Skin Infection Management: Evaluate The Incidence Of Skin Infection, The Percentage Of Acute Bacterial Skin And Skin Structure Infections (Absssi) Among Them, And Their Clinical And Therapeutic Management.Reference:3412	GC03



JULIAN CARLOS DE LA TORRE CISNEROS.Terapia De Rescate Con Ceftolozano-Tazobactam En La Infección Producida Por Pseudomonas Aeruginosa Multirresistente.Reference:3131	GC03	EDUARDO COLLANTES ESTEVEZ.Estudio Fase 3 Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo Que Evalúa La Eficacia Y Seguridad De Ustekinumab En El Tratamiento De Pacientes Refractarios A Anti-Tnf Alfa Con Espondiloartritis Axial Radiográfica Activa A Phase 3, M.Reference:0146/15	GC05
JULIAN CARLOS DE LA TORRE CISNEROS.Estudio De La Cinética De La Inmunidad T Cd8 Positivo Frente A Cmv En Trasplantados Renales Tratados Con Timoglobulina..Reference:2933	GC03	MARIA ANGELES AGUIRRE ZAMORANO.Estudio Multicéntrico, Aleatorizado, En Doble Ciego, Controlado Con Placebo Y Grupos Paralelos, De Ustekinumab En Sujetos Con Eritematoso Sistemático Activo.Reference:/3831	GC05
JULIAN CARLOS DE LA TORRE CISNEROS.Assessment Of The Incidence Of Clostridium Difficile Infections In Hospitalised Patients On Antibiotic Treatment.Reference:3350	GC03	Mª DOLORES LOPEZ MONTILLA.Ensayo Clínico Multicéntrico En Fase 3, Aleatorizado, Doble Ciego, Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad De Guselkumab Administrado Por Vía Subcutánea En Pacientes Con Artritis Psoriásica Activa.Reference:/3552	GC05
JORGE RODRIGUEZ GOMEZ.Epidemiología Y Eficacia De Tratamiento Con Fosfomicina En La Infección Del Tracto Urinario Causada Por Klebsiella Pneumoniae Resistente A Carbapenemas Y Colistina. Estudio Kapecor-Itu..Reference:2853	GC03	ALEJANDRO ESCUDERO CONTRERAS.Estudio En Fase I/II, Aleatorizado Y De Grupos Paralelos Para Evaluar La Eficacia, La Farmacocinética Y La Seguridad De Ct-P13 Subcutáneo Y Ct-P13 Intravenoso En Pacientes Con Artritis Reumatoide Activa.Reference:/3522	GC05
Mª DOLORES LOPEZ MONTILLA.“Estudio Controlado Aleatorizado, Multicéntrico, Doble Ciego, De Etanercept Y Metotrexato En Combinación O En Monoterapia En Sujetos Con Artritis Psoriásica “..Reference:0293/15	GC05	ALEJANDRO ESCUDERO CONTRERAS.Estudio De Fase II, Aleatorizado, Doble Ciego, Controlado Con Placebo, Para Evaluar La Seguridad Y La Eficacia De Filgotinib, Gs-9876 Y Gs-4059 En Pacientes Adultos Con Síndrome De Sjögren Activo. Reference:/3828	GC05
MIGUEL ANGEL CARACUEL RUIZ.Estudio De Fase 3, Aleatorizado, Doble Ciego, Controlado Con Placebo, Multicéntrico De La Seguridad Y Eficacia Analgésicas De La Administración Subcutánea De Tanezumab En Sujetos Con Artrosis De Cadera O De Rodilla..Reference:/2950	GC05	MARIA ANGELES AGUIRRE ZAMORANO.Estudio Aleatorizado, Doble Ciego, Controlado Por Placebo, De 52 Semanas De Duración Para Evaluar Los Acontecimientos Adversos De Especial Interés En Adultos Con Lupus Eritematoso Sistémico Activo, Con Autoanticuerpos Positivos Que Toman Belimumab.Reference:0320/12	GC05
MIGUEL ANGEL CARACUEL RUIZ.Estudio Observacional A Largo Plazo, Multicéntrico, Fase Iii, En Pacientes De Estudios Con Tanezumab Que Se Someten A Una Sustitución Total De Rodilla, Cadera U Hombro..Reference:/2959	GC05	EDUARDO COLLANTES ESTEVEZ.Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo Durante 16 Semanas, Seguido De Una Evaluación A Largo Plazo De La Eficacia Y La Seguridad De Ixekizumab (Ly2439821), En Pacientes Con Espondiloartritis Axial Radiológica Que Han Recidivado.Reference:/3026	GC05
ALEJANDRO ESCUDERO CONTRERAS.Estudio De Extensión, De Fase Ii, Multicéntrico, Abierto Para Evaluar La Eficacia Y Seguridad A Largo Plazo De Alx-0061 Subcutáneo En Sujetos Con Artritis Reumatoide De Moderada A Severa Que Hayan Completado Uno De Los Estudios Anteriores De Fase Iib Con .Reference:0064/15	GC05	ALEJANDRO ESCUDERO CONTRERAS.Estudio De Fase 3, Aleatorizado, Doble Ciego Comparando Abt-494 Con Placebo Y Con Adalimumab En Sujetos Con Artritis Reumatoide Activa Moderada A Grave En Tratamiento Con Metotrexato (Mtx) En Dosis Estables Y Que No Han Respondido De Forma Adecuada A Mtx .Reference:/3337	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio Multicéntrico, Con Una Parte A, Abierta, Seguida Por Una Parte B, Aleatorizada, En Doble Ciego, De Grupos Paralelos Y Controlada Con Placebo, Para Evaluar El Mantenimiento De La Remisión En Sujetos Con Espondiloartritis Axial Activa (Epxa) En Tra.Reference:/2894	GC05	Mª DOLORES LOPEZ MONTILLA.Estudio De Fase 4 Abierto, Randomizado, Y Controlado Que Compara La Eficacia De La Introducción De Adalimumab Y El Escalado De Dosis De Metotrexato En Pacientes Con Artritis Psoriásica (Control). Reference:/3239	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio Multicéntrico Abierto Para Evaluar Los Efectos Del Certolizumab Pegol En La Reducción De Las Crisis De Uveítis Anterior En Pacientes Con Espondiloartritis Axial Con Antecedentes De Uveítis Anterior. Reference:/3244	GC05	Mª DOLORES LOPEZ MONTILLA.Estudio Fase 3, Aleatorizado, Doble Ciego, Que Compara Abt-494 Con Placebo En Pacientes Con Artritis Psoriásica Activa, Con Una Historia Previa De Respuesta Inadecuada A Al Menos Un Fármaco Modificador De La Enfermedad (Fame) Biológico, En Artritis Psoriásica.Reference:/3631	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio De Fase Iib Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Intervalos De Dosis Y Grupos Paralelos, Para Evaluar La Eficacia Y La Seguridad De Bimekizumab En Pacientes Con Espondilitis Anquilosante Activa.Reference:/3342	GC05	ALEJANDRO ESCUDERO CONTRERAS.Estudio De Fase 3, Aleatorizado, Con Comparador Activo, Doble Ciego Para Comparar Abt-494 Con Abatacept En Sujetos Con Artritis Reumatoide De Actividad Moderada A Grave Con Respuesta Insuficiente O Intolerancia A Los Fármacos Biológicos (Farme) En Tratamiento.Reference:/3331	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio De Extensión, Abierto, Multicéntrico, Para Evaluar La Seguridad Y Eficacia A Largo Plazo De Bimekizumab En Pacientes Con Espondilitis Anquilosante.Reference:/3650	GC05	EDUARDO COLLANTES ESTEVEZ.Ensayo De Fase Iv, Aleatorizado, Doble Ciego, Controlado Con Placebo Y De Grupos Paralelos Para Evaluar La Eficacia Y La Seguridad De Golimumab (Mk-8259 [Sch 900259]) Tras La Retirada Del Tratamiento, En Comparación Con Su Continuación (Pauta Completa O R.Reference:/3525	GC05
ALEJANDRO ESCUDERO CONTRERAS.Estudio En Fase Ii, Multicéntrico, Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Seguridad Y La Eficacia De Ro7123520 Como Tratamiento Complementario En Pacientes Con Artritis Reumatoide Activa Moderada O Grave Y Con Respuesta Inadecuada.Reference:/3556	GC05	ALEJANDRO ESCUDERO CONTRERAS.Estudio Prueba De Concepto Aleatorizado, Doble Ciego, Controlado Con Placebo, Para Evaluar La Eficacia Y Seguridad De Ucb5857 Durante 12 Semanas En Pacientes Con Síndrome De Sjögren Primario.. Reference:0306/15	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio Multicéntrico, Aleatorizado, Doble Ciego Fase Iii De Secukinumab, Controlado Con Placebo Para Demostrar La Eficacia A Las 16 Semanas Y Evaluar La Seguridad, Tolerabilidad Y Eficacia A Largo Plazo En Un Período De 3 Años En Sujetos Con Espondilitis.Reference:0248/13	GC05	ALEJANDRO ESCUDERO CONTRERAS.A Comparative Study To Assess The Efficacy, Safety And Immunogenicity Of Y1b113 And Enbrel For The Treatment Of Rheumatoid Arthritis..Reference:0271/15	GC05
Mª DOLORES LOPEZ MONTILLA.Estudio De Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Fase Iii De Secukinumab Subcutáneo (150 Mg Y 300 Mg) En Jeringas Precargadas Para Demostrar La Eficacia (Incluida La Inhibición De Daño Estructural), Seguridad, Y Tol.Reference:0107/15	GC05	EDUARDO COLLANTES ESTEVEZ.Registro Multinacional De Características Clínicas, Incluida La Progresión Radiológica Y Carga De La Enfermedad Durante 5 Años En Contextos De La Vida Real (Patients With Axial Spondyloarthritis: Multi-Country Registry Of Clinical Characteristics, Includi.Reference:2457	GC05
Mª DOLORES LOPEZ MONTILLA.Estudio Multicéntrico, Aleatorizado, Doble Ciego, Con Control Activo Para Evaluar La Eficacia En La Semana 52 De Secukinumab En Monoterapia Por Vía Subcutánea En Comparación Con Adalimumab En Monoterapia Por Vía Subcutánea En Pacientes Con Artritis Psoriásica.Reference:/3345	GC05	ALEJANDRO ESCUDERO CONTRERAS.Estudio Ascore Sobre La Experiencia A Largo Plazo Con Abatacept S.C. En La Práctica Clínica Habitual..Reference:2686	GC05
MARÍA DEL CARMEN CASTRO VILLEGAS.Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo Para Evaluar La Seguridad, Tolerabilidad Y Eficacia De Secukinumab En Pacientes Con Espondiloartritis Axial No Radiográfica Activa Durante Un Período De 2 Años.Reference:/3550	GC05	EDUARDO COLLANTES ESTEVEZ.Evaluación Del Riesgo Cardiovascular Y De Sus Determinantes En Pacientes Con Artritis Reumatoide, Espondilitis Anquilosante Y Artritis Psoriásica.Reference:1789	GC05
EDUARDO COLLANTES ESTEVEZ.Estudio Fase 3, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Grupos Paralelos Para Evaluar La Eficacia Y Seguridad De Apremilast (Cc-10004) En El Tratamiento De Espondilitis Anquilosante Activa.Reference:0125/12	GC05	ALEJANDRO ESCUDERO CONTRERAS.An Observational, Prospective Cohort Study To Evaluate Safety And Efficacy Of RemeSimatm In Patients With Rheumatoid Arthritis..Reference:3161	GC05



MARÍA DEL CARMEN CASTRO VILLEGAS. A Multi-Center Observational Study To Evaluate The Real-Life Effectiveness Of Benepali Following Transition From Enbrel In Patients With Rheumatoid Arthritis And Axial Spondyloarthritis. (The Benefit Study).Reference:3636	GC05	MARIA JOSE MENDEZ VIDAL. Estudio En Fase Ii Con Mpd13280A Preoperatorio En Carcinoma Operable De Células Transicionales De Vejiga (Abacus)..Reference:0371/15	GC06
MARÍA DEL CARMEN CASTRO VILLEGAS. Tratamiento Precoz Con Terapia Biológica En Espondiloartritis Axial: Efectividad A 5 Años. Reference:3662	GC05	MARIA JOSE MENDEZ VIDAL. Mantenimiento De Acetato De Abiraterona En Combinación Con Docetaxel Tras Progresión De La Enfermedad A Acetato De Abiraterona En Pacientes Con Cáncer De Próstata Metastásico Resistente A La Castración (Cprcm). Estudio Fase Ii Aleatorizado..Reference:0246/13	GC06
EDUARDO COLLANTES ESTEVEZ. Registro Español De Acontecimientos Adversos De Terapias Biológicas Y Biosimilares En Enfermedades Reumáticas. Fase Iii. Reference:2880	GC05	MARÍA JESÚS RUBIO PÉREZ. Estudio De Fase Iii De Adxs11-001 Administrado Tras La Quimiorradioterapia Como Tratamiento Adyuvante En Cáncer De Cuello Uterino Localmente Avanzado De Riesgo Alto: Aim2Cerv. Reference:/3476	GC06
PILAR FONT UGALDE. Aplicabilidad Clínica De Un Protocolo De Disminución De Dosis Estandarizado En Pacientes En Remisión Clínica Persistente, Diagnosticados De Artritis Reumatoide (Âr) Y Tratados Con Antagonistas Del Tnf. Reference:2817	GC05	JUAN RAFAEL DE LA HABA RODRÍGUEZ. Ensayo De Fase Ii Aleatorizado De Palbiciclib Con Tratamiento Endocrino Adyuvante Estandar Frente A Monoterapia Con Tratamiento Endocrino Adyuvante Estandar En Cáncer De Mama Precoz Con Receptores Hormonales Positivo (Rh+) Y Her2-Negativo. Reference:/3483	GC06
ALEJANDRO ESCUDERO CONTRERAS. Estudio Observacional Transversal Para Evaluar La Adherencia Al Tratamiento En Pacientes Con Artritis Reumatoide En España..Reference:3582	GC05	MARIA TERESA CANO OSUNA. Estudio De Fase Iii Aleatorizado De Am0010 Combinado Con Folfox En Comparación Con Folfox En Monoterapia Para El Tratamiento De Segunda Línea En Pacientes Con Cáncer De Páncreas Metastásico Que Ha Progresado Durante O Después De Un Tratamiento De Primera. Reference:/3415	GC06
MARÍA DEL CARMEN CASTRO VILLEGAS. A Multicenter, Prospective, Observational Cohort Study To Evaluate The Real-World Safety And Effectiveness Of Erelzi, An Etanercept Biosimilar (Compact). Reference:4002	GC05	MARÍA JESÚS RUBIO PÉREZ. Eutroc-Pisarro: P53 Suppressor Activation In Recurrent High Grade Serous Ovarian Cancer, A Phase Ib/Ii Study Of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With Or Without Apr-246..Reference:/2893	GC06
ALEJANDRO ESCUDERO CONTRERAS. Estudio Sobre Cumplimiento Terapéutico En Pacientes Con Artritis Reumatoide En Tratamiento Con Fármacos Biológicos De Administración Subcutánea. Estudio Arco. Reference:2541	GC05	MARIA JOSE ORTIZ MORALES. Estudio De Fase 3, Multicéntrico, Aleatorizado Y Abierto, De 3 Grupos: Encorafenib + Cetuximab, Con O Sin Binimetinib, Frente A Irinotecán/Cetuximab O 5-Fluorouracilo (5-Fu)/Ácido Fólico (Fa)/Irinotecán (Foliri)/Cetuximab En Infusión, Con Una Evaluación. Reference:/3418	GC06
MARÍA DEL CARMEN CASTRO VILLEGAS. Estudio Multicéntrico, Observacional No Intervencionista, Transversal Y Retrospectivo, Para Evaluar El Control De La Actividad De La Enfermedad En Condiciones De Práctica Clínica Habitual En Pacientes Con Espondilitis Anquilosante Y Artritis Psoriásica Tra. Reference:4111	GC05	MARIA JOSE MENDEZ VIDAL. Estudio De Fase 3, Aleatorizado, Controlado, Multicéntrico Y Abierto, Para Comparar El Tivozanib Clorhidrato Frente Al Sorafenib En Sujetos Con Carcinoma De Células Renales Avanzado Resistente Al Tratamiento.. Reference:/3001	GC06
M ^a DOLORES LOPEZ MONTILLA. Registro Español De Artritis Psoriásica..Reference:2703	GC05	MARIA JOSE MENDEZ VIDAL. Estudio De Fase Iii, Multicéntrico, Multinacional, Aleatorizado, Abierto, Con Grupos Paralelos Sobre Avelumab* (Msb0010718C) Más Los Mejores Cuidados Paliativos Frente A Los Mejores Cuidados Paliativos Solos Como Tratamiento De Mantenimiento En Pacientes. Reference:/3714	GC06
ALEJANDRO ESCUDERO CONTRERAS. Proyecto Gema 2. Gota: Evaluación Y Manejo..Reference:2611	GC05	MARÍA JESÚS RUBIO PÉREZ. Estudio De Fase Iii, Multicéntrico, Aleatorizado, Abierto De Avelumab (Msb0010718C) En Monoterapia O En Combinación Con Doxorubicina Liposomal Pegilada Frente A Doxorubicina Liposomal Pegilada En Monoterapia En Pacientes Con Cáncer De Ovario Refractario/R. Reference:/3183	GC06
EDUARDO COLLANTES ESTEVEZ. Estudio No Intervencional Para Evaluar La Eficacia Del Certolizumab Pegol En Pacientes Con Espondiloartritis Axial En La Práctica Diaria A Non-Interventional Study To Assess The Effectiveness Of Certolizumab Pegol In Patients With Axial Spondyloarthritis. Reference:2736	GC05	IGNACIO PORRAS QUINTELA. Estudio En Fase 3, Aleatorizado, Doble Ciego Sobre Avelumab Combinado Con La Quimiorradioterapia De Referencia (Cisplatino Más Radioterapia Definitiva) En Comparación Con La Quimiorradioterapia De Referencia En El Tratamiento De Primera Línea De Pacientes. Reference:/3562	GC06
MIGUEL ANGEL CARACUEL RUIZ. Estudio Prospectivo, Multicéntrico Para Evaluar La Eficacia Y La Seguridad De Una Inyección Única De Hialuronato Sódico En Pacientes Con Artrosis De Rodilla. Reference:4025	GC05	MARÍA JESÚS RUBIO PÉREZ. Estudio De Fase Ii, Aleatorizado Y Doble Ciego Que Compara El Tratamiento Cada 3 Semanas Con Carboplatino (Auc 5) + 175 Mg/M2 De Paclitaxel, Con O Sin Nintedanib Concomitante Y De Mantenimiento, En El Carcinoma De Cuello Uterino Avanzado O Recidivante..Reference:0270/14	GC06
MARIA JOSE MENDEZ VIDAL. Combinaciones Con Medi4736 En El Carcinoma Renal Metastásico (Calypso). Reference:/3328	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio Multicéntrico, Doble Ciego, Randomizado, Controlado Con Placebo, Para Comparar Quimioterapia Más Trastuzumab Y Placebo Con Quimioterapia Más Trastuzumab Y Pertuzumab, Como Tratamiento Adyuvante En Pacientes Con Cáncer De Mama Primario Her-2 Positivo. Reference:0198/11	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio De Fase Ii En El Que Se Investiga La Combinación De Estrategias Preoperatorias En La Inmunoterapia De Pacientes Con Cáncer De Mama Primario, Er Positivo, Her2 Negativo, No Tratado Y Operable (Eclipse)..Reference:/3785	GC06	ENRIQUE ARANDA AGUILAR. Ensayo Fase Iii Doble Ciego, Multicéntrico, Aleatorizado, Controlado Con Placebo Para Evaluar La Eficacia Y Seguridad De Pertuzumab En Combinación Con Trastuzumab Y Quimioterapia En Pacientes Con Cáncer Gástrico Y De La Unión Gastro-Esofágica Metastásico. Reference:0312/12	GC06
MARÍA JESÚS RUBIO PÉREZ. Forward1: Estudio Abierto De Fase Iii Aleatorizado Para Evaluar La Seguridad Y La Eficacia De Mirvetuximab Soravtansina (Imgn853) Frente A La Elección Del Investigador De Quimioterapia En Mujeres Con Cáncer De Las Trompas De Falopio, Cáncer Peritoneal Pri. Reference:/3624	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio Multicéntrico, Abierto De Un Solo Brazo De Estudio De Seguridad De Herceptin S.C. En Combinación Con Perjeta Y Docetaxel, En El Tratamiento De Pacientes Con Cáncer De Mama Avanzado Her2 Positivo (Metastásico O Localmente Recurrente). Reference:0005/15	GC06
MARIA JOSE MENDEZ VIDAL. Estudio De Fase 2/3 Aleatorizado, Abierto, Multicéntrico Para Evaluar La Eficacia Y Seguridad De Rogaratinib (Bay 1163877) Comparado Con Quimioterapia En Pacientes Fgfr Positivos Con Carcinoma Urotelial Metastásico O Localmente Avanzado Que Hayan Recibido. Reference:/3780	GC06	MARIA JOSE MENDEZ VIDAL. Estudio De Extensión Y Observacional A Largo Plazo Multicéntrico, Abierto En Pacientes Incluidos Previamente En Un Estudio Clínico De Atezolizumab Promocionado Por Genentech Y/O F. Hoffmann-La Roche Ltd..Reference:/3868	GC06
MARIA JOSE MENDEZ VIDAL. Estudio De Fase Iii Aleatorizado, Doble Ciego, Controlado Con Placebo De Odm-201 Comparado Con Placebo, En Combinación Con El Tratamiento Estándar De Privación Androgénica Y Docetaxel En Pacientes Con Cáncer De Próstata Metastásico Sensible A Hormonas..Reference:/3339	GC06	ENRIQUE ARANDA AGUILAR. Estudio Fase Iii, Aleatorizado, Multicéntrico, Doble Ciego De Nivolumab Adyuvante O Placebo En Sujetos Con Cáncer Resecado De Esófago O De La Unión Gastroesofágica..Reference:/3123	GC06
MARIA JOSE MENDEZ VIDAL. A Multinational Randomised, Double-Blind, Placebo-Controlled, Phase Iii Efficacy And Safety Study Of Odm-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer..Reference:0194/14	GC06	MARIA JOSE MENDEZ VIDAL. Ensayo Clínico Aleatorizado, Fase Ii/Iii, Con Múltiples Brazos Y Multietapa, De Estrategias De Inmunoterapia En Cáncer De Próstata Metastásico Sensible A Hormonas..Reference:/3989	GC06
ENRIQUE ARANDA AGUILAR. Ensayo Clínico De Fase Iii, Aleatorizado, Controlado Con Tratamiento Activo, Con Enmascaramiento Parcial Y Con Detección De Biomarcadores, De Pembrolizumab En Monoterapia Y En Combinación Con Cisplatino + 5-Fluorouracilo Frente A Placebo + Cisplatino + 5-.Reference:0144/15	GC06		
MARIA JOSE MENDEZ VIDAL. Estudio En Fase Iii Sobre Erdafitinib En Comparación Con Vinflunina, Docetaxel O Pembrolizumab En Sujetos Con Carcinoma Urotelial Avanzado Y Anomalías Genéticas Seleccionadas En Fgfr..Reference:/3781	GC06		



ISIDORO BARNETO ARANDA.Estudio Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, Que Evalúa La Eficacia Y Seguridad De Canakinumab Frente A Placebo Como Terapia Adyuvante En Pacientes Adultos Con Cáncer De Pulmón No Microcítico (Nslc) Completamente Re.Reference:/3783	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio Fase Iii Aleatorizado, Multicéntrico, Abierto De Lapatinib, Trastuzumab, La Administración Secuencial De Ambos Y La Administración Combinada De Ambos Como Tratamiento Adyuvante En Paciente Con Cáncer De Mama Her2/Erb2 Positivo.Reference:0090/07	GC06
ENRIQUE ARANDA AGUILAR.Estudio Abierto, Aleatorizado, Fase 2 Que Compara S95005 Con Bevacizumab Frente A Capecitabina Con Bevacizumab En Pacientes Con Cáncer Colorrectal Metastático No Tratado Previamente Que No Son Candidatos A Terapia Intensiva..Reference:0015/16	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo De Fase Iii Para Comparar La Seguridad Y La Eficacia De Lapatinib Más Trastuzumab Más Un Inhibidor De La Aromatasa (Ia) Frente A Trastuzumab Más Un Ia Y Frente A Lapatinib Más Un Ia Como Tratamiento De Primera O Segunda Línea En Pacientes Posmenopá.Reference:0341/14	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Compleement-1: Estudio De Fase Iiib, Abierto, Multicéntrico, Para Evaluar La Seguridad Y La Eficacia De Ribociclib (Lee011) En Combinación Con Letrozol En El Tratamiento De Hombres Y Mujeres Pre/Postmenopáusicas Con Cáncer De Mama Avanzado (Cma) Con Recep.Reference:/3441	GC06	MARÍA JESÚS RUBIO PÉREZ.Estudio Aleatorizado Fase Iii De Quimioterapia Con Platino Y Paclitaxel Mas Bevacizumab Y Atezolizumab Frente A Quimioterapia Con Platino Y Paclitaxel Mas Bevacizumab En Carcinoma De Cérvix Metastático (Estadio Ibv), Persistente O Recurrente.Reference:/3947	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Me-344 En Cáncer De Mama Her2-Negativo En Estadio Temprano Con Metabolismo Mitocondrial Inducido Con Antiangiogénicos: Ensayo Fase 0.Reference:/3649	GC06	MARÍA JESÚS RUBIO PÉREZ.Engot-En3-Nsgo/Paleo: Ensayo Clínico De Fase Ii, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Palbociclib En Combinación Con Letrozol Versus Placebo En Combinación Con Letrozol Para Pacientes Con Cáncer Endometrial Avanzado O Recurrente Con Recep.Reference:/3526	GC06
MARIA JOSE MENDEZ VIDAL.Estudio En Fase Iii, Multicéntrico, Randomizado, Doble Ciego, Controlado Con Placebo Para Investigar Ipatasertib En Combinación Con Abiraterona Más Prednisona/Prednisolona, Comparado Con Placebo En Combinación Con Abiraterona Más Prednisona/Prednisolona, .Reference:/3474	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Fase Iii, Aleatorizado Y Doble Ciego De Quimioterapia Basada En Platino Con O Sin Atezolizumab, Seguida De Mantenimiento Con Niraparib Con O Sin Atezolizumab, En Pacientes Con Cáncer De Ovario, De Trompa De Falopio O Peritoneal Recidivante E Interv.Reference:/3988	GC06
MARIA JOSE MENDEZ VIDAL.Estudio Fase Iii Multicéntrico, Randomizado, Con Atezolizumab (Anticuerpo Anti Pd- L1) En Combinación Con Enzalutamida Frente A Enzalutamida Sola En Pacientes Con Cáncer De Próstata Resistente A La Castración Tras Fallo De Un Inhibidor De La Síntesis De .Reference:/3627	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Fase Iii, Internacional Y Aleatorizado De Trabectedina Mas Doxorubicina Liposomal Pegilada (Dlp) En Comparacion Con Carboplatino Mas Dlp En Pacientes Con Cáncer De Ovario Que Presentan Progresion En Los 6-12 Meses Siguiendo Al Ultimo Tratamiento .Reference:0037/14	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio De Fase Iii, Aleatorizado, Doble Ciego Y Controlado Con Placebo De Ipatasertib En Combinación Con Paclitaxel Para El Tratamiento De Pacientes Con Cáncer De Mama Triple Negativo O Cáncer De Mama Positivo Para Receptores Hormonales Y Negativo Para H.Reference:/4036	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Quimioterapia Neoadyuvante Con Nab-Paclitaxel En Pacientes Con Cáncer De Mama Her2 Negativo De Alto Riesgo (Etna).Reference:65/13	GC06
MARÍA JESÚS RUBIO PÉREZ.Ensayo Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Mantenimiento Con Olaparib En Monoterapia En Pacientes Con Cáncer De Ovario Con Mutación De Brca Y Recaída Platino Sensible, Que Están En Respuesta Completa O Parcial De.Reference:0132/13	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio Fase Iii Que Evalúa Palbociclib (Pd-0332991), Un Inhibidor De Quinasa Dependiente De Las Ciclinas (Cdk) 4/6, En Pacientes Con Cáncer De Mama Primario Con Receptores Hormonales Positivos Y Her2 Normal Y Alto Riesgo De Recidiva Tras Quimioterapia Ne.Reference:0059/14	GC06
MARÍA JESÚS RUBIO PÉREZ.Estudio Abierto Multicentrico, Controlado Y Aleatorizado De Fase Iii Paa Evaluar La Eficacia Y Seguridad Del Olaparib En Monoterapia Frente A La Quimioterapia Con Agente Unico De Leccion Por Le Medico En El Tratamiento Del Cáncer Ovario Recidivante Sensi.Reference:0066/15	GC06	ISIDORO BARNETO ARANDA.Ensayo Clínico Fase Ii, Exploratorio Y Muticéntrico, De Quimioinmunoterapia Neo-Adyuvante Para El Tratamiento Del Cáncer De Pulmón No Microcítico Estadio Iii Operable.Reference:/3338	GC06
MARÍA JESÚS RUBIO PÉREZ.Estudio De Fase Iiib, Aleatorizado, En Doble Ciego, Controlado Con Placebo Y Multicéntrico, Del Retratamiento Con Olaparib En Pacientes Con Cáncer Epitelial De Ovario Tratado Previamente Con Un Parpi Y Con Respuesta A La Repetición De La Quimioterapia Con.Reference:/3559	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo Fase Iii Aleatorizado, Multicéntrico, Abierto, De Grupos Paralelos Para Comparar La Eficacia Y Tolerabilidad De Fulvestrant (Faslodex®) Durante Tres Años En Combinación Con Anastrozol (Arimidex®) Durante 5 Años Versus Anastrozol Durante 5 Años Como.Reference:0165/07	GC06
MARÍA JESÚS RUBIO PÉREZ.Opinión - Estudio En Fase Iiib, Abierto, De Grupo Único Y Multicéntrico De La Monoterapia De Mantenimiento Con Olaparib En Pacientes Con Cáncer De Ovario Recidivante Sin Mutación De Brca En Línea Germinal Y Sensible Al Platino Que Están En Respuesta Parci.Reference:/3717	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio Fase Ii, Multicentrico, Aleatorizado, Doble Ciego, De Grupos Paralelos, Para Comparar La Eficacia Y Tolerabilidad De Fulvestrant (Faslodextm) 500Mg Con Placebo Y Fulvestrant (Faslodextm) 500Mg En Combinacion Con El Pd-0332991 (Palbociclib) Como Pr.Reference:0176/15	GC06
MARÍA JESÚS RUBIO PÉREZ.Ensayo Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Mantenimiento Con Olaparib En Monoterapia En Pacientes Con Cáncer De Ovario Avanzado, Estadio Iiib-iv De La Figo, Con Mutación De Brca Que Están En Respuesta Completa O .Reference:0136/13	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo Multicéntrico Fase Ii Para Evaluar La Eficacia Y Seguridad De Pembrolizumab Y Gemcitabina En Pacientes Con Cáncer De Mama Avanzado (Cma) Her2 Negativo.Reference:/3383	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, De Grupos Paralelos, Controlado Con Placebo, Para Evaluar La Eficacia Y La Seguridad De Olaparib Frente A Placebo Como Tratamiento Adyuvante En Pacientes Con Cáncer De Mama Her2 Negativo De Alto R.Reference:0124/14	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo Clínico Fase Ii Para Analizar La Respuesta A Olaparib De Pacientes Con Metilación Del Promotor Del Brca1 Y/O 2 Diganosticadas De Cáncer De Mama Avanzado.Reference:/3416	GC06
ISIDORO BARNETO ARANDA.Estudio De Fase Ii/Iii, Aleatorizado, Abierto Y De Dos Partes, De Dinutuximab E Irinotecán Versus Irinotecán Como Tratamiento De Segunda Línea En Sujetos Con Cáncer De Pulmón Microcítico En Recidiva O Resistente.Reference:/3560	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.“Estudio De Largo Seguimiento De Pacientes Con Cáncer De Mama Incluidos En Estudios En Estadios Precoces Del Grupo Geicam”..Reference:/3652	GC06
ISIDORO BARNETO ARANDA.Archer 1050: Estudio En Fase Iii, Aleatorizado, Abierto, Sobre La Eficacia Y Seguridad De Dacomitinib (Pf-00299804) Frente A Gefitinib, En El Tratamiento De Primera Línea Del Cáncer De Pulmón No Microcítico Localmente Avanzado O Metastático En Pacientes C.Reference:0020/13	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Clínico Fase Ii Abierto De Orteronel (Tak-700) En Cáncer De La Granulosa Ovárica Avanzado No Resecable O Metastático. Estudio Greko Ii..Reference:0050/14	GC06
MARIA JOSE MENDEZ VIDAL.Ensayo De Fase 2, Aleatorizado Y Doble Ciego Para Evaluar La Seguridad Y La Eficacia De Lenvatinib En Dos Dosis Iniciales Diferentes (18 Mg Y 14 Mg Una Vez Al Día) En Combinación Con Everolimus (5 Mg Una Vez Al Día) En Carcinoma De Células Renales Después.Reference:/3586	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Clínico Fase Ii Abierto De Enzalutamida En Cáncer De La Granulosa Ovárica Avanzado No Resecable O Metastático. Estudio Greko Iii..Reference:/3720	GC06
MARIA JOSE MENDEZ VIDAL.Ensayo Clínico En Fase Iii, Aleatorizado, Abierto Y Multicéntrico Para Comparar La Eficacia Y La Seguridad De Lenvatinib En Combinación Con Everolimus O Pembrolizumab Frente A Sunitinib En Monoterapia En El Tratamiento De Primera Línea De Sujetos Con Carc.Reference:/3347	GC06	RAQUEL SERRANO BLANCH.Estudio Fase Ii Para Evaluar La Eficacia Del Retratamiento Con Sunitinib En Pacientes Con Tumores Neuroendócrinos Pancreáticos Bien Diferenciados G1/2 (Pnet) Avanzados O Metastáticos Que Ya Han Fracasado A Un Tratamiento Con Sunitinib Previo (Estudio Res.Reference:/3068	GC06
		MARIA JOSE MENDEZ VIDAL.Estudio Fase Iii, Abierto, Multicentrico Y Randomizado Para Investigar La Eficacia Y Seguridad De MpdI3280A (Anticuerpo Anti-Pd-L1) Comparado Con Quimioterapia En Pacientes Con Cáncer Urotelial De Vejiga Localmente Avanzado O Metastático Después De Fallo .Reference:0311/14	GC06



ISIDORO BARNETO ARANDA.Estudio De Fase Iii, Abierto Y Aleatorizado Para Comparar Atezolizumab (Anticuerpo Anti-Pd-L1) Con Un Derivado Del Platino (Cisplatino O Carboplatino) En Combinación Con Pemetrexed O Gemcitabina En Pacientes Con Cáncer De Pulmón No Microcítico Y No Epider.Reference:/3554	GC06	ISIDORO BARNETO ARANDA.Ensayo De Fase Iii, Aleatorizado, Con El Anticuerpo Monoclonal Anti-Pd-1 Pembrolizumab (Mk-3475) En Comparación Con Placebo En Pacientes Con Cpnm En Estadios Iniciales Tras La Resección Y La Finalización Del Tratamiento Adyuvante De Referencia (Pearls)..Reference:0195/15	GC06
ISIDORO BARNETO ARANDA.Estudio Fase Iii, Abierto, Aleatorizado, De MpdI3280A (Anticuerpo Anti-Pd-L1) En Combinación Con Carboplatino + Paclitaxel Con O Sin Bevacizumab Comparado Con Carboplatino + Paclitaxel + Bevacizumab En Pacientes Con Cáncer De Pulmón No Epidermoide No .Reference:0055/15	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio De Fase Iii, Aleatorizado Y Doble Ciego Para Evaluar Pembrolizumab Más Quimioterapia Frente A Un Placebo Más Quimioterapia Como Tratamiento Neoadyuvante Y Pembrolizumab Frente A Un Placebo Como Tratamiento Adyuvante Para El Cáncer De Mama Triple N.Reference:/3439	GC06
ISIDORO BARNETO ARANDA.Estudio Fase Iii, Abierto, Multicéntrico, Aleatorizado Que Evalúa La Eficacia Y Seguridad De MpdI3280A (Anticuerpo Anti Pd L1) En Combinación Con Carboplatino + Paclitaxel O MpdI3280A En Combinación Con Carboplatino + Nab Paclitaxel Comparado Con Carb.Reference:0060/15	GC06	MARIA TERESA CANO OSUNA.Ensayo Clínico De Fase Iii, Aleatorizado, Doble Ciego Y Controlado Con Placebo, De Pembrolizumab (Mk-3475) En Combinación Con Cisplatino Y 5-Fluorouracilo En Comparación Con Placebo En Combinación Con Cisplatino Y 5-Fluorouracilo Como Tratamiento De Prime.Reference:/3689	GC06
ISIDORO BARNETO ARANDA.Estudio En Fase Iii, Abierto Y Aleatorizado Para Investigar La Eficacia Y Seguridad De Atelizumab (Anticuerpo Anti-Pd-L1) En Comparación Con El Tratamiento De Soporte Óptimo Despues De Quimioterapia Adyuvante Basada En Cisplatino En Pacientes Seleccionado.Reference:0192/15	GC06	MARÍA JESÚS RUBIO PÉREZ.Estudio De Extensión De Un Único Brazo, Abierto Y Multicentrico En Pacientes Con Tumores Sólidos Que Reciben Tratamiento Con Bevacizumab En Cualquiera De Los Estudios Esponsorizados Por F. Hoffmann- La Roche Y/O Genentech.Reference:0177/14	GC06
ENRIQUE ARANDA AGUILAR.Estudio Fase Iii Multicéntrico, Abierto, Randomizado, Con Tres Grupos De Tratamiento Para Investigar La Eficacia Y Seguridad De Cobimetinib En Combinación Con Atezolizumab Y De Atezolizumab En Monoterapia, Comparado Con Regorafenib, En Pacientes Con Adeno.Reference:/3267	GC06	ENRIQUE ARANDA AGUILAR.Ensayo Clínico Multicéntrico Randomizado, De Tratamiento De Mantenimiento Basado En Biomarcadores Para Primera Línea De Cáncer Colorrectal Metastásico (Modul)..Reference:0295/15	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio En Fase 3 Aleatorizado, Abierto, De Abemaciclib En Combinación Con Tratamiento Endocrino Adyuvante Estándar Frente A Monoterapia Con Tratamiento Endocrino Adyuvante Estándar, En Pacientes Con Cáncer De Mama En Estadios Iniciales, De Alto Riesgo, C.Reference:/3529	GC06	MARIA JOSE MENDEZ VIDAL.Estudio Multicéntrico, Abierto Con Un Solo Grupo De Tratamiento Para Evaluar La Seguridad De Atezolizumab En Pacientes Con Carcinoma Urotelial O No Urotelial Del Tracto Urinaio Localmente Avanzado O Metastásico..Reference:/3325	GC06
MARÍA JESÚS RUBIO PÉREZ.Estudio De Fase 2 De Prexasertib En Cáncer De Ovario Resistente O Recurrente Refractario A Derivados Del Platino.Reference:/3779	GC06	ISIDORO BARNETO ARANDA.Estudio De Fase Iii/Iv Multicéntrico, Con Un Solo Grupo De Tratamiento, Para Investigar La Seguridad A Largo Plazo Y La Eficacia De Atezolizumab (Tecentrig) En Pacientes Con Cáncer De Pulmón No Microcítico Localmente Avanzado O Metastásico, Tratados Previ.Reference:/3590	GC06
ALBERTO LUIS MORENO VEGA.Estudio De Fase I/Ii Sobre La Seguridad, La Tolerabilidad Y La Eficacia De Incagn01876 En Combinación Con Inmunoterapias En Sujetos Con Neoplasias Malignas Avanzadas O Metastásicas.Reference:/3609	GC06	MARÍA JESÚS RUBIO PÉREZ.Estudio Fase 2 Aleatorizado, Doble Ciego, Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad De Farletuzumab (Morab-003) En Combinación Con Carboplatino Más Paclitaxel O Doxorubicina Liposómica Pegilada (Plid) En Pacientes Con Cáncer De Ovario .Reference:0045/15	GC06
MARIA JOSE ORTIZ MORALES.Estudio Aleatorizado, Multicéntrico, De Grupos Paralelos Y De Fase Iii, Para Comparar La Eficacia De Arfolitixorin Frente A Leucovorin En Combinación Con 5-Fluorouracilo, Oxaliplatino Y Bevacizumab En Pacientes Con Cáncer Colorrectal Avanzado..Reference:/4072	GC06	ISIDORO BARNETO ARANDA.Multicenter, Double-Blind, Randomized, Parallel-Group Study To Assess The Efficacy And Safety Of Myl-14020 Compared With Avastin, In The First-Line Treatment Of Patients With Stage Iv Non-Squamous Non-Small Cell Lung Cancer.Reference:/3238	GC06
MARÍA JESÚS RUBIO PÉREZ.Estudio Fase 0, Farmacocinético/Farmacodinámico, Multicéntrico, Para Evaluar El Efecto Inhibidor De Azd2281 (Olaparib) Antes De La Cirugía En Pacientes Con Carcinoma De Endometrio Localizado..Referen-ce:0226/15	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Fase Ii De Olaparib De Mantenimiento Tras La Respuesta A Trabectedina Y Doxorubicina Liposomal Pegilada En Cáncer De Ovario Recurrente.Reference:/3869	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio De Fase Ii Randomizado, Multicéntrico, Abierto Para Evaluar La Eficacia Y Seguridad De Palbociclib En Combinación Con Fulvestrant O Letrozol En Pacientes Con Cáncer De Mama Metastasio Her2 Negativo, Er+ (Parsifal 1).Reference:0026/15	GC06	MARÍA JESÚS RUBIO PÉREZ.Ensayo Clínico Fase Iii, Aleatorizado, Doble Ciego, Multicéntrico De Olaparib Vs. Placebo En Pacientes Con Cáncer De Ovario Avanzado (Incluidos Las Pacientes Con Peritoneal Primario Y/O Cáncer De Trompa De Falopio) De Alto Grado Seroso O Endometrioide, Tr.Reference:0256/15	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Ensayo De Fase Ii, Multicéntrico, Internacional, No Controlado Para Identificar Los Mecanismos Moleculares De Resistencia Y Sensibilidad A La Reexposición A Palbociclib Tras La Progresión A Una Combinación De Palbociclib En Pacientes Con Cáncer De Mama Me.Reference:/3443	GC06	JUAN RAFAEL DE LA HABA RODRÍGUEZ.Estudio Fase Ii, Aleatorizado, Que Compara, En Primera Línea De Quimioterapia, Vinorelbina Oral, Como Agente Unico, En Dos Pautas De Administracion Diferentes En Pacientes Con Cancer De Mama Avanzado. Tempobrest 1..Reference:0233/15	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ.Trastuzumab Y Pertuzumab Sin Quimioterapia En Cancer De Mama Her+: Estrategia Adaptada En Funcion De La Respuesta Evaluada Por Fdg-Pet. Estudio Phergain.Reference:/3479	GC06	MARÍA JESÚS RUBIO PÉREZ.Estudio Clínico Multicéntrico De Fase Ii De Lurbinectedina (Pm01183) En Tumores Sólidos Avanzados Seleccionados A Multicenter Phase Ii Clinical Trial Of Lurbinectedin (Pm01183) In Selected Advanced Solid Tumors Basket.Reference:0358/14	GC06
MARIA JOSE MENDEZ VIDAL.Ensayo Clínico De Fase Ii De La Actividad De Radio 223 En Pacientes Con Cnáncer De Prós-tata Mestásico Resistente A La Castración (Cprcm) Con Progresión Asintomática Durante El Tratamiento Con Acetato De Abiraterona O Enzalutamida Y En Función Del Estado M.Reference:/3271	GC06	ISIDORO BARNETO ARANDA.Ensayo Clínico De Fase Iii Aleatorizado De Lurbinectedina (Pm01183)/Doxorubicina (Dox) En Comparación Con Ciclofosfamida (Ctx), Doxorubicina (Dox) Y Vincristina (Vcr) (Cav) O Topotecán Como Tratamiento En Pacientes Con Carcinoma Microcítico De Pulmon (Cmp.Reference:/3217	GC06
ENRIQUE ARANDA AGUILAR.Evaluación De Un Tratamiento De Mantenimiento Inmunomodulador En Pacientes Con Cáncer Colorrectal Metastasio Con Reducción Del Tumor Durante El Tratamiento De Inducción. Ensayo En Fase Lii..Referen-ce:0151/14	GC06	MARÍA JESÚS RUBIO PÉREZ.Estudio De Fase Ib/Ii Para Evaluar La Eficacia Y La Tolerabilidad De Pm01183 En Combinación Con Olaparib En Pacientes Con Tumores Sólidos Avanzados.Reference:/3448	GC06
MARÍA JESÚS RUBIO PÉREZ.Estudio En Fase Iii Aleatorizado Sobre Trabectedina (Et 743) Frente A La Quimioterapia Elegida Por El Clínico En Pacientes Con Cáncer Ovárico, Peritoneal Primario O Tubárico Con Fenotipo De Mutación En Brca O Brcaness – Mito-23.Reference:/3691	GC06	MARÍA JESÚS RUBIO PÉREZ.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Niraparib Maintenance Treatment In Patients With Hrd-Positive Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy.Reference:/3191	GC06
ENRIQUE ARANDA AGUILAR.Ensayo Clínico De Fase Iii, Aleatorizado Y Abierto De Pembrolizumab (Mk-3475) Frente A Paclitaxel En Sujetos Con Adenocarcinoma Gástrico O De La Union Gostroesofágica Avanzado Que Han Presentado Progre-sion Despues Del Tratamiento De Primera Línea Con Plat.Reference:0020/15	GC06	MARIA JOSE MENDEZ VIDAL.Estudio Fase Ii Multicéntrico Que Analiza El Valor Predictivo De Respuesta A Enzalutamida Del Gen De Fusión Tmprss2-Ets En Pacientes Con Cprc Metastásico No Tratados Previamente Con Quimioterapia.Reference:0267/14	GC06



MARIA JOSE MENDEZ VIDAL. Ensayo Fase Ii Para Evaluar El Tratamiento De Mantenimiento Con Olaparib En Pacientes Con Cáncer De Próstata Metastático Resistente A La Castración (Cpmrc) Después De Haber Alcanzado Una Respuesta Parcial O Enfermedad Estable Durante El Tratamiento Con Do. Reference:/3654	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Fase Ii Para Evaluar La Eficacia Y Seguridad Del Tratamiento Con Sunitinib En Pacientes Con Carcinoma Renal De Células Claras Metastático Que Han Progresado Al Tratamiento De Inmunoterapia En Primera Línea (Estudio Inmunosun). Reference:/3419	GC06
ISIDORO BARNETO ARANDA. Ensayo Fase Iii, Abierto Y Aleatorizado, Para Evaluar La Adición De Denosumab A La Quimioterapia Estándar De Primera Línea En Cáncer De Pulmón No Microcítico Avanzado. Reference:0191/14	GC06
MARIA TERESA CANO OSUNA. Randomized, Double-Blind, Phase 3 Study Evaluating Tas-102 Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc In Patients With Metastatic Gastric Cancer Refractory To Standard Treatments. Reference:/3348	GC06
MARIA TERESA CANO OSUNA. Estudio Fase I / Ii Con Nab-Paclitaxel (Abraxane®) Y Gemcitabina Seguido De Folfox Modificado (Ag-Mfolfox) En Pacientes Con Cáncer De Páncreas Metastático No Tratado. Reference:/3524	GC06
ENRIQUE ARANDA AGUILAR. Estudio Aleatorizado Fase 2 De Comparación De Diferentes Dosis-Pautas De Tratamiento De Inducción (Primer Ciclo) De Regorafenib En Pacientes Con Cáncer Colorrectal Metastático (Mcr). Reference:/3122	GC06
MARIA AUXILIADORA GÓMEZ ESPAÑA. Estudio Fase Ii Para Evaluar La Eficacia De Folfiri+Aflibercept En Pacientes Con Cáncer Colorrectal Metastático Tratado Previamente Con Oxaliplatino Con O Sin Polimorfismos De Ace. Estudio Polaf.. Reference:/3220	GC06
MARIA AUXILIADORA GÓMEZ ESPAÑA. Estudio Piloto Fase Ii Randomizado Multicéntrico Para Evaluar La Eficacia Y Seguridad Del Tratamiento Con Folfiri-Aflibercept Comparado Con Un Tratamiento Inicial Con Folfiriaflibercept (Durante 6 Ciclos) Seguido De Mantenimiento Con 5Fu-Aflibercept En Pa. Reference:/3528	GC06
MARIA AUXILIADORA GÓMEZ ESPAÑA. Estudio De Fase Iii, Aleatorizado, Secuencial Y Abierto, Para Evaluar La Eficacia De Folfox + Panitumumab Seguido Por Folfiri + Bevacizumab (Secuencia 1) Frente A Folfox + Bevacizumab Seguido Por Folfiri + Panitumumab (Secuencia 2) En Pacientes Con Cáncer. Reference:/3967	GC06
MARIA JOSE MENDEZ VIDAL. Estudio De Fase Iii, Aleatorizado, Para Evaluar Cabazitaxel Y Radioterapia Pelviana En Pacientes Con Cáncer De Prostata Localizado Con Alto Riesgo De Recaída, Según Un Diseño Factorial.. Reference:0333/13	GC06
MARÍA JESÚS RUBIO PÉREZ. Ensayo Clínico De Fase Ii Con Pembrolizumab Combinado Con Doxorubicina En El Cáncer Endometrial Avanzado, Recurrente O Metastático (Topic). Reference:/3750	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio De Fase Ii Multicéntrico, Multinacional, De Evaluación De Pertuzumab En Combinación Con Trastuzumab Y Quimioterapia Neoadyuvante Basada En Antraciclinas En Pacientes Con Cáncer De Mama Her2 Positivo Localmente Avanzado, Inflamatorio O Precoz.. Reference:0105/14	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio En Fase Iii, Multicéntrico, Aleatorizado Y Controlado Con Placebo De Atezolizumab (Anticuerpo Anti-Pd-L1) Combinado Con Nab-Paclitaxel En Comparación Con Placebo Con Nab-Paclitaxel En Pacientes Con Cáncer De Mama Triple Negativo Metastático No Tra. Reference:0018/16	GC06
MARIA JOSE MENDEZ VIDAL. Estudio De Fase Iii Multicéntrico, Randomizado, Controlado Con Placebo De Atezolizumab (Anticuerpo Anti-Pd-L1) En Monoterapia Y En Combinación Con Quimioterapia Basada En Platino En Pacientes Con Carcinoma Urotelial Localmente Avanzado O Metastático No Tr. Reference:/3417	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio De Fase Ii, Multicéntrico, Doble Ciego, Randomizado, Controlado Con Placebo Para Evaluar La Eficacia Y Seguridad De Atezolizumab O Placebo En Combinación Con Trastuzumab Emtansina En Pacientes Con Cáncer De Mama Localmente Avanzado O Metastático H. Reference:/3189	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Fase Iii, Doble Ciego, Controlado Con Placebo, Randomizado Y Multicéntrico De Atezolizumab (Anticuerpo Anti-Pd-L1) Como Tratamiento Adyuvante En Pacientes Con Carcinoma De Células Renales Con Alto Riesgo De Desarrollo De Metástasis Tras Nefrectomía. Reference:/3333	GC06
IGNACIO PORRAS QUINTELA. Estudio En Fase Iii Multicéntrico, Abierto, Randomizado, Con Dos Brazos De Tratamiento, Para Evaluar La Farmacocinética, La Eficacia Y La Seguridad De La Administración Subcutánea De La Combinación En Dosis Fijas De Pertuzumab Y Trastuzumab En Combinación. Reference:/3864	GC06
MANUEL JESUS VALLADARES AYERBES. Determinación Del Estado Mutacional Del Ras En Biopsias Líquidas De Sujetos Con Cáncer Colorrectal Metastático Ras No Mutado En Primera Línea: Estudio Observacional, Prospectivo Y Multicéntrico En España (Estudio Perseida). Reference:3860	GC06



MARIA JOSE MENDEZ VIDAL. Estudio Prospectivo Multicéntrico De Factores Pronósticos En Cáncer De Prostata Resistente A La Castración Tratados Con Abiraterona. Reference:2683	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Prospectivo Multicéntrico De Factores Pronósticos En Cáncer De Prostata Resistente A La Castración Tratados Con Docetaxel O Cabazitaxel.. Reference:2684	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Prospectivo Multicéntrico De Factores Pronósticos En Cáncer De Prostata Resistente A La Castración Tratados Con Enzalutamida. Reference:3352	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Prospectivo Multicéntrico De Factores Pronósticos En Cáncer De Prostata Resistente A La Castración Tratados Con Radium-223. Reference:3351	GC06
ISIDORO BARNETO ARANDA. Valoración De Las Escalas Geriátricas En La Toma De Decisión Terapéutica En El Paciente Anciano Con Cáncer De Pulmón No Microcítico (Cpnm) Avanzado O Metastático. Reference:3356	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio Observacional Retrospectivo Del Tratamiento Con Nab-Paclitaxel En Pacientes Con Cáncer De Mama Metastático Her2-Negativo En Condiciones De Práctica Clínica Habitual (Estudio Carema).. Reference:3724	GC06
JUAN RAFAEL DE LA HABA RODRÍGUEZ. Estudio Prospectivo De Registro De Pacientes Con Cáncer De Mama Localmente Avanzado No Resecable O Metastático (Cmm). Estudio Registem. Reference:3223	GC06
MARÍA JESÚS RUBIO PÉREZ. Estudio Post-Autorización Retrospectivo Y Multicéntrico Para Analizar La Eficacia Y Seguridad De La Combinación Con Trabectedina Y Doxorubicina Liposomal Pegilada (Dlp) Para El Tratamiento De Pacientes Con Cáncer De Ovario Recidivante (Cor) Sensible Al . Reference:2735	GC06
ALBERTO LUIS MORENO VEGA. Estudio Observacional Retrospectivo De Pacientes Con Tumores Del Estroma Gastrointestinal (Gist), Metastático O Localmente Avanzado, Tratado Con Sunitinib. Análisis Exploratorio De Factores Pronósticos Y Predictivos En Largos Respondedores.. Reference:3997	GC06
MARÍA JESÚS RUBIO PÉREZ. Estudio Español No Intervencional, Multicéntrico Y Retrospectivo Para Analizar La Eficacia Y Seguridad De Trabectedina En El Tratamiento De Pacientes Con Leiomioma Uterino Avanzado Recidivante Según Ficha Técnica. Reference:3787	GC06
PEDRO SANCHEZ MAURÍÑO. Evaluación De La Calidad De Vida De Pacientes Con Estreñimiento Incluido Por Opioides En Tratamiento Con Naloxegol. Estudio De Un Año De Seguimiento. Estudio Kyonal. Reference:3792	GC06
MARÍA JESÚS RUBIO PÉREZ. Estudio Observacional Retrospectivo Para Evaluar Las Estrategias De Tratamiento En Práctica Clínica Y La Evolución Clínica De Los Pacientes Con Cáncer De Ovario Avanzado En España: Estudio Ovoc (Evaluación Objetiva De Cáncer De Ovario).. Reference:4001	GC06
MARIA JOSE MENDEZ VIDAL. Análisis Retrospectivo De Factores Clínicos Asociados A Un Mayor Beneficio Con Axitinib En Cáncer Renal Metastático (Estudio Axilong). Reference:3789	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Observacional, Prospectivo Y Multicéntrico De Calidad De Vida En Relación Con La Fatiga Y El Síndrome Mano-Pie De Los Pacientes Con Carcinoma Renal Metastático Tratados Con Un Inhibidor De La Tirosina Quinasa En Primera Línea. Reference:3221	GC06
ENRIQUE ARANDA AGUILAR. S-Avant. Seguimiento Del Estudio Avant Hasta 8 Y 10 Años (Mediana De Seguimiento) En Pacientes Con Carcinoma De Colon. Reference:3486	GC06
MARIA JOSE ORTIZ MORALES. Observational Epidemiological Study Of Cancer-Associated Thrombosis Registry Of Thrombosis And Neoplasia Of Eom/ Estudio Observacional Descriptivo Sobre La Trombosis Asociada Al Cáncer. Registro De Trombosis Y Neoplasias De La Seom. Estudio Teseo. Reference:3875	GC06
MARIA JOSE MENDEZ VIDAL. Validación Del Consorcio De La Base De Datos Internacional De Cáncer Renal Metastático (Imdc) Como Clasificación Pronóstica Para Terapias Dirigidas (Inhibidores De La ITC/Mtor) En Segunda Línea Después Del Tratamiento Con Pazopanib Primera Línea (Spazo-2). Reference:3295	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Prospectivo De La Utilidad De La Biopsia Líquida Como Factor Predictor Y Pronóstico En Pacientes Con Carcinoma Urotelial Metastático En Progresión Tras Quimioterapia Basada En Platino. Reference:3612	GC06
MARIA JOSE MENDEZ VIDAL. Estudio Retrospectivo De Ámbito Español Para Evaluar La Eficacia Y Seguridad De Terapias Dirigidas Tras La Administración De Pazopanib Como Terapia De Primera Línea En Pacientes Con Carcinoma Metastático De Células Renales En La Práctica Clínica Habitual.. Reference:2636	GC06
ISIDORO BARNETO ARANDA. Detección De La Mutación T790M Mediante Tecnología Beaming En Pacientes Con Cpcnp Y Egfr Mutado En Estadio Iv. Estudio Lungbeam.. Reference:2930	GC06



ENRIQUE ARANDA AGUILAR.Perfil Clínico Y Manejo Terapeutico De Los Pacientes Con Cancer De Pancreas; Registro En Los Servicios Hospitalarios De Oncología Médica De España.Reference:2906	GC06
ROSA MARIA RODRIGUEZ ALONSO.Estudio Codepicup: Estudio Observacional, Multicéntrico, Proyectivo En Pacientes Con Cáncer De Origen Desconocido A Los Que Se Realiza El Test De Diagnóstico Epicup..Reference:3583	GC06
MARIA DOLORES NAVARRO CABELLO.Estudio De Fase 2 Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad De Una Vacuna, Asp0113, En Receptores Cmv-Seronegativos De Trasplante De Riñón Procedente De Donante Cmv-Seropositivo..Reference:0145/14	GC07
ALEJANDRO MARTÍN MALO.An Observer-Blind, Multi-Center, Placebo-Controlled, Parallel Group Study To Assess The Safety And Tolerability And To Characterize The Pharmacokinetics And The Pharmacodynamics Of Different Doses Of Bay 1213790 In Patients With End-Stage Renal Disease Un.Reference:4092	GC07
RAFAEL SANTAMARIA OLMO.Estudio Fase Iii, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Grupos Paralelos, Multicéntrico, Dirigido Por Eventos, Para Evaluar La Eficacia Y Seguridad De Finerenona, Asociada Al Tratamiento Estándar, En La Progresión De La Enfermedad Renal En.Reference:3335-1	GC07
RAFAEL SANTAMARIA OLMO.Estudio Fase Iii, Aleatorizado, Doble Ciego, Controlado Con Placebo, De Grupos Paralelos, Multicéntrico, Dirigido Por Eventos, Para Evaluar La Eficacia Y Seguridad De Finerenona, Asociada Al Tratamiento Estándar, En La Reducción De La Morbilidad Y Mortali.Reference:3334	GC07
RAFAEL SANTAMARIA OLMO.Ensayo Multicéntrico Internacional, Aleatorizado, Doble Ciego, Con Grupos Paralelos Y Controlado Con Placebo Del Efecto De Atrasentan Sobre Los Resultados Renales De Sujetos Con Diabetes Tipo 2 Y Nefropatía . Sonar: Ensayo De Nefropatía Diabética Con Atra.Reference:0190/13	GC07
MARIO ESPINOSA HERNÁNDEZ.A Randomized, Double-Blind, Placebo-Controlled, Phase Iii Study Of The Safety And Efficacy Of Oms721 In Patients With Inmunoglobulin A (Iga) Nephropathy (Artemis-Igan).Reference:3910	GC07
MARIO ESPINOSA HERNÁNDEZ.Un Estudio Observacional, No Intervencionista, Multicéntrico Y Multinacional De Pacientes Con Síndrome Hemolítico Urémico Atípico (Registro De Shua).Reference:2079/2	GC07
ALBERTO MANUEL RODRÍGUEZ BENOT.Seguimiento A Largo Plazo De Adultos Que Recibieron Alotrasplantes De Riñón E Hígado Y Que Han Participado Previamente En Un Ensayo Con Tacrolimus (Advagraf). Estudio Multicéntrico No Intervencional Posterior A La Autorización (Epa).Reference:2612	GC07
ALBERTO MANUEL RODRÍGUEZ BENOT.Impacto De Los Niveles De Tacrolimus En La Prevención Del Rechazo En Pacientes De Edad Avanzada Receptores De Trasplante Renal De Novo: Estudio Observacional Prospectivo En Las Condiciones De La Práctica Clínica Habitual (Bitácora).Reference:3976	GC07
MARIA LUISA AGÜERA MORALES.Registro Nacional De Rechazo Humoral: Estudio Epidemiológico Multicéntrico Observacional Prospectivo Para Evaluar Las Características Clínicas, Serológicas E Histológicas Y La Evolución A 5 Años Del Rechazo Humoral Post-Trasplante Renal En España..Reference:1762	GC07
MARIO ESPINOSA HERNÁNDEZ.A 6 Year, Multicentre, Non-Interventional, Post-Authorisation Safety Study For Patients Prescribed Jinarc For Autosomal Dominant Polycystic Kidney Disease.Reference:3656	GC07
RAFAEL SANTAMARIA OLMO.Estudio Multicéntrico, Prospectivo, Observacional, Para El Análisis De Factores De Progresión De La Enfermedad Renal Crónica En Pacientes Diabéticos Vs No Diabéticos.Reference:1855	GC07
RAFAEL SANTAMARIA OLMO.Estudio De La Carga De La Enfermedad En Pacientes Con Enfermedad De Fabry. Estudio Car E-Fabry.Reference:3566	GC07
FRANCISCO FUENTES JIMÉNEZ.Estudio Abierto, Multicéntrico Para Evaluar La Seguridad, Tolerabilidad Y Eficacia A Largo Plazo De Amg 145 En El C-Ldl En Sujetos Con Hipercolesterolemia Familiar Severa.Reference:0032/13	GC09
FRANCISCO FUENTES JIMÉNEZ.Estudio Abierto, Multicéntrico Y De Un Solo Grupo Para Evaluar La Seguridad, Tolerabilidad Y Eficacia De Evolocumab, Como Tratamiento Adyuvante De La Dieta Y Del Tratamiento Hipolipeminate, En La Reducción Del C-Ldl En Sujetos Pediátricos De 10 A 17 Años .Reference:3121	GC09
JOSE LOPEZ MIRANDA.Estudio De Extensión Abierto (Ole), Controlado Y Multicéntrico Para Evaluar La Seguridad Y La Eficacia A Largo Plazo De Amg 145.Reference:0086/13	GC09
FRANCISCO FUENTES JIMÉNEZ.Ensayo Clínico De Bajo Nivel De Intervención, Abierto Y Multicéntrico Para Evaluar El Efecto De Alirocumab Sobre El Volumen, La Arquitectura Y La Composición De La Placa Aterosclerótica En Pacientes Con Hipercolesterolemia Familiar Del Registro. Safehear.Reference:3830	GC09

MANUEL MONTERO PÉREZ-BARQUERO.Estudio Multicéntrico, Aleatorizado, Doble Ciego, De Grupos Paralelos, Con Control Activo, Para Evaluar La Eficacia Y Seguridad De Lcz696 Comparado Con Valsartan, Sobre La Morbilidad Y Mortalidad En Pacientes Con Insuficiencia Cardíaca (Clase Ii-Iv Nyha) .Reference:0216/13	GC09
FRANCISCO JESUS GOMEZ DELGADO.Estudio Multicéntrico, Aleatorizado, Doble Ciego, De Grupos Paralelos, Con Control Activo Y De 24 Semanas De Duración Para Evaluar El Efecto De Lcz696 Sobre El Nivel De Ntprobnp, Los Síntomas, La Capacidad De Realizar Ejercicio Y La Seguridad En Comparaci.Reference:3861	GC09
FRANCISCO FUENTES JIMÉNEZ.Odyssey Kids - Estudio Abierto De Ocho Semanas De Duracion, De Búsqueda De Dosis Repetidas, Secuencial, Para Evaluar La Eficacia Y Seguridad De Alirocumab En Niños Y Adolescentes Con Hipercolesterolemia Familiar Heterocigotica, Seguido De Una Fase De Exte.Reference:3237	GC09
FRANCISCO FUENTES JIMÉNEZ.Ensayo Aleatorizado, Doble Ciego, Controlado Con Placebo Y Con Grupos Paralelos Para Evaluar El Efecto De Sar236553/Regn727 Sobre La Aparición De Acontecimientos Cardiovasculares En Pacientes Que Han Experimentado Recientemente Un Síndrome Coronario Agudo.Reference:0314/12	GC09
FRANCISCO JAVIER DELGADO LISTA.Estudio Aleatorizado, Doble Ciego, Controlado Con Placebo, De Grupos Paralelos, Multicéntrico, Para Demostrar Los Efectos De Sotagliflozina Sobre Los Eventos Cardiovasculares Y Renales En Pacientes Con Diabetes Tipo 2, Factores De Riesgo Cardiovascular Y .Reference:3687	GC09
PABLO PÉREZ MARTÍNEZ.Estudio De Fase Iii, Internacional, Multicéntrico, Aleatorizado Y Abierto, Para Evaluar La Eficacia En La Reducción De Cldl Y Presión Arterial, Y La Seguridad De Trinomia® Versus Tratamiento Habitual En Pacientes De Muy Alto Riesgo Cardiovascular Sin Even.Reference:3346	GC09
FRANCISCO JAVIER DELGADO LISTA.Estudio A Largo Plazo, Aleatorizado, Doble Ciego, Controlado Con Placebo Para Determinar El Efecto De Albiglutida, Cuando Se Añade Al Tratamiento Hipoglucemiante Estándar, Sobre Eventos Cardiovasculares Mayores En Pacientes Con Diabetes Mellitus Tipo2.Reference:0049/15	GC09
FRANCISCO JAVIER DELGADO LISTA.Pemafibrato Para Reducir Los Episodios Cardiovasculares Mediante La Reducción De Los Triglicéridos En Pacientes Con Diabetes (Prominent).Reference:4108	GC09
FRANCISCO FUENTES JIMÉNEZ.Ensayo Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar El Efecto De 300 Mg De Inclisiran Sódico Administrado En Inyecciones Subcutáneas A Sujetos Con Hipercolesterolemia Familiar Heterocigotica (Hfhe) Y Elevado Colesterol De Las Lipoproteí.Reference:3651	GC09
JOSE LOPEZ MIRANDA.Estudio Mundial, Multicéntrico, Doble Ciego, Aleatorizado, Paralelo Y Controlado Con Placebo De Un Año De Duración Para Evaluar La Eficacia Y Tolerabilidad De Anacetrapib Añadido A Un Tratamiento En Curso Con Estatinasm, Combinado O No Con Otros Agentes M.Reference:0267/11	GC09
FRANCISCO JAVIER DELGADO LISTA.Efecto De Semaglutida Una Vez A La Semana Frente A Insulin Aspart Tres Veces Al Día, Ambas Añadidas A Metformina E Insulina Glargina Optimizada (U100), En Sujetos Con Diabetes Tipo 2 Ensayo De 52 Semanas, Multicéntrico, Multinacional, Abierto, Con Contro.Reference:3970	GC09
PABLO PÉREZ MARTÍNEZ.Estudio Aleatorizado, Doble Ciego, Controlado Con Placebo, De La Seguridad Y La Eficacia De Diferentes Dosis Y Pautas Posológicas De Evinacumab En Pacientes Con Hipercolesterolemia Crónica A Pesar Del Tratamiento Hipolipidemiante Máximo Tolerado.Reference:3778	GC09
JOSE LOPEZ MIRANDA.Estudio Observacional Retrospectivo Sobre El Uso De Evolocumab En Unidades De Medicina Interna De España (Retoss-Imu).Reference:3563	GC09
FRANCISCO FUENTES JIMÉNEZ.Estudio Observacional Multinacional Para Evaluar La Seguridad De Repatha En El Embarazo.Reference:3565	GC09
FRANCISCO JESUS GOMEZ DELGADO.Eu-Wide Cross-Sectional Observational Study Of Lipyd-Modifying Therapy Use In Secondary And Primary Care Da Vinci.Reference:3637	GC09
LUCIANO LÓPEZ JIMENEZ.Estudio Observacional, Transversal Para Describir La Calidad De Vida Relacionada Con La Salud En Pacientes Con Fibrilación Auricular No Valvular Tratados Con Anticoagulantes, Controlados Y No Controlados. Estudio Requil.Reference:3450	GC09
FRANCISCO FUENTES JIMÉNEZ.Long-Term Legacy Effects Of Ldl-C Lowering With Alirocumab: Observational Follow-Up Of The Odyssey Outcomes Study.Reference:3833	GC09
JOSE LOPEZ MIRANDA.Manejo Del Paciente Dislipémico Pre-Diabético En Las Unidades De Lípidos. Estudio Prelipid..Reference:3877	GC09



LUCIANO LÓPEZ JIMENEZ.Global Anticoagulant Registry In The Field Observing Treatment And Outcomes In Patients With Treated Acute Venous Thromboembolic Events In The Real World Garfield.Reference:2847	GC09
RAIMUNDO TIRADO MIRANDA.Global Anticoagulant Registry In The Field Observing Treatment And Outcomes In Patients With Treated Acute Venous Thromboembolic Events In The Real World.Reference:2877	GC09
JESÚS GONZÁLEZ LAMA.Ensayo Clínico En Fase Iii Multicéntrico, Aleatorizado, Doble Ciego, Controlado Por Placebo, Con Grupos Paralelos Para Investigar La Eficacia, Seguridad Y Tolerabilidad De Naloxona Hcl Lp Comprimidos En Pacientes Con Estreñimiento Inducido Por Opioides.Reference:/4034	GC12
ANTONIO HIDALGO REQUENA.Estudio Observacional, Transversal, Multicéntrico Para Describir El Perfil De Exacerbaciones De Los Pacientes Con Epoc Tratados Con Corticoides Inhalados En La Práctica Clínica Real De Atención Primaria En España. Estudio Opti; Non-Intervetional, Cross-Sec.Reference:3974/1	GC12
FRANCISCO JAVIER RUIZ MORUNO.Estudio Observacional Transversal Para Caracterizar La Epoc Grave En España. Estudio Clave.Reference:3696/3	GC12
ANTONIO HIDALGO REQUENA.Estudio Observacional Transversal Para Caracterizar La Epoc Grave En España. Estudio Clave.Reference:3696/4	GC12
ENRIQUE MARTÍN RIOBOO.Evaluación Del Control Glucémico En Pacientes Con Alto Riesgo Cardiovascular Y Diabetes Mellitus Tipo 2 En Consultas De Atención Primaria Y Cardiología.Reference:3249	GC12
JESÚS GONZÁLEZ LAMA.Registro Internacional, Multicentrico Y Prospectivo De Pacientes Hombres Y Mujeres Diagnosticados Recientemente Con Fibrilación Auricular Y Tratados Con Rivaroxaban..Reference:3010	GC12
JUAN MARIANO RODRÍGUEZ PORTILLO.Ensayo Clínico Fase Ii, Abierto, Para Evaluar La Eficacia De La Disminución De La Absorción Intestinal Del Fósforo En La Progresión De La Enfermedad Renal En Pacientes Con Síndrome Metabólico. Reference:0039/15	GC13
JUAN MARIANO RODRÍGUEZ PORTILLO.Estudio Doble Ciego, Aleatorizado, Controlado Con Placebo Para Evaluar El Efecto De Snf472 En La Progresión De La Calcificación Cardiovascular Además Del Tratamiento De Referencia En Pacientes Con Nefropatía Terminal (Nt) Sometidos A Hemodiálisis (Hd).Reference:/3294	GC13
JUAN MARIANO RODRÍGUEZ PORTILLO.Estudio No Intervencionista Para Investigar La Seguridad, La Efectividad Y La Adherencia De Velphoro A Corto Y A Largo Plazo En La Vida Real De Pacientes Con Hiperfosfatemia Sometidos A Hemodiálisis O A Diálisis Peritoneal.Reference:3353	GC13
JUAN MARIANO RODRÍGUEZ PORTILLO.Estudio Sobre El Efecto Del Suplemento Dietético Con Magnesio Sobre El Grado De Calcificación Vascular Y La Densidad Ósea En Pacientes Con Enfermedad Renal Crónica Grado 3B-4.Reference:/3953	GC13
INMACULADA CONCEPCIÓN HERRERA ARROYO.Ensayo Clínico Fase Ii, Unicéntrico, Abierto, Controlado Y Aleatorizado, Para Valorar La Eficacia De La Infusión Intra Arterial De Células Mononucleadas De Médula Ósea Autóloga En Pacientes Con Ictus Isquémico.Reference:/3645	GC14
JOSÉ MARÍA ARIZON DEL PRADO.Estudio Doble Ciego, Aleatorizado, Controlado Con Placebo, Multicentrico Para Evaluar La Eficacia De Omecantiv Y Mecarbil En La Mortalidad Y Morbilidad De Sujetos Con Insuficiencia Cardíaca Crónica Conf Raccion De Eyección Reducida.Reference:/3327	GC15
MIGUEL ÁNGEL ROMERO MORENO.Prevencción Secundaria De La Enfermedad Cardiovascular Em Ancianos (Secure). Reference:/3000	GC15
JUAN CARLOS CASTILLO DOMINGUEZ.Estudio De Fase 3, Multinacional, Aleatorizado Y Controlado Con Placebo De Arry-371797 En Pacientes Con Miocardiopatía Dilatada Sintomática Por Mutación Del Gen Lamina A/C.Reference:/3969	GC15
JOSÉ MARÍA ARIZON DEL PRADO.Estudio Multicéntrico, Aleatorizado, Doble Ciego, Prospectivo Para Evaluar El Efecto De Sacubitril/Valsartán Vs. Enalapril En La Actividad Física Diaria Utilizando Un Actígrafo De Muñeca En Pacientes Adultos Con Insuficiencia Cardíaca Crónica..Reference:/3388	GC15
DJORDJE PAVLOVIC DJUROVIC.An Open-Label, 2 X 2 Factorial, Randomized Controlled, Clinical Trial To Evaluate The Safety Of Apixaban Vs Vitamin K Antagonist And Aspirin Placebo In Patients With Atrial Fibrillation And Acute Coronary Syndrome Or Percutaneous Coronary Intervention.Reference:/3341	GC15
DJORDJE PAVLOVIC DJUROVIC.Estudio En Fase Iii, Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar Los Efectos De Dalcetrapib Sobre El Riesgo Cardiovascular (Cv) En Una Población Definida Genéticamente Con Síndrome Coronario Agudo Reciente (Sca): El Ensayo Dal-Gen..Reference:/3126	GC15

MANUEL PAN ÁLVAREZ-OSSORIO.Estrategia Antitrombótica Para Reducir Las Complicaciones Cardiovasculares, Neurológicas Y Hemorrágicas Tras Una Implantación Valvular Aórtica Por Vía Percutánea: Estudio Atlantis.Reference:/3686	GC15
MANUEL ANGUITA SÁNCHEZ.Tratamiento Con Betabloqueantes Tras Infarto De Miocardio Sin Fracción De Eyección Reducida.Reference:/3719	GC15
FRANCISCO JOSE HIDALGO LESMES.Estudio Observacional Retrospectivo Del Uso De Evolocumab En Unidades Españolas De Cardiología (Retoss-Cardio).Reference:3619	GC15
AMADOR LÓPEZ GRANADOS.Factores De Riesgo Asociados Con La Progresión De La Insuficiencia Cardíaca En Pacientes Con Fibrilación Auricular Tratados Con Anticoagulante Oral Directo.Reference:3834	GC15
AMADOR LÓPEZ GRANADOS.Registro Global De Tratamiento Antitrombótico Oral A Largo Plazo En Pacientes Con Fibrilación Auricular (Fase Ii/Iii Estados Miembros De La Ue/Aee).Reference:2594	GC15
JOSE LÓPEZ AGUILERA.Estudio Observacional Descriptivo De Conveniencia En Pacientes Tratados Con Dabigatrán Para La Prevención Del Ictus En Fibrilación Auricular No Valvular.Reference:3693	GC15
MANUEL ANGUITA SÁNCHEZ.Registro De Hipercolesterolemia Familiar En El Síndrome Coronario Agudo.Reference:3413	GC15
JUAN CARLOS CASTILLO DOMINGUEZ.Registro Observacional Prospectivo De Pacientes Con Insuficiencia Cardíaca.. Reference:3999	GC15
JOSÉ MARÍA ARIZON DEL PRADO.Registro Internacional Para Evaluar La Práctica Médica Con Observación Longitudinal Ára El Tratamiento De La Insuficiencia Cardíaca. Internacional Registry To Assess Medical Practice With Longitudinal Observation For Treatment Of Heart Failure.Reference:2816	GC15
SOLEDAD OJEDA PINEDA.Registro Multicentrico De Revascularización Secundaria. Registro Revasec.Reference:3639	GC15
MANUEL PAN ÁLVAREZ-OSSORIO.Ebc Main: Estudio Llevado A Cabo Por El Club Europeo De Bifurcaciones: Comparación Aleatorizada De La Implantación De Una O Dos Endoprótesis Para Tratar Las Lesiones De Bifurcaciones Del Tronco Común De La Arteria Coronaria Izquierda..Reference:2961	GC15
MIGUEL ÁNGEL ROMERO MORENO.Second-Generation Drug-Eluting Stents In Diabetes: A Randomized Trial (The Sugar Trial).Reference:3793	GC15
RAFAEL ROJAS CONTRERAS.Ensayo De Fase 3 Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Eficacia Protectora Y La Seguridad De Una Vacuna Terapéutica, Asp0113, En Receptores Seropositivos Para El Citomegalovirus (Cmv) Sometidos A Alotrasplante De Células Hemat.Reference:0123/13	GC16
MARÍA DEL CARMEN MARTÍN CALVO.Estudio Adaptativo Y Aleatorizado De Fase 3 Para Comparar La Eficacia Y La Seguridad De Defibrotide Frente Al Mejor Tratamiento De Soporte En La Prevención De La Enfermedad Venooclusiva Hepática En Pacientes Adultos Y Pediátricos Sometidos A Un Trasplante .Reference:/3340	GC16
JOAQUIN SÁNCHEZ GARCÍA.Ensayo Aleatorizado Y Doble Ciego Para Evaluar La Eficacia, La Seguridad Y La Inmuno-genicidad De Abp 798 En Comparación Con Rituximab En Sujetos Con Linfoma No Hodgkin (Lnh) De Células B Sd20+. Reference:/3190	GC16
JOAQUIN SÁNCHEZ GARCÍA.Estudio Multicéntrico De Fase 2/3 Para Evaluar La Seguridad Y La Eficacia De Blinatumomab Em Sujetos Con Linfoma No Hodgkin De Células B Agresivo Em Recaída/Refractario.Reference:/3269	GC16
JOSEFINA SERRANO LÓPEZ.Estudio De Fase Iii, Doble Ciego, Controlado Con Placebo De Quizartinib (Ac220) Administrado En Combinación Con Quimioterapia De Inducción Y Consolidación, Y Administrado Como Terapia De Mantenimiento A Sujetos De 18 A 75 Años Con Leucemia Mielógena Aguda.Reference:/3218	GC16
MIGUEL ANGEL ALVAREZ RIVAS.Estudio De Fase 3, Aleatorizado, Controlado Con Placebo, Doble Ciego Del Tratamiento De Mantenimiento Con Ixazomib Citrato Por Vía Oral (Mln9708) En Pacientes Con Mieloma Múltiple Después De Autotrasplante De Células Madre.Reference:0112/14	GC16
JOSEFINA SERRANO LÓPEZ.Estudio Fase 3, Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Comparar La Eficacia Y La Seguridad De Azacitidina Oral Más El Mejor Tratamiento De Apoyo Frente Al Mejor Tratamiento De Apoyo Como Terapia De Mantenimiento En Pacientes Con Leucemia M.Reference:0293/12	GC16
JOAQUIN SÁNCHEZ GARCÍA.Estudio De Fase 3, Doble Ciego Y Aleatorizado Para Comparar La Eficacia Y La Seguridad De Rituximab Más Lenalidomida (Cc-5013) Frente A Rituximab Más Placebo En Sujetos Con Linfoma Indolente Recidivante/Resistente..Reference:0202/13	GC16



RAFAEL ROJAS CONTRERAS.Estudio De Fase Iii Aleatorizado, Abierto Y Multicéntrico De Ruxolitinib Frente A La Mejor Terapia Disponible En Pacientes Con Enfermedad De Injerto Contra Huésped Crónica Refractaria A Corticosteroides Tras Trasplante Alogénico De Células Madre..Reference:/3551	GC16	MIGUEL ANGEL ALVAREZ RIVAS.Registro Posautorización No Intervencionista De Pacientes Con Mieloma Múltiple Recidivante Y Refractorio Tratados Con Pomalidomida, Que Han Recibido Al Menos Dos Tratamientos Previos, Incluyendo Lenalidomida Y Bortezomib, Y Que Hayan Experimentado Una Pro.Reference:2641	GC16
JOSEFINA SERRANO LÓPEZ.Estudio Fase Iii, Aleatorizado, Doble Ciego, De Quimioterapia De Inducción (Daunorrubicina O Idarubicina Y Citarabina) Y De Consolidación (Dosis Intermedias De Citarabina) Más Midostaurina (Pkc412) O De Quimioterapia Más Placebo En Pacientes Con Leucemia.Reference:/3871	GC16	JOAQUIN SÁNCHEZ GARCÍA.Estudio Observacional Post-Autorización Para Evaluar La Evolución En La Práctica Clínica Habitual De Pacientes Recién Diagnosticados De Síndrome Mielodisplásico (Smd) O Leucemia Mielomonocítica (Lmmc), En Función Del Momento De Inicio De Tratamiento Activ.Reference:2109	GC16
MIGUEL ANGEL ALVAREZ RIVAS.Estudio Piloto (Fase Ii) De Combinación De Pomalidomida/Dexametasona Asociado A Baja Dosis De Ciclofosfamida En Pacientes Con Mieloma Múltiple Refractorio Que Han Recibido Lenalidomida Y Bortezomib..Reference:0024/16	GC16	JOSÉ RAMÓN MOLINA HURTADO.Estudio Observacional Prospectivo Para Identificar Los Aspectos Clínicos Que Conducen A La Toma De Decisiones Terapéuticas En Pacientes Con Mielofibrosis..Reference:2570	GC16
JOSEFINA SERRANO LÓPEZ.Estudio Fase Iii, Multicéntrico, Aleatorizado, Abierto De Azacitidina (Vidaza®) Frente A Fludarabina Y Citarabina (Esquema Fluga) En Pacientes Ancianos Con Leucemia Mieloide Aguda De Nuevo Diagnóstico. Reference:0148/14	GC16	MARGARITA FERNANDEZ DE LA MATA.Evaluación Retrospectiva No Intervencional Posterior A La Autorización Del Uso De Idelalisib En Pacientes Con Leucemia Cinfocítica Crónica (Llc) En Recaída/Refractaria (R/R) En España.Reference:4026	GC16
MARGARITA FERNANDEZ DE LA MATA.Estudio Multicéntrico, No Aleatorizado Y Abierto, Para Evaluar La Eficacia Y Seguridad De Ibrutinib Seguido Por Consolidación Con Ofatumumab, En Pacientes Con Leucemia Linfocítica Crónica (Llc) O Linfoma Linfocítico De Células Pequeñas (Llcp) Sin Tratamie.Reference:/3520	GC16	JOAQUIN SÁNCHEZ GARCÍA.Estudio Observacional Retrospectivo Sobre El Tratamiento De Linfoma De Células Del Manto Con Ibrutinib En La Práctica Clínica Habitual.Reference:3832	GC16
MARÍA DEL CARMEN MARTÍN CALVO.Ofatumumab Como Parte Del Régimen De Acondicionamiento De Intensidad Reducida (Ric) En Pacientes Con Linfoma B No-Hodgkin De Alto Riesgo Que Reciben Un Trasplante Alogénico De Progenitores Hematopoyéticos.Reference:0020/12	GC16	MARGARITA FERNANDEZ DE LA MATA.Estudio Observacional Retrospectivo Del Tratamiento De La Leucemia Linfocítica Crónica (Llc) Con Ibrutinib En La Práctica Clínica Habitual.Reference:3977	GC16
MIGUEL ANGEL ALVAREZ RIVAS.Tratamiento De Inducción Con Bortezomib, Melfalán Y Prednisona (Vmp) Seguido De Lenalidomida Y Dexametasona (Rd) Frente A Carfilzomib, Lenalidomida Y Dexametasona (Krd) Más/Menos Daratumumab, 18 Ciclos, Seguido De Tratamiento De Consolidación Y Mantenimie.Reference:/3870	GC16	RAFAEL ROJAS CONTRERAS.Estudio Sobre Las Complicaciones Clínicas Directas E Indirectas Derivadas De La Detección De La Infección Por Citomegalovirus (Cmv) En Pacientes Con Trasplante Alogénico De Células Progenitoras Hematopoyéticas (Alo-Tph) Estudio Cmv-Alotph.Reference:3591	GC16
MIGUEL ANGEL ALVAREZ RIVAS.Estudio Fase Ii Multicéntrico De Carfilzomib, Lenalidomida Y Dexametasona (Krd) Como Inducción, Seguido De Melfalán A Altas Dosis Y Trasplante Autólogo De Células Progenitoras De Sangre Periférica, Consolidación Con Krd Y Mantenimiento Con Lenalidomida Y .Reference:0298/14	GC16	MIGUEL ANGEL ALVAREZ RIVAS.Impacto De La Monitorización De Enfermedad Mínima Residual Mediante Citometría De Flujo En El Manejo Del Mieloma Múltiple.Reference:3752	GC16
JOSEFINA SERRANO LÓPEZ.Estudio De Eficacia De Inecalcitol En Combinación Con Decitabina En Pacientes Con Leucemia Mieloide Aguda No Aptos Para Quimioterapia Estándar.Reference:/3777	GC16	JOAQUIN SÁNCHEZ GARCÍA.Estudio De Caracterización Farmacológica Ex Vivo De Tratamientos En Hemopatías Malignas, Mediante Uso De La Plataforma Automatizada De Citometría De Flujo Exvitch..Reference:2634	GC16
JOSÉ RAMÓN MOLINA HURTADO.Ensayo Intergrupo Para Niños O Adolescentes Con Lnh-B O Lla-B (Lla-L3): Evaluación De La Eficacia Y Seguridad De Rituximab Para Pacientes De Alto Riesgo.Reference:0279/11	GC16	MIGUEL ANGEL ALVAREZ RIVAS.Estudio Para La Validación De Un Test De Medicina Personalizada Ex Vivo En Mieloma Múltiple.Reference:2699	GC16
JOSÉ RAMÓN MOLINA HURTADO.Estudio De Fase Iiib Multicéntrico, Internacional, Abierto, Con Un Solo Grupo De Tratamiento Para Evaluar La Seguridad De Obinutuzumab Como Agente Único O En Combinación Con Quimioterapia En Pacientes Con Leucemia Linfática Crónica Recurrente/Refractaria .Reference:0148/13	GC16	JOSE MANUEL QUESADA GÓMEZ.Efecto De La Administración De Diferentes Regímenes De Tratamiento De Hidroferol® Cápsulas De Gelatina Blanda (Calcifediol) Y Colecalciferol (Dibase®) En Los Niveles De 25(Oh)D Y Marcadores De Remodelado Óseo En Mujeres Postmenopáusicas Con Deficiencia De.Reference:/3653	GC17
JOSEFINA SERRANO LÓPEZ.Estudio Fase Iii, Multicéntrico, Aleatorizado Y Abierto Con La Guadecitabina (Sgi-110) En Comparación Con El Tratamiento De Elección En Adultos Con Leucemia Mieloide Aguda Tratados Previamente.Reference:/3557	GC16	JOSE MANUEL QUESADA GÓMEZ.Estudio No Intervencional Con Binosto 70Mg En Forma De Comprimidos Efervescentes Administrados Una Vez A La Semana Para Investigar Los Acontecimientos Gastrointestinales Y Los Errores De Medicaciones..Reference:3071	GC17
JOSEFINA SERRANO LÓPEZ.Estudio Aleatorizado De Fase Iii Para Comparar El Trióxido De Arsénico (Ato) Combinado Con Atr A E Idarubicina Frente A Quimioterapia Estándar Basada En Atr Y Antraciclinas (Aida) En Pacientes Con Leucemia Promielocítica Aguda De Alto Riesgo De Nuevo Diag.Reference:/3782	GC16	ÁLVARO ARJONA SÁNCHEZ.Ensayo Clínico Multicéntrico, Randomizado, Para Evaluar La Eficacia Y Seguridad De La Quimioterapia Intraperitoneal Hipertermica (Hipec) Con Mitomicina C Asociada A Cirugía En El Tratamiento Del Carcinoma Colorrectal Localmente Avanzado..Reference:0131/15	GC18
JOSEFINA SERRANO LÓPEZ.Acceso Ampliado De Bincyto En Pacientes Con Leucemia Linfoblástica Aguda, Estudio Observacional Retrospectivo (Estudio Neuf).Reference:3695	GC16	RAFAEL BURGOS MARÍN.Evaluación Del Cambio En La Expresión Emocional En Pacientes Con Trastorno Por Déficit De Atención E Hiperactividad (TDAH) Con Respuesta Inadecuada Al Metilfenidato Tras Cambio En Su Estrategia Terapéutica A Lisdexanfetamina Dimesilato (Ldx) Conforme Fic.Reference:3661	GC20
JOAQUIN SÁNCHEZ GARCÍA.Epas Estudio Post-Autorización De Seguridad (Epas) Prospectivo, No Intervencionista, Diseñado Como Registro De Enfermedad De Pacientes Con Síndromes Mielodisplásicos (Smd) De Bajo Riesgo (Ipss Bajo E Intermedio-1) Sin Delección 5Q Aislada Y Dependencia Tr.Reference:2638	GC16	MARIA ELENA MATEOS GONZALEZ.Protocolo Internacional Colaborativo De Tratamiento Para Niños Y Adolescentes Con Histiocitosis De Células De Langerhans.Reference:/3332	GC23
JOSEFINA SERRANO LÓPEZ.Estudio Observacional Prospectivo Sobre La Supervivencia Global Y La Calidad De Vida En Pacientes De Mayores De 60 Años Diagnosticados De Leucemia Mieloide Aguda En España, Tratados Según La Práctica Clínica Habitual. Estudio SvIma.Reference:3658	GC16	MONTSERRAT ANTON GAMERO.Estudio En Fase Iii Multicéntrico Y Abierto De Alxn1210 En Niños Y Adolescentes Con Síndrome Hemolítico Urémico Atípico (Shua).Reference:/3477	GC23
MIGUEL ANGEL ALVAREZ RIVAS.Estudio Observacional Para Valorar La Carga De La Enfermedad, En Términos De Calidad De Vida Relacionada Con La Salud Y Costes Sanitarios Directos, En Pacientes Con Mieloma Múltiple De Nuevo Diagnóstico No Candidatos A Trasplante Autólogo De Progenitores H.Reference:3253/2	GC16	MARIA ELENA MATEOS GONZALEZ.Estudio De Fase Ii Abierto Global Para Evaluar El Efecto De Dabrafenib En Combinación Con Trametinib En Pacientes Niños Y Adolescentes Con Glioma De Alto Grado (Hgg) Recidivante O Refractorio Con Mutación Braf V600 Positiva.Reference:/3941	GC23
		MARIA ELENA MATEOS GONZALEZ.Estudio Prospectivo Internacional De Meduloblastoma Riesgo Estándar Clínico En Niños Mayores De 3 A 5 Años Con Perfil Bajo Riesgo Biológico (Pnet 5 Mb - Lr) O Perfil Medio De Riesgo Biológico (Pnet 5Mb -Sr).Reference:0316/15	GC23
		MARIA ELENA MATEOS GONZALEZ.Ensayo Internacional Pediátrico En Tumor Hepático.Reference:/3616	GC23
		EDUARDO LÓPEZ LASO.Un Registro Internacional De Enfermedad Que Recoge Datos Sobre Manifestaciones, Intervenciones Y Resultados En Pacientes Con Complejo Esclerosis Tuberosa.Reference:2060	GC23



JUAN LUIS PÉREZ NAVERO. Estudio Internacional Aleatorizado, Controlado, Doble Ciego Y De Grupos Paralelos Para Investigar La Seguridad Y La Tolerancia De Una Leche De Fórmula Infantil Parcialmente Fermentada Que Contiene Oligosacáridos Prebióticos En Lactantes Nacidos A Término S. Reference:3912	GC23	EDUARDO AGÜERA MORALES. Estudio De Extensión En Fase Iii, Multicéntrico, A Largo Plazo Sobre La Seguridad Y Eficacia De Avp-786 (Bromhidrato De [D6]-Dextrometorfano Deuterado [D6-Dm]/Sulfato De Quinidina [Q]) Para El Tratamiento De La Agitación En Pacientes Con Demencia De Tipo .Reference:/3991	GE01
MARÍA DOLORES ORDOÑEZ DÍAZ. Ensayo Clínico Para Valoración De La Eficacia De La Lactoferrina En La Prevención De La Sepsis En Recién Nacidos Prematuros. Bimonitorización De Los Mecanismos Antinflamatorios, Antioxidantes Y De La Microbiota Intestinal. Lactoprem. Reference:/3335	GC23	EDUARDO AGÜERA MORALES. Estudio De Fase Iii Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo, Con Diseño De Grupos Paralelos, Para Evaluar La Eficacia, La Seguridad Y La Tolerabilidad De Avp-786 (Bromhidrato De Deudextrometorfano [D6-Dm]/Sulfato De Quinidina [Q]). Reference:/3721	GE01
MARÍA-VICTORIA RODRÍGUEZ BENÍTEZ. Efectos De La Suplementación Con Probióticos Durante El Periodo Neonatal Sobre El Recién Nacido Prematuro.. Reference:2718	GC23	EDUARDO AGÜERA MORALES. Estudio Multicéntrico, Aleatorizado, Doble Ciego Y Controlado Con Placebo En Sujetos Con Esclerosis Múltiple Recurrente Para Evaluar La Eficacia Y La Seguridad De Biib033 Como Tratamiento Adicional A Los Tratamientos Antinflamatorios Modificadores De La E. Reference:/3630	GE01
IRENE GRACIA AHUFINGER. Colonización Intestinal Por Enterobacterias Multirresistentes En Pacientes Con Trasplante Renal Y Hepático: Estudio Multicéntrico De Cohortes. Reference:2595	GC24	EDUARDO AGÜERA MORALES. Estudio En Fase Ii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Y De Grupos Paralelos De Aducanumab (Biib037) En Sujetos Con Deterioro Cognitivo Leve Debido A La Enfermedad De Alzheimer O Con Demencia De La Enfermedad De Alzheimer Leve Para Evalu. Reference:/4031	GE01
IRENE GRACIA AHUFINGER. Impacto De La Colonización Intestinal Por Enterobacterias Multirresistentes En Las Infecciones Sistémicas, Eich Y Mortalidad De Pacientes Receptores De Trasplante Alogénico De Médula Ósea.. Reference:3592	GC24	EDUARDO AGÜERA MORALES. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Aducanumab (Biib037) In Subjets With Early Alzheimer'S Disease.. Reference:/0150/15	GE01
IRENE GRACIA AHUFINGER. Registro De Infecciones Por Bacterias Multirresistentes_ Seimc_2017. Reference:3835	GC24	EDUARDO AGÜERA MORALES. Efectos De Levosimendán Oral (Odm-109) En La Función Respiratoria De Pacientes Con Ela. Reference:/3827	GE01
ANTONIO RIVERO ROMAN. Estudio Fase Iii Aleatorizado, Multicéntrico Abierto, De Grupos Paralelos, De No Inferioridad, Para Evaluar La Eficacia, Seguridad Y Tolerabilidad Del Cambio De Una Terapia Antirretroviral Basada En Ini, Itinn O Ip A Una Pauta De Tratamiento Intremuscular. Reference:/3248	GC26	EDUARDO AGÜERA MORALES. Estudio De Retirada Aleatorizado En Fase Ii, Controlado Con Placebo Y Doble Ciego Con Reclutamiento Enriquecido Para Evaluar La Eficacia Y La Seguridad De Biib074 En El Tratamiento Del Dolor Sufrido Por Sujetos Con Neuropatía De Fibras Pequeñas Confirmada. Reference:/3715	GE01
ANTONIO RIVERO ROMAN. A Phase Iii, Randomised, Double-Find, Multicentre, Parallelgroup, Non-Inferiority Study Evaluating The Efficacy, Safety, And Tolerability Of Dolutegravir Plus Lamivudine Compared To Dolutegravir Plus Tenofovir/ Emtricitabine In Hiv-1-Infected Treatment-Nai. Reference:/3192	GC26	EDUARDO AGÜERA MORALES. A 52-Week Open-Label Extension Study Of Pimavanserin For The Treatment Of Agitation And Aggression In Subjects With Alzheimer'S Disease. Reference:/3386	GE01
ANTONIO RIVERO ROMAN. Estudio Fase Iiib, Aleatorizado, Multicéntrico, Abierto, De Grupos Paralelos, De No Inferioridad Que Evalúa La Eficacia, Seguridad Y Tolerabilidad De Cabotegravir De Acción Prolongada Más Rilpivirina De Acción Prolongada Administrados Cada 8 Semanas O Cad. Reference:/3632	GC26	EDUARDO AGÜERA MORALES. Estudio En Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo Y De Grupos Paralelos Para Evaluar La Eficacia Y Seguridad De Crenezumab En Pacientes Con Enfermedad De Alzheimer De Prodrómica O Leve. Reference:/3478	GE01
ANTONIO RIVERO ROMAN. Estudio De Fase 3, Aleatorizado Y Doble Ciego Para Evaluar La Seguridad Y La Eficacia De Gs-9883/Emtricitabina/Tenofovir Alafenamida En Comparación Con Abacavir/Dolutegravir/Lamivudina En Adultos Infectados Por El Vih-1 Sin Tratamiento Antirretroviral Pre. Reference:/3124	GC26	ROBERTO VALVERDE MOYANO. Ensayo Clínico Fase Ii, Multicéntrico, Abierto, Controlado Y Aleatorizado, Para Valorar La Eficacia De La Infusión Intra Arterial De Células Mononucleadas De Médula Ósea Autóloga En Pacientes Con Ictus Isquémico. Reference:0255/13	GE01
ANTONIO RIVERO ROMAN. Estudio De Fase 3, Aleatorizado Y Doble Ciego Para Evaluar La Seguridad Y La Eficacia De Gs-9883/Emtricitabina/Tenofovir Alafenamida En Comparación Con Dolutegravir+Emtricitabina/Tenofovir Alafenamida En Adultos Infectados Por El Vih-1 Sin Tratamiento Ant. Reference:/3125	GC26	EDUARDO AGÜERA MORALES. A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, And Pharmacokinetic Study Of Azd3293 In Early Alzheimer Disease (The Amaranth Study).. Reference:/3069	GE01
ANTONIO RIVERO ROMAN. Estudio En Fase 3, Aleatorizado Y Doble Ciego Para Evaluar La Seguridad Y Eficacia Del Cambio De Un Régimen Formado Por Dolutegravir Y Abc/3Tc, O Una Combinación De Dosis Fijas (Cdf) De Abc/Dtg/3Tc A Una Cdf De Gs 9883/F/Taf En Sujetos Infectados Por El V. Reference:0369/15	GC26	EDUARDO AGÜERA MORALES. Estudio De 24 Meses, De Grupos Paralelos, Doble Ciego Y Controlado Con Placebo Para Evaluar La Eficacia Y La Seguridad De E2609 En Pacientes Con Enfermedad De Alzheimer Temprana. Reference:/3865	GE01
ANTONIO RIVERO ROMAN. Ensayo En Fase 3, Randomizado, Controlado Con Tratamiento Activo Y Doble Ciego Para Evaluar La Eficacia Y Seguridad Del Régimen Combinado De Darunavir/Cobicistat/Emtricitabina/Tenofovir Alafenamida (D/C/F/Taf) Administrado Una Vez Al Día Frente Al Régimen. Reference:0114/15	GC26	EDUARDO AGÜERA MORALES. Registro De Seguridad Prospectivo Y Observacional A Largo Plazo De Pacientes Con Esclerosis Múltiple Que Han Participado En Ensayos Clínicos Con Cladribina. Reference:0106/11	GE01
ANTONIO RIVERO ROMAN. Estudio De Fase 3, Aleatorizado, Controlado Con Tratamiento Activo Y Abierto Para Evaluar El Cambio De Tratamiento A Un Régimen En Un Solo Comprimido Administrado Una Vez Al Día De Darunavir/Cobicistat/Emtricitabina/Tenofovir Alafenamida (D/C/F/Taf) Fren. Reference:0272/14	GC26	EDUARDO AGÜERA MORALES. Estudio En Fase Ii, Multicéntrico, Aleatorizado, Doble Ciego Y Controlado Con Placebo, En Grupos Paralelos, Que Evalúa La Eficacia Y Seguridad De Mtau9937A En Pacientes Con Enfermedad De Alzheimer De Fase Prodrómica A Leve.. Reference:/3692	GE01
ISABEL MARIA MACHUCA SANCHEZ. Evaluación De La Mortalidad Asociada A Diferentes Estrategias De Manejo Clínico De La Bacteriemia Por Klebsiella Pneumoniae Resistente A Carbapenemas Y Colistina. Estudio Kapecor.. Reference:2848	GC26	EDUARDO AGÜERA MORALES. Estudio Abierto Para Evaluar La Eficacia Y La Seguridad De Ocrelizumab En Pacientes Con Esclerosis Múltiple Remitente-Recidivante Que Tienen Una Respuesta Subóptima A Un Ciclo Adecuado De Tratamiento Modificador De La Enfermedad.. Reference:/3120	GE01
ISABEL MARIA MACHUCA SANCHEZ. Eficacia De La Descontaminación Instestinal En Pacientes Colonizados Por Klebsiella Pneumoniae Resistente A Carbapenemes Y A Colistina.. Reference:2849	GC26	EDUARDO AGÜERA MORALES. Estudio De Fase Iii, Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Placebo Y De Grupos Paralelos Para Evaluar La Eficacia Y Seguridad De Gantenerumab En Pacientes Con Enfermedad De Alzheimer Precoz (De Prodrómica A Leve) Y Los Sub-Estudios Sube. Reference:/3911	GE01
ISABEL MARIA MACHUCA SANCHEZ. Cohorte Española De Pacientes Con Infección Por Vih Mayores De 50 Años Para El Estudio De Fragilidad Y La Función Física. (Hiv-Functrail). Reference:3753	GC26	EDUARDO AGÜERA MORALES. Plegridy (Peginterferon) Real World Effectiveness And Safety Observational Program.. Reference:3163	GE01
FERNANDO SÁNCHEZ LÓPEZ. Estudio De Extensión, Multicéntrico Y Con Dosis Ciega Para Determinar La Seguridad Y La Eficacia A Largo Plazo De Dos Dosis De Bg00012 En Monoterapia En Pacientes Con Esclerosis Múltiple Recidivante-Remitente. Reference:0133/09	GE01	EDUARDO AGÜERA MORALES. Evaluación De Las Necesidades De Información De Pacientes Con Esclerosis Múltiple En España: Preocupaciones, Preferencias Y Nivel De Satisfacción Según Su Personalidad Y Características Clínicas Y Funcionales (Infoseek-Ms).. Reference:3596	GE01
EDUARDO AGÜERA MORALES. Open-Label, Randomised, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy And Safety Study Of Bg00012 In Children From 10 To Less Than 18 Years Of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension. Reference:/3268	GE01		



EDUARDO AGÜERA MORALES.Estudio Postautorización De Seguridad, Prospectivo, Multicéntrico Y Observacional Para Evaluar El Perfil De Seguridad A Largo Plazo Del Tratamiento Con Lemtrada (Alemtuzumab) En Pacientes Con Formas Recidivantes De Esclerosis Múltiple..Reference:2879	GE01	MARÍA JOSÉ REQUENA TAPIA.Estudio De Fase Iii, Aleatorizado, Controlado Con Placebo Y Doble Ciego De Jnj-56021927 En Combinación Con Acetato De Abiraterona Y Prednisona En Comparación Con Acetato De Abiraterona Y Prednisona En Sujetos Con Cáncer De Próstata Metastásico Resistente .Reference:0344/14	GE05
EDUARDO AGÜERA MORALES.Estudio Observacional, No Intervencionista Para Evaluar Los Cambios En La Calidad De Vida En Pacientes Con Esclerosis Múltiple Remitente Recurrente Tratados Con Alemtuzumab (Lemtrada) En Condiciones De Práctica Clínica Habitual..Reference:3042	GE01	MARÍA JOSÉ REQUENA TAPIA.Estudio Fase 3 Aleatorizado, Doble-Ciego Y Controlado Con Placebo De Jnj-56021927 Más Terapia De Privación De Andrógenos (Tpa) Frente A Tpa En Sujetos Con Cáncer De Próstata Metastásico Hormonosensible (Cpmhs) De Baja Carga Tumoral...Reference:0215/15	GE05
EDUARDO AGÜERA MORALES.Registro Español De Pacientes Tratados Con Acetato De Glatiramero (Copaxone®) 40Mg/MI.Reference:3007	GE01	MARÍA JOSÉ REQUENA TAPIA.The Leadership 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial To Evaluate The Efficacy And Safety Of 2 Doses Of Aqx-1125 Targeting The Ship1 Pathway In Subjects With Interstitial Cyst.Reference:/3387	GE05
JUAN RUANO RUIZ.Estudio En Fase Iii De Retirada Aleatorizada, Doble Ciego, Controlado Con Placebo Y Multicéntrico Para Investigar La Eficacia Y La Seguridad De Pf-04965842 En Pacientes De 12 O Más Años De Edad Con Dermatitis Atópica Moderada O Grave Con La Opción De Un T.Reference:/3942	GE03	MARÍA JOSÉ REQUENA TAPIA.Características Y Manejo De Los Pacientes Diagnósticos De Síntomas Del Tracto Urinario Inferior Por Hiperplasia Benigna De Próstata Atendidos En España..Reference:3944	GE05
JUAN RUANO RUIZ.Estudio En Fase Iii Multicéntrico Y De Extensión A Largo Plazo Para Evaluar La Eficacia Y La Seguridad De Pf-04965842, En Monoterapia O En Combinación Con Medicamentos Tópicos, Administrado A Pacientes De 12 Años O Más Con Dermatitis Atópica Moderada O Gr.Reference:/3996	GE03	MARÍA JOSÉ REQUENA TAPIA.Estudio Observacional Y Transversal Para La Optimización Del Diagnóstico De Metástasis En Fase De Cprc MO En La Práctica Clínica Habitual En España (Estudio Identifica).Reference:3635	GE05
JUAN RUANO RUIZ.A Phase 2B Randomized, Double Blind, Placebo Controlled, Multicenter, Dose Ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-067008.Reference:/4090	GE03	ANTONIO ÁLVAREZ KINDELÁN.Estudio Sobre La Incidencia De Tromboembolismo Pulmonar En Pacientes Intervenido Quirúrgicamente Por Carcinoma Broncogénico. Estudio Qeler..Reference:2812	GA01
JUAN RUANO RUIZ.Estudio Multicéntrico De Fase 3, Aleatorizado, Doble Ciego, Controlado Con Placebo Y Fármaco Comparador Activo, Para Evaluar La Eficacia Y La Seguridad De Guselkumab En El Tratamiento De Pacientes Con Psoriasis En Placa De Moderada A Grave.Reference:0251/14	GE03	FRANCISCA CUEVAS PAREJA.Ensayo Clínico Multicéntrico, Aleatorizado, Controlado, Con Evaluador Ciego, Para Evaluar La Eficacia De Un Hidrogel De Extracto De Hoja De Olivo Como Tratamiento De Úlceras Cutáneas.Reference:/3530/15	GA02
JUAN RUANO RUIZ.Estudio Multicéntrico De Fase Iii, Aleatorizado, Doble Ciego Para Evaluar La Eficacia Comparativa De Guselkumab (Cnto1959) Y Secukinumab En El Tratamiento De La Psoriasis En Placa De Moderada A Grave.Referen- ce:/3438	GE03	LUIS MANUEL ENTRENAS COSTA.Estudio Piloto De Reslizumab En Pacientes Con Asma Grave Que No Han Respondido A Omalizumab.Reference:/3444	GA03
JUAN RUANO RUIZ.Estudio Multicéntrico, Aleatorizado, Doble Ciego, Con Control Activo Y Placebo Para Investigar La Eficacia Y Seguridad De Ligelizumab (Qge031) En El Tratamiento De La Urticaria Crónica Espontánea (Uce) En Adolescentes Y Adultos Inadecuadamente Controlada .Reference:/3972	GE03	LUIS MANUEL ENTRENAS COSTA.Estudio Observacional Para Describir La Prevalencia De Asma Grave En Centros Hospitalarios Españoles.Reference:3593	GA03
JUAN RUANO RUIZ.Estudio De Fase 3, Multicéntrico, Aleatorizado, Doble Ciego Y Comparado Con Placebo, Para Evaluar La Eficacia Y La Seguridad De Baricitinib En Combinación Con Corticosteroides De Administración Tópica En Pacientes Adultos Con Dermatitis Atópica De Modera.Reference:/3971	GE03	MARÍA NURIA FEU COLLADO.Importance Of Responsiveness Evaluation And Standardization With Proteomics On Obstruction Aiming For Novel And Significant Endpoint.Reference:3934	GA03
JUAN RUANO RUIZ.Estudio Multicéntrico, Aleatorizado, Con Doble Enmascaramiento Y Controlado Con Placebo, Para Evaluar La Eficacia Y Seguridad De Mirikizumab Con Secukinumab Y Placebo En Pacientes Con Psoriasis En Placas Moderada A Grave. Oasis-2.Reference:/3873	GE03	LUIS MANUEL ENTRENAS COSTA.Estudio Fase Iv, Observacional, Multinacional Sobre El Control De La Enfermedad Y Los Resultados Notificados Por Los Pacientes En Tratamiento Con Inhaladores De Combinación A Dosis Fija Para Asma Persistente Y Epoc En La Práctica Clínica Habitual (Sprint).Reference:2856	GA03
JUAN RUANO RUIZ.Estudio De Fase Iii, Aleatorizado, Con Doble Enmascaramiento, Controlado Con Placebo, De Grupos Paralelos Y Multicéntrico De Un Anticuerpo Monoclonal Anti-Ox40L (Ky1005) En La Dermatitis Atópica De Moderada A Grave.Reference:/4064	GE03	JOSE MANUEL VAQUERO BARRIOS.Calidad De Vida En Pacientes Con Hipertensión Y Pulmonar (Hap Y Hptec) Y Su Percepción Sobre La Calidad De La Atención Recibida.Reference:3788	GA03
JUAN RUANO RUIZ.A Randomized Double-Blind, Placebo-Controlled, Phase 3 Trial To Evaluate The Efficacy And Safety To Tralokinumab Monotherapy In Patients With Moderate To Sever Atopic Dermatitis Who Are Candidates For Systemic Therapy..Reference:/3523	GE03	ANA BARRERA MARTIN.Estudio Prospectivo Observacional Sobre Una Muestra De Pacientes Malnutridos Con Intolerancia Gastrointestinal Tras La Administración De Una Fórmula Peptídica Alta En Calorías Y Proteínas Con Mct.Reference:3277	GA04
JUAN RUANO RUIZ.Ensayo Aleatorizado, Doble Ciego, Controlado Con Placebo, De Grupos Paralelos, Multicéntrico, De Fase 3 Que Investiga La Eficacia, La Seguridad Y La Tolerabilidad De Tralokinumab Administrado En Combinación Con Corticosteroides Tópicos A Pacientes Adultos.Reference:/4028	GE03	Mª ÁNGELES GÁLVEZ MORENO.Estudio Abierto Para Evaluar La Seguridad Y La Eficacia De Cor-003 (2S,4R-Ketoconazol) En El Tratamiento Del Síndrome De Cushing Endógeno.Reference:/3216	GA04
ANTONIO VÉLEZ GARCIA-NIETO.Estudio Clínico Abierto Para Evaluar La Eficacia Y La Seguridad A Largo Plazo De Dimetil-fumarato En Adultos Con Psoriasis Crónica En Placas Moderada-Grave En La Práctica Clínica (Estudio Dimeskin 1).Reference:/3587	GE03	Mª ÁNGELES GÁLVEZ MORENO.Estudio Abierto, Multicéntrico, De Acceso Expandido De Pasireotida S.C. En Pacientes Con Enfermedad De Cushing (Seascape).Reference:0151/11	GA04
JUAN RUANO RUIZ.Aplicación De Técnicas Genómicas Y De Procesamiento De Imagen Mediante Inteligencia Artificial Para La Obtención De Un Modelo Predictor De Riesgo De Melanoma.Reference:2740	GE03	Mª ÁNGELES GÁLVEZ MORENO.Estudio De 26 Semanas Aleatorizado, Doble Ciego, Controlado, Multicéntrico Con Grupos Paralelos Para Evaluar La Eficacia Y Seguridad De Sotagliflozina En Comparación Con Empagliflozina Y Placebo En Pacientes Con Diabetes De Tipo 2 Que Tienen Un Control Gl.Reference:/3690	GA04
MARÍA JOSÉ REQUENA TAPIA.Estudio Aleatorizado, Doble Ciego Y Comparativo De Zytiga (Acetato De Abiraterona), Más Dosis Bajas De Prednisona, Más Terapia De Privación De Andrógenos (Tpa), Frente A Tpa Sola En Sujetos Con Cáncer De Próstata Metastásico Sin Tratamiento Hormonal Prev.Reference:0280/12	GE05	Mª ÁNGELES GÁLVEZ MORENO.Regain Control Ensayo Mundo Real Pragmático, De 26 Semanas Con 6 Meses De Extensión, Aleatorizado, Abierto, De 2 Brazos Paralelos, Para Evaluar Los Resultados De Los Beneficios Clínicos Y De Salud De La Transición A Toujeo En Comparación A Las Insulinas D.Reference:0230/15	GA04
		Mª ÁNGELES GÁLVEZ MORENO.Efecto Y Seguridad De Semaglutida 2,4 Mg Una Vez A La Semana En Sujetos Con Sobre- peso U Obesidad Y Diabetes Tipo 2.Reference:/3863	GA04
		Mª ÁNGELES GÁLVEZ MORENO.Estudio Adaptativo, Aleatorizado, Doble Ciego Y Controlado Con Placebo Para Evaluar La Mejoría Sintomática Y El Control Metabólico En Adultos Con Hipoparatiroidismo Sintomático Tratados Con Hormona Paratiroidea Humana Recombinante [Pthhr(1-84)].Reference:/3688	GA04
		ELENA GARCÍA MARTÍNEZ.Un Estudio Observacional, No Intervencionista, Multicéntrico Y Multinacional De Pacientes Con Síndrome Hemolítico Urémico Atípico (Registro De Shua).Reference:2079	GA04



M ^a ÁNGELES GÁLVEZ MORENO. Estudio Europeo, Observacional, De Pasireotida Lar En Acromegalia - Estudio Acronis. Reference:3420	GA04	DANIELA HERVÁS SOTOMAYOR. Registro Universal De Implantación De Prótesis Valvular Aórtica De Sorin. Sure Avr. Reference:3655	GA09
RAFAEL PALOMARES ORTEGA. Estudio Retrospectivo Y Multicéntrico En Práctica Clínica Habitual Con Isglt2 (Dapagliflozina) Y Idpp4 (Sitabliptina) En Pacientes Con Diabetes Tipo 2 En España. Estudio Dapa-Rwe. Reference:3487	GA04	JUAN ANTONIO VALLEJO CASAS. Estudio Epidemiológico, Retrospectivo, Longitudinal Para Caracterizar La Historia Natural De Los Pacientes Con Carcinoma Diferenciado De Tiroides Avanzado En España Y Portugal. Estudio Erudit. Reference:3664	GA10
M ^a ÁNGELES GÁLVEZ MORENO. Estudio Observacional, Trasversal Y Multicéntrico Para Valorar El Grado De Actividad De La Enfermedad De Los Pacientes Acromegálicos En España Según La Escala Acrodat. Estudio Acrodat. Reference:3597	GA04	JOSE ANGEL ALCALA PARTERA. Nalmefeno Para La Reducción Del Consumo De Alcohol En El Trastorno Bipolar En Comorbilidad Con Trastorno Por Consumo De Alcohol. Reference:3451/2	GA12
PALOMA MORENO MORENO. Ensayo Clínico Multicéntrico, Aleatorizado, Controlado, Con Evaluador Ciego, Para Evaluar La Eficacia Y La Seguridad De Un Hidrogel Que Contiene Extracto De Hoja De Olivo Como Tratamiento De Úlceras Cutáneas. Reference:/3530/21	GA04	FERNANDO SARRAMEA CRESPO. Nalmefeno Para La Reducción Del Consumo De Alcohol En El Trastorno Bipolar En Comorbilidad Con Trastorno Por Consumo De Alcohol. Reference:3451/3	GA12
MARÍA JOSÉ PÁRRAGA QUILES. Ensayo Clínico, Multicéntrico Aleatorizado Y Enmascarado (Ciego) Con Topiramato Versus Placebo Para El Tratamiento De Recién Nacidos Con Asfixia Perinatal Tratados Con Hipotermia Moderada Corporal Total. Reference:0291/11	GA05	JUAN LUIS PRADOS OJEDA. Estudio De Extensión, Abierto, De Seguridad A Largo Plazo De Eskatmina En La Depresión Resistente Al Tratamiento. Seguridad Y Mantenimiento De La Respuesta Al Tratamiento Con Esketamina Con Dosis Repetidas En Intervalos Determinados Por La Gravedad De Los. Reference:/3330	GA12
ELENA GÓMEZ GUZMÁN. Estudio Multicéntrico, Abierto, Aleatorizado, Basado En Acontecimientos, Para Evaluar La Eficacia, La Seguridad Y La Farmacocinética De Macitentan Frente Al Tratamiento De Referencia En Niños Con Hipertensión Arterial Pulmonar. Reference:/3633	GA05	JUAN LUIS PRADOS OJEDA. Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado Con Producto Activo, Para Evaluar La Eficacia, Seguridad Y Tolerabilidad De Dosis Flexibles De Esketamina Intranasal Más Un Antidepresivo Oral En Sujetos Adultos Con Depresión Resistente Al Tratamiento. Reference:/3272	GA12
INES M ^a TOFÉ VALERA. Efecto Del Alopurinol En Pacientes Con Encefalopatía Hipóxico-Isquémica Tratados Con Hipotermia – Albino – Ensayo Clínico Multicéntrico, Aleatorizado, Ciego, Controlado Con Placebo. Reference:/3481	GA05	JUAN LUIS PRADOS OJEDA. Estudio Multicéntrico, Aleatorizado, Doble Ciego Y Controlado Con Producto Activo De Esketamina Intranasal Más Un Antidepresivo Oral Para La Prevención De Las Recaídas En Depresión Resistente Al Tratamiento. Reference:/3273	GA12
ELENA GÓMEZ GUZMÁN. Estudio Multicéntrico, Abierto, Para Evaluar La Seguridad, Tolerabilidad, Farmacocinética Y Farmacodinámica De Lcz696, Seguido De Un Estudio De 52 Semanas, Aleatorizado, Doble Ciego, Paralelo Controlado Con Fármaco Activo Para Evaluar La Eficacia Y Seguridad. Reference:/3336	GA05	ANA DE LUXÁN DE LA LASTRA. Nalmefeno Para La Reducción Del Consumo De Alcohol En El Trastorno Bipolar En Comorbilidad Con Trastorno Por Consumo De Alcohol. Reference:3451	GA12
MARIA DOLORES RUIZ GONZALEZ. Estudio De Fase Ii Aleatorizado, Doble Ciego, Controlado Con Placebo Para Evaluar La Seguridad Y La Eficacia De Medi8897, Un Anticuerpo Monoclonal Con Una Semivida Prolongada Frente Al Virus Respiratorio Sincitial, En Prematuros Sanos. Reference:/3580	GA05	JUAN PEDRO OSORIO RAMOS. Estudio Para La Evaluación De La Funcionalidad En Pacientes Recientemente Diagnosticados De Esquizofrenia, Que Han Iniciado Pamito De Paliperidona Trimestral. Reference:3663	GA12
MARÍA JOSÉ PÁRRAGA QUILES. Paracetamol Versus Ibuprofeno En Recién Nacidos Prematuros Con Diagnóstico De Ductus Arterioso Persistente Hemodinámicamente Significativo: Ensayo Clínico Aleatorizado. Reference:/3784	GA05	INMACULADA HERRADOR MONTIEL. Caracterización Y Epidemiología En España Del Dolor Irruptivo Oncológico. Reference:/3193	Anesthesia Unit
JAVIER CABALLERO VILLARRASO. Ensayo Clínico Multicéntrico, Aleatorizado, Controlado, Con Evaluador Ciego, Para Evaluar La Eficacia Y Seguridad De Un Hidrogel Que Contiene Extracto De Hoja De Olivo Como Tratamiento De Úlceras Cutáneas. Reference:/3530/20	GA06	ANTONIO NARANJO RODRÍGUEZ. Tratamiento Con Ligadura Sin Resección Del Esófago De Barrett Corto. Reference:2600	Digestive Unit
RAFAEL GIMENEZ GOMEZ. Eficacia Y Seguridad Del Bimatoprost De Liberación Lenta En Pacientes Con Glaucoma De Ángulo Abierto O Hipertensión Ocular The Efficacy And Safety Of Bimatoprost Sr In Patients With Open-Angle Glaucoma Or Ocular Hypertension. Reference:0360/14	GA07	JOSÉ MARÍA GALLARDO VALVERDE. Estudio Multicéntrico, Aleatorizado, Controlado Con Placebo Y Doble Ciego Para Evaluar La Eficacia Y La Tolerabilidad Del Hidrocloruro De Diltiazem Al 2% En El Tratamiento De La Fisura Anal Crónica, Y Extensión De Diseño Abierto De 24 Semanas. Reference:/3119	General and Digestive Surgery Unit
JOSÉ MARÍA GALLARDO GALERA. Ensayo Clínico En Fase Iv Para Evaluar Las Variantes Genéticas De La Vía Del Vegf Como Biomarcadores De Eficacia Del Tratamiento Con Aflibercept En Pacientes Con Degeneración Macular Asociada A La Edad (Dmae) Neovascular. Estudio Bioimage. Reference:0143/13	GA07	SIMON FUENTES CAPARROS. Registro Multicéntrico De Tratamiento De Pacientes De Escoliosis En Andalucía. Reference:/3041	Traumatology Unit
RAFAEL GIMENEZ GOMEZ. Estudio Prospectivo, Con Doble Enmascaramiento, Aleatorizado, Multicéntrico, Con Comparador Activo Y Grupos Paralelos De 6 Meses De Duración Para Evaluar La Seguridad Y La Eficacia Hipotensora Ocular De Pg324 Solución Oftálmica En Comparación Con Ganfort®. Reference:/3447	GA07	MANUEL GALAN GUTIÉRREZ. Estudio De Fase 3 Aleatorizado, Doble Ciego, Controlado Con Placebo Para Evaluar Upadacitinib En Sujetos Adolescentes Y Adultos Con Dermatitis Atópica Moderada O Grave. Reference:/4029	Dermatology Unit
RAFAEL GIMENEZ GOMEZ. Combinación De Dosis Fijas Sin Conservantes De Tafluprost Al 0,0015% / Timolol Al 0,5% En Pacientes Con Glaucoma De Angulo Abierto O Hipertensión Ocular: Efectividad Clínica, Tolerabilidad Y Seguridad En El Mundo Real. Reference:3564	GA07	GLORIA MARÍA GARNACHO SAUCEDO. Registro De Hemangiomas De La Aedv. Reference:3595	Dermatology Unit
RAFAEL CABALLOS CASTILLA. Ensayo Clínico En Fase Iv, Abierto, Aleatorizado, De 3 Brazos, Multicéntrico Y De 12 Meses De Duración, Para Evaluar La Eficacia Y Seguridad De Dos Regímenes De Tratamiento, Bimensual O Prn Flexible Individualizado De Tratar Y Extender, Versus Un Régimen. Reference:0260/12	Ga07	LUCRECIA GARCÍA MARTINEZ. Impact Of The Provaur Stewardship Program On Linezolid Resistance In A Tertiary University Hospital: A Before-After Interventional Study. Reference:3130	Pharmacy Unit
JOSÉ GARCÍA-REVILLO GARCÍA. Eficacia Y Seguridad En La Administración Intraarterial De Rexmyelocel-T En El Tratamiento De La Isquemia Crítica De Extremidades Inferiores En Pacientes Con Diabetes Mellitus: Ensayo Controlado Con Placebo, Doble Ciego, Aleatorizado, Multicéntrico. Reference:/3118	GA08	MANUEL SANTAMARIA OSSORIO. A Multi-Center, Open-Label, Single-Arm Trial To Evaluate Efficacy, Pharmacokinetics, And Safety And Tolerability Of Igsc 20% In Subjects With Primary Immunodeficiency. Reference:/3040	Immunology & Allergy Unit
IGNACIO MUÑOZ CARVAJAL. Registro Multicéntrico Europeo Para Evaluar Los Resultados En Pacientes Con Cirugía De Bypass Coronario Con Injerto: Tratamiento De Conductos Vasculares Con Duragraf, Un Novedoso Inhibidor Del Daño Endotelial. Reference:3276	GA09	MANUEL SANTAMARIA OSSORIO. Estudio Pid-Rsv: Estudio Etimológico Sobre La Incidencia De Infecciones Respiratorias Agudas (Ira) Causadas Por El Virus Respiratorio Sincitial (Vrs) Que Requieren Hospitalización En Poblaciones Pediátricas Con Inmunodeficiencia Primaria (Idp). Reference:2927	Immunology & Allergy Unit
		RAFAEL LEÓN LÓPEZ. A Phase 2 Proof-Of-Concept Study To Evaluate The Efficacy And Safety Of Medi3902 In Mechanically Ventilated Patients For Prevention Of Nosocomial Pneumonia Caused By Pseudomonas Aeruginosa. Reference:/3992	Intensive Care Unit
		JUAN CARLOS POZO LADERAS. Determinants Of Antimicrobial Use And De-Escalation In Critical Care (Diana Study). Reference:3461	Intensive Care Unit
		JOSE CARLOS ESTEVEZ MARIA. Estudio De Extensión Abierto Y Multicéntrico Para Evaluar La Seguridad Y Eficacia A Largo Plazo De Lacosamida Como Tratamiento Complementario Para Las Crisis Tónico-Clónicas Generalizadas Primarias No Controladas En Pacientes Con Epilepsia Idiopática Gene. Reference:/3625	Neurology Unit



JOSE CARLOS ESTEVEZ MARIA.Estudio Aleatorizado, Doble Ciego, Controlado Con Placebo, De Búsqueda De Dosis Para Evaluar La Eficacia Y La Seguridad De Padsevonil Como Tratamiento Adyuvante De Crisis Focales En Sujetos Adultos Con Epilepsia Fármacorresistente..Reference:/3946	Neurology Unit
JOSE CARLOS ESTEVEZ MARIA.Estudio Doble Ciego, Aleatorizado, Controlado Con Placebo, De Grupos Paralelos, Multicéntrico Para Evaluar La Seguridad Y La Eficacia De Lacosamida Como Tratamiento Complementario Para Las Crisis Tónico-Clónicas Generalizadas Primarias No Controladas En P.Reference:/3626	Neurology Unit
JOSE CARLOS ESTEVEZ MARIA.A 12 Month Noninterventional, Postmarketing, Multicenter Study To Evaluate The Effectiveness Of Briviact (Briviaracetam) As Adjunctive Therapy In Patients With Epilepsy With Partial-Onset Seizures In Daily Clinical Practice.Reference:3548	Neurology Unit
Mª TERESA CACERES REDONDO.Prevalencia De La Enfermedad De Parkinson Avanzada En Pacientes Tratados En Los Hospitales Del Sistema Público Español. Estudio Paradise.Reference:3904	Neurology Unit
JOSÉ EDUARDO ARJONA BERRAL.Protocolo Para Estudio Clínico, Uso De Ultrasonido Transvaginal Para Confirmar La Colocación De Microinsertos Essure® En Las Mujeres: Demostración De Eficacia.Reference:2003	Gynecology & Obstetrics Unit
JOSÉ EDUARDO ARJONA BERRAL.Estudio Clínico Multicéntrico E Internacional Para Evaluar La Seguridad Y La Eficacia Del Producto Sanitario Essure (Modelo Ess505) Para Evitar El Embarazo En Mujeres Que Deseen Una Anticoncepción Permanente..Reference:2447	Gynecology & Obstetrics Unit
AMALIA PALACIOS EITO.Phase Iiib Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRh Antagonist Versus GnRh Agonist Plus Flare Protection In Patients With Very High Risk Localized Or Locally Advanced Prostate Cancer. A Joint Study Of T.Reference:/3722	Onco-radiotherapy Unit
AMALIA PALACIOS EITO.Enzalutamida Y Radioterapia Hipofraccionada En Cc!Ncer De Prc3Stata Localizado De Riesgo Intermedio..Reference:/3553	Onco-radiotherapy Unit
MARÍA ESPINOSA CALVO.Optimizing Irradiation Through Molecular Assessment Of Lymph Node.Reference:2637	Onco-radiotherapy Unit
MARÍA ANGELES TEJERO HERNÁNDEZ.Estudio En Fase I, En Abierto, De Dosis Única Y No Randomizado Para Evaluar La Farmacocinética (Fc) Y La Farmacodinámica (Fd) De Edoxaban En Pacientes Pediátricos.Reference:/3215	Pediatrics Unit
RAFAEL GONZALEZ DE CALDAS MARCHAL.Factores Farmacogenómicos Y Monitorización Terapéutica Como Predictores De Respuesta A Anti-Tnfs En Enfermedad Inflamatoria Intestinal En Niños.Reference:3411	Pediatrics Unit
LUIS ZURERA TENDERO.Ensayo Clínico En Fase Iii De Therasphere Intraarterial Para El Tratamiento De Pacientes Con Carcinoma Hepatocelular (Chc) No Resecable. A Phase Iii Clinical Trial Of Intra-Arterial Therasphere® In The Treatment Of Patients With Unresectable Hepatocellula.Reference:2925	Radiodiagnostic Unit





IMIBIC
INSTITUTO MAIMÓNIDES DE
INVESTIGACIÓN BIOMÉDICA
DE CÓRDOBA



JUNTA DE ANDALUCÍA



UNIVERSIDAD DE CÓRDOBA